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Abstract
The innate immune system is the first line of host defense against invading pathogens.
In multicellular organisms, specialized innate immune cells recognize conserved
pathogen-associated molecular patters (PAMPs) with germline-encoded pattern
recognition receptors (PRR). Thereby, the organism discriminates between self
and non-self and engages mechanisms to eliminate the invader. Beside PAMPs,
PRRs recognize mislocalized self-molecules, so called danger-associated molecular
patterns (DAMPs), which are indicators of tissue or cellular damage.
Upon PAMP or DAMP recognition, PRRs induce innate immune signaling path-
ways leading to the activation of pro-inflammatory genes and interferon produc-
tion, which are important mediators of inflammation. Therefore the recognition
of invading pathogen and thereby activation of innate immune signaling pathways
determines the success of the immune system to eliminate the potential threat.
Innate immune signaling pathways largely depend on phosphorylation cascades.
Today, global phosphorylation changes are analyzed by mass spectrometry, how-
ever the number of detected phosphopeptides remains unchanged despite technical
improvements. Therefore, we investigated the issue of phosphopeptide detection in
mass spectrometry.
The analyses of phosphopeptide-enriched samples revealed lower signal intensi-
ties in MS1 spectra compared to total cell lysate samples, which resulted in poor
phosphopeptide detection with mass spectrometry. Based on these observations,
we hypothesized that the phosphate groups of phosphopeptides account for this
poor detection. Indeed, we significantly increased the signal intensities in MS1
spectra after enzymatic removal of phosphate groups from phosphopeptides, and
consequently we detected three-times more peptides in phosphatase-treated sam-
ples. Validation experiments elucidated that most of the newly detected peptides
were initially phosphorylated. Moreover, the newly detected peptides enlarged the
activated signaling network upon Salmonella infection. Importantly, we identified
known innate immune signaling pathways, which were missing in the analyses of
phospho-enriched samples.
Taken together, the phosphate groups of phosphopeptides globally suppress pep-
tide ionization efficacy and therefore account for the low phosphopeptide detection
rate by mass spectrometry. By removing the phosphate groups, we identify three
times more peptides after phosphatase treatment. The newly detected peptides en-
large the network of activated innate immune signaling pathways upon Salmonella
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infection and include signaling pathways that are important but have not been de-
tected in phospho-enriched samples. Therefore our findings improve the analyses
of innate immune signaling pathways by mass spectrometry and consequently the
understanding of innate immunity.
One of the main mechanisms to eliminate invading microbes is by phagocytosis
and degradation within phago-lysosomes. However, professional pathogens have
developed various defense mechanisms to resist intracellular killing and can even
use innate immune cells as replicative niches. For example, the bacterial pathogen
Francisella tularensis causes a severe and life-threatening disease called tularemia
in humans, because Francisella survives and replicates in macrophages and den-
dritic cells. Critical for Francisella pathogenicity is the ability of the phagocytosed
bacteria to escape from the phagosome to the host cytosol. Even though we know
that genes encoded on the Francisella pathogenicity island (FPI) are essential for
escaping from the phagosome, the mechanism is unknown. Homology analyses have
suggested that the FPI encodes a type 6 secretion system (T6SS). However exper-
imental evidence is missing, which show that the FPI encodes a functional T6SS.
Therefore, we investigated whether the FPI encodes a functional T6SS and what
impact a functional T6SS has on Francisella virulence in vitro and in vivo.
We showed that the FPI of Francisella novicida (F. novicida) encodes a functional
T6SS that assembles exclusively at bacterial poles. T6SS function depended on
the unfoldase ClpB, which specifically recognizes contracted T6SS sheaths lead-
ing to their disassembly. Furthermore we characterized FPI genes that showed no
homology with known T6SSs. We identified IglF, IglG, IglI and IglJ as structural
components of the T6SS and PdpC, PdpD, PdpE and AnmK as potential T6SS ef-
fector proteins. Whereas PdpE and AnmK were dispensable for phagosomal escape,
AIM2 inflammasome activation and virulence in mice, pdpC - and pdpD-deficient
bacteria were impaired in all aforementioned analyses. This suggests that PdpC and
PdpD are bacterial effector proteins involved in phagosomal escape and thereby in
the establishment of a F. novicida infection.
Taken together, F. novicida uses its T6SS to deliver the effector proteins PdpC
and PdpD into host cells. PdpC and PdpD are involved in phagosomal rupture and
consequently in bacterial escape to the cytosol. These findings are a major break-
through in the understanding of Francisella pathogenicity and could lead to new
vaccination strategies to eradicate the life-threatening human disease tularemia.
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-8- I. Introduction
1 Innate Immunity
All living organisms face the challenge of fighting off invading pathogens and there-
fore need to discriminate between self and non-self. After detecting non-self, the
organisms need to react to the potential threat and eliminate it, otherwise the
organism may not survive the pathogen. The reaction of an organism to a poten-
tial threat is executed by the immune system and called immune response. Even in
prokaryotes basic forms of immunity can be found, such as restriction enzymes and
clustered regularly interspaced palindromic repeats (CRISPR) that recognize and
restrict bacteriophages [1]. Furthermore, unicellular amoebae, like Dictyostelium,
developed the ability to internalize foreign material for feeding [2].
The evolution of multicellular organisms allowed for a more sophisticated immune
system with specialized immune cells. In invertebrates, such as sponges, snails, in-
sects, worms or jellyfishes, the ability to internalize material was developed even
further and received the name phagocytosis. During phagocytosis, specialized cells
called phagocytes detect and internalize foreign material with their surface recep-
tors, thereby discriminating between self and non-self [3]. The identification of the
receptors that recognize specific patterns on foreign material led to the discovery of
innate immunity; a concept first proposed by Charles Janeway in 1989 [4]. The re-
ceptors of the innate immune system, better known as pattern recognition patterns
(PRRs) are germline-encoded, and thus invariable. Their specific ligands are called
pathogen-associated molecular patterns (PAMPs) or danger-associated molecular
patterns (DAMPs). [4, 5].
The immune system continued to develop in vertebrates, which have both an in-
nate and adaptive immune system. The adaptive immune system consists of B and
T cells that express immunoglobulins (antibodies) and T cell receptors (TCRs),
respectively [6]. However, the fundamental concept of self/non-self discrimination
holds true for antibodies and TCR, but the way of recognition is different. In in-
nate immunity germline-encoded PRRs are limited to conserved patterns of foreign
material. In contrast, TCRs and antibodies of the adaptive immune system are
plastic and thereby adapt to newly arising patterns on foreign material (called
antigen). This huge recognition range is generated through somatic instead of
germline-encoded mechanisms. Antigen specificity is generated through receptor
gene segment recombination events, which create any target specificity of the re-
ceptor [7,8]. As receptor recombination requires time, the adaptive immune system
reaches maximal efficiency after days or weeks of first antigen exposure, whereas
the innate immune system acts effectively immediate after first PAMP or DAMP
exposure. However, PAMPs or DAMPs do not directly activate T and B cells. Cells
of the innate immune system produce and present the antigen required for TCR or
antibody development to the cells of the adaptive immune system. Thus, the in-
nate and adaptive immune system act cooperatively to mount an efficient immune
response and to eradicate a detected threat [6, 8, 9].
Around 1900, the discovery of antibodies and phagocytes initiated the research
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field of the innate and adaptive immune system. However, more adequate tech-
niques were available to purify antibodies and thereby enabling the research into
the function of antibodies. This resulted in a attention shift from the discovery
of phagocytes by Metchnikoff to the discovery of antibodies by Ehrlich [10, 11]. It
took almost a century until Charles Janeway proposed the basic concepts of innate
immunity in a lecture at the Cold Spring Harbor Symposium in 1989 [4], thereby
re-starting research in innate immunity. However, the understanding of the innate
immune system still lags behind the understanding of the adaptive immune system.
Given that the innate immune system is the first line of defense against invading
pathogens, it is crucial to understand how the innate immune system is activated.
Moreover the innate immune system is required for an efficient adaptive immune
response. However, the crosstalk between the innate and adaptive immune system
remains elusive and therefore has to be studied in more depth.
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1.1 Cells of the innate immune system
When pathogens enter an organism, they are immediately recognized by the innate
immune system, which prevents them from spreading throughout the organism.
The physical and chemical barrier of the innate immune system are the epithe-
lial cells in the skin, lung or gastrointestinal tract, which prevent free access of
pathogens into the body. However, pathogens have developed mechanisms, which
allow them to penetrate through these physical and chemical barriers. In such cases,
a second layer of innate immunity stands guard underneath the epithelial cell layer
or in the blood stream to detect and kill invading pathogens. This layer includes
humoral innate immune components and specialized innate immune cells [9, 12].
The humoral innate immune components are soluble molecules that bind to and
kill invading pathogens or opsonize them for efficient innate immune cell recogni-
tion and phagocytosis. Two prominent components of humoral innate immunity
are antimicrobial peptides (AMPs) and the complement system. AMPs, such as
defensins and cathelicidins, are inserted into pathogen membranes and destabilize
them, which kills the pathogen [13].
The complement system recognizes and binds pathogen surfaces. Deposition of
complement components on the pathogen surface results in the formation and in-
sertion of a pore into the pathogen membrane that kills the pathogen. Moreover,
the decoration of the pathogen surface with complement components opsonize the
pathogen and thereby favor pathogen phagocytosis by innate immune cells [14].
In addition to pathogen killing and opsonization, complement activation generates
soluble cleavage products such as C3a and C5a, which attract innate immune cells
to the site of infection and provide activation and survival signals for T cells [1517].
The importance of the crosstalk between different components of the innate im-
mune system as well as the crosstalk between the innate and adaptive immune sys-
tem is highlighted by the role of the complement system. Complement-dependent
pathogen detection results in pathogen opsonization that facilitates pathogen up-
take by innate immune cells. In parallel, soluble cleavage products during the pro-
cess of opsonization attract innate and adaptive immune cells to the site of infection
and facilitate immune cell activation. Consequently, the local, complement-driven
inflammation initiates a multilayered, complex immune response involving soluble
and cellular components of the innate and adaptive immune system.
The recognition of invading pathogens through specialized innate immune cells
is absolutely crucial for an efficient immune response. Innate immune cells largely
originate from haematopoietic stem cells (HSCs) in the bone marrow (Figure I.1).
The HSCs generate all mature blood cells and produce roughly 109 red blood cells
and 108 immune cells per hour [18]. During the process of stem cell differentiation,
the HSCs pass through various progenitor stages, each accompanied by a loss of
trans-differentiation capability. Even though it is clear that HSCs follow a differ-
entiation path with various progenitor stages, the hierarchy of differentiation from
HSCs to fully differentiated cells is still debated. Various models of HSCs differ-
entiation exist to date [1922]. The common denominator of all these models is
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Figure I.1 Differentiation of haematopoietic stem cells. Haematopoietic stem cells (HSCs)
in the bone marrow generate all mature blood cells. HSCs differentiate through various multipo-
tent progenitors cells (MPPs). MPPs then split into two main directions following the common
myeloid or common lymphoid progenitor route (CMPs or CLPs, respectively). CMPs differentiate
into all red blood cells (erythrocytes and megakaryocytes) and the majority of innate immune
cells, whereas CLPs differentiate into cells of the adaptive and innate immune system. MEP,
Megakaryocyte-erythrocyte progenitor; GMP, Granulocyte-monocyte progenitor. Adapted from
Wang and Wagers [18].
the existence of two distinct progenitor cells; the common lymphoid progenitors
(CLPs) and the common myeloid progenitors (CMP). The CLPs differentiate to B
and T cells and are therefore the source of the adaptive immune system. Moreover,
CLPs differentiate into innate lymphocytes including natural killer (NK) cells and
innate lymphoid cells (ILCs). Thus, CLPs contribute to the development of the
innate immune system [23].
In contrast, CMPs develop into myeloid-erythroid progenitors (MEP) and granu-
locyte -monocyte progenitors (GMPs). MEPs give rise to red blood cells, includ-
ing erythrocytes and megakaryocytes. GMPs differentiate into the majority of in-
nate immune cells including monocytes/macrophages, dendritic cells, neutrophils,
eosinophils, basophils and mast cells [18]. Therefore, GMPs contribute significantly
to the development of innate immune cells. Innate immune cells are categorized
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into eight different groups based on surface protein markers and immune function.
These eight groups and their function in innate immunity are discussed in more
detail in the next paragraphs.
Monocytes
Monocytes are phagocytes and are found in the blood stream, where they circu-
late with a short lifetime. To maintain monocyte numbers in the blood, the bone
marrow has to produce new monocytes constantly. In the bone marrow, monocyte
differentiation depends on macrophage colony-stimulating factor (M-CSF). In mice,
two monocyte subgroups are found and distinguished by the differential expression
of surface markers. The first subgroups are proinflammatory (Ly6Chi) monocytes,
which express high levels of lymphocyte antigen 6C (Ly6C) and C-C chemokine
receptor 2 (CCR2) but low levels of CX3C chemokine receptor 1 (CX3CR1). The
second subgroup are patrolling (Ly6Clow) monocytes, which express low levels of
Ly6C and CCR2 but high levels of CXC3CR1 [24].
Proinflammatory monocytes are potent pathogen killers and accumulate at the
site of infection or sterile injury in a CCR2-dependent manner. In addition, pro-
inflammatory monocytes transport antigens from the site of infection to lymph
nodes, where they present the antigen to adaptive immune cells and thereby ac-
tivate them [25]. Moreover, proinflammatory monocytes can differentiate into ma-
crophages or dendritic cells and replenish the pool of tissue-resident macrophages
or dendritic cells under steady-state and tissue injury conditions [26,27].
Patrolling monocytes survey the vasculature by constant crawling along the en-
dothelial layer of blood vessels. Yona and colleagues suggest that patrolling mono-
cytes originate from proinflammatory monocytes and have anti-inflammatory func-
tions [28]. Given that patrolling monocytes can immediately migrate into the tissue
after bacterial infections [29], they are involved in early inflammation responses as
well as tissue repair after injury [30].
In humans, three monocyte subsets are described. The classical monocytes are sim-
ilar to proinflammatory monocytes in mice and are characterized by CD14++ and
CD16- (FCγRIII immunoglobulin receptor). Nonclassical monocytes are defined
by CD14+ and CD16++, representing murine patrolling monocytes. In contrast to
mice, humans harbor a third subset of monocytes, namely intermediate monocytes,
which are defined by CD14+ and CD16+. These intermediate monocytes are on the
transition between classical and nonclassical monocytes harboring both phagocytic
function and anti-inflammatory effects [31, 32].
Taken together, monocytes are important mediators of inflammation due to their
high mobility, their aggressive pro-inflammatory state and their high plasticity.
Their mobility enables them to migrate to the site of tissue injury or infection.
Their pro-inflammatory state allows them to efficiently encounter and kill invading
pathogens. Their plasticity allows them to differentiate into tissue-resident macro-
phages and dendritic cells, thereby contributing to cell homeostasis in the tissue.
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Moreover, plasticity allows proinflammatory monocytes to trans-differentiate into
patrolling monocytes. This monocyte trans-differentiation switches from pro- to
anti-inflammatory immune responses, resulting in tissue repair. Thus monocytes
are potent pathogen killing cells but also mediate the restitution of the infected or
injured tissue.
Macrophages
Macrophages are the first phagocytes described by Metchnikoff in 1905 [10]. Ma-
crophages populate many types of tissue and are therefore also called tissue-
resident macrophages. Compared to monocytes, macrophages show reduced motil-
ity but elevated phagocytic activity [33]. Depending on the localization, each
macrophage population shows a tissue-specific transcriptional profile [34]. The ma-
jor macrophage populations are located in the liver (Kupffer cells), lung (alveolar
macrophages), brain (microglia) and spleen (splenic macrophages), but macropha-
ges are also found in the heart, dermis, pancreas and intestine [24, 28, 35, 36]. A
dogma established by van Furth and colleagues claimed that tissue-resident ma-
crophages are continuously replenished by monocytes from the bone marrow [37].
However, recent publications challenge this dogma. They suggest that the major
macrophage populations are established at the embryonic state, despite the fact
that monocytes partially contribute to the repopulation of tissue-resident macro-
phages of the heart, dermis, pancreas and intestine [26, 27, 38, 39]. Two observa-
tions strongly support this new hypothesis. Firstly, tissue-resident macrophages
have the capacity to self-maintain their populations and secondly, they are present
in embryos from day 10.5 on and therefore are developed before the generation of
hematopoietic stem cells [36].
The main function of macrophages is the maintenance of tissue homeostasis. Ma-
crophages remove cellular material, like apoptotic cells, from the tissue by phago-
cytosis [40]. Importantly, the removal of cellular material is silent, as the receptors
involved in phagocytosis of dead self-material fail to induce an immune response.
Therefore no inflammatory stimulators are produced during this process [41]. Be-
sides maintaining tissue homeostasis, macrophages are activated by the detection of
non-self material. Once they are activated, they have three functions in the tissue:
host defense, wound healing and immune regulation. Historically, macrophages are
categorized into classically activated (M1) and alternatively activated (M2) ma-
crophages [42, 43]. M1 macrophages express high levels of IL-12, which stimulates
cytotoxic Th1 cells [44] and low levels of IL-10, a potent anti-inflammatory cy-
tokine [45]. M1 macrophages are activated by tumor necrosis factor α (TNFα)
and interferon (IFN)-γ. They enhance intracellular pathogen killing, cytokine se-
cretion and expression of co-stimulatory molecules to activate other innate and
adaptive immune cells. IFN-γ is produced by natural killer (NK) cells and the
T cell subgroup Th1. Even though both TNFα and IFN-γ induce the expression
and secretion of pro-inflammatory cytokines, only IFN-γ induces the production of
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oxygen and nitrogen radicals. Both radicals have potent bactericidal activities [46].
Besides being activated by other cells, macrophages produce their own activation
signals by PRR-dependent danger recognition. For example, macrophage Toll-like
receptor (TLR) signaling induces the expression of TNFα and IFN-β, a close rel-
ative of IFN-γ. TLR and IFN signaling is discussed in more details in chapter I,
section 1.2.1 and 1.3.
In contrast to M1 macrophages, the M2 macrophage state is induced by interleukin-
4 (IL-4) or IL-13. IL-4 is one of the earliest markers of tissue injury and is produced
by basophils, mast cells or Th2 cells [47]. Upon activation, M2 macrophages express
arginase-1 and the mannose and IL-4α receptor [48]. In macrophages, Arginase ex-
pression is important for the production of extracellular matrix and therefore tissue
repair [49]. In contrast to M1 macrophages, M2 macrophages are unable to present
antigens to adaptive immune cells, they show decreased pathogen killing capacity
and they produce minimal amounts of pro-inflammatory cytokines like IL-12 [50].
Instead, M2 macrophages express high levels of anti-inflammatory IL-10 which is
required for tissue repair after pathogen invasion or injury.
Even though the M1 and M2 classification is widely accepted, additional macrophage
activation states have been described and extend beyond the historical M1 and M2
macrophage classification [50, 51]. Based on experimental data, Mosser and col-
leagues have proposed an adapted activation state model to illustrate the different
activation states with a color scheme. In this activation model, the three primary
colors represent the three main macrophage functions; host defense, wound healing
and immune regulation. The summary of signals that activate a macrophage is
compared to the mixture of the three primary colors resulting in a unique color. In
the color scheme, the primary colors gradually blend into each other with infinite
numbers of intermediate colors. Thus the macrophage activation state is seen as
continuum between the three major functions host defense, wound healing and im-
mune regulation. Therefore, the state of macrophage activation is rather a mixture
of different functions than a strict classification into the three main functions host
defense, wound healing and immune regulation. As a consequence, an activated
macrophage can for example show host defense and wound healing properties at
the same time, depending on the activation signals the macrophage received.
Dendritic cells
Ralph Steinman discovered dendritic cells (DCs) in 1973 and received the Nobel
Prize for his discovery in 2011 [52]. DCs are prototypic antigen presenting cells,
which link the innate and adaptive immune system [53]. DCs constitutively ex-
press the surface markers CD45, major histocompatibility complex II (MHC-II)
and CD11c. Plasmacytoid DCs (pDCs) and classical DCs (cDCs) constitute the
two major groups in a very heterogeneous DC population. cDCs cover the major-
ity of DC subpopulations and are further divided into lymphoid and nonlymphoid
cDCs and Langerhans cells (LCs) [54]. Similar to tissue-resident macrophages, LCs
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in the dermis have the potential of self-renewal and do not originate from the bone
marrow [55, 56]. In contrast to LCs, cDCs and pDCs cannot self-renew and they
are constantly replenished from the bone marrow. However under certain circum-
stances, cDCs proliferate locally in the tissue [57,58].
Regardless of DC localization in the body, DCs constantly sample their environ-
ment for PAMPs and DAMPs as an indicator of tissue injury or infection. To
detect PAMPs and DAMPs, DCs express a diverse arsenal of different PRRs [59].
After PAMP or DAMP recognition and internalization, the PAMP or DAMP is
processed intracellular and the resulting antigen is loaded onto the surface re-
ceptor MHC-II. MHC-II-antigen-loaded DCs migrate to the lymph nodes, where
they activate naïve T cells to launch an effective adaptive immune response [60,61].
Neutrophils
Neutrophils originate from myeloid precursors in the bone marrow. They are short-
lived under steady state conditions and constantly undergo apoptosis [46]. Gra-
nulocyte colony-stimulating factor (G-CSF) and granulocyte-macrophage colony-
stimulating factor (GM-CSF) are important for neutrophil progenitor prolifera-
tion in the bone marrow [62, 63]. Neutrophils circulate in the blood and are re-
cruited to the site of infection or injury through cytokines produced by macropha-
ges [64, 65]. Importantly, G-CSF and GM-CSF produced at the site of infection
are anti-apoptotic and stimulate neutrophil survival and increase neutrophil re-
sponsiveness to the infection [66, 67]. As neutrophils circulate in the blood, cell
adhesion at the side of infection or injury is very important to induce an immune
response [68]. Once at the site of infection or injury, neutrophils produce cytokines
that attract and activate innate and adaptive immune cells [69, 70].
Neutrophils are the most effective pathogen killers of the innate immune sys-
tem [33]. They primarily kill complement- or antibody-opsonized extracellular
pathogens by phagocytosis; or kill extracellular pathogens directly through neu-
trophil extracellular traps (NETs). After phagocytosis of extracellular pathogens,
intracellular granules fuse with the pathogen-containing phagosome. Granules con-
tain digestive and hydrolytic enzymes and their fusion with the phagosome expose
pathogens to these strong microbicidal molecules [7173]. In addition, neutrophils
produce reactive oxygen species, which are their most important mediators of
pathogen killing [33,74,75]. The production of reactive oxygen species is described
in more detail in chapter I, section 2.
As a side effect of antimicrobials, they induce tissue damage when released by neu-
trophils. Therefore, the release of granular content requires tight control. Moreover,
neutrophils induce tissue repair mechanisms in macrophages at the site of infection
or injury to compensate for antimicrobial-induced tissue damage [76,77].
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Innate lymphocytes
Innate lymphocytes (ILCs) originate from the common lymphocyte precursor (CLP)
in the bone marrow. In contrast to B or T cell maturation, ILC maturation hap-
pens independent of somatic recombination [78, 79]. ILCs are enriched at barrier
tissues such as skin, lung and intestine. Mature ILCs serve as an early source of
cytokines to activate innate and adaptive immune cells [80]. ILCs are divided into
three classes.
Group 1 ILCs (ILC1s) are the best-studied class and include among others natural
killer (NK) cells. NK cells are important for the defense against viral pathogens
and tumor cells [81]. ILC1s produce IFN-γ and TNFα in response to the pro-
inflammatory cytokine IL-12 produced by tissue-resident macrophages [82, 83].
IFN-γ and TNFα fully activate macrophages as described in the previous para-
graph. Thus, ILC1s promote inflammation in response to infections or injuries [80].
Group 2 ILCs (ILC2s) are important in host defense against extracellular parasites.
IL-25 and IL-33 are produced in response to parasite infections and induce tissue
repair mechanisms in ILC2s [84, 85]. Moreover, ILC2s are an important source of
IL-13 that acts on intestinal goblet cells. In goblet cells, IL-13 increases mucus pro-
duction to hinder parasite entry and enhances muscle contractility to mechanically
remove parasites from the intestine [85].
Group 3 ILCs (ILC3s) are important in the host defense mechanism against fungi or
bacteria and produce the cytokines IL-17 and IL-22 in response to IL-1β, IL-6 and
IL-23 [8688]. IL-22 act on non-hematopoietic cells and stimulate the production
of antimicrobial peptides [89], thereby limiting pathogen dissemination and tissue
damage. In addition, ILC2s and ILC3s have distinct functions in the promotion or
limitation of chronic inflammation depending on the stimuli and location [80].
Mast cells, basophils, eosinophils
Mast cells, basophils and eosinophils belong to the group of granulocytes, like neu-
trophils. They originate from precursors in the bone marrow.
Mast cells and basophils act in a similar way by inducing a type-2-immune response
in tissue-resident immune cells, which is characterized by anti-inflammatory signal-
ing and tissue repair [90]. Upon activation, mast cells and basophils release their
granular content in a IgE-dependent manner, a process called degranulation [91].
Basophil degranulation contributes to the control of helminth infections [92]. As
described for neutrophils, the granular content of basophils and mast cells is highly
cytotoxic and immunogenic, leading to strong immune responses. Thus excessive
and recurrent degranulation of basophils and mast cells play an important role in
IgE-mediated chronic, allergic inflammation and asthma [93,94].
On the other hand, eosinophils have a short lifetime. They accumulate in the intesti-
nal tissue, where they control intestinal homeostasis and the survival of antibody-
producing plasma cells [9597]. Eosinophils are maintained in the intestinal tissue
by IL-13-producing ILC2s [98]. Pathogen- or allergen-induced inflammation acti-
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vates eosinophils, leading to their degranulation and the release of the granular,
highly cytotoxic content [99]. In addition, eosinophils release mitochondrial DNA
as extracellular traps to kill extracellular pathogens [100].
Taken together, innate immune cells are mostly integrated in barrier tissues of
the skin, intestine, liver, spleen or lung. In these tissues, innate immune cells wait
for invading pathogens or tissue injury to immediately induce inflammation and
eliminate the potential threat. In addition to this host defense mechanism, innate
immune cells are involved in tissue homeostasis guaranteeing that the physical
barrier is kept intact. Moreover, innate immune cells either regulate their own ac-
tivation state or cross-activate other innate and adaptive immune cells. Only when
the adaptive immune system is activated in an innate immune-dependent manner,
a maximal and efficient immune response can be reached.
Given that antimicrobials are cytotoxic, innate immune cell activation harms the
own tissue or organs, thus their activation is tightly regulated and innate immune
cells have the ability to repair tissue.
Deregulation of innate immune cells is either associated with autoimmune diseases,
caused by uncontrolled immune cell activation, or associated with recurring infec-
tions and cancer, as a result of immune cell activation failure [46, 51, 80]. This
highlights the importance of the regulation and adequate activation of the innate
immune system to balance the benefits and disadvantages for the organism.
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1.2 Pattern recognition receptors
As described in chapter I, section 1, the discrimination between self and non-self is
the key mechanism in innate immunity. Innate immune cells use germline-encoded
receptors, so-called pattern recognition receptors (PRRs), to recognize conserved
microbial molecules known as pathogen-associated molecular patterns (PAMPs).
However, also non-immune cells express PRRs and can thereby recognize PAMPs
and thus contribute to local inflammation [4]. Importantly, PAMPs are subjected
to low mutation rates because they have a detrimental role in pathogen biology.
Therefore, PAMPs are an ideal ligand for germline-encoded PRRs, which them-
selves are invariable. The most prominent PAMP is the gram-negative bacterial
outer membrane component lipopolysaccharide (LPS), though bacterial flagellin,
lipoproteins of gram-positive bacteria or unmethylated DNA and viral RNA are
also recognized by PRRs [101]. Over the years it has been discovered that PRRs
also recognize host-derived signals, better known as danger-associated molecular
patters (DAMPs), alarmins or endogenous adjuvants. DAMPs are normally hid-
den within cells or cellular compartments and they are released or secreted un-
der conditions of cellular stress or tissue injury [102104]. Prototypic DAMPs are
Interleukin-1 (IL-1), IL-33, high-mobility group box 1 (HMGB1), amyloid β (Aβ),
mitochondrial DNA, ATP, uric acid and double- and singlestranded RNA [40,105].
The PRRs are either membrane bound or cytosolic. The membrane bound PRRs
are either anchored in the plasma membrane surveying the extracellular space or
anchored in endosomal membranes surveying phagocytosed material for the pres-
ence of potential harm [106]. Historically, five different PRR classes have been iden-
tified, namely the Toll-like receptors (TLRs), the C-type lectin receptors (CLRs),
the nucleotide-binding and oligomerization domain (NOD)-like receptors (NLRs),
the retinoic acid inducible gene-I (RIG-I)-like receptors (RLRs) and the absent in
melanoma 2 (AIM2)-like receptors (ALRs) [5]. Recently, many new cytosolic PRRs
that recognize DNA or cyclic-di-nucleotides (CDNs) were discovered [107].
PRR activation results in the transcriptional activation of a ligand-specific set of
pro-inflammatory cytokines and/or interferons (IFN) or to the activation of in-
flammasomes. Inflammasomes, cytokines and IFNs are essential mediators of an
efficient innate and adaptive immune response [106,108]. Given that PRRs are the
crucial receptors for recognizing non-self, the different classes and their ligands are
described in the next paragraphs.
Toll-like receptors
Toll-like receptors (TLRs) are by far the best studied PRRs and include TLR1-10
in humans and TLR1-9 and TLR11-13 in mice [106]. TLRs are localized to the
plasma membrane (TLR1,5,6,10), on intracellular endosomes (TLR3,7-9,11-13) or
to both compartments (TLR2,4) and the localization is critical for signaling [109].
TLRs consist of three important domains for ligand recognition and signaling. The
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horseshoe-like leucin-rich repeats (LRRs) recognize and bind the ligand, the trans-
membrane domain anchors the PRR in the membrane and the Toll/interleukin-1
receptor (TIR) homology domain is responsible for downstream signaling [8, 110].
Endosomal TLR7-9 are anchored in the membrane as preformed dimers and are im-
portant for the recognition of invading viruses [111]. Single stranded RNA (ssRNA)
activates TLR7 and TLR8, whereas unmethylated DNA activates TLR9 [112].
All plasma membrane-localized TLRs and TLR3 are anchored in the membrane as
monomers [111]. After ligand recognition, these TLRs form homo- or heterodimers.
TLR3 and TLR5 form homodimers after double stranded RNA (dsRNA) and bac-
terial flagellin recognition, respectively [113, 114], whereas TLR4 forms homod-
imers after recognition of a wide range of PAMPs and DAMPs, however the most
prominent one is bacterial LPS [106]. Recently, it has been speculated that many
described TLR4-activating PAMPs and DAMPs has been contaminated with LPS
and thus these results are misleading. TLR4 activation is described in more details
in chapter I, section 1.2.1.
In contrast to TLR3, -4 and -5, heterodimers of TLR1 and TLR2 recognize tri-
acylated lipoproteins [115], whereas heterodimers of TLR2 and TLR6 recognize
di-acylated lipoproteins. Lipoproteins are important components of the bacterial,
fungal and parasitic cell wall but are also present on viral particles [116].
In addition to humans, mice express TLR11, -12 and -13, which recognize bacterial
flagellin, parasitic profilin and bacterial ribosomal RNA, respectively. Like TLR7-
9, they exist as preformed dimers and are localized to endosomes [107].
Activated TLRs, with the exception of TLR3, recruit via their cytosolic TIR do-
mains the two signal adaptors myeloid differentiation primary response protein 88
(MYD88) and MYD88 adaptor-like protein (MAL). MYD88/MAL recruitment re-
sults in the activation of nuclear factor kappa-light-chain-enhancer of activated B
cells (NF-κB) and adaptor protein 1 (AP-1) (Figure I.2). NF-κB and AP-1 are tran-
scription factors and induce the expression of pro-inflammatory genes [106, 111].
In contrast, TLR3 and TLR4 recruit via their TIR domains the signal adaptors
TIR domain-containing adaptor protein-inducing IFN-β (TRIF) and TRIF-related
adaptor molecule (TRAM). TRIF/TRAM recruitment to TLR3 and TLR4 acti-
vates the transcription factor IFN regulatory factor 3 (IRF3) to induce the expres-
sion of type-I-interferon [113].
Taken together, TLR signaling activates both immune and non-immune cells to
effectively fight a pathogen infection. Moreover, TLR signaling induces inflamma-
tion to propagate the immune response. In chapter I, section 1.2.1 the activation
mechanism of TLR4 and the underlying signaling cascade is described in more
detail.
C-type lectin receptors
C-type lectin receptors (CLRs) are primarily found on the plasma membrane. Hun-
dreds of CLRs have been identified and form a very heterogeneous group. CLRs
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Figure I.2 Schematic overview of selected innate immune signaling pathways. In-
nate immune cells signal via different pathways from the plasma membrane, endosomes and
the cytosol to induce the expression of pro-inflammatory genes, type-I-interferon (IFN) or IFN-
stimulated genes. MEK, Mitogen-activated protein kinase (MAPK)/extracellular signal-regulated
kinase (ERK) kinase; MKK, MAPK kinase; JNK, c-Jun N-terminal kinase; AP-1, Adaptor pro-
tein 1; NOD, Nucleotide-binding oligomerization domain-containing protein; RIPK2, Receptor-
interacting serine/threonine-protein kinase; TLR, Toll-like receptor; MYD88, Myeloid differenti-
ation primary response protein 88; TRAF, Tumor necrosis factor (TNF) receptor associated fac-
tor; IRAK, Interleukin-1 receptor associated kinase; TAK1, Transforming growth factor (TGF)
beta-activated kinase 1; TAB, TAK1 binding protein; IkB, I kappa B; IKK, IkB kinase; TRIF,
Toll-interleukin receptor (TIR) domain-containing adapter protein inducing IFNβ; TBK, TANK-
binding kinase; IRF, Interferon regulatory factor; TRIM, Tripartite motif-containing protein;
RIG, Retinoic acid inducible gene; MDA, Melanoma differentiation gene; MAVS, Mitochondrial
antiviral signaling protein; TRADD, TNF receptor type 1-associated Death domain (DD) protein;
TANK, TRAF family member-associated nuclear factor kappa-light chain enhancer of activated
B cells (NF-κB) activator; NAP, NF-κB-activating kinase-associated protein; SINTBAD, TBK1-
binding protein 1; FADD, FAS-associated death domain protein; CASP8, Caspase-8; IFNR, IFN
receptor; JAK, Janus kinase; STAT, signal transducer and activator of transcription; ISRE, IFN-
stimulated response element; GAS, Gamma-activated sequence. Adapted from Dreier et al. Chap-
ter III, section 1.
are characterized by a C-type lectin-like domain (CTLD) and recognize different
carbohydrates on the cell surface of viruses, bacteria and fungi [106]. Based on their
structure, the CLRs are divided into 17 different groups [117,118]. The best charac-
terized CLRs are Dectin-1 and Dectin-2. Dectin-1 is expressed by DCs, macropha-
ges, neutrophils and monocytes and recognizes fungal β-1,3-glucans [119], as well as
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bacteria-bound mucins and bacterial β-glucans [120]. Upon ligand recognition, ac-
tivated Dectin-1 recruits and activates the kinase SYK through the cytosolic ITAM
domain [121,122]. Consequently, receptor-activated SYK activates the NF-κB and
mitogen activated protein kinase (MAPK) signaling pathway through TRAF6 and
TAK1, respectively, resulting in pro-inflammatory gene expression [123]. The NF-
κB and MAPK signaling pathway is discussed in greater details in chapter I, section
1.2.1.
Dectin-2 is activated through fungal α-mannans [124] or the parasite Schisto-
soma [125]. Dectin-2 activation by IgE causes an allergic reaction [126]. In contrast
to Dectin-1, Dectin-2 misses the intracellular ITAM domain. Therefore, Dectin-2
needs to bind to FcRγ, which contains the ITAM domain for downstream signaling.
The downstream signaling of the FcRγ ITAM domain is analogues to the Dectin-1
signaling and both result in the expression of pro-inflammatory genes [106].
NOD-like receptors
NOD-like receptors (NLRs) are cytosolic receptors that consist of a N-terminal
effector domain, a central nucleotide-binding and oligomerization domain called
NACHT and C-terminal LRRs [127]. There are 23 NLR family members in hu-
mans and more than 34 in mice [128]. The NLRs are categorized into 4 subfamilies
(NLRA,B,C,P) based on the N-terminal effector domains.
The NLRA subfamily includes only CIITA and contains an acidic transactivation
effector domain. CIITA transcriptionally activates MHC class II genes, which en-
ables cells to present antigens to adaptive immune cells [129].
The NLRB subfamily includes only NAIP in humans but includes NAIP1-7 in mice.
NAIPs contain multiple baculoviral inhibitory repeat like effector domains (BIRs).
The role of NAIP proteins is discussed in greater detail in chapter I, section 1.4.1.
The NLRC subfamily consists of NLRC1-5 and NLRX1. NLRC1, -2 and -4 contain
a caspase activation and recruitment effector domain (CARD), whereas NLRC3,
-5 and NLRX1 have an unidentified effector domain. NLRC1 (NOD1) and NLRC2
(NOD2) are the best studied NLRs and recognize peptidoglycan moieties of Gram-
negative and/or Gram-positive bacteria [130, 131]. NOD1 and NOD2 oligomerize
after peptidoglycan moiety recognition and activate NF-κB through the recruit-
ment of receptor-interacting serine/threonine-protein kinase 2 (RIPK2) (Figure
I.2) [132]. In parallel to NF-κB activation, NOD1 and NOD2 activate TAK1 to
induce MAPK signaling [133]. NF-κB and MAPK signaling induce the expression
of pro-inflammatory genes and is discussed in greater details in chapter I, section
1.2.1. In addition to NF-κB and MAPK activation, NOD1, NOD2 and NLRX1
activate autophagy through the recruitment of ATG16L1 [134,135].
Moreover, NLRC3 negatively regulates NF-κB signaling [136], NLRC4 induces in-
flammasome activation [137] and NLRC5 acts as transcriptional activator of MHC
class I genes [138]. NLRC4-dependent inflammasome activation is discussed in more
details in chapter I, section 1.4.1.
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The NLRP subfamily harbors a pyrin effector domain (PYD) and consists of
NLRP1-14 in humans. In mice, three variants of NLRP1 (Nlrp1a-c), seven variants
of NLRP4 (Nlrp4a-g) and three variants of NLRP9 (Nlrp9a-c) exist. In contrast to
humans, mice lack homologs of NLRP7, -8, -11 and -13 [128]. NLRP1 was the first
discovered inflammasome receptor [139]. However, the best studied inflammasome
receptor is NLRP3 [140]. NLRP3-dependent inflammasome activation is discussed
in more details in chapter I, section 1.4.1.
In addition to NLRP1 and NLRP3, NLRP2, -6, -7 and -12 have been proposed to
induce an inflammasome [141144]. However, it is debated whether these receptors
resemble an inflammasome. Besides inflammasome activation, NLRP2 and NLRP6
regulate pro-inflammatory gene expression [145147]. Moreover, NLRP4 is a nega-
tive regulator of autophagy and type-I-interferon signaling [148,149]. The function
of the remaining NLRPs is completely unknown and requires further investigation.
RIG-I-like receptors
The RIG-I-like receptors (RLRs) detect the presence of foreign cytosolic RNA
through three DexH/D box helicases and possess a CARD domain for downstream
signaling [150]. RLRs include three members: the retinoic acid-inducible gene-I
(RIG-I), the melanoma differentiation gene 5 (MDA5) and the laboratory of ge-
netics and physiology 2 (LGP2) [151]. LGP2 is a negative regulator of RIG-I and
MDA5 [152]. RIG-I and MDA5 detect features, such as 5' triphosphate RNA, long
double-stranded RNA or poly-uridine regions [153155], that are only present on
viral but not self RNA. Based on RNA length, RIG-I and MDA5 recognize each a di-
verse group of viruses [156]. After RNA-dependent RIG-I or MDA5 activation, they
bind via their CARD domain to the adaptor molecule mitochondrial antiviral sig-
naling protein (MAVS), which is anchored to mitochondrial membranes [157,158].
After RIG-I or MDA5 binding, MAVS undergoes self-oligomerization [159] and the
MAVS oligomer recruits and activates TNF receptor associated factor 2, 5 and 6
(TRAF2,-5 and-6) (Figure I.2). Consequently, TRAF2/5/6 activate TANK-binding
kinase 1 (TBK1) and IκB kinase  (IKK-). These two kinases activate the tran-
scription factors IRF3 and IRF7, which enter the nucleus and induce the expression
of type-I-IFNs. Moreover, TRAF2 and -6 activate NF-κB leading to the expression
of pro-inflammatory cytokines [160].
AIM2-like receptors
The AIM2-like receptors (ALRs) recognize intracellular, cytosolic DNA and con-
tain two domains: a pyrin (PYD) and a HIN200 domain. Similar to NLRPs, the
effector PYD domain is responsible for downstream protein-protein interactions
and signaling, whereas the HIN200 domain is responsible for DNA binding [106].
To date, two members of the ALR family have been identified, namely AIM2 and
IFI16. AIM2 activate an inflammasome after the recognition of at least 80 bp long
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dsDNA [161165], which will be discussed in more detail in chapter I, section 1.4.
On the other hand, IFI16 has been shown to express type-I-IFN [166, 167]. How-
ever, a study by Gray and colleagues have shown that none of the ALRs is involved
in type-I-IFN induction [168]. Furthermore, IFI16 has also been reported to acti-
vate an inflammasome [107]. However, if IFI16 truly resembles an inflammasome
requires further investigation.
Cytosolic DNA sensors
As described above, ALRs recognize cytosolic dsDNA. However, many more pro-
teins exist with the ability to recognize cytosolic DNA or cyclic-di-nucleotides
(CDNs). The most prominent members of this group of proteins are the cyclic-
GMP-AMP (cGAMP) synthase (cGAS) [169,170] and the stimulator of IFN genes
protein (STING) [171].
cGAS binds to the backbone of cytosolic dsDNA, which induces a conformational
change in the cGAS active site that enables the active site to catalyze cGAMP
synthesis [172]. About 15 base pairs of dsDNA binds and activates cGAS in vitro.
However, in vivo, longer pieces of dsDNA are required for cGAS activation [173].
STING is localized to the membrane of the endoplasmic reticulum (ER) [174]
and recognizes the second messenger cGAMP produced by cGAS [175, 176]. In
addition, STING directly recognizes ci-di-AMP, which is secreted by intracellular
Listeria [177] or DNA from intracellular viruses, bacteria and parasites [171]. How-
ever, the recent discovery of cGAS-dependent DNA binding upstream of STING
suggests that STING is not a direct but indirect sensor of DNA through cGAS.
After cGAMP-dependent STING activation, STING translocates from the ER to
an ER-Golgi intermediate compartment [178]. Translocated STING recruits TBK1
and IRF3, resulting in TBK1-dependent STING and IRF3 phosphorylation at a
conserved LxIS phospho-motif. Interestingly, the LxIS phospho-motif is also im-
portant for MAVS and TRIF signaling, the two other signaling pathways that
result in type-I-IFN production [179,180]. The phosphorylation of IRF3 results in
its homodimerization and translocation into the nucleus, where IRF3 induces the
expression of type-I-IFNs. In addition to IRF3 activation, STING phosphorylates
the IKK complex leading to NF-κB-dependent pro-inflammatory gene expression.
Besides cGAS and STING, proteins containing a DExD/H box domain have been
shown to bind cytosolic DNA, CDNs or RNA. For example, DDX41 and DDX3 are
proteins of the group of cytosolic DNA sensors. The ATP-dependent RNA helicase
DDX41 binds DNA and CDNs thereby inducing IFN expression through STING
and TBK1 [181]. On the other hand, DDX3 interact with RIG-I, MDA5 and MAVS
to induce IFNs in response to viral RNA [182]. Additional DDX and IFIT proteins
are thought to be involved in cytosolic nucleotide sensing and their specific role in
the cellular immune response requires clarification [107].
In summary, PRRs play an important role in the innate immune response against
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invading pathogens. In order to activate an immune response, PRRs recognize
conserved PAMPs and DAMPs, which indicate an ongoing infection or tissue in-
jury. Upon PRR activation, PRR signaling cascades induce the expression of pro-
inflammatory genes in immune and non-immune cells, which activate the cell itself
as well as surrounding immune cells to effectively resolve the infection or tissue
injury. Thus, PRR activation serves as the initial signaling event to activate the
immune system. Given that different PRRs recognize specific ligands, the immune
response can be tailored to various kinds of infections or tissue injuries to ade-
quately respond to the threat. However, pathogens have developed mechanisms,
which interfere with PRR signaling to dampen or redirect the immune response.
How pathogens modulate the immune response is discussed in greater details in
chapter I, section 2.1 and 2.2.
1.2.1 Toll-like receptor 4
Toll-like receptor 4 (TLR4) was the first functionally described TLR in mam-
mals [183] and the discovery of this essential innate immune receptor and its
Drosophila homologue TOLL was awarded with the Nobel prize in 2011 [184,185].
As described in chapter I, section 1.2, the main PAMP recognized by TLR4 is the
major Gram-negative bacterial outer membrane component LPS, which is com-
posed of Lipid A, a core oligosaccharide and the O antigen [186]. The LPS compo-
nent Lipid A anchors LPS in the bacterial membrane and is the TLR4-activating
part of LPS. However, TLR4 cannot bind to Lipid A directly and therefore re-
quires a multireceptor complex composed of CD14, LPS-binding protein (LBP)
and myeloid differentiation factor 2 (MD-2) [106].
CD14 is localized to cholesterol rich regions in the plasma membrane, which are
called lipid rafts. Lipid rafts are the signaling centers of the plasma membrane,
clustering together many important cytosolic receptor signaling components [187].
In the plasma membrane each TLR4 monomer interacts with one MD-2 protein
outside of lipid rafts [187189].
LBP is a soluble protein that extracts LPS monomers from bacteria and presents
it to the plasma membrane receptor CD14 [190]. LPS-loaded CD14 in lipid rafts
induces TLR4/MD-2 heterodimer relocalization to lipid rafts, where LPS is trans-
ferred from CD14 to MD-2. The LPS transfer induces monomeric TLR4/MD-2
dimerizationm which is absolutely essential for signaling [191, 192]. Besides trans-
ferring LPS to MD-2, CD14 directly endocytoses LPS under certain conditions,
thereby delivering LPS to the cytosol [193].
The cytosolic TIR domains of TLR4 are in close proximity to each other after TLR4
homodimerization and now able to bind to the downstream adaptor molecules
MYD88 and MAL, which are both essential for signal transduction [194196].
MYD88 and MAL binding to TLR4 is only possible in lipid rafts, as MAL is lo-
calized to the plasma membrane by phosphatidylinositol 4,5-bisphosphate (PIP2),
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which is typically found in lipid rafts [197]. MYD88 binding to TLR4 induces its
oligomerization to form a large signaling platform called the myddosome [198].
Once the oligomerization has taken place, the C-terminal death domain (DD) of
MYD88 recruits IL-1 receptor-associated kinase (IRAK) family members (Figure
I.2) [198,199]. First, the serine/threonine kinase IRAK4 is recruited by the myddo-
some which subsequently recruits and phosphorylates IRAK1 and IRAK2 thereby
activating them [200,201]. Phosphorylated IRAK1 and IRAK2 then recruit the E3
ubiquitin ligase TNF receptor associated factor 6 (TRAF6), which ubiquitinates
the IRAK proteins with special K63/M1-linked hybrid polyubiquitination (pUb)
chains [202,203]. The K63-linked pUb chains then recruit the TAK1/TAB1-3 com-
plex, whereas the M1-linked pUb chains recruit the canonical IKK complex con-
sisting of IKKα, IKKβ and IKKγ (NEMO) [203]. Forming hybrid pUb chains are
an elegant way to bring the IKK and TAK1 complex together as TAK1 phosphory-
lates IKKβ for canonical NF-κB activation [204]. Once IKKβ is activated by TAK1,
IKKβ phosphorylates the NF-κB inhibitor IκBα, which is then polyubiquitinated
and consequently degraded by the proteasomal machinery [205,206]. Given that the
NF-κB inhibitor IκBα is degraded, the p50/p65 NF-κB heterodimer translocates
to the nucleus where it induces the expression of pro-inflammatory genes [207].
Aside from NF-κB activation, TAK1 activates the MAPKs p38 and JNK, which
subsequently activate the transcription factor AP-1 [204]. AP-1 is a dimeric tran-
scription factor composed of Jun, Fos or ATF protein heterodimers and regulates
in conjunction with NF-κB the expression of pro-inflammatory genes [208].
Besides MYD88/MAL-dependent TLR4 signaling at the plasma membrane, TLR4
is endocytosed in a CD14-dependent manner. This process causes TLR4 to be re-
located from the plasma to endosomal membranes [209, 210]. In endosomes, the
TIR domains of TLR4 interact with the TIR domain-containing adaptor protein
inducing IFNβ (TRIF)-related adaptor molecule (TRAM). It has been speculated
that MAL that bound to TLR4 at the plasma membrane is replaced by TRAM
at the endosomal membranes, though the exact mechanism by which this occurs
is still unknown [106]. Once TRAM is bound to TLR4, it recruits TRIF. Conse-
quently, TRIF induces type-I-IFN production through the subsequent recruitment
and activation of TRAF3, TBK1 and IKK [211, 212]. Next, TBK1 and IKK
phosphorylate IRF3 causing its translocation into the nucleus where it induces
type-I-IFN expression [180, 213]. A more detailed description of TRIF signaling
can be found in chapter I, section 1.2. In addition to type-I-IFN induction, TRIF
activates NF-κB and IRF7 in a TRAF6-dependent and IRAK1/IKK-dependent
manner, respectively [212,214,215].
Taken together, TLR4 recognize a lot of different PAMPs and DAMPs and is there-
fore activated by multiple pathogenic infections. However, it is speculated that the
TLR4-activating PAMPs and DAMPs have been contaminated with LPS, thereby
resulting in misleading conclusions. TLR4 signaling at the plasma membrane in-
duces the expression of pro-inflammatory genes through MYD88-dependent NF-κB
and MAPK signaling, whereas endosomal TLR4 induces TRIF-dependent type-I-
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IFN production. Thus, cellular localization dictates distinct TLR4 signaling path-
ways. Moreover, the ability to recruit multiple signaling branches to activated
TLR4 in a temporal distinct fashion tightly regulates the signaling array, allowing
for signal branching, incorporation of other signaling events and multilayered in-
duction of pro-inflammatory genes. However as TLR4 induces a very broad array
of pro-inflammatory genes, dysfunction or successful interference with TLR4 sig-
naling can have a dramatic influence on the immune response, such as bacterial
modifications of their Lipid A to render it undetectable for TLR4 [216,217].
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1.3 Interferon
As described in chapter I, sections 1.2 and 1.2.1, TLR3- and TLR4-dependent sig-
naling induces the expression of type-I-interferons (type-I-IFNs).
IFNs were first described in 1957 as a substance produced by cells, which is involved
in defeating influenza infections [218,219]. Based on their receptor activation, three
IFN classes exist, namely type-I-, -II- and -III-IFNs [220, 221]. Each IFN class in-
duces the expression of a unique set of interferon stimulated genes (ISGs) via their
corresponding receptors and under specific conditions [222], thereby equipping cells
with potent weapons to fight viral, parasitic and bacterial infections [223]. Even
though IFNs induce potent killing mechanisms, IFNs also suppress the immune
system and thereby allowing the spread of viral and bacterial infections [224]. The
different IFN classes are described in more details in the following.
Type-I-IFNs are the largest class and they are produced by almost all cells [224].
Type-I-IFNs mainly include IFN-β and 13 partially homologous IFN-α subtypes
in humans (14 subtypes in mice). Additional type-I-IFN members are the poorly
described IFN-, IFN-κ, IFN-ω, IFN-θ and IFN-δ [225].
The set of ISGs induced by type-I-IFNs is defined by the receptor density in
the plasma membrane and the binding affinity of the specific IFN to the recep-
tor [226, 227]. Type-I-IFNs bind to IFN-α receptor 1 (IFNAR1)/IFNAR2 het-
erodimers at the plasma membrane [228], which induce IFNAR1/IFNAR2 ligation
and thereby trigger the phosphorylation of receptor associated kinases Janus kinase
1 (JAK1) and tyrosine kinase 2 (TYK2). Activated JAK1 and TYK2 phosphory-
late highly conserved tyrosine residues on the IFN receptor, which enables signal
transducer and activator of transcription 1 (STAT1) and STAT2 binding [229,230].
STAT1/2 receptor binding leads to their auto-phosphorylation on conserved tyro-
sine residues (e.g. STAT1 on Y701) and subsequent STAT1/STAT2 heterodimer-
ization. STAT1/STAT2 heterodimers expose their nuclear localization signal and
interact with IFN regulatory factor 9 (IRF9) to form the ISG factor 3 (ISGF3)
complex [231234]. ISGF3 translocates into the nucleus, where it binds to IFN-
stimulated response elements (ISREs) in the promoter region of ISGs and induces
their transcription [235,236].
Type-III-IFNs have been recently discovered, they include IFN-λ1,-2,-3 and -4 and
show structural similarity with the IL-10 cytokine family [237,238]. Type-III-IFNs
bind to IL-10 receptor 2 (IL-10R2) and IFN-λ receptor 1 (INFLR1), which form the
active receptor heterodimer [222, 239]. Importantly, type-III-IFNs activate exclu-
sively epithelial cells because IFNLR1 is only expressed in these cells [239]. Apart
from different receptor binding, type-III-IFNs induce the same signaling cascade
and a similar set of ISGs compared to type-I-IFNs [240].
Type-II-IFNs only consist of IFN-γ, which is predominantly produced by T cells
and innate lymphocytes [241,242]. In contrast to type-I- and -II-IFNs, IFN-γ forms
homodimers and binds to a receptor heterotetramer, which is composed of two
IFN-γ receptor 1 (IFNGR1) and two IFNGR2 [243]. Even though only T and
NK cells express IFN-γ, the IFNGR subunits are widely spread and thus almost
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all cells respond to IFN-γ [244]. Instead of receptor-associated JAK1 and TYK2
in type-I-IFN signaling, JAK1 and JAK2 are associated with and activated by
IFNGR [245, 246]. In contrast to type-I-IFN signaling, JAK1 and JAK2 phospho-
rylate only STAT1. Phosphorylated STAT1 forms STAT1 homodimers, which are
called the IFN-gamma activation factor (GAF). GAF translocates into the nucleus,
where it binds to γ-activated sequences (GAS) in the promoter region of ISGs and
induces their transcription [247]. Interestingly, many IFN-γ-induced ISGs them-
selves are transcription factors (e.g. IRF-1) and are therefore able to change the
transcriptional profile of an IFN-γ-activated cell [248].
Taken together, IFNs are important mediators of inflammation in innate immune
and non-immune cells through the induction of hundreds of ISGs. As a result of
ISG expression, invading pathogens are encountered at the site of cellular entry,
which limits pathogen spreading.
I. Introduction -29-
1.4 Inflammasomes
In 2002, Tschopp and co-workers were the first to coin the term inflammasome, to
describe a cytosolic, multiprotein complex formed by an inflammasome receptor,
the adaptor molecule apoptosis associated speck-like protein containing a CARD
(ASC) and caspase-1 [139]. The inflammasome is an important component of the
innate immune system and induces a strong immune response. As described for
other PRRs, each inflammasome receptor recognizes specific ligands or signals,
which induce receptor oligomerization (Figure I.3). The receptor oligomer serves
as a recruitment and oligomerization platform for the adaptor molecule ASC. ASC
forms long filaments, which aggregate into a one-micron large complex called the
ASC speck. The ASC speck then serves as an activation platform for caspase-
1 [249,250]. As described in chapter I, section 1.2, the four PRRs NLRP1, NLRP3,
NLRC4 and AIM2 as well as the protein pyrin have been shown to induce an in-
flammasome [249]. The inflammasome receptors sense a variety of different PAMPs
and DAMPs, for example bacterial flagellin, pore-forming toxins, cytosolic DNA,
extracellular ATP, uric acid crystals or the presence of intracellular bacterial ef-
fector molecules [251]. Upon activation, autoproteolytic cleavage of caspase-1 in
the inflammasome complex induces a lytic form of programmed cell death called
pyroptosis [139, 252]. Pyroptosis is morphologically distinct from other forms of
cell death, such as apoptosis or necroptosis, and is characterized by plasma mem-
brane rupture and the release of cytosolic content, cell swelling, positive Annexin
V staining, chromatin condensation and absence of DNA laddering and loss of
mitochondrial membrane potential [253, 254]. Cell lysis has an important role in
inflammasome-dependent immune activation as many DAMPs are released from
cells, which causes the inflammation to propagate to the surrounding. In addition
to inflammation, pyroptosis destroys the replicative niche of intracellular bacte-
ria and thereby exposes them to the extracellular milieu where they are primarily
killed by neutrophils [254,255].
Another hallmark of pyroptosis is caspase-1-dependent cleavage and release of in-
terleukin (IL)-1β and IL-18 [256]. IL-1β and IL-18 potently induce inflammation
and recruit additional immune cells to the site of infection. Moreover, IL-18 leads
to T and NK cell-dependent IFN-γ production [257].
Recently, Gasdermin-D has been discovered as the main driver of pyroptosis [258
260]. Caspase-1-dependent Gasdermin-D cleavage at aspartate D276 produces N-
terminal Gasdermin-D fragments that form membrane pores, which result in cell
lysis [261264]. More importantly, Gasdermin-D is specific to pyroptosis given
that only caspase-1, and not apoptotic caspases, efficiently cleaves Gasdermin-
D. Moreover, a few N-terminal Gasdermin-D fragments already induce pyropto-
sis [258260]. Interestingly, Gsdmd -deficient cells still induce pyroptosis at later
time points after inflammasome activation suggesting that there is another medi-
ator of inflammasome-dependent pyroptosis besides Gasdermin-D [259].
As inflammasome activation induces a strong immune response, ligand recogni-
tion and inflammasome assembly are tightly controlled. Importantly, deregulated
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inflammasome signaling is associated with a variety of autoimmune and autoin-
flammatory diseases, as well as an increased susceptibility to pathogenic infections,
making them a primary target for current research in innate immunity [249, 255].
In the next sections, the different inflammasome components and their regulation
are discussed in more details.
1.4.1 Inflammasome receptors
NLRC4
With respect to receptor activation, NLRC4 is the best-studied inflammasome (Fig-
ure I.3). NLRC4 has been identified to respond to bacterial flagellin [137,265,266],
however the needle and rod subunit of the bacterial type III secretions system
(T3SS) also activate NLRC4 [267, 268]. Interestingly, NLRC4 does not directly
bind its ligands via leucin rich repeats as described for TLRs, but uses upstream
sensors, so-called NAIPs, that have the ability to directly bind NLRC4 activa-
tors [269]. In mice, NAIP1 recognizes the T3SS needle protein, NAIP2 the T3SS
rod protein and NAIP5/6 flagellin [268, 270]. Humans only have one NAIP that
recognizes the T3SS rod protein [271]. However, it has been reported that a sec-
ond isoform called NAIP* exists in humans and this isoform recognizes bacterial
flagellin instead of the T3SS rod protein [272].
Besides the characterization of the exact ligands, structural analyses of NLRC4 ac-
tivation has resolved the receptor complex induced after ligand recognition. NLRC4
is structured in leucin rich repeats (LRRs), a central NOD oligomerization domain
and a CARD domain. Under steady state conditions, the LRRs inhibit NLRC4
by masking the central NOD oligomerization domain [273]. NAIP ligand binding
induces a conformational change in NAIP, which enables NAIP to serve as nucle-
ation surface for NLRC4 activation. NLRC4 forms a wheel- or disk-like structure
and its assembly works like the domino effect. The initially activated NAIP and
every newly activated NLRC4 in the growing receptor protomer serves as new
nucleation surface for the next NLRC4 molecule. Importantly, activated NAIPs
cannot activate a second NAIP protein, therefore the resulting NAIP-NLRC4 pro-
tomer contains one single NAIP and 9-11 NLRC4 molecules [274276]. On top of
the NAIP-NLRC4 protomer, the NLRC4 CARD domains recruit ASC leading to
ASC oligomerization. In contrast to NLRPs, NLRC4 can directly recruit caspase-1
through its CARD domain. However, as this caspase-1 recruitment is sufficient for
cell death, IL-1β release is completely ASC-dependent [277].
NLRC4 activation is not only ligand-dependent but also relies on post-translational
modifications. It has been shown that NLRC4 phosphorylation at S533 in the NOD
domain by protein kinase C (PKC) is important for NLRC4 activation in response
to Salmonella but not Shigella infections [278, 279]. How this phosphorylation in-
fluences the activation of NLRC4 and why this only works for Salmonella but not
Shigella remains unclear.
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Taken together, NAIPs bind bacterial ligands to induce an NLRC4 inflammasome
to fight bacterial infections. The conformational switch from auto-inhibited to the
active NLRC4 protomer is the major regulatory step in NLRC4 inflammasome ac-
tivation. Thus, interfering with NLRC4 auto-inhibition might lead to a constitutive
active NLRC4, resulting in sustained inflammation. Indeed, gain of function muta-
tions resulting in a constitutive active NLRC4 cause a recurrent autoinflammatory
disease called macrophage activation syndrome (MAS) [280282].
NLRP3
NLRP3 is by far the most studied inflammasome receptor and consists of LRRs,
a central NOD oligomerization domain and an effector pyrin (PYD) domain (Fig-
ure I.3). NLRP3 has been discovered as inflammasome receptor in the context
of bacterial infections [140]. Today, more than 30 different PAMPs and DAMPs
are known to activate NLRP3, including uric acid crystals, silica, asbestos, alum,
extracellular ATP, pore-forming toxins, dysfunctional mitochondria, phagosomal
damage, RNA-DNA hybrids as well as several viral, bacterial, fungal and protozoan
pathogens [249,250]. As these triggers are very diverse, it is still unclear how NLRP3
recognizes all these different stimuli. However, it has been shown that almost all
NLRP3 activators induce the release of intracellular potassium [283]. Therefore
NLRP3 can be seen as a "guardian" of cell integrity. Nevertheless, whether NLRP3
directly senses low levels of intracellular potassium or whether another sensor is
required for NLRP3, remains unknown. Over the years, several proteins including
GBP5, PKR and SHP have been shown to directly bind to and influence NLRP3
inflammasome activation [284286]. However, the involvement of GBP5 and PKR
in NLRP3 activation could not be reproduced in other studies [287, 288]. Thus it
is questionable at the moment whether these identified proteins influence NLRP3
activation or not.
Recently, three independent groups have reported a critical role for NIMA-related
kinase 7 (NEK7) in NLRP3 oligomerization downstream of potassium eux [289
291]. Moreover they have shown direct interaction between NEK7 and NLRP3.
Whether NEK7 is the potassium eux sensor and the initiator of NLRP3 oligomer-
ization in a similar way to NAIP proteins in the NLRC4 inflammasome has not
been adressed by these studies and could shed light on how NLRP3 is activated.
Besides NLRP3 regulation through direct interaction partners, NLRP3 activation
is regulated by posttranslational modifications. TLR signaling upregulates the ex-
pression of NLRP3 and induces NLRP3 deubiquitination by the Lys63-specific
deubiquitinase BRCC3, which is critical for NLRP3 activation [292].
A better understanding of the activation and regulation of NLRP3 is especially
important as NLRP3 is associated with many autoinflammatory and autoimmune
diseases [293]. NLRP3 mutations are found in cryopyrin-associated periodic syn-
droms (CAPS), where NLRP3 mutations lead to NLRP3 hyperactivation which
results in recurrent fever and inflammation [294, 295]. Another autoinflammatory
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disease where metabolic changes lead to the deposition of uric acid (MSU) crystals
in the joints, is gout [296]. These MSU crystals activate the NLRP3 inflammasome,
which causes severe joint inflammation and pain [297]. Moreover, type 2 diabetes
is associated with NLRP3 activation, which leads to obesity-induced inflammation
and cell death of pancreatic β-cells. As a consequence, these patients get glucose
tolerant and insulin insensitive [298,299].
Taken together, NLRP3 is activated by more than 30 different PAMPs and DAMPs,
which are all related to the metabolic state of the cell. Even though a lot of re-
search has been directed to the discovery of the NLRP3 activation mechanism, it
is still unclear how NLRP3 senses all these different stimuli and what the structure
of an activated NLRP3 receptor complex is. However, understanding the NLRP3
activation mechanism and the composition of the NLRP3 inflammasome complex
is of particular importance as NLRP3 is involved in many autoinflammatory and
autoimmune diseases.
AIM2
AIM2 recognizes cytosolic and microbial double stranded DNA (dsDNA) [162164]
and plays therefore an important role in the host defense against various viruses
and intracellular bacteria such as Listeria or Francisella (Figure I.3) [300303].
AIM2 has a N-terminal pyrin (PYD) and a C-terminal HIN200 domain but lacks
a NOD domain for self-oligomerization [165]. Therefore AIM2 activation is fun-
damentally different compared to activation of NLRC4, and the receptor complex
formed by AIM2 most likely differs from the wheel-like shape of the NAIP-NLRC4
complex. The HIN200 domain binds to four base pairs in the big DNA groove and
several HIN200 domains form filaments around dsDNA [304]. The long linker be-
tween the HIN200 and PYD domain suggests that the PYD domains from several
DNA-bound AIM2 molecules form a PYD complex that serves as starting point
for ASC oligomerization [165,304].
AIM2 is not only activated during pathogenic infections, but is also involved in
cancer development. Reduced cellular AIM2 levels are associated with prostate
or colorectal cancer development. Cancer cells are thought to have a discontinued
nuclear envelope as a result of their high division rate. As a consequence of a discon-
tinued nuclear envelope, cytosolic AIM2 has access to nuclear DNA and thereby
would induce inflammasome-dependent cancer cell death [305308]. In addition,
increased AIM2 expression is associated with autoimmune diseases like psoriasis,
abdominal aortic aneurysm and systemic lupus erythematosus [309311]. As shown
for psoriasis, it is very likely that the different autoimmune diseases are linked to
the recognition of self-DNA in the cytosol [311].
Taken together, AIM2 recognizes cytosolic dsDNA in the context of viral and bacte-
rial infections. Moreover, AIM2 is involved in cancer development and autoimmune
diseases, most likely through the recognition of mislocalised self-DNA in the cy-
tosol [312].
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Figure I.3 Overview of canonical inflammasome activation. Activated canonical inflam-
masome receptors recruit the adaptor molecule ASC, which oligomerizes and forms a large mul-
tiprotein complex called the ASC speck. The ASC speck then recruits pro-caspase-1, which is
activated by auto-proteolysis. Active caspase-1 cleaves Gasdermin-D and processes the cytokines
pro-IL-1β and pro-IL-18 to their mature form. The N-terminal Gasdermin-D fragment induces
pyroptosis, a lytic form of cell death, and thereby releases IL-1β and IL-18. (a) Pyrin is activated
upon dephosphorylation, which result from bacteria-induced RHOA inactivation. (b) NLRP3
is activated by over 30 different stimuli, which results in a decrease in intracellular potassium.
NLRP3 activation requires NEK7 binding. (c) NAIP proteins directly recognize flagellin, and the
needle and rod subunit of the bacterial T3SS. The activated NAIP recruits and activates NLRC4
(d) AIM2 recognizes cytosolic host or microbial double stranded DNA (dsDNA). T6SS, Type
6 secretion system; PYD, pyrin domain; CARD, Caspase recruitment domain; CC, coiled coil;
P2X7, P2X purinoceptor 7; ROS, reactive oxygen species; mtDNA, mitochondrial DNA; LRR,
Leucin rich repeat; NOD, Nucleotide-binding oligomerization domain; NLRP3, NACHT, LRR
and PYD (NLR)-containing protein 3; NEK7, NIMA-related kinase 7; T3SS, Type 3 secretion
system; NAIP, NLR family, apoptosis inhibitory protein; BIR, Baculovirus inhibitor of apoptosis
protein repeat; NLRC4, NACHT, LRR and CARD-containing protein 4; CMV, Cytomegalovirus;
GBP, Guanylate binding proteins; AIM2, Absent in melanoma 2; IL, Interleukin. Adapted from
Broz and Dixit [249].
Pyrin
Pyrin (also called TRIM20) is encoded by theMEFV gene [249] and is structured in
a pyrin (PYD) domain, two B-boxes and one coiled coil domain in mice. In contrast
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to mice, human pyrin contains a C-terminal B30.2 domain (Figure I.3). Mutations
in this B30.2 domain are associated with the autoinflammatory disease Familial
Mediterranean Fever (FMF) in humans. Two independent groups have reported
that pyrin acts as a negative regulator of other inflammasomes, as FMF is induced
by loss of function mutations in the B30.2 domain [313, 314]. Indeed supportive
data for this hypothesis was published in 2015 showing direct interaction of pyrin
with NLRP1 and NLRP3 via B30.2 domain. This interaction leads to autophagic
degradation of the proteins, which inhibits the inflammasomes [315]. However, a
second hypothesis to explain the FMF phenotype has been proposed on the ob-
servations that gain of function mutations in the B30.2 domain lead to excessive
caspase-1 activation and IL-1β release [316]. Data supporting the second hypoth-
esis was published in 2014 showing that pyrin itself forms an inflammasome [317].
Therefore, it is very likely that FMF results from a constantly activated pyrin in-
flammasome due to gain of function mutations in the B30.2 domain rather than
loss of NLRP1 and NLRP3 inhibition [317].
Even though it was shown in 2014 that pyrin activates an inflammasome, its acti-
vation mechanism was under debate. It has been shown that pyrin recognizes the
inactivation of RHOA, which is a member of the small GTPase family responsible
for actin polymerization. RHOA inactivation occurs through RHOA modifications
induced by bacterial Clostridium difficile toxin B or effector proteins of the bac-
terial T6- and T3SS [317,318]. Interestingly, pyrin does not recognize inactivation
of RAC or CDC42, two close homologs of RHOA. Moreover, it has been reported
that pyrin and ASC are localized to actin rich regions. In addition, pyrin has been
shown to detect aberrations in actin depolymerization as a result of RHOA inacti-
vation [293,319]. Given that pyrin gets activated irrespective of the type of RHOA
modification and localizes to actin [317], it is likely that instead of direct RHOA
modification sensing, pyrin detects downstream consequences of RHOA inactiva-
tion related to altered actin dynamics. As mouse and human pyrin detect RHOA
inactivation and mice are lacking the B30.2 domain, it is unlikely that this domain
is responsible for actin-dependent pyrin activation.
In 2016, Park and colleagues resolved the activation mechanism of pyrin [320].
Under steady state conditions, pyrin is phosphorylated by kinases downstream of
RHOA, which enables 14-3-3 protein binding and thereby pyrin inhibition. Upon
bacterial infections, their effectors or toxins inactivate RHOA, which consequently
results in pyrin de-phosphorylation and thereby its activation. In line with these
observations, S242A gain of function mutations are associated with another pyrin-
related autoinflammatory disease called pyrin-associated autoinflammation with
neutrophilic dermatosis [321].
Taken together, pyrin is inhibited through constant phosphorylation by down-
stream kinases of RHOA. Upon bacteria-induced RHOA inactivation, pyrin phos-
phorylation is blocked and therefore it can assemble an inflammasome. However, it
remains unclear what role the B30.2 domain has in inflammasome activation and
induction of autoinflammatory diseases like FMF and pyrin-associated autoinflam-
mation with neutrophilic dermatosis.
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1.4.2 ASC
The apoptosis associated speck-like protein containing a CARD (ASC) consists of
two domains, namely CARD and pyrin (PYD) [322]. All activated inflammasome
receptor protomers generate a nucleation site for ASC recruitment and oligomer-
ization. ASC recruitment to the receptor oligomer happens through PYD-PYD
homotypic interactions with the PYD domains of NLRP1, NLRP3, AIM2 and
pyrin [323, 324]. Once ASC has been recruited by the receptor oligomer, the ASC
PYD domains form long three start helical filaments, while the CARD domains
on the surface of the PYD filaments serve as recruitment domains for caspase-1.
In addition, the ASC CARD domains nucleate the different ASC PYD filaments
into a single, macromolecular complex called the ASC speck [277,325]. Mutations
in the PYD domain that abrogate filament formation are completely deficient in
cell death and IL-1β release, thereby highlighting the importance of ASC speck
formation for inflammasome signaling [277,325].
Regarding NLRC4, the situation is a bit different, as NLRC4 possesses a CARD
instead of a PYD domain. Therefore, activated NLRC4 can directly recruit and
activate caspase-1. Indeed cell death is not diminished in Asc-deficient compared
to wild-type macrophages when treated with NLRC4-specific activators [252,266],
however IL-1β release is dramatically reduced. This shows that the ASC speck is
essential for efficient caspase-1 activation and IL-1β release [252,266]. Most likely,
the first ASC bind to the CARD domain of NLRC4 thereby providing its PYD do-
main for ASC oligomerization. This is supported by a paper of Dick and colleagues,
who have shown that caspase-1-dependent Gasdermin-D cleavage as a prerequisite
for cell death is not affected in Asc-deficient macrophages, while IL-1β cleavage
is dramatically reduced [277]. Thus, the ASC speck enables signal amplification
from small and local ligand concentrations to the production of large amounts of
active cytokines. In the case of NLRC4 activation, one ligand molecule bound to
one NAIP protein induces a robust immune response [249].
As ASC oligomerization is such a potent inducer of inflammation, ASC activation
is tightly regulated. For example, ASC is phosphorylated by SYK and JNK at mul-
tiple sites and this phosphorylation is required for caspase-1 activation [326, 327].
Moreover, IKKα acts as a negative regulator of ASC oligomerization by localizing
ASC to the nucleus and thereby sequestering ASC away from the inflammasome
receptors in the cytosol. IKKα-dependent ASC phosphorylation is required for
IKKα binding to ASC [328]. Besides ASC phosphorylation, a recent report has
shown critical ASC deubiquitination by USP50 for ASC speck formation [329]. In
addition to mice, humans express pyrin only proteins (POPs) that bind to ASC
and inhibit ASC speck formation [330332].
Taken together, inflammasome receptor-dependent ASC oligomerization induces
the formation of a cytosolic complex called ASC speck. The ASC speck efficiently
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activates caspase-1 to produce large amounts of mature IL-1β and IL-18. To reg-
ulate ASC speck formation, various post-translation modifications have been de-
scribed. However, it is still unclear what components are part of the ASC speck;
except ASC, the inflammasome receptor and caspase-1. Thus the ASC speck serves
as signal amplification step to transform a local, small amount of ligand into a
global immune response.
1.4.3 Caspase-1
The term caspase was first introduced in 1996 where the "C" refers to cysteine
protease and "aspase" to the ability to cleave proteins after an aspartate [333].
However, today caspase is better known for Cysteine-dependent aspartate-directed
protease. Caspases are divided into two groups: apoptotic and inflammatory cas-
pases. Apoptotic caspases are involved in the execution of a immunologically silent
form of cell death called apoptosis. They include the initiator caspase-2, -8, -9
and -10 and the executioner caspase-3, -6 and -7. Inflammatory caspases include
caspase-1, -4, -5, -11 and -12 in humans, where caspase-11 is expressed in mice
and caspase-4 and -5 in humans only [334]. All inflammatory caspases except for
caspase-12 are activated by known inflammasomes [139]. However, we cannot ex-
clude that caspase-12 is activated by a yet to be discovered inflammasome.
In 1989, caspase-1 was first described to cleave IL-1β into its active form, there-
fore it was initially named IL-1β-converting enzyme (ICE) [335,336]. Caspase-1 is
expressed as an inactive pro-form and contains a CARD domain. The ASC speck
recruits pro-caspase-1 via CARD-CARD interactions, bringing two pro-caspase-1
molecules into close proximity. Consequently, pro-caspase-1 is auto-proteolytically
cleaved into the CARD, p20 (including the catalytic cysteine) and p10 subunit. Ac-
tive caspase-1 dissociate from the ASC speck and forms a heterodimeric cysteine
protease that is composed of two p20 and two p10 subunits [252,256]. Caspase-1 has
two main functions in cells. On one hand, caspase-1 induces pyroptosis through the
cleavage of Gasdermin-D and on the other hand processes the cytokines pro-IL-1β
and pro-IL-18 into their mature form. Interestingly, even though the active cysteine
of caspase-1 is essential for both pyroptosis and cytokine processing, a caspase-1
uncleavable mutant still induces pyroptosis but not cytokine processing [252].
Taken together, inflammasomes activate caspase-1, which cleaves intracellular sub-
strates including Gasdermin-D, IL-1β and IL-18. Thus, caspase-1 executes pyrop-
tosis and activates IL-1β and IL-18, both leading to the propagation of the immune
response.
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1.4.4 Interleukin-1β / Interleukin-18
The interleukin (IL) family is composed of 11 soluble members: IL-1α, IL-1β, IL-1
receptor agonist (IL-1Ra), IL-18, IL-33 and IL-1F5, -6, -7, -8, -9 and -10 [337]. IL-1
family members have a huge impact on immune response progression and are the
main drivers of inflammation.
The best characterized IL-1s are IL-1β and IL-18, which propagate inflammation
by binding to and thereby activating the plasma membrane receptors IL-1 receptor
1 (IL-1R1)/IL-1 accessory protein (IL-1RAP) and IL-18R/IL-18RAP, respectively.
IL-1R1/IL-18R signaling activates the NF-κB and MAPK pathway in a MYD88-
dependent manner, which induces the expression of pro-inflammatory genes as
described in chapter I, section 1.2.1. Interestingly, whereas IL-1α, IL-33 and IL-
1Fs are expressed as active molecules, IL-1β and IL-18 are expressed as an inactive
pro-form. To obtain the active cytokines, pro-IL-1β and pro-IL-18 are cleaved by
caspase-1 upon inflammasome activation [139,338].
All IL-1 family members, except for IL-1Ra, are expressed without a classical signal
peptide for ER/Golgi-dependent secretion [339]. Therefore, it is unclear through
which mechanism the IL-1 cytokines are released from cells. IL-1β and IL-18 are
shown to be secreted in a caspase-1-Gasdermin-D-dependent manner as IL-1β se-
cretion but not IL-1β processing is impaired in GsdmD-deficient cells [258, 260].
Thus it might be that the IL-1 cytokines are passively released upon inflammasome-
dependent cell death.
Given that IL-1β and IL-18 are potent pro-inflammatory cytokines, they are reg-
ulated at many stages. First, they are expressed in an inactive pro-form and re-
quire inflammasome-dependent maturation. Second, IL-1Ra competes with IL-1β
for IL-1R binding, whereas IL-R2 binds to IL-1RAP at the plasma membrane and
thereby sequestering IL-1RAP from IL-1R1 [340, 341]. Third, IL-18 binding pro-
tein (IL-18BP) competes with IL-18 for IL-18R binding [342]. In all three cases,
IL-1β and IL-18 receptor signaling is blocked and therefore prevents inflammation
to propagate.
Many auto-inflammatory diseases, including different forms of arthritis, various in-
flammatory skin diseases, multiple sclerosis, systemic lupus erythematosus, asthma,
Crohn's disease and ulcerative colitis, are associated with either elevated levels of
active IL-1β and IL-18 in the circulation or excessive IL-1R signaling, [339]. Thus,
there is an urgent need to better understand inflammasome activation, which could
lead to the identification of mechanisms to block or decrease IL-1β and IL-18 mat-
uration and thereby interfering with these severe and persistent diseases.
1.4.5 The non-canonical inflammasome
In contrast to the previously described canonical, caspase-1-activating inflamma-
somes, a non-canonical inflammasome was discovered in 2011 and was shown to ac-
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Figure I.4 Overview of the non-canonical inflammasome activation. Caspase-11 is acti-
vated by direct binding of bacterial LPS. Active caspase-11 cleaves Gasdermin-D. The N-terminal
Gasdermin-D fragment induces pyroptosis, a lytic form of cell death. GBPs facilitate caspase-
11-dependent LPS recognition from vacuolar bacteria such as Salmonella. Moreover, caspase-11
activates the canonical NLRP3 inflammasome, which lead to caspase-1 activation and conse-
quently IL-1β and IL-18 maturation and release. LPS, Lipopolysaccharide; PYD, pyrin domain;
CARD, Caspase recruitment domain; NLRP3, NACHT, LRR and PYD-containing protein 3;
GBP, Guanylate binding protein; IL, Interleukin. Adapted from Broz and Dixit [249].
tivate caspase-11 in mice (or caspase-4/-5 in humans) (Figure I.4) [343]. Caspase-11
activation is the main driver of bacteria-induced septic shock and thus LPS-induced
lethality, which is a major cause of death worldwide [258,259,344,345]. In contrast
to receptor-dependent caspase-1 activation, caspase-11 activation requires direct
binding to intracellular LPS [346]. Active caspase-11 cleaves Gasdermin-D but
not IL-1β or Il-18, thereby inducing cell death but not cytokine release. However,
caspase-11 activates the canonical NLRP3 inflammasome, which then processes
IL-1β and IL-18 through caspase-1 activation. Caspase-11-dependent NLRP3 ac-
tivation requires potassium eux, which is most likely induced by caspase-11-
dependent cell death [343, 347349]. Moreover, caspase-11 is transcriptionally ac-
tivated by TLR signaling. In the context of a bacterial infection, expression of
interferon-stimulated genes is required for caspase-11-dependent recognition of cy-
tosolic LPS [350, 351]. As described in research article IV in chapter V, section 1,
we show that IFN signaling induces the expression of guanylate binding proteins
(GBPs), which in turn exposes bacterial LPS to caspase-11 in the cytosol [288].
However the exact mechanism of LPS presentation to caspase-11 is not fully un-
derstood.
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Taken together, caspase-11 activation upon cytosolic LPS binding induces the non-
canonical inflammasome, which is the main driver of septic shock, a major contribu-
tor to bacteria-induced lethality worldwide. However, it is still not fully understood
how LPS activates caspase-11 in vivo. For a better understanding of septic shock,
it is essential to study the mechanism of LPS presentation to caspase-11 in more
details. Notably, mice are six orders of magnitude more resistant to septic shock
than humans due to lower LPS sensitivity [352]. Thus, results from murine septic
shock models require careful considerations when conclusions are drawn and trans-
lated to humans.
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2 Intracellular bacterial pathogens
As described in chapter I, section 1.1, innate immune cells are one of the first
detectors of invading pathogens and have the ability to efficiently kill them. As
described in chapter I, section 1.2, innate immune cells are equipped with pattern
recognition receptors (PRRs) to detect invading pathogens and to induce an im-
mune response.
Monocytes, tissue-resident macrophages and neutrophils are professional phago-
cytes and efficiently kill bacterial pathogens. Upon surface receptor-dependent bac-
terial recognition, these three innate immune cell types take up bacteria, a process
that is called phagocytosis [10]. Phagocytosis encloses the bacteria in a host-derived
vacuolar compartment called the phagosome, which subsequently matures into a
phagolysosome through lysosomal fusion events. Lysosomes contain bactericidal
proteases like cathepsins, which are exposed to the bacteria after phagosomal fu-
sion and thereby degrade the contents of phago-lysosomes, such as internalized
pathogens [353]. Moreover, along the maturation process, the phagosome acidifies
to a pH of around 5.5 by the V-ATPase, which pumps protons into the phagosome.
Phagosomal acidification not only inhibits pathogen growth, but also enhances the
killing capacity of lysosomal molecules and provides substrates for the generation
of reactive oxygen species (ROS) [354].
The nicotinamine adenine dinucleotide phosphate oxidase (NADPH oxidase) com-
plexes incorporate into the phagosomal membrane and produce short-lived reac-
tive oxygen species (ROS), such as O2
- [33]. In the phagosome, O2
- is converted
by superoxide dismutase and myeloperoxidase into hydrogen peroxide (H2O2) and
hypochlorous acid (HOCl), respectively [353,355]. ROS are powerful oxidants that
cause DNA, membrane lipid and protein damage thereby harming the bacte-
ria [33]. Reactive nitrogen species (RNS) are another radical class that are pro-
duced in phagosomes. They are generated by the inducible nitric oxide (NO) syn-
thase (iNOS), which produces NO. NO is further transformed into peroxynitrate
(ONOO-) upon reaction with ROS [356]. RNS interfere with DNA replication and
inactivate zinc- and metalloproteins, thereby inhibiting bacterial duplication and
respiration, respectively [356].
In addition to ROS and RNS production, phagosomes acquire bactericidal metals
such as copper and zinc [357].
Additionally, in neutrophils, antimicrobial peptides (AMPs)-containing granules
fuse with phagosomes. AMPs are a diverse group of molecules, which target bacte-
rial membranes to induce bacteriolysis. They include defensins, cathelicidins, endo-
and exopeptidases, lysozymes, cathepsins and matrix metalloproteases [353].
Even though the phagosome is very efficient in bacterial killing, intracellular bac-
teria such as Salmonella or Mycobacterium have developed diverse mechanisms to
resist or avoid killing within phagosomes and they can even remodel the phago-
some into a replicative niche. In these cases, phagocytes can sequester important
bacterial nutrients like essential amino acids or iron away from the phagosome and
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thereby inhibit or decrease intracellular bacterial replication [33,358].
Escape from the phagosome into the cytosol of phagocytes might seem an ideal
solution to avoid phago-lysosomal degradation, yet only a minority of intracellu-
lar bacterial pathogens uses this strategy. The reason for this is most likely that
the cytosol features many additional bacterial killing mechanisms as well as many
pattern recognition receptors that alert cells of bacterial presence, and even might
induce host cell death. For example it has been shown that phagocytes sequester
nutrients in cellular compartments that are not accessible for the bacteria, thereby
reducing bacterial replication [358]. Furthermore, bacterial replication is restricted
by autophagy, an intracellular protein degradation process that can also engulf cy-
tosolic bacteria in a process called xenophagy. Xenophagy is initiated by autophagy
cargo receptors that recognize ubiquitin chains, which are added to the bacterial
surface by cytosolic ubiquitin ligases [359]. Moreover, autophagy cargo receptors
recognize galectin-8, which binds to β-galactosides that are exposed to the cytosol
upon phagosomal damage. Xenophagy-dependent bacterial engulfment results in
autophagosome formation, which then fuses with lysosomes to kill the engulfed
bacteria.
Another cytosolic bacterial killing mechanism is mediated by GBP-dependent bac-
terial lysis and described in great details in research articles IV and V in chapter
V, section 1. Moreover, inflammasome activation results in cell death and thereby
destruction of the bacterial replicative niche and consequently the exposure of the
bacteria to other innate immune cells [251,254].
Taken together, phagocytes are the most potent bacterial killers of the innate im-
mune system. They are equipped with an arsenal of mechanisms to eradicate bac-
teria. However, bacteria have developed mechanisms to interfere with the cellular
killing machineries by either resisting the applied stress, actively neutralizing the
bactericidal molecules or blocking the induction of the cellular killing machinery to
use phagocytes as replicative niche. In the next sections, two bacterial pathogens
and their different approaches to use phagocytes as their replicative niche are de-
scribed in more details.
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2.1 Salmonella
Salmonellae are Gram-negative, intracellular bacteria with a wide host range. The
species Salmonella enterica includes more than 2500 serovars distinguished by their
LPS and flagellar antigens [360,361]. Salmonella enterica subsp. enterica serovars
account for most of the Salmonella-associated health problems and induce three
distinct diseases in humans: typhoid fever, gastroenteritis and bacteremia.
Salmonella enterica subsp. enterica serovar Typhi (hereafter S. Typhi) and Paraty-
phi are human-restricted pathogens and cause the systemic disease typhoid fever
[360,361]. More than 20 Million cases of typhoid fever are counted annually result-
ing in more than 400'000 deaths per year [362].
In contrast to S. Typhi, non-typhoidal Salmonella (NTS) serovars Enteritidis and
Typhimurium (hereafter S. Typhimurium) are the major causes of gastroenteri-
tis in immunocompetent and bacteremia in immunocompromised humans. Around
90 Million humans suffer from NTS-induced gastroenteritis with around 150'000
deaths annually [363], whereas NTS-induced bacteremia is commonly observed in
HIV-positive adults or African children already burdened by malaria or malnutri-
tion. Out of 100'000 children in Sub-Saharan Africa, 300 develop NTS bacteremia
with 200'000 child deaths annually [364,365]. Thus, the overall Salmonella burden
combining typhoid fever, gastroenteritis and bacteremia leads globally to a Million
deaths a year. This mortality rate is most likely an underestimate as exact num-
bers from the rural African areas are missing and all healthy 16 month old children
in Malawi have detectable Salmonella-specific antibodies, indicating an universal
exposure of new born children to Salmonella in Africa [363,366].
Salmonella infections are mostly associated with poor hygiene standards, as Sal-
monella infects humans orally by contaminated food or water. Once in the small
intestine, NTS and typhoidal Salmonella differ in their dissemination. Importantly,
NTS-induced gastroenteritis is restricted to acute intestinal inflammation without
dissemination beyond the gastrointestinal tract, whereas NTS-induced bacteremia
and S. Typhi-induced typhoid fever is a chronic infection associated with bacterial
dissemination beyond the gastrointestinal tract.
In the case of NTS-induced gastroenteritis, a small proportion of luminal S. Ty-
phimurium induces their uptake into epithelial cells of the small intestine by using
the Salmonella pathogenicity island 1 (SPI-1) type 3 secretion system (T3SS-1)
or they are taken up by M cells [367]. The T3SS-1 injects an arsenal of effector
proteins into epithelial cells to induce actin rearrangement and membrane ruing,
leading to the engulfment and cellular uptake of S. Typhimurium [368,369]. Besides
inducing bacterial uptake, T3SS-1 effectors actively promote intestinal inflamma-
tion by inducing the production of the cytokine IL-8 in epithelial cells [370, 371].
As a consequence, IL-8 facilitates transepithelial migration of neutrophils from
the lamina propria into the intestinal lumen, where they produce ROS. ROS con-
verts microbiota-derived thiosulfate into tetrathionate, which is used by Salmonella
but not the microbiota as electron acceptor during anaerobic or microaerophilic
growth [372]. Moreover, intestinal inflammation results in the production and
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luminal secretion of lipocalin 2. Lipocalin 2 sequesters the microbiota-derived
siderophore enterochelin but not the Salmonella-derived siderophore salmochelin.
Siderophores bind to iron and then are taken up by the bacteria to metabolite iron.
Thus, Salmonella starve the microbiota from iron [373]. The consequence of Sal-
monella-induced inflammation is a growth advantage of Salmonella in the lumen of
the small intestine relative to the microbiota, thereby subsequently outcompeting
the microbiota.
Once Salmonella has penetrated into epithelial cells, it resides in the phagosome
and secretes effector proteins of a second T3SS encoded on SPI-2 (T3SS-2) to mod-
ify the phagosome into a so called Salmonella containing vacuole (SCV) [374]. The
SCVmodifications include changes in its cholesterol, phospholipid and protein com-
position [375378]. In addition, T3SS-2 effectors induce the coupling of the SCV to
the microtubule network to enable intracellular movement of the SCV [379, 380].
Moreover, switching from T3SS-1 to T3SS-2 expression has an anti-inflammatory
effect. The T3SS-2 reduce the delivery of NLRC4 activators into the cell and T3SS-2
effectors actively block cytosolic pro-inflammatory signaling cascades [381384]. All
these mechanisms help Salmonella to establish an intracellular, vacuolar replicative
niche to survive in epithelial cells.
Whereas S. Typhimurium induces gastroenteritis in immunocompetent humans,
S. Typhimurium induces severe bacteremia in mice. Therefore, S. Typhimurium is
used as a mouse model for bacteremia in immunocompromised humans [385]. In
NTS-induced bacteremia, S. Typhimurium infects the host orally, as seen for NTS-
induced gastroenteritis, ending up in the small intestine, where S. Typhimurium
crosses the epithelial layer and disseminates via the blood stream into multiple
organs, such as the liver and spleen [386]. There, S. Typhimurium infects macro-
phages and establishes an SCV as described for epithelial cells.
However, once S. Typhimurium has crossed the epithelial layer, it is detectable
by soluble components of the innate immune system. Indeed, reactive hydroxyl
groups in the O-antigen repeat units of LPS activate the complement component
C3 leading to the deposition of C3b on the bacterial surface, which favors bacterial
phagocytosis by immune cells [387, 388]. As described in chapter I, section 1, the
complement system induces bacteriolysis via insertion of a membrane attack com-
plex into the bacterial membrane. However, S. Typhimurium avoids complement-
dependent lysis by the expression of long O-antigen chains. The long O-antigens
create a physical distance between the deposited membrane attack complex and the
bacterial outer membrane, thereby avoiding its destruction [389,390]. Nevertheless,
the soluble complement component C5a, which is produced during complement ac-
tivation, attracts neutrophils to the site of infection and enhances LPS-dependent
TLR4 signaling in monocytes, thereby favoring bacterial killing at the infection
site [391,392].
Once S. Typhimurium has crossed the epithelial layer, it downregulates the ex-
pression of flagellin and the T3SS-1, thereby avoiding flagellin-mediated, TLR5-
dependent immune activation. Indeed, TLR5 has a minor effect in immune detec-
tion of S. Typhimurium, whereas TLR2, TLR4 and TLR9 are the major inducers
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of inflammation in NTS-induced bacteremia [393, 394]. Furthermore, downregula-
tion of flagellin and the T3SS-1 components PrgJ and PrgI reduces the activation
of the NLRC4 inflammasome by intracellular S. Typhimurium [267,395], and thus
might specifically serve to avoid detection during the systemic phase of the dis-
ease. However, intracellular S. Typhimurium LPS still activates the non-canonical
inflammasome in a GBP-dependent manner, thus leading to cell death and cytokine
maturation [288, 351]. Inflammasome-dependent cell death upon S. Typhimurium
infection has a beneficial role for the host because cell death destroys the replicative
niche of Salmonella and exposes the bacteria to neutrophils, which are the most
potent bacterial killers [396]. The role of GBPs in non-canonical inflammasome
activation is described in research article IV in chapter V, section 1.
In contrast to NTS-induced local, self-limiting gastroenteritis characterized by di-
arrhea and abdominal pain, S. Typhi induces a chronic and relapsing infection
called typhoid fever in healthy humans [360,361]. S. Typhi uses the same infection
route as S. Typhimurium and crosses the epithelial layer in the small intestine to
disseminate into the body. However, the first signs of typhoid fever occur around 2
weeks after the initial infection [397,398]. During the first two weeks of infection, S.
Typhi evades immune recognition in the small intestine and the blood stream due
to several additional virulence mechanism that it has acquired and due to a loss
of certain genes that are normally present in gastroenteritis-inducing Salmonella.
The most important gene acquisition is the viaB locus located on SPI-7, which en-
codes 10 genes that are important for the regulation, biosynthesis and export of the
virulence-associated (Vi) capsular polysaccharide [399, 400]. Vi capsular polysac-
charides cover the bacterial surface and have no free hydroxyl groups, therefore the
complement system cannot be activated [401]. In contrast to S. Typhimurium, S.
Typhi expresses shorter LPS O-antigens that are entirely shielded by Vi capsular
polysaccharides [402]. Moreover, the SPI-7-encoded protein TviA represses T3SS-1
and flagella expression in conditions of low osmolarity that is present in the intesti-
nal mucosa. Therefore S. Typhi is becoming stealthy as soon as it transmigrates
through the epithelial layer [403, 404]. Besides this major differences between S.
Typhi and S. Typhimurium, effector proteins important in establishing gastroen-
teritis in S. Typhimurium infections are absent or present as pseudogenes in S.
Typhi, which might contribute to the difference in disease outcome [405,406].
In summary, Salmonella enterica induce gastroenteritis, bacteremia or typhoid
fever depending on the serovar and humans health. Salmonella infections contribute
heavily to the worldwide burden of gastrointestinal diseases and bacteria-caused
death, especially in immunocompromised adults and children in the developing
world. Thus, understanding the Salmonella-host interplay between immune recog-
nition of the host and immune evasion by Salmonella might help to develop new ap-
proaches for reducing the global burden of Salmonella infections. S. Typhimurium
is a model organism for intracellular, vacuolar bacterial pathogens, especially in
the field of innate and cell-autonomous immunity. However, the mouse models es-
tablished with S. Typhimurium do not completely resemble the in vivo situation
in humans and besides, mice cannot be infected with S. Typhi [407,408]. Thus the
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interpretation of experimental findings done in mice and the resulting conclusions
for a human infection require careful consideration.
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2.2 Francisella
Francisella tularensis is a Gram-negative, intracellular bacterial pathogen; it is
highly infectious and causes the zoonotic disease tularemia, which is characterized
by fever, aches and signs of toxicity lasting for several days. In humans, the mor-
tality rate of untreated pneumonic tularemia reaches up to 60 % [409]. Francisella
tularensis is divided into 4 subspecies (subsp.), where subsp. tularensis (F. tularen-
sis ; also known as type A) and subsp. holarctica (F. holarctica; also known as type
B) are the most virulent ones in humans. In contrast to F. tularensis, Francisella
tularensis subsp. novicida (F. novicida) causes tularemia in immunocompromised
humans, however, it is highly virulent in mice [410412]. Thus F. novicida is used
as a mouse model to study tularemia. The fourth subspecies is Francisella medi-
asiatica and causes an intermediate disease phenotype in humans [413].
Francisella tularensis transmits by terrestrial and aquatic mammals, amoebae or
arthropods; or via inhalation of infectious aerosols. Arthropod transmission is
thought to be the dominant route between animals but also between animals and
humans [414,415]. Due to its high virulence, high morbidity and ease of transmis-
sion, the US centers for Disease Control and Prevention classified F. tularensis as
a Tier 1 select agent because of its potential to become a bioterrorist weapon [416].
Upon oral, subcutaneous or pneumonic transmission, Francisella tularensis mostly
infects phagocytes, where they survive and replicate (Figure I.5) [417]. As Fran-
cisella tularensis cannot trigger its own uptake, opsonization of Francisella tu-
larensis by the complement system helps the bacteria to be taken up by phagocy-
tosis [418, 419]. Even though opsonization favors bacterial uptake, non-opsonized
Francisella tularensis can be taken up by macrophages with the help of the mannose
receptor. Thus, Francisella tularensis uses different internalization mechanisms and
receptors to get into phagocytes [420]. Interestingly, the bacterial LPS and cap-
sule protect Francisella tularensis from complement-induced bacterial lysis despite
complement opsonization [421].
Within macrophages, the bacteria-containing phagosome acquires both early and
late endosomal markers, such as EEA-1, LAMP-1 and RAB5. However before lyso-
somal fusion, Francisella tularensis escapes from the phagosome into the cytosol,
which normally happens between 1-4 hours post entry [422424]. Phagosomal es-
cape is completely dependent on the Francisella pathogenicity island (FPI), as
FPI-deficient strains are unable to escape from the phagosome [425428]. Whereas
it is clear that the FPI is crucial for phagosomal escape, there is conflicting data
about the triggering signal for phagosomal escape. Two independent groups pos-
tulate that phagosomal acidification triggers Francisella escape into the cytosol
because blocking phagosomal acidification reduces the presence of Francisella in
the cytosol [429, 430]. However, a third group has shown that phagosomal acidifi-
cation is not the trigger for bacterial escape [431]. Thus if phagosomal acidification
is the trigger for Francisella to escape into the cytosol requires clarification. More-
over, it is not understood how the FPI induces phagosomal escape. However it is
known that the FPI encodes genes with some homology to a type 6 secretion sys-
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Figure I.5 The Francisella infection model. Francisella tularensis subspecies survive and
replicate in the cytosol of phagocytes, primarily macrophages and dendritic cells. Upon bac-
terial phagocytosis, Francisella tularensis escapes from the phagosome to the cytosol in an
FPI-dependent manner. In the cytosol, bacterial DNA is recognized by cGAS, which leads to
the production of the cyclic di-nucleotide cGAMP. cGAMP is recognized by STING, leading
to IRF3-dependent transcription of type-I-IFN, such as IFN-β. IFN-β then binds to and acti-
vates IFNaR, which induces via STAT1/STAT2 heterodimers the expression of ISG, among them
GBP2 and GBP5. GBP2/GBP5-dependent bacterial lysis exposes bacterial DNA to the cytosol,
where it activates the AIM2 inflammasome. IFN, interferon; IFNaR, IFN α receptor; STAT, sig-
nal transducer and activator of transcription; ISRE, IFN stimulated response elements; GBP,
Guanylate binding protein; FPI, Francisella pathogenicity island; cGAMP, cyclic-GMP-AMP;
cGAS, cGAMP synthase; STING, Stimulator of IFN genes protein; IRF, IFN regulatory factor;
AIM2, absent in melanoma 2.
tem (T6SS). The potential role and mechanism of the FPI in Francisella virulence
is described in the next paragraph and in chapter III, section 2.
Even though the FPI is important for Francisella intracellular survival despite the
host type, certain FPI genes are differentially required for the survival in arthro-
pods, amoebae or mammalian hosts [432, 433]. Besides differential requirement
of FPI genes for virulence, the cytosolic site of bacterial replication is distinct
in various hosts. Whereas Francisella escapes into the cytosol in arthropod and
mammalian cells, Francisella replicates in intact vacuoles in amoebae [434, 435].
Thus, the FPI is differently used for the infection of various hosts, though the exact
mechanisms that regulate host specificity are not fully understood.
In mammals, Francisella tularensis largely evades immune recognition through
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different mechanisms. Especially while infection establishment during the first 72
hours, the most virulent strain F. tularensis suppresses all pro-inflammatory sig-
nals [436]. In general, virulence of different Francisella tularensis subspecies nega-
tively correlates with the activation of the immune system. Francisella tularensis
suppresses immune recognition by the expression of a capsule. Indeed, acapsular
Francisella strains are more sensitive to antibody-mediated killing and attenuated
in a guinea pig or mouse infection model [437440]. The capsule size is between
100-250 kDa and the composition is similar to the repeating O-antigen subunits
of Francisella LPS [441443]. As expected from the structural similarity, many
enzymes are shared between LPS and capsule biosynthesis, however the capsule is
not anchored in the membrane by lipid A as seen for LPS [438,444,445].
Besides capsule expression, Francisella modifies its LPS to avoid immune recog-
nition. The Francisella Lipid A is tetraacylated compared to hexaacylation in
most Gram-negative bacteria. In addition, the acyl chains are 16-18 carbons long
compared to 12-14 carbons in E. coli and the sugar backbone of Lipid A is ei-
ther non-phosphorylated or mono-phosphorylated. When the sugar backbone is
mono-phosphorylated, the phosphate groups are masked by the addition of galac-
tosamines [216,217,443,446448]. All these LPS modifications diminish the recog-
nition of Francisella LPS by TLR4 and thereby no TLR4-dependent induction of
pro-inflammatory genes is observed in Francisella infections [186, 449]. The only
TLR that is activated by F. novicida and F. holarctica is TLR2 through the recog-
nition of bacterial lipoproteins [450452].
Besides preventing TLR4 activation, the lack of phosphates on Lipid A changes
the overall charge of Francisella LPS that gives raise to resistance to antimicrobial
peptides (AMPs) [186,453].
As a consequence of LPS modifications, F. novicida does not activate the non-
canonical inflammasome because its Lipid A cannot be recognized by caspase-
11 [344]. Francisella LPS is initially produced with pentaacylated Lipid A and af-
terwards, one acyl chain is removed by LpxF in the periplasm [446]. Interestingly,
pentacylated Lipid A produced by LpxF mutants is recognized by caspase-11 but
undetectable by TLR4 [344,446].
In addition, type IV pili have been shown to be required for full virulence in F.
tularensis. However, type IV pili phenotypically vary between Francisella culture
conditions and therefore conflicting data exist about the importance of type IV pili
in virulence [454456].
As mentioned above, Francisella tularensis primarily uses the cytosol of phagocytes
as replicative niche (Figure I.5). In phagocytes, cytosolic F. novicida induces type-
I-IFN in a MYD88/TRIF-independent manner indicating that TLR2 signaling from
the plasma membrane is not required for this process [457]. Indeed, type-I-IFN is
induced by the synergistic recognition of cytosolic DNA by cGAS and IFI16 [167],
which signal via STING to induce IRF1/IRF3 translocation into the nucleus and
consequently induce type-I-IFNs [457459]. However, the contribution of IFI16 in
Francisella-induced type-I-IFN is questionable, as Gray and colleagues have shown
that IFI16 is not involved in type-I-IFN production in mice [168]. While the path-
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way leading to type-I-IFN is well understood in the context of F. novicida infection,
it is less clear upon F. holarctica infections. F. holarctica induces type-I-IFN in a
STING- and TLR2-dependent manner [459,460]. How TLR2 and STING signaling
regulate type-I-IFN production is currently unknown.
Cytosolic F. novicida and F. holarctica activate the AIM2 inflammasome, the
second immune signaling pathway activated in mice [137, 300302]. Indeed, it has
been shown that F. novicida and F. holarctica neither induce the NLRP1, NLRP3,
NLRC4 nor pyrin inflammasome in mice [302, 461, 462]. To activate the AIM2 in-
flammasome, type-I-IFN production is absolutely required. We and others have
shown that type-I-IFN induces the expression of guanylate binding proteins (GBPs)
that target cytosolic F. novicida, induce bacteriolysis and consequently the release
of bacterial DNA into the cytosol [458, 463]. Importantly, GBPs are not required
for Francisella escape into the cytosol and not required for AIM2 inflammasome
assembly [463]. GBP involvement in F. novicida-dependent AIM2 inflammasome
activation is described in more details in research article IV in chapter III, section
V.
Interestingly, another member of the small GTPase family, IRGB10, has been found
to be recruited to cytosolic F. novicida in a GBP-dependent manner and has shown
to be required for AIM2 inflammasome activation [464]. While this indicates that
GBPs do not themselves possess membranolytic activity but rather serve as re-
cruitment factors for other proteins (e.g. IRGB10), it is unclear if IRGB10 directly
lyses F. novicida in the cytosol or itself recruits a yet uncharacterized cytosolic
membrane attack complex similar as membrane-deposited C3 in the complement
system.
As seen for murine cells, Francisella escapes from the phagosome is essential for
virulence in human cells, as F. holarctica and F. novicida mutants deficient for
phagosomal escape are completely avilurent [465]. However in contrast to murine
cells, F. novicida, F. holarctica and F. tularensis activate NLRP3 in human ma-
crophages and in a Hek293 reconstitution system [466]. Why murine NLRP3 fails
to detect Francisella tularensis remains unknown.
In addition to the activation of NLRP3 in human macrophages, IL-1β release
is decreased in pyrin-deficient primary human monocytes infected with F. novi-
cida [467], indicating that F. novicida activates the pyrin inflammasome as well.
Interestingly, pyrin is expressed at functional levels in murine macrophages nev-
ertheless unable to be activated by F. novicida [317]. One big difference between
human and mouse pyrin is the lack of the C-terminal B30.2 domain in murine
pyrin [314]. If the B30.2 domain is responsible for F. novicida detection and how
the B30.2 domain detects F. novicida is not known. Pyrin has been reported to
sense bacteria-induced RHOA modifications [317, 320]. However it is not reported
so far that Francisella tularensis uses actin-based motility or expresses Rho GT-
Pase modifiers. Another interesting aspect about pyrin is its cellular expression
profile. Fresh human monocytes express pyrin at high levels, while the expression
decreases during monocyte to macrophage differentiation. This reduction of pyrin
expression correlates with the ability to release active IL-1β in response to Fran-
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cisella infection [468,469]. Interestingly, macrophage differentiation in the presence
of M-CSF maintains pyrin expression levels and the capacity to release IL-1β upon
Francisella infection [467].
Taken together, Francisella tularensis activates a limited number of innate im-
mune signaling pathways due to modifications of its LPS and to capsule expression.
Moreover, there is a negative correlation between immune detection and virulence.
Whereas F. novicida activates a robust immune response leading to bacterial clear-
ance in immunocompetent humans, the highly virulent F. tularensis is almost not
detected by the immune system leading to high mortality rates. One reason for this
phenomenon might reside in the bacterial robustness to intracellular stress, as F.
novicida is more sensitive to H2O2-mediated killing compared to F. tularensis [470],
or in the bacterial sensitivity to GBP-induced lysis. Overall, the highly virulent
strain F. tularensis does not provide the cytosolic signal to activate NLRP3, AIM2
or pyrin that is necessary for an efficient immune response.
2.2.1 The Francisella pathogenicity island
As described above, Francisella tularensis virulence relies on phagosomal escape
and this is Francisella pathogenicity island (FPI)-dependent [422, 426, 428]. The
FPI is encoded on a genome sequence of 33 kb, contains 16-18 open reading frames
(ORFs) depending on the Francisella tularensis strain and represents a low G/C
content compared to the rest of the genome, indicating the acquisition over hor-
izontal gene transfer [426, 471]. 16 ORFs of the FPI (FTN_1309 - FTN_1324)
are conserved in all sequenced Francisella tularensis strains and the FPI is dupli-
cated in three out of four Francisella tularensis subspecies (Figure I.6 b) [471,472].
The two FPIs are functionally redundant and F. tularensis can tolerate the loss
of one copy without substantial virulence defect [473475]. F. novicida has only
one identified FPI copy on the genome. However, there is a gene cluster called
Francisella novicida island (FNI) in the F. novicida genome that shows some ho-
mology with the FPI, even though functional analysis of this second gene cluster
is missing [471,476].
Bioinformatical analysis of the FPI has identified weak homology of at least 7 FPI
genes with type 6 secretion system (T6SS) gene clusters from other bacteria [477].
The bacterial T6SS is a protein secretion system and has been first functionally
described in Vibrio cholerae in 2006 [478]. Based on homology analysis, the T6SS is
thought to originate from bacteriophages [479,480]. T6SSs are present in almost 25
% of all Gram-negative bacteria including Salmonella, Pseudomonas, Vibrio and
Burkholderia [481,482]. They have a role in virulence, host immunomodulation and
interbacterial killing [483487].
The T6SS composes of a baseplate complex in the bacterial membrane and a
contractile injectisome (Figure I.6 a). The baseplate complex is anchored in the
bacterial outer membrane by the lipoprotein TssJ, which interacts with TssM (also
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Figure I.6 The Francisella pathogenicity island. (a) Model of T6SS dynamics. T6SS as-
sembly starts at the baseplate complex (A), which consists of TssJ, TssM TssL, TssK and TssE.
The baseplate complex subsequently recruits the tip complex VgrG/PAAR and effector proteins
(B), followed by Hcp that forms hexameric rings. Around the Hcp tube a sheath of VipA/VipB is
formed (C). Upon a trigger, the T6SS sheath contracts and thereby propels the tip complex, the
associated effector proteins and the Hcp tube into the target cell (D). The contracted sheath is
then recognized by the unfoldase ClpV (E), which disassembles the sheath and therefore prepares
the bacteria for another T6SS assembly (F). (b) Genome locus of the Francisella pathogenicity is-
land (FPI) of Francisella tularenis subspecies novicida. The FPI consist of at least 16 genes, which
are conserved among all four Francisella tularensis subspecies. The genes highlighted in colors
show homology with T6SS components explained in (a) and are color-matched. OM, outer mem-
brane; IM, Inner membrane; T6SS, Type 6 secretion system; Tss, Type 6 secretion; VgrG, Valine-
glycine-rich repeat protein G; PAAR, Proline-alanine-alanine-arginine protein; Hcp, Haemolysin
coregulated protein; ClpV, Caseionlytic protease virulence; Vip, ClpV-interacting protein; Pdp,
Pathogenicity determinant protein; Igl, Intracellular growth locus; DotU, Defect in organelle
trafficking U.
called IcmF) that is anchored in the inner membrane and spans the periplasm.
TssL (also called DotU) is the second baseplate complex protein and is anchored
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in the inner membrane, where it interacts with TssM [488492]. TssM and TssL
interact with TssK and TssE, which form the actual baseplate in the bacterial cy-
toplasm [493]. The T6SS assembly starts with the recruitment of the tip complex
to the baseplate (Figure I.6 a). The tip complex is composed of a trimeric VgrG
complex and PAAR proteins, which sit on top of the VgrG complex [494496].
Together, the tip complex forms the arrowhead of the T6SS. At the baseplate,
VgrG recruits the inner tube protein Hcp that forms stacking rings of Hcp hexam-
ers with a diameter of 40 A. Therefore the Hcp tube is too small for the delivery
of most folded effector proteins as described for type 3- or type 4 secretion sys-
tems [479, 480, 497]. Around the Hcp tube, a sheath composed of VipA and VipB
is build. Together, Hcp, VipA and VipB form the shaft of the arrow of the T6SS.
Interestingly, in vitro studies have shown sheath filament disintegration by ClpV, a
Clp family AAA+ adenosine triphosphatase (ATPase) [498,499]. Clp family mem-
bers form hexameric rings and unfold proteins by pulling the proteins through their
central ring [500].
Basler and colleagues have visualized T6SS dynamics in bacteria showing that a
VipA-containing sheath structure extends, contracts, disassembles and reassembles
again. T6SS contraction mechanically shortens the T6SS sheath thereby pushing
out the inner tube together with the tip complex. Indeed, T6SS contraction is re-
quired for Hcp and tip secretion into the supernatant and delivery of tip complex
proteins into target cells [501,502].
Importantly, ClpV only recognizes and disassembles the contracted form of the
T6SS sheath [499,503].
Besides VgrG and PAAR, the T6SS tip complex can contain more proteins, which
all show specific effector functions in the target cell. These proteins act as lysozymes,
actin modifiers, nucleases, lipidases, muramidases or peptidases [482,494,504506].
Interestingly, structural T6SS components such as VgrG and PAAR harbor do-
mains with effector functions as well [494,496].
The additional effector proteins bind to and decorate the tip complex or reside
within the proximal part of the Hcp lumen, thereby being delivered to the target
cell [496,507]. As the effector proteins could also destroy the T6SS-positive bacte-
ria, they are usually co-expressed together with immunity proteins that inactivate
the effectors [504,505].
T6SS activity is strongly regulated in bacteria, because T6SS expression and as-
sembly is costly. T6SS expression is regulated by transcription factors that are
activated for example by quorum sensing, biofilm formation, iron depletion or
temperature [508511]. In addition, bacteria can induce full T6SS activity upon
surface sensing or cell-cell contact [499,501,512].
Taken together, the T6SS delivers effector proteins into prokaryotic and eukaryotic
target cells. The delivery is dependent on T6SS sheath contraction. The contracted
sheath is then recognized by ClpV that disassembles the sheath again thereby pro-
viding starting material for the assembly of a new T6SS.
As mentioned above, it is speculated that the Francisella pathogenicity island
(FPI) expresses a T6SS. Over the years the function of many FPI-encoded genes
I. Introduction -53-
have been analyzed resulting in conflicting observations regarding their impact on
virulence and their potential to express a T6SS. In the next section, the different
FPI genes and their potential function in virulence are discussed in more details.
As we are only working with F. novicida in our lab, the nomenclature of the FPI
is based on F. novicida as defined by Ludu and colleagues in 2008 (Figure I.6
b) [427].
Pathogenicity determinant protein A (PdpA; FTN_1309) shows no homology
with known T6SS gene. It is involved in virulence as F. novicida pdpA mutants (F.
novicida ∆pdpA) show reduced growth in primary murine bone marrow-derived
macrophages (BMDMs) and J774 macrophages compared to wild-type F. novi-
cida. Moreover, F. novicida ∆pdpA is avirulent in a chicken embryo infection
model [513, 514]. Interestingly, F. novicida ∆pdpA remains LAMP1-positive 12
hours post-infection indicating a defect in phagosomal escape [513].
PdpB (FTN_1310; also called icmF) shows homology with the membrane span-
ning T6SS baseplate complex component TssM. Indeed, PdpB is located to the
inner bacterial membrane and spans the periplasm [477]. F. novicida ∆pdpB has
a growth defect in J774 macrophages [515,516].
Intracellular growth locus E (IglE; FTN_1311) shows homology with the base-
plate complex component TssJ. Indeed, IglE is a lipoprotein and located to the
bacterial outer membrane, where it interacts with PdpB in the periplasm, confirm-
ing the functional homology with TssJ [477,517]. Moreover, F. novicida ∆iglE has
a growth defect in J774 macrophages [515].
Valine-glycine-rich repeat protein G (VgrG; FTN_1312) shows homology with the
tip complex component VgrG. However, the Francisella VgrG is much shorter than
the one of Vibrio and encodes only the cell puncturing domain without additional
N- or C-terminal effector domains [413]. F. novicida ∆vgrG shows a reduction in
cytoplasmic bacteria, intracellular growth and IL-1β release in J774 macrophages
comparable to a FPI mutant [515, 518]. These observations suggest that the FPI
encodes a T6SS. However FPI-independent VgrG secretion has been also shown,
which has been not observed in Vibrio cholera or Pseudomonas aeruginosa and
thus argues against an FPI-encoded T6SS [494,518].
IglF (FTN_1313) has no homology with known T6SS genes [477]. It is involved
in intracellular growth as F. novicida ∆iglF shows a growth defect in J774 ma-
crophages [515]. Moreover, a bacterial two hybrid screen has identified a specific
interaction between IglF and IglG [476]. The authors of this paper propose IglF as
a T6SS effector protein, however biological evidence for this suggestion is lacking
in the paper.
IglG (FTN_1314) shows homology to the tip complex protein PAAR [476, 477].
However, the function of IglG is controversial. Four independent groups have
shown no growth defect of F. holarctica ∆iglG in BMDMs and J774 macropha-
ges [516,519521], whereas two independent groups have reported a growth defect
for F. novicida ∆iglG and F. holarctica ∆iglG in the same cells [476,515]. In line
with the distinct observations in growth, there are conflicting results about the
importance of IglG in vivo. In one publication, the bacterial burden of F. hol-
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arctica ∆iglG in the skin, liver and spleen upon subcutaneous mice infection is
reduced [516], whereas the bacterial burden in the spleen and liver is unchanged
in another publication using the same bacteria and infection model [521]. In line
with the first observation, mice infected with F. novicida ∆iglG and F. tularensis
∆iglG survive the infection, whereas all mice infected with wild-type Francisella
die within the first seven days of infection [476]. Importantly, microinjected F.
holarctica ∆iglG grows normally in J774 macrophages and BMDMs [520]. Thus,
the role and function of IglG is still under debate, even though the recent work of
Rigard and colleagues strongly suggests that IglG is an important virulence factor
involved in phagosomal escape and might interact at the T6SS tip with potential
effector proteins such as IglF [476].
IglH (FTN_1315) shows homology to the baseplate component TssE [476,477]. It
is involved in intracellular growth as F. novicida ∆iglH shows a growth defect in
J774 macrophages [515].
Defect in organelle trafficking U (DotU; FTN_1316) shares homology with the
baseplate complex component TssL. Indeed, DotU is located to the inner mem-
brane where it stabilizes PdpB [477,515]. Furthermore, F. novicida ∆dotU shows
a growth defect in J774 macrophages [515].
IglI (FTN_1317) has no homology with known T6SS genes [477]. The role of IglI
in Francisella virulence is controversially discussed in the field. F. novicida IglI
is secreted into J774 macrophages in a FPI-dependent manner and intracellular
growth and IL-1β production is IglI-dependent [515,518]. In line with these obser-
vations, F. tularensis ∆iglI is avirulant in a mouse infection model [522]. However,
F. holarctica ∆iglI grows normally in J774 macrophages but fails to replicate in
BMDMs [519,520]. Importantly, microinjected F. holarctica ∆iglI grows normally
in J774 macrophages and BMDMs [520]. Thus, IglI might have subspecies specific
roles and further investigations are required to clarify the function of IglI.
IglJ (FTN_1318) has no homology with known T6SS genes [477]. It is required for
intracellular survival as F. novicida ∆iglJ shows a growth defect in J774 macro-
phages [515] and iglJ deletion in F. tularensis attenuates virulence in mice [522].
PdpC (FTN_1319) has no homology with known T6SS genes [477]. It has no im-
pact on intracellular survival as F. novicida ∆pdpC replicates normally in J774
macrophages [515]. However, pdpC deletion in F. tularensis and F. holarctica
attenuates bacterial growth in J774 macrophages and BMDMs and reduces the
amount of cytosolic bacteria in these cells [519522]. In line with these observa-
tions, F. tularensis ∆pdpC is completely avirulent in an intranasal mouse infection
model [522]. Interestingly despite bacterial clearance at the end of the infection, a
subset of F. tularensis ∆pdpC specifically disseminates from the lung to the spleen
but not the liver, where they replicate to a certain extend [522]. Thus, PdpC might
have a subspecies- and tissue-specific function.
PdpE (FTN_1320) has no homology with known T6SS genes [477]. It does not
affect intracellular growth of F. novicida and F. holarctica in J774 macrophages
and BMDMs [515,516,520]. Moreover, PdpE is not involved in IL-1β release [516].
Thus, the role of PdpE in Francisella infection is not clear.
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IglD (FTN_1321) has homology to the baseplate component TssK [476,477]. How-
ever, F. novicida ∆iglD replicates normally in J774 macrophages [515] arguing
against the theory of a FPI-encoded T6SS.
IglC (FTN_1322) has homology to the inner tube protein Hcp [476, 477]. IglC is
important for F. novicida, F. holarctica and F. tularensis virulence and is often
used as avirulent control in many publications [515,516,519,520,523].
IglB (FTN_1323) and IglA (FTN_1324) show homology to the sheath pro-
teins VipB and VipA, respectively [476, 477, 523]. They are required for intra-
cellular growth of F. novicida and F. holarctica in J774 macrophages and BMDMs
[425, 515, 516, 520]. Indeed, Clemens and colleagues have solved the atomic struc-
ture of a F. novicida IglA/IglB filament that shares structural homology with the
sheath of the T6SS [523].
PdpD (FTN_1325) has no homology with known T6SS genes [477] and is not
conserved in all Francisella tularensis subspecies. Whereas F. novicida has a 48
codon insertion compared to F. tularensis, F. holarctica only harbors a truncated
version of pdpD that is most likely not functional [427]. Even though F. novicida
∆pdpD does not show any growth defect in J774 macrophages and BMDMs, in-
fections of chicken embryos and mice show an enhanced survival when infected
with F. novicida ∆pdpD [427]. Thus, the discrepancy between in vitro and in vivo
infections requires further investigation.
Anhydro-N-acetylmuramic acid kinase (AnmK; FTN_1326) has no homology
with known T6SS genes [477] and is also not conserved in all Francisella tularensis
subspecies. Whereas F. novicida has a full length anmK, F. holarctica lacks anmK
and F. tularensis has two prematured stop codons in the anmK sequence, which
most likely render AnmK non-functional [427]. Moreover, F. novicida ∆anmK
shows no growth defect in J774 macrophages and BMDMs and bacterial loads of
infected chicken embryos and mice are comparable to wild-type F. novicida [427].
Thus, the role of AnmK in F. novicida virulence requires further investigation.
Taken together, the FPI is essential for Francisella tularensis virulence by me-
diating bacterial escape from the phagosome into the cytosol. Different research
groups have examined the impact of FPI genes on bacterial escape into the cy-
tosol, on activation of the cellular immune response, on intracellular growth and
on virulence in vivo. However, the results of the different studies contradict each
other, partially due to the use of different bacterial strains and cell lines.
Moreover, homology of FPI genes with components of T6SSs has resulted in the
assumption that the FPI encodes a T6SS. Indeed, cryo-electron microscopy studies
have solved the structure of an IglA/IglB filament that shows structural similarity
with T6SS sheaths. However, the evidence is lacking that these IglA/IglB sheaths
are part of an active and dynamic T6SS. Moreover, the impact of T6SS dynam-
ics on Francisella tularensis virulence in vitro and in vivo is unclear. Especially
puzzling for the understanding of the potential Francisella T6SS is the lack of an
ATPase on the FPI to disassemble the contracted sheath again, as seen for other
T6SS-expressing bacteria. Without the ATPase, the T6SS is not functional in bac-
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teria. Thus, a comprehensive analysis of the FPI and the formation and activity of
the potential T6SS would greatly increase our understanding about the key viru-
lence factor of Francisella tularensis in establishing a life-threatening infection in
humans.
Chapter II
Aim of Research
The aim of my PhD thesis is the investigation of innate immune cell activation upon
bacterial infections and the bacterial mechanisms used to infect host cells and evade
killing within phagolysosomes. Understanding the activation of innate immune cells
is of particular interest as they result in the expression of pro-inflammatory genes
and the production of interferons, which control bacterial infections. The investi-
gation of innate immune cell activation upon bacterial infections is conducted in
three different projects.
In the first project, we investigate phosphorylation changes in innate immune cells
upon bacterial infections with mass spectrometry. Innate immune signaling path-
ways largely depend on phosphorylation cascades, therefore analyzing phospho-
rylation changes give information about the activated innate immune signaling
pathways. However, current mass spectrometric techniques show limitations in the
detection of phosphopeptides. Therefore, we will improve the detection of phospho-
peptides to get a comprehensive picture of phosphorylation changes in innate im-
mune cells. To achieve this aim, we will infect primary murine bone marrow-derived
macrophages (BMDMs) with the intracellular model bacteria S. Typhimurium and
analyze phosphorylation changes during the first 8 hours of infection with mass
spectrometry.
In the second project, we investigate bacterial mechanisms to infect host cells and
evade killing in phagolysosomes. As a model organism, we study the intracellular
bacterium Francisella novicida, which escapes from the phagosome before it fuses
with lysosomes by destroying the phagosomal membrane and entering the cytosol,
a step essential for Francisella pathogenicity. It has been shown that Francisella
pathogenicity island (FPI)-encoded genes are involved in phagosomal escape and
it has been suggested that the FPI-encoded genes assemble a type 6 secretion
system (T6SS). However, to date it is unclear whether or not the FPI encodes a
functional T6SS and whether the functional T6SS is responsible for phagosomal
escape. Thus, we will analyze if the FPI encodes a functional T6SS and determine
its consequences on Francisella novicida virulence in vitro and in vivo.
In the third project, we investigate the composition and stoichiometry of canonical
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inflammasome complexes. The inflammasome complex is a multiprotein signaling
complex, which is an important mediator of inflammation. However, the composi-
tion of the inflammasome complex is not well defined. Therefore we will stimulate
the formation of different canonical inflammasome complexes, pull down the in-
flammasome complex and determine the components and their stoichiometry by
mass spectrometry.
Chapter III
Results
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ABSTRACT (148 words) 
Mass spectrometry-based proteomics has become the method of choice to pinpoint 
and monitor thousands of post-translational modifications, predominately 
phosphorylation sites, in cellular signaling studies. Critical for achieving this analytical 
depth is the enrichment for phosphorylated peptides prior to LC-MS analysis. Despite 
the high prevalence of this modification, the numbers of identified phosphopeptides 
lag behind those achieved for unmodified peptides, and the cause for this still 
remains controversial. Here we introduce an effective phosphatase protocol that 
considerably improves global ionization efficiency and therefore overall sensitivity 
and coverage of standard phosphoproteomics studies. We demonstrate the power of 
our method on the model system of Salmonella-infected macrophages by extending 
the current quantitative picture of immune signaling pathways involved in infection. In 
combination with a new sensitive, label-free targeted MS method for phosphorylation 
site validation, our novel approach thus opens new avenues to explore cellular 
phosphorylation based signaling networks in more detail.   
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Main text (~4200 words) 
 
Alterations in cell signaling have been associated with almost all major diseases and 
are therefore in the center of biological research for the last decades. Mass 
spectrometry (LC-MS) based proteomics has become the method of choice to 
identify and quantitate key modifications, most frequently phosphorylation sites, 
involved in signaling pathways on a system-wide level. Recent advances in 
instrumentation, software and sample preparation allow for extensive 
phosphoproteome analysis covering tens of thousands phosphorylation sites in large-
scale studies. To achieve this analytical depth, enrichment of phosphorylated 
peptides prior to LC-MS analysis is required. Albeit this workflow is now routinely 
used and well established, the number of phosphorylated peptides identified in one 
dimensional LC-MS analyses lags behind those achieved for unmodified peptides1-4, 
despite a high number of phosphopeptide species being present in these samples as 
demonstrated in multidimensional and targeted LC-MS experiments5,6. The 
underlying reasons for reduced identification rates of phosphorylated peptides have 
been assessed and discussed, sometimes controversially, in previous studies. This 
includes suppressed ionization efficiency in positive ion mode due to the increase in 
negative changes7,8, less efficient fragmentation that limit MS/MS-spectra 
assignment9, reduced binding efficiency during reverse phase chromatography10, and 
losses during purification and chromatography due to interactions with metal parts11. 
However, all studies to date addressing low identification rates of phosphorylated 
peptides are based on a few pre-selected peptides12 or small-scale synthetic peptide 
libraries13, and report contradictory results, ranging from either no impact12 to 
reduced MS signals upon phosphorylation7. Besides, most of the results in these 
studies were obtained using MALDI ionization that has nowadays been almost 
completely replaced by ESI for the analysis of complex phosphopeptide samples. 
Here, we developed a highly efficient phosphatase-based protocol and investigated 
this issue on a phosphoproteome wide level. To this end we used phosphopeptide 
enriched samples obtained from HeLa S3 cells and Salmonella-infected 
macrophages to analyze innate immune signaling. This allowed us to assess the 
impact of phosphorylation on thousands of peptides with unprecedented detail and 
under real experimental conditions. We demonstrate that after enzymatic removal of 
all phosphate groups in phosphopeptide enriched samples, precursor ion intensities 
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and proteome coverage increased several folds. We further show that most of the 
additional peptides identified after phosphatase treatment were indeed 
phosphorylated and that phosphopeptide quantities were conserved. Finally, using 
western blots and targeted mass spectrometry, we could define the exact sites of 
phosphorylation and validate the observed abundance changes for most targets. 
Overall, using our simple approach, we largely extend the current quantitative picture 
of immune signaling pathways involved in Salmonella infection. 
 
RESULT AND DISCUSSION 
Ionization efficiency is globally reduced in phosphopeptide enriched samples 
It is still under debate if phosphorylation has a negative impact on peptide 
identification by LC-MS. To address this issue on a phosphoproteome wide level, 
with currently employed LC-MS instrumentation and under real experimental 
conditions, we prepared phosphopeptide enriched samples and developed a highly 
efficient dephosphorylation protocol to directly compare identified phosphopeptides 
with their unmodified counterparts. In contrast to the synthetic peptides libraries used 
in previous studies12,13, the samples deployed in this study reflect real 
phosphopeptides generated in large-scale phosphoproteomics studies including 
frequent missed cleavages, large abundance differences and common 
contaminations5.  
 
Crucial for this comparison is the efficient removal of all phosphate groups from 
phosphopeptide enriched samples. Therefore, we developed a novel quantitative 
workflow, outlined in Fig. 1, based on a mix of two potent phosphatases (lambda- and 
alkaline-phosphatase) and applied it to phosphopeptide enriched samples obtained 
from whole HeLa S3 cell lysates. As shown in Fig. 2a and Supplementary Tables 1-3, 
the phosphatase mix virtually removed all phosphorylations after only 1 hour of 
treatment (>99.7% complete). Interestingly, after removing phosphorylations, the 
number of unique peptide sequences identified by LC-MS increased almost 2-fold 
(Fig. 2b). When looking at the LC-MS chromatograms (Supplementary Figure 1) we 
noticed an approximate 10-fold increase in precursor ion intensities after 
phosphatase treatment (Fig. 2c), across the full MS abundance range 
(Supplementary Figure 2). Apparently, the MS signals are globally suppressed during 
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electrospray ionization for phosphopeptide enriched samples. Most likely, the high 
concentration of negatively charged phosphate groups present in these samples 
suppressed the formation of positively charged ions required for MS analysis 
(positive mode) and reduced the overall MS response. It is important to note that a 
similar global decrease in ESI-MS response has been found previously upon the 
presence of negatively charged anionic detergents, like SDS10,14. Here, MS signal 
losses were observed starting at 10 mM, a concentration range that is also reached 
by the phosphopeptides present in a typical phosphoproteomics LC-MS experiment 
(Supplementary Figure 2). 
 
To further test the hypothesis of global ion suppression in phosphopeptide enriched 
samples, we looked at unmodified peptides coming from unspecific binders and 
commonly found contaminants (e.g. keratins, trypsin). Interestingly, the MS signals of 
these peptides were also strongly suppressed to almost the same level as 
phosphorylated peptides (Fig. 2d) confirming our hypothesis. The higher and more 
variable increase observed for phosphopeptides indicates that phosphorylation had 
an additional, albeit small, negative impact on ionization efficiency which is more 
phosphopeptide dependent. The slightly higher suppression of phosphopeptides also 
suggests that there is a higher proportion of phosphorylated than unmodified 
peptides amongst the additional peptides identified after phosphate removal. In 
summary, due to its much higher impact, sample matrix related ion suppression is the 
main driver of the reduced MS response/identification rates observed.  
 
To analyze this background dependent general ion suppression in more detail, we 
spiked 20 unmodified reference peptides into two different complex peptide matrices 
consisting of either a whole human cell digest or a phosphopeptide enriched human 
sample. Subsequently, we monitored and compared the MS response of these 20 
peptides for both peptide matrices at three different concentrations to determine 
differences in ion suppression. As shown in Fig. 2e, increasing amounts of 
background reduced the MS response of all 20 peptides, however, the suppression 
was significantly stronger for phosphopeptide enriched backgrounds. This was 
observed for two different LC-MS platforms with generally higher ion suppression 
being found for the Q Exactive LC-MS platform (Supplementary Figure 3a and 
Supplementary Table 4). Importantly, the difference in ion suppression between the 
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two backgrounds increased with amount. While for 0.2 µg of background the median 
target peptide intensity was 20% lower in the phosphopeptide enriched matrix 
compared to the whole cell digest background, the difference increased to 2.5-fold for 
the highest background amount applied (Supplementary Figure 3b). This increasing 
difference as a function of background concentration could be described by a 
logarithmic curve levelling off at around 2.5-fold (Supplementary Figure 3c). The 
increased ion suppression of phosphopeptide enriched over whole cell lysate 
samples confirms our previous findings of a profound and global ion suppression of 
all peptide ions, including unmodified species, in phosphopeptide enriched samples. 
Notably, the smaller impact on ion suppression observed here compared to the 
previous experiment (Fig. 2d, 8-fold) was most likely due to the use of a whole cell 
digest sample, which has different properties and a higher complexity compared to 
the dephosphorylated sample alone. 
 
To conclude, we observed considerably increased identification rates after enzymatic 
phosphate removal that were predominantly based on enhanced precursor ion 
intensities. This led to MS sequencing of additional peptide precursor ions, which 
were almost completely suppressed in the original phosphopeptide enriched sample 
(Supplementary Figure 4a). Notably, favorable MS fragmentation behavior and 
associated higher ion scores after phosphatase treatment could be observed that 
explained a small part of around 7% of the coverage enhancement (Supplementary 
Figure 4b).  
 
Application to immune signaling in response to Salmonella infection 
After successfully establishing and testing the new protocol, we enlarged the 
experimental setup and analysed phosphorylation dynamics of macrophages upon 
bacterial infection. Salmonella enterica subsp. enterica serovar Typhimurium (S. 
Typhimurium) is a Gram-negative facultative intracellular bacterium and a major 
cause of food-borne enterocolitis. Salmonella is one of the best-studied intracellular 
pathogens and the innate immune signaling pathways that are engaged during 
Salmonella infection of macrophages have been well described15,16. We infected 
murine primary bone marrow derived macrophages (BMDMs) with S. Typhimurium 
∆orgA for 0, 1, 2, 4 and 8 hours in biological triplicates and the samples were 
subjected to our in-depth label-free quantitative phosphoproteomics LC-MS analysis 
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described above. To increase phosphoproteome coverage, all samples were 
analyzed on two LC-MS platforms with different MS-sequencing characteristics and 
the results were combined (Supplementary Tables 5-7). Using the standard 
phosphoproteomics approach, we quantified 6607 phosphopeptides from the 
phosphopeptide enriched samples (Supplementary Figure 5a). When implementing 
the additional phosphatase treatment, precursor ion intensities were strongly 
enhanced (Supplementary Figure 5b-e) and the number of quantified peptides 
increased significantly by a factor of 2.3 to 15’494 peptides (Supplementary Figure 
5a). Thus, we could confirm the initial observations shown above for human cell 
lysates. It is important to note that the large majority (87%) of all phosphopeptides 
quantified before phosphatase treatment were also covered after phosphatase 
treatment, indicating that this additional procedure had little impact on MS 
detectability. The small number (13%) of peptides exclusively quantified in their 
phosphorylated state mainly comprised very short and basic peptides, whose mass 
fell outside the analyzed mass range after phosphate group removal. Since any 
information about the phosphorylation is lost after phosphatase treatment, we next 
assessed (I) the proportion of phosphopeptides in the additional peptides quantified, 
(II) the conservation of peptide quantities and (III) finally validated a subset of the 
most interesting peptides using sensitive, high-resolution targeted MS and western 
blot analyses. 
 
Phosphopeptide content of additional identified peptides 
Having shown that we can considerably increase peptide coverage by phosphate 
group removal, we next evaluated how many of these additional peptides identified 
were actually phosphorylated. Therefore, we used a Random Forest classification 
algorithm and trained it using unmodified serine or threonine containing peptides 
identified in the phosphopeptide enriched samples before phosphatase treatment as 
negative and confidently identified phosphopeptides as positive controls. The list of 
investigated features included; the number of trypsin missed cleavages, peptide 
molecular weight, Intensity Based Absolute Quantification (iBAQ) value of the 
originating protein17, peptide evidence in the PhosphoSitePlus database (PSite+ 
Evidence)18 and peptide amino acid frequencies. We subsequently applied the 
Random Forest model to classify the candidate phosphopeptides; i.e. all 
phosphopeptides and all unmodified peptides (originating from unspecific binding 
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peptides or contaminants) extracted from our phosphoproteomics dataset. As 
illustrated in Supplementary Figure 6a, the selected features allowed a clear 
separation between unmodified and phosphorylated peptides for all datasets. Using 
the resulting distribution of Posterior Error Probabilities, we computed a conservative 
estimate of the phosphopeptide False Discovery Rate (FDR) of 0.175; i.e. 
approximately 82.5% of the additional peptides identified after phosphatase 
treatment were expected to have been phosphorylated (Supplementary Figure 6b). 
This value is similar to the TiO2 enrichment efficiency achieved in this experiment 
(83%, Supplementary Figure 5f) and further indicates that we do have a similar and 
high content of phosphorylated peptides in the additionally identified peptides. 
 
The most discriminating feature of the random forest algorithm included 
phosphorylation site evidence (Supplementary Figure 6c). More than 80% of all 
identified peptides, phosphorylation has already been reported to be phosphorylated 
in the PhosphoSitePlus database18 (Supplementary Figure 6d). Further top features 
include protein abundance (iBAQ), the content of serine, proline and missed 
cleavages in the peptide sequence (Supplementary Figure 6c). Like in other affinity 
purification strategies19, high abundant proteins are more likely to be unspecific 
binders and therefore contaminants than lower concentrated proteins 
(Supplementary Figure 6e). A high occurrence of serine in phosphopeptides is also 
expected, since it represents the preferred site of phosphorylation5. The high 
discriminating power of proline points to the presence of the sequence motif “SP” that 
is targeted by the very potent ERK kinases. As the “SP/TP” kinase motif is one of the 
most prominent20, we determined its content in the peptides identified before and 
after phosphatase treatment (Supplementary Figure 7a). We obtained similar 
numbers of the “SP/TP” motif in the peptides identified before and after phosphatase 
treatment. Importantly, the occurrence was much higher than in a whole cell digest. 
The same was also true for other known kinase motifs (Supplementary Figure 7b-d, 
Supplementary Tables 8-9). Together, this supports the high content of 
phosphopeptides present in the additionally identified peptides.  
 
To further prove the validity of the additional peptides for phosphoproteomics studies, 
we carried out a chemical approach that removes Ser-/Thr-linked phosphate groups 
from peptides by beta-elimination21,22. In contrast to the enzymatic phosphorylation 
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removal, the site of phosphorylation can still be determined by LC-MS, due to the 
formation of a dehydrated side chain (Supplementary Figure 8a). When applied to 
our sample, we could identify, even after several optimization steps, no more than 
around 2500 dehydration sites and therefore a much lower number of 
phosphorylations compared to our standard phosphoproteomics approach. 
Additionally, beta-elimination remained incomplete for many phosphopeptides 
(Supplementary Table 10). Thus, despite its advantage of preserving phosphorylation 
site information, the low coverage and yield did not make this chemical approach 
applicable as a general tool for large-scale quantitative phosphoproteomics 
workflows. Nonetheless, it was interesting to see that the 2500 phosphopeptides 
identified by this chemical approach overlapped much better with the phosphatase 
treated dataset than the phosphopeptide enriched dataset (Supplementary Figure 
8b). This not only further proves the phosphopeptide content of the additional 
peptides identified after phosphatase treatment, but also indicates that some 
phosphorylated peptides escape detection by the standard phosphoproteomics 
workflow.  
 
To check which phosphopeptides have a lower chance of LC-MS identification, we 
had a closer look on the peptides exclusively identified before and after phosphatase 
treatment. Interestingly, we found significant differences in the content of basic and 
acidic amino acids (Supplementary Figure 9a&b), in that peptides identified before 
phosphatase treatment contained more basic and less acidic residues. This can be 
explained by the fact that phosphate groups remain negatively charged during MS 
ionization and reduce the charge state of the corresponding peptide ions 
(Supplementary Figure 9c). Since a net charge of at least two is required for MS-
sequencing in ESI positive mode, more basic amino acids are necessary to 
compensate the negative charges of the phosphate groups. This largely explains the 
increased coverage achieved after phosphate removal, because most of the 
identified peptides contained only few (1-2) basic amino acids (Supplementary Figure 
9d). Notably, MS-sequencing of very basic peptides (>4 basic amino acids) is 
improved upon charge state reduction23, which we also observed for the 
phosphopeptides identified in this study (Supplementary Figure 9e, Supplementary 
Table 11). However, since these peptides represent only a minor fraction of all 
identified peptides (<2%), the contribution to the overall coverage is negligible. It is 
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important to note that the low coverage of peptides with few basic amino acids might 
point to a general overrepresentation of peptides with basic kinase motifs (containing 
K, H or R; e.g. KxS or RRxS) in standard LC-MS based phosphoproteomics studies, 
since phosphorylations next to tryptic cleavage sites (K,R) induce missed cleavages 
and are often found in peptides with high basic amino acid levels24. On the other 
hand, the content of acidic amino acids had much less impact on peptide detectability 
in the present dataset (Supplementary Figure 9f). 
 
To conclude, these experiments confirmed that most of the additional peptides 
identified after phosphatase treatment were originally phosphorylated and that the 
main increase in coverage followed from peptides with only few basic amino acids 
that are lowly charged upon phosphorylation and therefore not MS-sequenced by 
standard phosphoproteomics LC-MS analysis.  
 
Quantitative information is conserved after phosphatase treatment 
Having shown that most of the newly detected peptides were indeed phosphorylated, 
we next assessed their suitability for quantification. Therefore, we first compared the 
number of significantly regulated peptides identified before and after phosphatase 
treatment. Overall, we found twice as many significantly regulated peptides after 
phosphatase treatment (Fig. 3a). Peptides significant after phosphate removal 
covered about 90% of the significantly regulated peptides found in the 
phosphorylated sample (Fig. 3a). The corresponding proteins matched the same GO-
terms and KEGG pathways25,26 (Supplementary Tables 12-13), indicating that the 
phosphatase treatment has, if at all, only a minimal impact on phosphopeptide 
quantification and that the coverage of our study could thus also be extended to the 
quantitative level (Fig 3b, Supplementary Figure 10a). Indeed, when correlating the 
ratios of significantly regulated peptides obtained before and after phosphatase 
treatment we obtained a very high coefficient of determination (r2=0.914, Fig. 3c). 
Even when only considering the significantly regulated peptides obtained after 
phosphatase treatment and comparing them to the ratios of the corresponding 
phosphopeptide, the correlation and accuracy were high (r2=0.817, Supplementary 
Figure 10b), indicating that the regulation trend could be correctly determined for 
96.2% of the phosphopeptides from their dephosphorylated counterparts.  
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It is important to note that the higher number of significantly regulated peptides 
obtained after phosphatase treatment is not only related to the overall increase in 
peptide coverage, but also a consequence of the improved MS response 
(Supplementary Figure 5b). In fact, signal-to-noise ratios were increased and 
coefficients of variation (CVs) were decreased across all sample triplicates after 
phosphatase treatment (Fig. 3d). As a consequence of this elevated precision, p-
values were generally lower and more peptides passed the given significance 
threshold applied (Supplementary Figure 11).  
 
To conclude, the phosphatase treatment could increase the number of significantly 
regulated peptides and this increase is due to an overall increase in peptide 
coverage as well as improved precision.  
 
Innate immune signaling pathway dynamics upon Salmonella infection 
As shown in Figure 3b, we were able to increase the number of phosphoproteins per 
innate immune signaling pathway after phosphatase treatment. As the activation of 
innate immunity is very important to fight a Salmonella infection, we further analyzed 
these innate immune signaling pathways by subjecting the identified proteins to a 
STRING based protein-protein interaction analysis27. To obtain a better network 
coverage, we included 25 additional proteins known to be important for signaling but 
not detected in our analysis. With the inclusion of these proteins, STRING could build 
an interaction network with 94 out of 102 proteins from our analysis. In agreement 
with the KEGG analysis, the phosphatase treatment doubled the amount of 
interacting proteins in the STRING network (Fig. 4a). Especially the TLR and 
JAK/STAT signaling pathways were represented in much greater detail after 
phosphatase treatment (Fig 4a). During Salmonella infection TLR4 responds to 
bacterial lipopolysaccharide (LPS) and signals through the MYD88 / NF-κB axis to 
induce the expression of pro-inflammatory proteins like, TNFa, IL-1β or caspase-11. 
Moreover, TLR4 signals through TRIF / IKKε to induce type I interferons, which then 
activate the JAK/STAT signaling pathway28-30. The TLR4 as well as JAK/STAT 
signaling pathway are very important for a successful innate immune response 
against invading bacteria like Salmonella15.  
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As the JAK/STAT signaling pathway is activated upon TLR4-dependent type I 
interferon production30, we wanted to confirm this hierarchy in the phosphatase 
treated samples. We first analyzed signaling downstream of TLR4 by looking at NF-
κB and IKKε phosphorylation. The NF-κB complex is activated through 
phosphorylation of subunit p65 (Rela) at S536 and IKKε is activated by S172 
phosphorylation31,32. Western blot analysis showed NF-κB activation as soon as 30 
min post infection, which was consistent with an increase in phosphopeptide 
abundance of proteins upstream of NF-κB (e.g. IRAK2, 3, 4 or IKKβ (Ikbkb) (Fig. 4c). 
Similar to NF-κB activation, IKKε is phosphorylated as soon as 30 min post infection. 
In line with this, the upstream IKKε activator TRIF (Ticam1) showed a similar peptide 
abundance pattern in the phosphatase treated samples (Fig. 4c). Even more striking, 
STAT1 phosphorylation at Y701 and therefore activation of the Jak/STAT signaling 
pathway33 happened after TLR signaling and the peptides detected after 
phosphatase treatment showed a very similar abundance pattern (e.g. STAT3, 
STAT6 or IRF9) (Fig. 4c). Especially the STAT6 peptide abundance pattern 
phenocopied STAT1 activation (Fig. 4c). Therefore, we were able to correlate the 
abundance profile of specific peptides identified after phosphatase treatment to 
signaling dynamics of the analyzed innate immune signaling pathways. 
 
Interestingly, a cluster of significantly regulated proteins associated with the RIG-I 
signaling pathway (Fig. 4a). This pathway is linked to cytosolic dsRNA recognition 
upon viral infections and, so far, not linked to bacterial infections34. Thus, its role in 
mounting a proper immune response against bacterial pathogens needs to be 
examined.  
 
Taken together, there is a clear correlation between the dynamics of the detected 
peptides after phosphatase treatment and the known phosphorylation pattern of 
proteins in the same pathway. Therefore, the new workflow provided extended 
insights into the activation profile of signaling pathways over time.  
 
Validation of significant peptides 
Validation of quantitative results by an orthologues approach is crucial in any large-
scale study35. It is desirable that such a method not only confirms the change in 
abundance, but also to confirms and precisely localize the phosphorylation. One well 
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established method to validate phosphorylation sites is the usage of phosphorylation 
specific antibodies. Indeed, the phosphorylation dynamics of p38 T180 / Y182 before 
and after phosphatase treatment were identical and resembled the phosphorylation 
pattern observed by Western blot (Fig. 4d). However, for most hits identified after 
phosphatase treatment, the availability of specific antibodies was highly limited. 
Therefore, we focused on parallel reaction monitoring (PRM) LC-MS assays36,37 to 
validate 24 phosphopeptide candidates that belong to proteins involved in innate 
immune signaling (Fig. 4a and Supplementary Table 14).  
 
Here, we carried out two different workflows; the standard stable-isotope dilution 
(SID-) PRM approach that requires synthetic heavy peptide references (Fig. 5a) and 
a novel, high-selective label-free quantification (LFQ-) PRM workflow based on 
conventional database search identification that does not require any internal 
standards or reference MS spectra (Fig. 5b). This was only possible by applying a 
more selective precursor ion selection (0.7 Th, before 2 Th) and a higher resolution 
(>120k at 200m/z, before 30k) than previously reported36,37. This boosted the quality 
of MS/MS spectra and enabled unambiguous and sensitive quantification and 
identification of target phosphopeptides. The LFQ-PRM is particularly interesting for 
the validation of phosphorylation sites, since, due to their identical parent ion mass, 
all potential sites of a peptide are covered by a single PRM assay. Conversely, in the 
SID-PRM approach, every potential phosphorylation site requires a different assay 
and therefore a different heavy reference peptide38.  
 
When applied to our samples, we first performed LFQ-PRM analyses with different 
sensitivity settings (see method sections for details). Overall, using this simple 
approach, we could identify and quantify 18 unique phosphorylation sites located on 
15 of the 24 selected phosphopeptide candidates (Table 1, Supplementary Tables 
16-19). Notably, LFQ-PRM allowed the identification and quantification of different 
phosphorylation sites within peptides using a single assay as illustrated for the two 
sites monitored in the peptide “DA(p)TPPV(p)SPINMEDQER” (Fig. 5c-e, 
Supplementary Figure 12). This was possible due to the full chromatographic 
separation and the presents of specific transitions of the two variants (Fig. 5d). The 
same was true for the peptide “AASGSQPEPSPDQSATNSPESSSR” for which three 
different phosphorylations could be identified and quantified (Supplementary Figure 
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13). Interestingly, the LFQ-PRM workflow was particular effective in identifying long 
phosphopeptides (>20 amino acids), while many of the shorter peptides (<10 amino 
acids) were not covered (Table 1). This might point to the general favorable 
identification of longer peptides by database searching, due to their higher number of 
fragments and reduced search space, usually with higher significance than shorter 
peptides39. Because larger peptides are still difficult and expensive to synthesize, the 
LFQ-PRM approach seems to be an excellent complement to the standard SID-PRM 
workflow. Still, spiking in heavy reference peptides is the method of choice for 
sensitive and confident quantification in targeted MS. Therefore, we ordered synthetic 
mono-phosphorylated heavy reference peptides covering all known phosphorylation 
sites of the missing peptides and, if no site has been reported so far, all possible sites 
were included (Supplementary Table 15). After establishing SID-PRM assays, we 
applied them to quantitate phosphorylation sites of the selected peptides from 
phosphopeptide enriched samples using the same high selective MS parameters as 
for the LFQ-PRM workflow. This enabled the precise localization of 4 additional 
phosphorylation sites on 4, mostly shorter, peptide candidates (Supplementary Table 
20). The remaining 5 phosphopeptide candidates could not be detected and 
validated by SID-PRM. In total, 19 (79%) of the 24 selected candidate 
phosphopeptides were validated, two were phosphorylated at multiple positions, and 
the abundance change was confirmed for 18 of them (Table 1, Supplementary Table 
21). For instance, the ratios of the two sites obtained by LFQ- and SID-PRM for 
peptide “DA(p)TPPV(p)SPINMEDQER” matched very well the ratios obtained from 
the large-scale phosphatase samples and confirmed their significant upregulation 
after 4 hours of infection (Fig. 5e). In fact, a good correlation between LFQ- and SID-
PRM and the large-scale phosphatase dataset was observed for all significantly 
regulated hits (Supplementary Figure 15), further confirming the validity of our 
peptide candidates for quantitative phosphoproteomics analysis. 
 
To conclude, we localized the phosphorylation site(s) and verified their abundance 
change(s) for the large majority (>80%) of selected hits. In particular, the LFQ-PRM 
workflow performed very well validating most of the selected phosphopeptide 
candidates of interest and therefore represents an attractive addition to the standard 
SID-PRM target validation. 
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CONCLUSION 
We present a straightforward and very effective workflow that considerably increased 
the analytical depth achieved in monitoring phosphoproteomics changes of immune 
signaling pathways involved in infection. This was achieved by a simple additional 
phosphatase treatment step after phosphopeptide enrichment that significantly 
increased MS-sensitivity by several folds. As a result, coverage and quantification 
were improved, which are of particular importance when working with limited sample 
amounts. Despite these advantages, the complete enzymatic dephosphorylation 
strategy is by no means perfect. Most obviously, modification localization information 
is lost, making it necessary to carry out additional validation experiments. 
Furthermore, quantification of single sites in multiply phosphorylated peptides can be 
challenging, since, after dephosphorylation, only the sum of all phosphorylation forms 
of a peptide are quantified. However, as shown in Supplementary Figure 10b, the 
ratios of doubly phosphorylated peptides before and after phosphatase treatment 
correlated very well. This was due to fact that the significantly regulated sites had a 
much higher stoichiometry and mainly contributed to the dephosphorylated peptide 
abundance.  
 
Clearly, equally efficient and uniform dephosphorylation or negative charge 
neutralization strategies that preserve phosphorylation site information would be 
desirable. We thoroughly evaluated different dephosphorylation methods in this 
study, including chemical and enzymatic approaches, but found enzymatic 
phosphatase treatment to be by far the most efficient method providing most peptide 
identifications. An interesting approach would be enzymatic phosphoric acid removal, 
which would transform phosphorylations to MS-detectable dehydrated sites, but 
available enzymes are currently limited to specific peptides species40 preventing its 
application to global studies. Finally, despite the good enrichment efficiency achieved 
in this study (>80%, Supplementary Figure 5f), the method will certainly benefit from 
recent, highly efficient phosphopeptide enrichment technologies3,4,41. Here, almost 
every additionally identified peptide after phosphate removal would originate from a 
phosphopeptide, which will speed up target validation.  
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Overall, albeit not perfect, the dephosphorylation strategy applied clearly 
demonstrates that ion suppression considerably limits the potential of large-scale LC-
MS based phosphoproteomics studies, which are currently all based on 
phosphopeptide enriched samples. Furthermore, the observed biases against acidic 
and peptides with few basic amino acids might point, despite the impressive 
coverages achieved in recent studies, to a general underrepresentation of acidic 
phosphopeptides and kinase motifs and an overrepresentation of motifs containing 
basic amino acids that favor missed cleavages in present large-scale datasets. For 
this reason, overcoming ion suppression during LC-MS for samples enriched for 
phosphopeptides is an important step towards comprehensive and unbiased 
phosphoproteomics analyses.  
 
METHODS 
Cell culture and infection. 
HeLa S3 cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM, 
Invitrogen, Carlsbad, CA) supplemented with 10% heat-inactivated fetal calf serum 
(FCS) and penicillin-streptomycin (100 IU/ml and 100 μg/ml, respectively, GIBCO) at 
37°C in a 5% CO2 atmosphere in a humidified incubator. Cells were collected by 
centrifugation, washed twice with PBS and stored in liquid nitrogen until further use. 
Primary murine bone marrow derived macrophages (BMDMs) were differentiated in 
DMEM (Sigma) with 20 % M-CSF (supernatants of L929 mouse fibroblasts), 10% v/v 
FCS, 10 mM HEPES, nonessential amino acids and penicillin (100 IU/ml) / 
streptomycin (100 μg/ml) (all BioConcept). 1 day before infection, BMDMs were 
seeded into 6- or 96-well plates (Greiner) at a density of 1.5 x 106 or 5 x 104 cells per 
well in DMEM (Sigma) with 10 % M-CSF (supernatants of L929 mouse fibroblasts), 
10 % v/v FCS, 10 mM HEPES and nonessential amino acids (all BioConcept). 
Salmonella enterica subsp. enterica serovar Typhimurium strain SL1344 ΔorgA 
(hereafter S. Typhimurium ΔorgA) were grown over night at 37°C with aeration in 
lysogeny broth (LB) medium supplemented with 90 μg/ml streptomycin (Sigma) and 2 
μg/ml tetracycline (ICN Biomedicals). The bacteria were added to the BMDMs at a 
multiplicity of infection of 100. The plates were centrifuged for 5 min at 500xg to 
ensure similar adhesion of the bacteria to the cells and were incubated at 37°C for 
the indicated length of time. After 60 min, the medium was replaced with fresh 
medium containing 100 μg/ml gentamicin (BioConcept) to kill extracellular bacteria 
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and after 120 min, the medium was replaced with fresh medium containing 10 μg/ml 
gentamicin (BioConcept) for the residual time of infection. 
 
Sample preparation. 
BMDMs were seeded in 6-well plates and infected with S. Typhimurium ΔorgA as 
indicated above. At the indicated time points, the plates were put on ice and the 
BMDMs washed twice with ice-cold 1x phosphate-buffered saline (PBS). 80 μl urea 
lysis buffer (8 M urea (AppliChem), 0.1 M Ammoniumbicarbonate (Sigma), 1x 
PhosSTOP (Roche)) was added to each well and incubated on ice for 10 min. For 
HeLa cell preparation, 107 cells were lysed in 200 µl urea lysis buffer. Samples were 
vortexed, sonicated at 4°C (Hielscher), shaked for 5 min on a thermomixer 
(Eppendorf) at room temperature and centrifuged for 20 min at 4°C full speed. 
Supernatants were collected and protein concentration was measured with BCA 
Protein Assay kit (Invitrogen). Per sample, 2 mg of protein mass were used, 1.9 mg 
were employed for phosphopeptide enrichment and 100 µg for protein quantification 
by TMT. At first, disulfide bonds were reduced with tris(2-carboxyethyl)phosphine 
(TCEP) at a final concentration of 10 mM at 37°C for 1 hour. Free thiols were 
alkylated with 20 mM iodoacetamide (IAM, Sigma) at room temperature for 30 
minutes in the dark and access of IAM were quenched by adding excess of N-
acetylcysteine. Samples were incubated for 4 h with Lys-C endopeptidase (1:200 
w/w), diluted with 0.1 M ammoniumbicarbonate to a final urea concentration of 1.6 M 
and digested overnight at 37°C with sequencing-grade modified trypsin (Promega) at 
a protein-to-enzyme ratio of 50:1. Subsequently, peptides were desalted on a C18 
Sep-Pak cartridge (VAC 3cc, 500 mg, Waters) according to the manufacturer’s 
instructions, split in peptide aliquots of 1.9 and 0.1 mg, dried under vacuum and 
stored at -80°C until further use.  
 
Phosphopeptide enrichment. 
Phosphopeptides were isolated from 1.9 mg of total peptide mass with TiO2 as 
described previously42. Briefly, dried peptides were dissolved in an 80% acetonitrile 
(ACN)–2.5% trifluoroacetic acid (TFA) solution saturated with phthalic acid. Peptides 
were added to the same amount of equilibrated TiO2 (5-µm bead size, GL Science) in 
a blocked Mobicol spin column (MoBiTec) that was incubated for 30 minutes with 
end-over-end rotation. The column was washed twice with the saturated phthalic acid 
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solution, twice with 80% ACN and 0.1% TFA, and finally twice with 0.1% TFA. The 
peptides were eluted with a 0.3 M NH4OH solution. The pH of the eluates was 
adjusted to be below 2.5 with 5% TFA solution and 2 M HCl. Phosphopeptides were 
again desalted with C18 reversed-phase spin columns according to the 
manufacturer’s instructions (Microspin, Harvard Apparatus), dried under vacuum and 
stored at -80°C until further use.   
 
Enzymatic peptide dephosphorylation using phosphatase 
Dried phosphopeptides were dissolved in 50 µl reaction buffer (50 mM HEPES, 100 
mM NaCl, 1 mM MnCl2, 1 mM MgCl2, pH 7.4), 2000 units of Lambda Protein 
Phosphatase (Lambda PP) and 20 units of Alkaline Phosphatase Calf Intestinal (CIP, 
both from New England BioLabs) were added and the sample was shaken at 600 
rpm and 30°C for 1 h. After adding 10 µl of 5% TFA solution, peptide samples were 
desalted, dried under vacuum and stored at -80°C until further use.   
 
Chemical peptide Ser-/Thr-dephosphorylation by beta-elimination  
The beta-elimination was carried as previously described21. In brief, dried 
phosphopeptides were dissolved in 90 µl of 10% water in methanol and 3 µl of 0.15 
M Ba(OH)2 using ultra sonication. The reaction was allowed to proceed for 1 h at 
45°C under continuous shaking at 600 rpm, mixtures were neutralized by addition of 
3 µl of 0.3 M HCl, and dried under vacuum. Samples were dissolved in 100 µl of 
0.1% TFA and desalted, dried under vacuum and stored at -80°C until further use.   
 
TMT labeling 
Sample aliquots containing 25 µg of dried peptides were subsequently labeled with 
isobaric tag (TMT 6-plex, Thermo Fisher Scientific) following a recently established 
protocol43. To control for ratio distortion during quantification, a peptide calibration 
mixture consisting of six digested standard proteins mixed in different amounts were 
added to each sample before TMT labeling. After pooling the TMT labeled peptide 
samples, peptides were again desalted on C18 reversed-phase spin columns 
according to the manufacturer’s instructions (Macrospin, Harvard Apparatus) and 
dried under vacuum. We carried out two independent 6-plex TMT experiments 
covering all six time points with biological duplicates. 
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HpH fractionation of TMT labeled samples  
TMT-labeled peptides were fractionated by high-pH reversed phase separation using 
a XBridge Peptide BEH C18 column (3,5 µm, 130 Å, 1 mm x 150 mm, Waters) on an 
Agilent 1260 Infinity HPLC system. Peptides were loaded on column in buffer A 
(ammonium formate (20 mM, pH 10) in water) and eluted using a two-step linear 
gradient starting from 2% to 10% in 5 minutes and then to 50% (v/v) buffer B (90% 
acetonitrile / 10% ammonium formate (20 mM, pH 10) over 55 minutes at a flow rate 
of 42 µl/min. Elution of peptides was monitored with a UV detector (215 nm, 254 nm). 
A total of 36 fractions were collected, pooled into 12 fractions using a post-
concatenation strategy as previously described44, dried under vacuum and subjected 
to LC-MS/MS analysis. 
 
LC-MS/MS analysis 
The setup of the μRPLC-MS system was as described previously43. Chromatographic 
separation of peptides was carried out using an EASY nano-LC 1000 system 
(Thermo Fisher Scientific), equipped with a heated RP-HPLC column (75 μm x 50 
cm) packed in-house with 1.9 μm C18 resin (Reprosil-AQ Pur, Dr. Maisch). Aliquots 
of 1 μg total peptides were analyzed per LC-MS/MS run using a linear gradient 
ranging from 95% solvent A (0.15% formic acid, 2% acetonitrile) and 5% solvent B 
(98% acetonitrile, 2% water, 0.15% formic acid) to 30% solvent B over 180 minutes 
at a flow rate of 200 nl/min. Mass spectrometry analysis was performed on a dual 
pressure LTQ-Orbitrap Elite or Q-Exactive HF mass spectrometer equipped with a 
nanoelectrospray ion source (both Thermo Fisher Scientific) and a custom made 
column heater set to 60°C. For LFQ samples, each MS1 scan (acquired in the 
Orbitrap) was followed by collision-induced-dissociation (CID, acquired in the linear 
ion trap) of the 20 most abundant precursor ions with dynamic exclusion for 60 
seconds. Total cycle time was approximately 2 s. For MS1, 1E6 ions were 
accumulated in the Orbitrap cell over a maximum time of 300 ms and scanned at a 
resolution of 240,000 FWHM (at 400 m/z). MS2 scans were acquired at a target 
setting of 10,000 ions, accumulation time of 25 ms and rapid scan rate using a 
normalized collision energy of 35%. The preview mode was activated and the mass 
selection window was set to 2 Da. LFQ-MS1 based experiment were also carried out 
on a QE-HF. Here, 3E6 ions were collected for MS1 scans for no more than 100 ms 
and analyzed at a resolution of 120,000 FWHM (at 200 m/z). MS2 scans were 
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acquired of the 20 most intense precursor ions at a target setting of 100,000 ions, 
accumulation time of 50 ms, isolation window of 1.4 Th and at resolution of 15,000 
FWHM (at 200 m/z) using a normalized collision energy of 28%. All TMT samples 
were analyzed on the QE-HF using the same setting as above with a few 
adjustments as recently described43. MS2 scans of only the 10 most abundant 
precursor ions were performed and the collision energy was increased to 35%. The 
mass isolation window was set to 1.1 Th and the resolution of the MS2 scans was 
increased to 30,000 FWHM (at 200 m/z). Total cycle time was approximately 1-2 s.  
 
Phosphopeptide analysis using label-free quantification 
The acquired raw-files were imported into the Progenesis QI software (v2.0, 
Nonlinear Dynamics Limited), which was used to extract peptide precursor ion 
intensities across all samples applying the default parameters. The generated mgf-
files were searched using MASCOT against a decoy database (consisting of forward 
and reverse protein sequences) of the predicted proteome from mus musculus 
(UniProt, download date: 2016/11/6, total 33984 entries) and homo sapiens (UniProt, 
download date: 2015/06/29, total 41158 entries) including known contaminants such 
as porcine trypsin, human keratins and high abundant bovine serum proteins 
(Uniprot). The search criteria were set as follows: full tryptic specificity was required 
(cleavage after lysine or arginine residues, unless followed by proline); 3 missed 
cleavages were allowed; carbamidomethylation (C) was set as fixed modification; 
oxidation (M) and phosphorylation (STY) were applied as variable modifications; 
mass tolerance of 10 ppm (precursor) and 0.6 (CID, ion trap) and 0.02 Da (HCD, 
orbitrap) (fragments). The database search results were filtered using the ion score to 
set the false discovery rate (FDR) to 1% on the peptide and protein level, 
respectively, based on the number of reverse protein sequence hits in the datasets. 
The relative quantitative data obtained were normalized and statistically analyzed 
using SafeQuant43 (see statistical data analysis below for details). Localization 
confidence was determined using Ascore45 as implemented in Scaffold-PTM (version 
2.1.3, Proteome Software Inc., Portland, OR). 
 
Protein quantification using TMT  
The acquired raw-files were converted to the mascot generic file (mgf) format using 
the msconvert tool (part of ProteoWizard, version 3.0.4624 (2013-6-3)). The mgf files 
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were searched, using Mascot (Matrix Science, Version 2.4.0), against the mus 
musculus database mentioned above including the six Calibration-mix Proteins 
(uniprot accession numbers: P00489, P02789, P01012, P02666, P00722, B6V3I5, 
www.uniprot.org downloaded 22/10/2014)43. The Mascot search criteria were set as 
follows: 10 ppm precursor ion mass tolerance, 0.02 Da fragment ion mass tolerance, 
full tryptic specificity required (cleavage after lysine or arginine residues unless 
followed by proline), maximum 2 missed cleavages, fixed modifications: 
carbamidomethylation (C) and TMT6plex (K and peptide n-terminus), variable 
modification: oxidation (M). The database search results were post-processed using 
the Scaffold Q+ software (version 4.3.2, Proteome Software Inc., Portland, OR). 
Here, protein scores were calculated using the Protein Prophet algorithm46. Next, 
peptide and protein level identifications were filtered to achieve a maximum False 
Discovery Rate of 1%, on both levels. The FDR was determined using the Scaffold 
Local FDR algorithm. Proteins that contained similar peptides and could not be 
differentiated based on MS/MS analysis alone were grouped to satisfy the principles 
of parsimony. Proteins sharing significant peptide evidence were grouped into 
clusters. 
 
TMT reporter ion intensities were extracted using Scaffold Q+. Protein relative 
quantification was performed using our in-house developed SafeQuant R package43. 
This analysis included multiple steps; adjustment of reporter ion intensities for 
isotopic impurities according to the manufacturer’s instructions, global data 
normalization by equalizing the total reporter ion intensity across all channels, 
summation of reporter ion intensities per protein and channel, calculation of protein 
abundance ratios and testing for differential abundance using empirical Bayes 
moderated t-statistics where the resulting p-values, reflect the probability of detecting 
a given mean abundance difference across sample conditions by chance alone. 
 
Statistical data analysis 
SafeQuant Description 
Quantitative analysis results from label-free and TMT quantification were further 
processed using the SafeQuant R package v.2.3.2. 
(https://github.com/eahrne/SafeQuant/) to obtain protein relative abundances. This 
analysis included global data normalization by equalizing the total peak/reporter 
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areas across all LC-MS runs, summation of peak areas per protein and LC-MS/MS 
run, followed by calculation of protein abundance ratios. The summarized protein 
expression values were used for statistical testing of between condition differentially 
abundant proteins. Here, empirical Bayes moderated t-Tests were applied, as 
implemented in the R/Bioconductor limma package 
(http://bioconductor.org/packages/release/bioc/html/limma.html). The resulting per 
protein and condition comparison p-values were adjusted for multiple testing using 
the Benjamini-Hochberg method. 
 
Underlying Statistical Assumptions  
All LC-MS analysis runs are acquired from independent biological samples. To meet 
additional assumptions (normality and homoscedasticity) underlying the use of linear 
regression models and Student t-Test MS-intensity signals are transformed from the 
linear to the log-scale. 
 
Linear Regression 
Unless stated otherwise linear regression was performed using the ordinary least 
square (OLS) method as implemented in base package of R v.3.1.2 (http://www.R-
project.org/). 
 
Power 
The sample size of three biological replicates was chosen assuming a within-group 
MS-signal Coefficient of Variation of 10%. When applying a two-sample, two-sided 
Student t-test this gives adequate power (80%) to detect protein abundance fold 
changes higher than 1.65, per statistical test. Note that the statistical package used 
to assess protein abundance changes, SafeQuant, employs a moderated t-Test, 
which has been shown to provide higher power than the Student t-test47. We did not 
do any simulations to assess power, upon correction for multiple testing (Benjamini-
Hochberg correction), as a function of different effect sizes and assumed proportions 
of differentially abundant proteins. 
 
Validation of hits by targeted LC-MS 
24 phosphopeptide candidates (Supplementary Table 14) were selected for 
validation using PRM analysis. First, a label-free quantification approach for all 
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peptides was carried out. Therefore, the precursor ion masses were calculated for all 
candidates in their mono-phosphorylated form and for charge states 2+, 3+ and 4+. 
After feeding the mass lists into the QE-HF, MS/MS scans were acquired in a 
targeted fashion for all masses. Importantly, the mass list was split to keep cycle 
times below 4 seconds. In a first round, MS2 scans were acquired at a target setting 
of 3e6 ions, max. accumulation time of 150 ms, isolation window of 0.7 Th and at 
resolution of 60,000 FWHM (at 200 m/z) using a normalized collision energy of 27%. 
The acquired MS2 spectra were database searched using Mascot (same parameters 
as described above) and MaxQuant39 using the same settings as described 
recently48. In brief, MS raw files were imported to MaxQuant software (version 
1.5.1.2) and peak lists were searched against the same database of the predicted 
proteome from mus musculus (UniProt, download date: 2016/11/6, total 33984 
entries) and common contaminants as used for the Mascot search. The search 
criteria were set as follows: carbamidomethylation (C) was set as fixed modification; 
oxidation (M) and phosphorylation (STY) were applied as variable modifications; false 
discovery rate was set to 0.01 for proteins and peptides (minimum length of 7 amino 
acids) and was determined by searching a reverse database. Enzyme specificity was 
set as C-terminal to arginine and lysine, and a maximum of three missed cleavages 
were allowed in the database search. Peptide identification was performed with an 
allowed initial precursor mass deviation up to 7 p.p.m. and an allowed fragment mass 
deviation 20 p.p.m.  
 
Confidently identified phosphopeptide candidates (identification by one search 
engine setting a FDR cut-off of 1% based on decoy hits was sufficient) were then 
excluded from analysis (Supplementary Table 16-17) and the samples were re-
analyzed using a more sensitive targeted MS approach with higher cycle times. 
Therefore, max. ion accumulation time was set to 500 ms and the resolution was set 
to 240,000 FWHM (at 200 m/z). Using this LFQ-PRM approach, phosphorylation 
sites could be identified for 15 of the 24 selected candidates by Mascot/MaxQuant 
(Supplementary Table 18). Subsequently, PRM assays for LFQ quantification by 
Skyline were generated for all identified phosphopeptides using an in-house R-script 
that extracts the most intense and isoform specific transitions of each peptide from 
the annotated MS2 spectra. For the remaining candidates, heavy reference peptides 
were ordered covering all known and possible phosphorylation site (Supplementary 
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Table 15). In a first step of this stable isotope dilution (SID) based parallel reaction-
monitoring (PRM) quantification37, MS assays were generated from a shotgun LC-MS 
analysis of a mixture containing 500 fmol of each reference phosphopeptide. The 
mass spectrometric analysis and data analysis was similar to above with the 
following changes; a LC gradient of 60 minutes was used, 3e6 ions were 
accumulated for MS1 and scanned at a resolution of 120,000 FWHM (at 200 m/z). 
MS2 scans were acquired at a target setting of 100,000 ions, accumulation time of 50 
ms and a normalized collision energy of 28%. For database searching by Mascot 
isotopically labeled arginine (+10 Da) and lysine (+8 Da) were added as variable 
modifications and the mass tolerance for MS2 fragments was set to 0.02 Da. The 
resulting dat-file was imported to skyline version 3.6.0 (https://brendanx-
uw1.gs.washington.edu/labkey/project/home/software/Skyline/begin.view) to 
generate a spectral library and select the 5 to 10 best transitions for each peptide. 
For the quantitative SID-PRM experiment, the resolution of the orbitrap was set to 
120,000 FWHM (at 200 m/z) and the fill time was set to 250 ms to reach a target 
value of 3e6 ions. Ion isolation window was set to 0.7 Th and the first mass was fixed 
to 100 Th. Each condition was analyzed in biological triplicates. All raw-files obtained 
from the SID-PRM and LFQ-PRM analysis were imported into Skyline for peptide 
quantification. For LFQ-PRM, only peaks/transitions that could be validated by 
confidently identified MS2 spectra using database searching were employed for 
quantification. To control for variation in injected sample amounts, precursor ion 
intensities obtained from an additional MS1 scan were used for normalization. Here, 
the intensity of all precursor ion with a charge of 2+ and more were extracted using 
Progenesis QI software (v2.0, Nonlinear Dynamics Limited) as described above, 
summed and used for normalization.  
 
Immunoblot analysis. 
BMDMs were seeded in 6-well plates and infected with S. Typhimurium ΔorgA and at 
the indicated time points, the samples were collected as describes above. 10 μg 
protein were subjected to SDS-polyacrylamid gels and electroporated onto PVDF 
membrane. Primary antibodies used were mouse anti-phospho-p65 (S536), rabbit 
anti-phospho-IKKε (S172), rabbit anti-IKKε, rabbit anti-phospho-STAT1 (Y701), rabbit 
anti-STAT1, rabbit anti-phospho-p38 (T180/Y182), rabbit anti-p38α (all Cell 
signalling; 1:1000 in 0.3% BSA/ 1x TBST), mouse anti-p65 (Santa Cruz; 1:1000 in 
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0.3% BSA/ 1x TBST) and mouse anti-actin (Millipore; 1:5000 in 0.3% BSA/ 1x TBST) 
and incubated overnight at 4°C. Secondary antibodies used were goat anti-mouse 
HRP and goat anti-rabbit HRP (both Southern Biotech, 1:3000 in 0.3% BSA/ 1x 
TBST) and incubated for 1 h at room temperature. Blots were analysed on a 
ImageQuant LAS4000 (GE Healthcare). 
 
Data availability 
All mass spectrometry raw data files have been deposited to the ProteomeXchange 
Consortium (accession code PXD007528, 
http://proteomecentral.proteomexchange.org, reviewer login: username: 
reviewer91090@ebi.ac.uk, password: AAGlAPa4) via the PRIDE partner repository49. 
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Table	1:	Validation	of	selected	phosphopeptide	candidates	by	targeted	LC-MS	 	 	 	 	
Selected	phosphopeptide	candidate	 Gene	 Validated	phosphorylation	sites1	
Phosphorylation	
position	in	protein	
Phosphorylation	
site	known2	
Change	(4h/0h),			
(+)	PO4ase	
Change	confirmed		by	
PRM-MS,	(-)	PO4ase	
AASGSQPEPSPDQSATNSPESSSR	 Bcl3	 AASGS[+80]QPEPSPDQSATNSPESSSR	 364	 no	 ↑	 Yes	
AASGSQPEPSPDQSATNSPESSSR	 Bcl3	 AASGSQPEPS[+80]PDQSATNSPESSSR	 369	 yes	 ↑	 Yes	
AASGSQPEPSPDQSATNSPESSSR	 Bcl3	 AASGSQPEPSPDQSATNS[+80]PESSSR	 377	 no	 ↑	 Yes	
ASEQGAEVSPQPMAPHPGPDPK	 Ikbke	 ASEQGAEVS[+80]PQPMAPHPGPDPK	 665	 yes	 ↑	 Yes	
DAAFSSLSPPAVPASACPDLDLHYLALR	 Tbkbp1	 ND	 ND	 ND	 ↑	 ND	
DATPPVSPINMEDQER	 Junb	 DAT[+80]PPVSPINMEDQER	 252	 yes	 ↑	 Yes	
DATPPVSPINMEDQER	 Junb	 DATPPVS[+80]PINMEDQER	 256	 yes	 ↑	 Yes	
FHSFSFHELK	 Irak4	 FHS[+80]FSFHELK	 166	 no	 ↑	 Yes	
FRISHELESSSSEVN	 Spp1	 FRIS[+80]HELESSSSEVN	 283	 yes	 ↓	 Yes	
FSGISGCSDGASQEEGSASSTK	 Rictor	 FSGISGC[+57]S[+80]DGASQEEGSASSTK	 1576	 yes	 ↓	 Yes	
GYVSTTIK	 Stat6	 GY[+80]VSTTIK	 641	 yes	 ↑	 Yes	
KGSSSNEPSSDSLSSPTLLAL	 Fos	 KGS[+80]SSNEPSSDSLSSPTLLAL	 362	 yes	 ↑	 Yes	
KKPTPIQLNPAPDGSAVNGTSSAETNLEALQK	 Map2k1	 KKPTPIQLNPAPDGSAVNGTSS[+80]AETNLEALQK	 25	 yes	 ↑	 Yes	
NQHSLYTATTPPSSSPSR	 Tab3	 NQHSLYTATT[+80]PPSSSPSR	 408	 yes	 ↑	 Yes	
QPPSPASKPLPDDPNPA	 Nfkbib	 QPPS[+80]PASKPLPDDPNPA	 346	 yes	 ↓	 Yes	
QSSGASSSSFSSSR	 Ddx3x	 QSS[+80]GASSSSFSSSR	 606	 yes	 ↑	 Yes	
QSSGASSSSFSSSR	 Ddx3x	 QSSGASSSS[+80]FSSSR	 612	 yes	 ↑	 Yes	
RSPSPPEACR	 Irf8	 RS[+80]PSPPEACR	 162	 yes	 ↑	 Yes	
RSPSPPEACR	 Irf8	 RSPS[+80]PPEACR	 164	 yes	 ↑	 Yes	
RSISCVSPEREENMENGR	 Irf9	 RSISC[+57]VS[+80]PEREENMENGR	 139	 yes	 ↑	 Yes	
RVSPEPELQLR	 Ifih1	 RVS[+80]PEPELQLR	 602	 yes	 ↓	 Yes	
SLSAPQDK	 Ripk2	 SLS[+80]APQDK	 364	 yes	 ↑	 Yes	
SPLTSTTESVGK	 Ticam1	 ND	 ND	 ND	 ↓	 ND	
TLVHSSSDGHIDPQHTAGK	 Tab3	 TLVHS[+80]SSDGHIDPQHTAGK	 101	 yes	(human)	 ↑	 Yes	
TLVHSSSDGHIDPQHTAGK	 Tab3	 TLVHSSS[+80]DGHIDPQHTAGK	 103	 yes	 ↑	 Yes	
TNGISDVQISPTLQR	 Jak2	 TNGISDVQIS[+80]PTLQR	 523	 yes	 ↑	 Yes	
TPVDDWTPPAR	 Trim25	 T[+80]PVDDWTPPAR	 84	 yes	 ↑	 Yes	
VCSIDLEIDSLSSLLDDMTK	 Zyx	 VCS[+80]IDLEIDSLSSLLDDMTK	 144	 yes	 ↓	 ND	
VSLESLK	 Ticam1	 ND	 ND	 ND	 ↓	 ND	
YTVGGSETFDSLTDLVEHFK	 Ptpn6	 ND	 ND	 ND	 ↓	 ND	
1)	Phosphorylated	amino	acids	are	followed	by	[+80]	
2)	Phosphorylation	sites	reported	in	the	phosphoSitePlus	database	(version:	2016/04/10,	http://www.phosphosite.org)	
ND	=	not	detected	
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Figure legends 
Figure 1: Extended phosphoproteomics approach overview. In a first step, cells 
were lysed, proteins extracted and digested to peptides. Then, phosphopeptides 
were enriched (we used TiO2 based enrichment, but the method is compatible with 
other enrichment strategies (e.g. IMAC)) followed by label-free quantification (LFQ) 
single dimension (1D) LC-MS analysis. Additionally, sample aliquots were subjected 
to protein quantification using tandem mass tags (TMT) to control for protein 
expression changes. All quantitative data were then statistically analyzed using our 
in-house software SafeQuant. To increase phosphoproteome coverage, we carried 
out a simple additional 1D-LC-MS experiment without the need for time and sample 
consuming fractionation steps. Specifically, remaining phosphopeptide sample 
aliquots were subjected to a phosphatase treatment that globally removed all serine, 
threonine and tyrosine phosphorylations followed by LFQ 1D-LC-MS and statistical 
analysis. In a final analysis, hits of interest were validated to determine the site of 
phosphorylation and confirm its quantification by either western blot or targeted LC-
MS experiments.  
 
Figure 2. LC-MS analysis of phosphopeptide enriched human cell digests 
before (-) and after (+) enzymatic phosphate removal. Number of identified unique 
phosphorylated (a) and all (b) peptides. Mean (line) as well as individual values for 
each replicate are shown. (c) Distribution of MS1 precursor intensities determined in 
both experiments. The median MS1 intensities are indicated. The change in MS1 
intensities was significant (unpaired t-Test; two-tailed distribution assuming equal 
variance; homoscedastic, p-value <0.001). (d) Histogram showing the fold change of 
MS1 signals after phosphatase treatment for unmodified (green, n=5643) and 
phosphorylated peptides (blue, n=8694). The values indicate the median MS1 
intensities. (e) Box plot showing the distribution of MS1 precursor intensities 
determined for 20 unmodified peptides spiked into different amounts of either a 
human cell digest (blue) or a phosphopeptide enriched sample thereof (black). Each 
box spans the interquartile range. The notches extend to the most extreme data 
point, which is no more than 1.5 times the interquartile range from the box. The thick 
horizontal line in each box indicates the median. Abbreviations: 
PO4ase=phosphatase. The calculated significance (t-Test; two-tailed distribution 
assuming equal variance; homoscedastic, p-value <0.001 (***)) are indicated. 
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Figure 3. Phosphatase treatment improved the quantification of significantly 
regulated peptides and proteins. (a) Representation of significantly regulated 
peptides (q-value < 0.01) in bone marrow-derived macrophages infected for 0.5, 1, 2, 
4 and 8 h with S. Typhimurium ΔorgA before (blue) and after (red) phosphatase 
(PO4ase) treatment compared to uninfected cells. (b) Significantly enriched (p<0.01) 
immune signaling pathways (KEGG) of the corresponding proteins represented in (a). 
(c) Plot of ratios after 4 hours of infection of overlapping peptide sequences changing 
significantly in both datasets (q-value <0.01, MS-intensity >1E4). The linear 
regression (black dashed line) and the corresponding equation and R-square value 
are also shown. (d) Number of quantified hits with a CV <20 % between biological 
replicates after (red) and before (blue) phosphatase treatment. 
 
Figure 4. Peptide phosphorylation dynamics before correlated with peptide 
abundances after phosphatase treatment. (a) STRING-based analysis of protein-
protein interactions before (blue) and after (red) phosphatase treatment. Proteins 
highlighted in yellow were detected in phospho- and phosphatase-treated samples 
and in white proteins that were additional added to enlarge the network. Proteins 
validated by parallel reaction monitoring (PRM, see Figure 5) are indicated (*). 
Proteins analyzed by western blot (b and d) are shown with bigger font size. (b) 
Western blot analysis of protein phosphorylation in bone marrow-derived 
macrophages infected with S. Typhimurium ΔorgA representing the activation of 
MYD88 (p65), TRIF (IKKε) and JAK/STAT (STAT1) signaling pathways. (c) Peptide 
abundance of the signaling pathways represented in (b) after phosphatase treatment. 
(d) Comparison of western blot analysis of p38 MAPK phosphorylation in bone 
marrow-derived macrophages infected with S. Typhimurium ΔorgA with the 
respective peptide abundances before (blue) and after (red) phosphatase treatment. 
b,c Data are representatives of three independent experiments. 
 
Figure 5. Validation of selected significantly regulated phosphopeptide 
candidates by targeted MS. Significantly changing dephosphorylated peptides were 
selected (Table 1) and subjected to validation by parallel reaction monitoring (PRM) 
to determine phosphorylation positons and validate abundance changes thereof. For 
this, we carried out two different strategies; (a) the classical stable isotope dilution 
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(SID)-PRM and a novel and (b) simple label-free quantification (LFQ)-PRM approach. 
For SID-PRM, heavy reference peptides carrying all possible phosphorylations were 
synthesized, analyzed by shotgun LC-MS and the 5-10 most intense fragments were 
selected for quantification. After spiking these heavy reference peptides in each 
phosphopeptide enriched sample, these and their light counterparts deriving from the 
endogenous phosphoprotein, were quantified using corresponding PRM assays. For 
LFQ-PRM (b), no heavy reference peptides are required and only the light peptide 
ions are subjected to PRM analysis. Here, an additional database search is carried 
out to identify the corresponding phosphopeptides and determine the most suited 
fragments for quantification. (c) For the peptide “DATPPVSPINMEDQER“ two 
different phosphorylation sites (pS7 and pT3) were identified (Supplementary Figure 
13a&b). The location of shared (*, black) and discriminating (*, red) b- and y-
fragments for the two peptides are indicated. (d) Quantification of both sites by PRM. 
Due to the presence of pS7 specific fragments (y13) and different elution times, both 
phosphorylation site could be accurately quantified. (e) Ratios determined for the two 
phosphorylation sites identified in peptide “DATPPVSPINMEDQER“ by the three 
different quantitative approaches performed (LFQ-/SID-PRM and LFQ-MS1 using 
untreated (-) PO4ase or dephosphorylated (+) PO4ase samples). The median value 
(line) as well as individual values for each replicate are shown.    
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Figure 2: 
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Supplementary	 Figure	 1:	 Base	 peak	 chromatograms	 displaying	 peptide	 elution	 patterns	 for	
phosphopeptide	 enriched	 samples	 before	 (blue)	 and	 after	 (red)	 phosphate	 removal	 using	
phosphatase	 treatment.	 Triplicate	 analyses	 were	 carried	 out	 for	 each	 condition.	 The	 relative	
abundance	scale	was	fixed	for	chromatograms	to	the	number	in	the	corner	indicating	the	absolute	
ion	current	intensity	of	the	most	intense	peak.	
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Supplementary	Figure	2:	
	
	
Supplementary	Figure	2:	Correlation	of	precursor	 ion	 intensities	determined	before	 (-)	and	after	
(+)	 phosphatase	 (PO4ase)	 treatment.	 Squared	 Pearson	 correlation	 coefficients	 (R2)	 and	 a	 line	
showing	perfect	correlation	(black,	dashed)	are	indicated.	(n=3471).	
Calculation	of	phosphopeptide	concentration	during	LC-MS	analysis:	Considering	that	a	total	of	1ug	
(around	1	nmol	at	an	average	peptide	mass	of	1000	Da)	of	phosphopeptides	were	analyzed	over	an	
LC	 gradient	 of	 90	 minutes	 at	 a	 flow	 rate	 of	 200	 nl/min	 (total	 volume	 18	 µl),	 the	 average	
phosphopeptide	concentration	can	be	estimated	to	be	around	55	mM.	This	concentration	is	well	in	
the	range	for	which	ionization	suppression	(starting	at	a	concentration	of	10	mM)	was	observed	for	
other	anionic	molecules,	 like	frequently	used	detergents,	 for	 instance	SDS,	that	are	also	negatively	
charged	in	the	mobile	phase	used	here	(0.1%	formic	acid)1,2.			
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Supplementary	Figure	3:	
	
	
Supplementary	Figure	3:	Precursor	 ion	 intensities	determined	for	20	unmodified	peptides	spiked	
in	different	amounts	to	a	whole	human	cell	digest	and	a	phosphopeptide	enriched	sample.	(a)	Box	
plots	 showing	 the	 distribution	 of	 MS1-intensites	 obtained	 for	 20	 reference	 peptides	 spiked	 in	 3	
different	 amounts	 of	 human	 cell	 digest	 (blue)	 or	 a	 phosphopeptide	 enriched	 human	 cell	 lysate	
(black).	(b)	Box	plots	showing	the	distribution	of	MS1-intensites	ratio	measured	in	phosphopeptide	
enriched	 versus	 non-enriched	 background.	 The	 notches	 extend	 to	 the	 most	 extreme	 data	 point,	
which	 is	no	more	 than	1.5	 times	 the	 interquartile	 range	 from	 the	box.	The	 thick	horizontal	 line	 in	
each	box	indicates	the	median.	The	calculated	significance	(t-Test;	two-tailed	distribution	assuming	
equal	 variance;	 homoscedastic),	 p-values	 <0.001	 (***))	 are	 indicated.	 (c)	 Correlation	 of	 ratios	
determined	in	(b).	Each	box	spans	the	interquartile	range.	Squared	Pearson	correlation	coefficients	
(R2)	and	the	fitting	equation	are	shown.		
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Supplementary	Figure	4:	
	
	
Supplementary	 Figure	 4:	 Evaluation	 of	 tandem	mass	 spectrometric	 analysis	 of	 phosphopeptides	
identified	 +/-	 phosphatase	 treatment.	 (a)	 To	 investigate	 in	more	 detail	 the	 increased	 number	 of	
peptide	 sequences	 identified	 after	 phosphate	 removal	 (here	 referred	 to	 as	 phosphopeptide	
candidates),	 we	 determined	 how	 many	 precursors	 of	 the	 additional	 peptides	 were	 actually	 MS-
sequenced	 in	 their	 phosphorylated	 form	 before	 phosphatase	 treatment	 according	 to	 their	 charge	
state	(z).	Surprisingly,	we	could	find	matching	MS/MS	spectra	(using	a	precursor	mass	tolerance	of	5	
ppm	and	a	retention	time	tolerance	of	300	sec)	for	only	15%	of	the	phosphopeptide	candidates.	This	
indicates	 that	 85%	of	 the	 phosphopeptide	 candidates	were	 not	 identified	 in	 their	 phosphorylated	
state,	because	the	precursor	ion	intensity	was	too	low	for	triggering	MS-sequencing.	Therefore,	the	
observed	global	ion	suppression	(Fig.	2c)	is	the	main	cause	for	the	low	number	of	identified	peptides	
in	 phosphopeptide	 enriched	 samples.	 We	 additionally	 determined	 the	 numbers	 for	 matching	
acetylated	 peptides,	 which	 should	 not	 be	 present	 in	 the	 phosphopeptide	 enriched	 sample	 and	
presents	a	good	negative	control	to	determine	random	matching	events.	Here,	we	could	match	8.3%	
of	 the	 hits,	 meaning	 that	 only	 around	 7%	 of	 the	 phosphopeptide	 candidates	 were	 in	 fact	 MS-
sequenced	 in	 their	 modified	 form.	 Finally,	 we	 also	 found	 a	 similar	 small	 number	 of	 matches	 for	
unmodified	peptides.	This	shows	that	the	phosphopeptide	candidates	were	also	not	present	in	their	
unmodified	but	phosphorylated	form	in	the	original	phosphopeptide	enriched	sample.	(b)	Difference	
in	mascot	ion	score	calculated	for	phosphorylated	and	unmodified	peptides.	Unchanged	scores	(blue	
dashed	 line)	 and	 the	median	 value	 are	 indicated.	 This	 indicates	 that	 phosphorylation	 has	 a	 slight	
negative	 impact	 on	 peptide	 identification	 confidence	 and	 this	 improved	 after	 phosphorylation	
removal.	This	might	also	contribute	to	the	increased	identification	rates	achieved	after	phosphatase	
treatment,	however,	only	to	small	degree.	The	large	majority	of	additional	hits	arise	from	the	overall	
increased	MS-response	and	the	resulting	MS-sequencing	of	additional	precursor	ions.		
Number	of	phosphopep-de	candidate	ions	(iden-fied	exclusively	a:er	PO4ase	treatment)	
that	were	also	MS-sequenced	in	their	phosphorylated	form	before	PO4ase	treatment	
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Supplementary	Figure	5:	
		
Supplementary	 Figure	 5:	 LC-MS	 analysis	 of	 phosphopeptide	 enriched	murine	macrophages	 after	
Salmonella	 infection	 for	 6	 different	 time	 points	 before	 (-)	 and	 after	 (+)	 enzymatic	 phosphate	
removal.	(a)	Venn	diagram	showing	the	unique	peptide	sequences	identified	before	(blue)	and	after	
(red)	 phosphatase	 treatment.	 (b)	 Box	 plot	 illustrating	 the	 distribution	 of	 MS1	 precursor	 ion	
intensities	determined	for	the	different	durations	of	infection	before	(blue)	and	after	(red)	enzymatic	
phosphate	 removal.	 Each	 box	 spans	 the	 interquartile	 range.	 The	 notches	 extend	 to	 the	 most	
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extreme	data	point,	which	is	no	more	than	1.5	times	the	interquartile	range	from	the	box.	The	thick	
horizontal	 line	 in	each	box	 indicates	 the	median.	The	 increase	of	MS1	 intensities	determined	after	
PO4ase	treatment	for	the	different	time	points	(paired	t-Test;	two-tailed	distribution	assuming	equal	
variance;	homoscedastic)	was	significant	(p-value	<0.001)	for	all	samples.	(c)	Correlation	of	precursor	
ion	 intensities	 determined	 before	 (-)	 and	 after	 (+)	 phosphatase	 treatment	 for	 one	 representative	
condition	(8h).	Squared	Pearson	correlation	coefficients	(R2)	and	a	 line	showing	perfect	correlation	
(black,	 dashed)	 are	 indicated.	 (d)	 Histogram	 showing	 the	 fold	 change	 of	 MS1	 signals	 after	
phosphatase	 treatment	 for	 unmodified	 (green)	 and	 phosphorylated	 peptides	 (blue)	 for	 one	
representative	 sample	 (8h).	 The	 numbers	 indicate	 the	median	 values.	 (e)	 Box	 plot	 illustrating	 the	
distribution	 of	 median	MS1	 precursor	 ion	 intensities	 fold	 changes	 determined	 for	 all	 18	 samples	
after	 enzymatic	 phosphate	 removal	 for	 unmodified	 (green)	 and	 phosphorylated	 (blue)	 peptides.	
Each	box	spans	the	interquartile	range.	The	notches	extend	to	the	most	extreme	data	point,	which	is	
no	more	than	1.5	times	the	 interquartile	range	from	the	box.	The	thick	horizontal	 line	 in	each	box	
indicates	 the	 median.	 The	 differences	 of	 ratios	 determined	 for	 unmodified	 and	 phosphorylated	
peptides	 was	 significant	 (paired	 t-Test;	 two-tailed	 distribution	 assuming	 equal	 variance;	
homoscedastic,	p-value	<0.001).	(f)	Box	plot	showing	the	proportions	(in	%)	of	phosphorylated	over	
all	 peptides	 identified	 in	 the	 TiO2	 enriched	 samples.	 Each	 box	 spans	 the	 interquartile	 range.	 The	
notches	extend	to	the	most	extreme	data	point,	which	 is	no	more	than	1.5	times	the	 interquartile	
range	from	the	box.	The	thick	horizontal	line	in	each	box	indicates	the	median.	(n=2799	for	Figures	
b-f).		Abbreviations:	PO4ase=phosphatase.		
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Supplementary	 Figure	 6:	 Phosphopeptide	 content	 of	 additional	 identified	 peptides.	 We	 used	 a	
Random	 Forest	 classification	 algorithm3	 to	 show	 that	 the	 novel	 peptides	 identified	 in	 the	 PO4ase	
treated	 samples	 have	 phospho-specific	 features.	 The	 list	 of	 investigated	 features	 included;	 the	
number	 of	 trypsin	 missed	 cleavages	 (Nb.	 Miscleavages),	 peptide	 molecular	 weight	 (Molecular	
Weight),	 Intensity	 Based	 Absolute	 Quantification	 (iBAQ)	value	 of	 the	 originating	 protein4,	 the	
number	 of	 entries	 in	 the	 PhosphoSitePlus	 database	 per	 identified	 peptide(PSite+	 Evidence)5	 and	
finally	 the	 prevalence	 of	 each	 amino	 acid	 per	 peptide;	 i.e.	 amino	 acid	 count	 divided	 by	 peptide	
length	(amino	acid	one-letter	code).	
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Table: (-) PO4ase Train, Classification Accuracy 0.94 
 (Labelled) - (Labelled) + 
(Predicted) - 476 39 
(Predicted) + 24 461 
 
Table: (-) PO4ase Test, Classification Accuracy 0.92 
 (Labelled) - (Labelled) + 
(Predicted) - 469    44 
(Predicted) + 31   456 
 
Table: (+) PO4ase, Classification Accuracy 0.88, FDR 0.175 
 (Labelled) - (Labelled) + 
(Predicted) - 469    90 
(Predicted) + 31   410 
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To	train	the	classification	algorithm,	unmodified	serine	or	threonine	containing	peptides	identified	in	
the	phosphopeptide	enriched	samples	before	PO4ase	treatment	were	used	as	negative	controls	and	
confidently	 identified	 phosphopeptides,	 found	 in	 the	 phosphopeptide	 (no	 PO4ase)	 and	 beta-
elimination	datasets,	were	used	as	positive	controls.	
In	total,	the	training	dataset	(PO4	Train)	included	500	negative	control	peptides	(assigned	a	negative	
class	 label)	 and	 an	 equal	 number	 of	 positive	 control	 peptides	 (assigned	 a	 positive	 class	 label).	
Additionally,	a	separate	test	set	(PO4	Test)	with	the	same	number	of	negative	and	positive	control	
peptides	as	the	training	dataset	was	compiled.	This	test	dataset	was	used	to	demonstrate	that	our	
confidently	 identified	phosphopeptides	 could	be	distinguished	 from	unmodified	peptides	 found	 in	
our	 phospho-enriched	 samples,	 in	 the	 feature	 space	 described	 above.	 When	 classifying	 the	 test	
dataset	peptides	using	the	Random	Forest	algorithm	a	classification	accuracy	of	92%	was	achieved	
(b).	 A	 Receiver	 Operator	 characteristics	 curve	 is	 shown	 in	 (a)	 (The	 Area	 Under	 Curve	 was	 0.98).	
Clearly,	 the	 phosphopeptides	 take	 on	 dramatically	 different	 values	 with	 respect	 to	 the	 selected	
features	fed	to	the	Random	Forest	algorithm.	To	better	understand	how	the	phosphopeptides	differ	
from	 unmodified	 peptides,	 we	 ranked	 the	 importance	 of	 each	 feature	 by	 the	 Mean	 Decrease	
Accuracy;	 i.e.	 the	 decrease	 in	 classification	 accuracy	 as	 the	 values	 of	 a	 feature	 are	 randomly	
permutated	 (c).	 The	 top-ranking	 features	 were	 PSite+	 Evidence,	 iBAQ	 and	 the	 prevalence	 of	 the	
amino	 acids	 serine	 and	 proline.	 It	 is	 intuitive	 that	 our	 identified	 phosphopeptides	 are	 listed	more	
frequently	 in	 the	 PhosphoSitePlus	 database	 than	 the	 identified	 unmodified	 peptides.	 It	 is	 also	
expected	 that	 nonspecifically	 enriched	 peptides	 (i.e	 the	 identified	 unmodified	 peptides)	 map	 to	
highly	abundant	proteins.	A	 likely	explanation	 for	 the	differences	 in	 serine	and	proline	prevalence	
among	 positive	 and	 negative	 controls	 (serine	 and	 proline	 occur	 more	 frequently	 in	 the	
phosphopeptide	set)	is	that	the	“SP”	sequence	is	a	frequently	targeted	motif	by	several	kinases,	like	
ERK.	
Next,	we	created	a	second	test	datasets	(PO4ase)	by	randomly	sampling	500	peptides	only	identified	
in	 the	 PO4ase	 treated	 samples	 (i.e.	 a	 set	 of	 phosphopeptide	 candidates)	 and	 adding	 the	 500	
unmodified	(negative	control)	peptides	in	PO4	Test.	
When	 applying	 the	 Random	 Forest	 classification	 algorithm,	 the	 candidate	 phosphopeptides	 were	
separated	 from	 the	 unmodified	 negative	 control	 peptides	 with	 88%	 accuracy	 (b).	 A	 Receiver	
Operator	characteristics	curve	is	shown	in	(a,	The	Area	Under	Curve	was	0.94).	As	described	in	Choi	
et	 al.6	 the	 False	 Discovery	 Rate	 (FDR)	 can	 be	 computed	 from	 the	 distribution	 of	 Posterior	 Error	
Probabilities	(PEP)	assigned	to	the	phosphopeptide	candidate	set	(Eq.	1).	
𝐹𝐷𝑅 = 1𝑛 𝑃𝐸𝑃)*)+, 	
Equation	S1)	
Applying	Eq.	1	to	the	PO4ase	dataset	gives	us	an	estimated	FDR	of	0.175;	i.e.	approximately	82.5%	of	
the	500	randomly	sampled	phosphopeptide	candidates	were	expected	to	have	been	phosphorylated	
prior	to	PO4ase	treatment.	We	regard	this	as	a	conservative	estimate	of	the	FDR	as	(I)	the	selected	
features	 do	 not	 allow	 for	 perfect	 classification	 on	 training	 data.	 The	 classification	 accuracy	 of	 the	
training	data	was	94%	(b).	(II)	We	ignore	the	possibility	that	a	peptide	could	be	present	in	the	sample	
as	 both	 unmodified	 and	 phosphorylated.	 (III)	 As	 described	 below	 the	 phosphopeptides	 only	
identified	after	PO4ase	 treatment	have	slightly	different	 sequence	characteristics	 compares	 to	 the	
phosphopeptides	 identified	 before	 PO4ase	 treatment,	 which	 likely	 explains	 why	 they	 were	 not	
identified	prior	to	removal	of	the	phosphate	group.		 	
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Supplementary	Figure	7:	
	
Supplementary	 Figure	 7:	 Prevalence	 of	 a	 few	 selected	 frequent	 kinase	 motifs	 in	 the	 peptides	
identified	before	(blue)	and	after	(red)	phosphatase	treatment.	The	proportions	are	also	indicated	
for	peptides	 identified	after	b-elimination	 (orange)	and	 for	a	non-enriched	 total	 cell	digest	 sample	
(purple).		See	Supplementary	Tables	9&10	for	details.	
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Supplementary	Figure	8:	
	
	
Supplementary	Figure	8:	Beta-elimination	of	phosphopeptide	enriched	samples	according	to	Poot	
et.	 al.7.	 (a)	 Overview	 of	 the	 beta-elimination	 procedure.	 Phosphopeptide	 enriched	 samples	 were	
treated	 with	 barium	 hydroxide	 (0.15M)	 for	 1	 h	 at	 37°C	 to	 remove	 phosphoric	 acid	 from	
phosphorylated	serine	and	threonine	residues	by	beta-elimination.	The	remaining	dehydrated	sites	
(red)	on	serine	and	threonine	were	then	identified	by	LC-MS	analysis.	Notably,	this	approach	is	only	
applicable	 to	 serine	 and	 threonine	 phosphorylations	 and	 does	 not	 remove	 phosphoric	 acid	 from	
tyrosines.	 Chemical	 formulas	 were	 generated	 using	 PubChem	 Sketcher	 v2.4	
(https://pubchem.ncbi.nlm.nih.gov/edit2/index.html)	 (b)	 Pie	 chart	 indicating	 the	 overlap	 (in	 %)	 of	
the	 phosphopeptides	 identified	 by	 beta-elimination	 with	 the	 datasets	 obtained	 before	 and	 after	
phosphatase	(PO4ase)	treatment.					
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Supplementary	Figure	9:	
	
	
Supplementary	Figure	9:	Evaluation	of	physiochemical	properties	of	peptide	 identified	before	 (-)	
and	after	(+)	phosphatase	treatment.	(a)	Boxplot	showing	the	distribution	of	the	proportion	of	basic	
amino	 acids	 (histidine,	 lysine	 and	 arginine)	 to	 all	 amino	 acids	 of	 peptides	 identified	 before	 (blue,	
n=891)	 and	 after	 (red,	 n=8887)	 PO4ase	 treatment.	 The	notches	 extend	 to	 the	most	 extreme	data	
point,	which	is	no	more	than	1.5	times	the	interquartile	range	from	the	box.	The	thick	horizontal	line	
in	 each	 box	 indicates	 the	 median.	 The	 calculated	 significance	 (unpaired	 t-Test;	 two-tailed	
distribution	 assuming	 equal	 variance;	 homoscedastic),	 p-values	 <0.001	 (***),	 <0.01	 (**))	 are	
indicated.	 (b)	 Like	 (a)	 for	 the	 proportion	 of	 acidic	 (glutamate	 and	 aspartate)	 amino	 acids.	 (c)	 Bar	
chart	 illustrating	 the	 change	 in	 precursor	 ion	 charge	 states	 of	 identified	 triple	 charged	
phosphorylated	peptides	after	phosphate	removal.	 (d)	Bar	chart	showing	the	combined	number	of	
unique	peptides	 identified	 in	both	datasets	 containing	different	numbers	of	basic	amino	acids.	 (e)	
Plot	 showing	 the	 percentage	 of	 all	 identified	 peptides	 covered	 by	 both	 datasets	 for	 peptides	
containing	 different	 numbers	 of	 basic	 amino	 acids.	 The	 lines	 indicate	 the	 linear	 regression	
determined	 for	 both	 datasets.	 The	 corresponding	 equations	 and	 R-square	 values	 are	 also	 shown.	
Both	slopes	were	significant	non-zero	(p<0.025	(red),	p<0.01	(blue)).	(f)	Like	(e)	for	the	proportion	of	
acidic	 (glutamate	 and	 aspartate)	 amino	 acids.	 Both	 slopes	 were	 significant	 non-zero	 (p<0.01).	
Abbreviations:	PO4ase=phosphatase,	AA=amino	acid.		
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Supplementary	Figure	10:	
	
	
Supplementary	 Figure	 10:	 Functional	 and	 quantitative	 analysis	 of	 differentially	 abundant	
phosphorylated	 peptides.	 (a)	 Significantly	 enriched	 (p<0.01)	 GO-terms	 of	 the	 corresponding	
proteins	represented	in	Figure	3a.	(b)	Plot	of	ratios	showing	all	peptides	with	overlapping	sequences	
before	 and	 after	 PO4ase	 treatment	 quantified	 after	 4	 hours	 of	 infection	 applying	 the	 following	
filters:	coefficient	of	variation	(CV)	below	20%	(only	before	PO4ase),	MS-Intensity	>10,000,	q-value	
<0.01	 (only	 after	 PO4ase).	 Ratios	 determined	 from	 single	 (blue)	 and	 doubly	 (red)	 phosphorylated	
peptides	 (before	 phosphatase	 treatment)	 as	 well	 as	 the	 R-square	 value	 are	 shown.	 Besides,	 the	
number	of	false	hits	showing	different	ratio	trends	and	the	corresponding	error	rate	are	indicated.	 	
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Supplementary	Figure	11:	
		
Supplementary	 Figure	 11:	 Impact	 of	 phosphatase	 treatment	 on	 determined	 quantification	
statistics.	 (a)	 Median	 p-values	 (unpaired	 t-Test;	 two-tailed	 distribution	 assuming	 equal	 variance;	
homoscedastic,	 determined	 by	 SafeQuant8	 determined	 for	 all	 quantified	 peptides	 of	 the	 different	
infection	time	points	to	the	control	samples	for	datasets	(-,	n=6607)	and	(+,	n=14,603)	phosphatase	
(PO4ase).	The	time	points	(colors)	as	well	as	the	median	value	(black	line)	are	indicated.	(b)	Number	
of	 hits	 with	 p-value	 <0.05	 for	 all	 different	 time	 points	 and	 both	 datasets.	 (c)	 Volcano	 plot	 of	
phosphopeptide	quantified	after	0	and	4	hours	of	infection	generated	by	SafeQuant.	The	number	of	
hits	 passing	 a	 q-value	 of	 0.01	 (grey	 line)	 are	 indicated	 (n=6607).	 (d)	 like	 (c)	 after	 phosphatase	
treatment	(n=14,603).		
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Supplementary	Figure	12:	
	
	
Supplementary	Figure	12:	Identification	and	quantification	of	two	different	phosphorylation	sites	
one	 peptide	 “DATPPVSPINMEDQER“	 by	 LFQ-PRM	 (workflow	 see	 Fig.	 5).	 (a)	 MS/MS	 spectrum	
showing	 the	 identification	 of	 phospho-serine	 at	 position	 7	 by	 LFQ-PRM	 and	 MaxQuant9.	 The	
assigned	 b-	 (blue)	 and	 y-	 (red)	 ions	 are	 indicated.	 (b)	 Like	 (a)	 for	 the	 identification	 of	 phospho-
threonine	at	position	3.	(c)	Quantitative	LFQ-PRM	analysis	of	pS7	isoform	using	Skyline	and	an	assay	
generated	 from	 (a).	The	different	 fragments	employed	 for	quantification	are	 indicated.	 (d)	 Like	 (c)	
for	the	isoform	pT3.	
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Supplementary	Figure	13:	
	
Supplementary	Figure	13:	Identification	and	quantification	of	three	different	phosphorylation	sites	
one	peptide	“AASGSQPEPSPDQSATNSPESSSR“	by	LFQ-PRM	(workflow	see	Fig.	5).	(a)	Sequences	of	
three	 phospho-isoforms	 identified	 by	 LFQ-PRM	 on	 one	 peptide	 candidate	 selected	 for	 validation.	
The	positions	of	the	sites	are	 indicated	(red).	(b)	Transition	based	quantification	by	LFQ-PRM	using	
Skyline10	 for	 all	 three	 phosphorylation	 isoforms	 found	 on	 the	 double	 charged	 precursor	 ion.	 Site	
specific	transitions	allowed	the	separate	quantification	of	all	three	isoforms.	(c)	Like	(b)	for	the	triple	
charged	precursor	ion.	(d)	Bar	chart	showing	the	summed	MS-intensities	of	all	transitions	employed	
for	quantification	of	the	pS18	isoform	at	0	and	4	hours	of	infection	for	the	double	charged	precursor.	
The	contribution	of	each	transition	is	shown	with	different	colors	(see	(b)).	(e)	Like	(d)	for	the	triple	
charged	precursor	ion.	See	(c)	for	fragment	colors.	All	corresponding	values	are	shown	in	Table	1.		
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Supplementary	Figure	14:	
	
	
Supplementary	 Figure	 14:	 Correlation	 of	 ratios	 determined	 from	 successfully	 validated	
phosphopeptides	 candidates	 quantified	 in	 the	 large-scale	 experiment	 (after	 phosphatase	
treatment)	 and	 by	 follow	 up	 targeted	 parallel	 reaction	 monitoring	 (PRM)	 MS	 analysis	 (no	
phosphatase	 treatment).	 All	 hits	 were	 validated	 using	 triplicate	 samples	 for	 no	 and	 4	 hours	 of	
infection.	Pearson	correlation	coefficients	(r)	and	a	line	showing	perfect	correlation	(black,	dashed)	
are	indicated.	
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Francisella requires dynamic type VI secretion
system and ClpB to deliver effectors for
phagosomal escape
Maj Brodmann1,*, Roland F. Dreier1,*, Petr Broz1 & Marek Basler1
Francisella tularensis is an intracellular pathogen that causes the fatal zoonotic disease
tularaemia. Critical for its pathogenesis is the ability of the phagocytosed bacteria to escape
into the cell cytosol. For this, the bacteria use a non-canonical type VI secretion system
(T6SS) encoded on the Francisella pathogenicity island (FPI). Here we show that in F. novicida
T6SS assembly initiates at the bacterial poles both in vitro and within infected macrophages.
T6SS dynamics and function depends on the general purpose ClpB unfoldase, which
specifically colocalizes with contracted sheaths and is required for their disassembly. T6SS
assembly depends on iglF, iglG, iglI and iglJ, whereas pdpC, pdpD, pdpE and anmK are
dispensable. Importantly, strains lacking pdpC and pdpD are unable to escape from
phagosome, activate AIM2 inflammasome or cause disease in mice. This suggests that PdpC
and PdpD are T6SS effectors involved in phagosome rupture.
DOI: 10.1038/ncomms15853 OPEN
1 Focal Area Infection Biology, Biozentrum, University of Basel, Klingelbergstrasse 50/70, CH-4056 Basel, Switzerland. * These authors contributed equally to this
work. Correspondence and requests for materials should be addressed to P.B. (email: petr.broz@unibas.ch) or to M.Ba. (email: marek.basler@unibas.ch).
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F
rancisella tularensis is a Gram-negative bacterium that
causes the zoonotic disease tularaemia in human and animal
host. The severity of tularaemia varies depending on the
route of infection and the type of strain. The Francisella tularensis
subsp. tularensis is the most virulent strain and aerosol
transmission of a few bacteria can cause lethal pneumonia in
humans1. Given the low infectious dose and the severity of the
infection, subsp. tularensis has been classified as Tier 1 select
agent. The related strain Francisella tularensis subsp. novicida
(F. novicida) has in contrast low virulence in humans, but is
highly virulent in mice and thus often used as a laboratory model
for tularaemia2. The pathogenicity of both Francisella species is
linked to their ability to replicate in the cytosol of phagocytes,
such as macrophages or dendritic cells. After phagocytosis, the
bacteria shortly reside within a membrane-bound phagosome, but
subsequently disrupt the phagosomal membrane and escape into
the host cell cytosol, where they replicate3.
While phagosomal escape is essential for Francisella intracel-
lular replication and virulence in vivo, it also allows the host to
mount anti-microbial and innate immune defenses. Among these
are the production of type I interferons (type I IFNs) via
the cGAS-STING-IRF3 axis, the production of antimicrobial
guanylate-binding proteins (GBPs) and the activation of the
AIM2 (absent in melanoma 2) inflammasome, which controls
the release of mature IL-1b and IL-18 as well as the induction
of host cell death through pyroptosis4–11. Interferon production
and inflammasome activation require the recognition of bacterial
DNA in the cytosol, and have been linked to the lysis of cytosolic
Francisella. Mice deficient in these responses fail to control
bacterial replication, resulting in a fatal disease4–6,8,9. Francisella
virulence and the escape from the phagosomal compartment
requires a gene cluster referred to as the Francisella Pathogenicity
Island (FPI)12. Two nearly identical copies of the FPI are found
in subspecies tularensis, holarctica and mediasiatica. The
F. novicida genome contains only a single FPI copy13, but
features a related island called ‘Francisella novicida Island
(FNI)’14,15. The FPI has been suggested to encode a non-
canonical type VI secretion system (T6SS)16,17, which based on
gene content and phylogeny is proposed to represent a unique
T6SS subtype (T6SSii)18.
T6SS is a nanomachine capable of delivery of effector proteins
across target cell membranes of both bacterial and eukaryotic cells
and thus is often required for bacterial competition and
pathogenesis19–23. One of the hallmarks of this system is its
highly dynamic assembly that can be visualized by live-cell
fluorescence microscopy24,25. Assembly of T6SS starts by
formation of a membrane complex formed of TssJ, TssL and
TssM26. This is followed by assembly of a baseplate complex from
TssE, TssF, TssG, TssK and also VgrG, PAAR spike as well as
TssA in some organisms27–31. Baseplate complex then initiates
assembly of a long Hcp tube and TssB, TssC (or VipA, VipB)
sheath wrapped around the tube32. Both spike and Hcp tube can
associate with effectors and are delivered together into target cells
upon rapid sheath contraction33–39.
Even though the F. novicida sheath is structurally similar to the
sheath of canonical T6SS of V. cholerae40,41, it is unclear to what
extent the canonical T6SS assembly mechanisms apply to
Francisella. The reason is that Francisella T6SS is highly
divergent and clear homologues of several core components are
missing, such as TssE, TssF and TssG. In addition, many
components such as TssK, VgrG, Hcp and PAAR have only low
primary sequence homology to the canonical T6SS components.
For example, IglG was recently shown to be structurally similar to
PAAR proteins, which are required for T6SS function15,29. On the
other hand, the FPI cluster contains many genes of unknown
function, such as iglF, iglI, iglJ, pdpA, pdpC, pdpE, pdpD
and anmK. PdpA, PdpC and PdpD were identified by
mass-spectrometry as secreted by Francisella T6SS and
PdpC/PdpD were proposed to be effectors required for
phagosomal escape, intracellular growth and virulence42–48.
Interestingly, the FPI cluster lacks a homologue of an unfoldase
ClpV, which is present in all canonical T6SS clusters and
recycles contracted sheaths14,24,49,50. Overall, the non-canonical
gene composition suggests a unique mode of action of the
Francisella T6SS.
Here we show that F. novicida T6SS sheath cycles between
assembly, contraction and disassembly. Interestingly, the vast
majority of T6SS sheath assemblies initiate close or at the cell
pole. We show that ClpB colocalizes with contracted sheaths and
is required for sheath disassembly, however, is dispensable for
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Figure 1 | A schematic overview of Francisella T6SS genes. Assignments for gene functions are based on previous studies cited in the main text and our
observations: Black—structural components; Green—secreted structural components; Purple—secreted effectors; Blue—unfoldase; White—no clear
evidence for function; Shaded—required for efficient assembly. The Francisella FPI (pdpA–anmK) nomenclature and the canonical T6SS nomenclature for the
F. novicida genes is shown. Genes are drawn in scale.
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sheath assembly and contraction. T6SS dynamics and function
depends on iglF, iglG, iglI and iglJ, while pdpC and pdpD are
specifically required for phagosomal escape and virulence in a
mouse model of tularaemia, but also for the engagement of the
host innate immune response.
Results
Francisella T6SS is dynamic and assembles on the cell pole.
Francisella T6SS has a non-canonical gene composition and lacks
ClpV suggesting unique mode of action (Fig. 1). To understand
Francisella T6SS assembly and function, we searched for
conditions that would allow us to image subcellular localization
of TssB homologue IglA. We have serendipitously discovered
that F. novicida iglA-sfGFP grown to an exponential phase in
BHI media induced expression of IglA-sfGFP upon prolonged
incubation on an agarose pad under a glass coverslip.
Importantly, the increase in expression correlated with an
increase in number of IglA-sfGFP structures detected in the
bacteria (Fig. 2a,b). Time-lapse imaging at a rate of 20 frames per
minute showed that IglA-sfGFP structures extended across the
bacteria within 30 and 120 s with assembly speeds between 5 and
15 nm s 1. After full assembly, the IglA-sfGFP structures
immediately contracted to approximately half of their original
length and became brighter (Fig. 2c; Supplementary Fig. 1a;
Supplementary Movies 1 and 4). After contraction, the sheath
structures were disassembled during the nextB2–3min (Fig. 2c;
Supplementary Fig. 1a). The average fluorescence intensity of the
bacteria before and after one cycle of assembly, contraction and
disassembly was similar, suggesting that IglA-sfGFP remained
stable and folded during this cycle (Supplementary Fig. 1b).
Importantly, no IglA-sfGFP structures were detected in the
bacteria lacking the TssM homologue encoded by pdpB (Fig. 1),
suggesting that assembly of IglA-sfGFP structures is dependent
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Figure 2 | Increase of GFP intensity correlates with increased number of dynamic T6SS per bacterium. (a) GFP signal intensities of F. novicida U112
iglA-sfGFP and fluorescence background were measured every minute for three regions of interest containing 1–30 bacteria. Two independent experiments
were carried out. GFP intensity increase in a single F. novicida U112 iglA-sfGFP bacterium is shown at different time points. First image is a merge of
phase contrast and GFP channels, following images represent GFP channel only. (b) Number of bacteria and T6SS structures were counted at time points
between 0 and 120min in three regions of interest containing 36–191 bacteria. Two independent experiments were carried out. Error bars represent s.d.
(c,d) IglA-sfGFP localization in F. novicida U112 iglA-sfGFP wild type (c) and DpdpB (d). Arrowheads indicate T6SS sheath assembly and contraction. First
image is a merge of phase contrast and GFP channels, following images represent GFP channel only. (e) Model for quantification of T6SS assembly position.
Pole area was determined as 50% of total surface area equally distributed to both poles. (f) Model from e applied to F. novicida U112 iglA-sfGFP and
V. cholerae 2740-80 vipA-msfGFP. Merge of phase contrast and GFP channels is shown. For a,c,d and f 3.3 3.3mm fields of view are shown.
Scale bar, 1mm.
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on the function of the whole T6SS (Fig. 2d; Supplementary
Movie 2). The dynamics of IglA-sfGFP localization is similar to
that of VipA-sfGFP in V. cholerae and is consistent with the fact
that IglA and IglB form a structure closely resembling V. cholerae
T6SS sheath25,40,41.
Interestingly, we also noticed that IglA-sfGFP sheaths were
preferentially assembled from the bacterial pole and thus often
formed structures as long as the bacterial length. To quantify the
preference for subcellular localization, we divided the bacterial
perimeter equally to a polar region and a mid-cell region (Fig. 2e)
and counted assemblies initiated in these two equally large
regions. Out of 851 assemblies, 821 assemblies (96.5%) were
initiated in the polar region. As a control, we performed the same
analysis for V. cholerae and show that only 53.8% (425 from 790)
assemblies were initiated in the polar region (Fig. 2f) as expected
for assemblies without preferred localization24,25,51. Taken
together, we show that F. novicida assembles a dynamic T6SS
sheath on the cell poles and that the sheath cycles through
assembly, contraction and disassembly similarly to what was
previously described for other canonical T6SSs.
ClpB is required for disassembly of contracted sheaths. The fact
that contracted sheaths were quickly disassembled without
apparent degradation of IglA-sfGFP suggested that F. novicida
recycles contracted sheaths using a mechanism similar to the
canonical ClpV-mediated sheath disassembly. The closest
homologue of V. cholerae ClpV in F. novicida genome is ClpB
(FTN_1743) (36% sequence identity). Interestingly, clpB was
previously shown to be required for survival of various stresses52
but also essential for intracellular replication and virulence of
F. novicida53,54.
Here we show that F. novicida lacking clpB mainly contained
bright IglA-sfGFP foci (Fig. 3a). Time-lapse imaging showed
that the F. novicida DclpB occasionally assembled new sheaths
with kinetics similar to that of the parental strain but after
contraction, the sheaths were never disassembled and remained
intact in the bacteria (Fig. 3a,b; Supplementary Movies 1 and 4).
Such assembly was still dependent on functional T6SS, as no
sheath extensions and contractions were detected in F. novicida
DclpB/pdpB. However, some bright, non-dynamic IglA-sfGFP
foci were detected in the absence of both clpB and pdpB
(Supplementary Fig. 2a; Supplementary Movie 2). This indicates
that activity of ClpB is required for recycling of contracted
sheaths, however, in case of a defect in ClpB function, some
non-dynamic IglA-sfGFP foci may form also in the absence of a
fully functional T6SS.
To test directly the role of ClpB in disassembly of the
contracted sheaths, we introduced clpB-mCherry2 fusion to the
native locus on the chromosome of the iglA-sfGFP or wild-type
strain. Fusing mCherry2 to ClpB had no influence on the ability
of F. novicida to survive heat shock indicating that such fusion is
fully functional (Supplementary Fig. 2d). ClpB-mCherry2
subcellular localization cycled between uniform cytosolic and
punctate localization and this dynamics was dependent on
the presence of pdpB (Supplementary Fig. 2b,c, Supplementary
Movie 3). When IglA-sfGFP and ClpB-mCherry2 were imaged
simultaneously, ClpB spots colocalized specifically with the
contracted sheaths (Fig. 3c; Supplementary Movies 3 and 5).
F. novicida uses the T6SS to escape from phagosome of cells
like macrophages and consistently IglA-sfGFP spots could be
detected in intracellular bacteria, implying the assembly of T6SS
sheaths40. To test whether sheath assembly is dynamic under
physiological conditions during infection, we infected primary
murine bone marrow-derived macrophages (BMDMs) from
wild-type C57BL/6 mice for 1 h with exponentially grown
F. novicida. After washing away non-phagocytosed bacteria, the
infected cells were fixed, stained with phalloidin and anti-F.
novicida LPS antibody and analysed by super resolution
structured illumination microscopy (SIM) to determine the
relative localization of actin, bacteria and T6SS sheaths
(Fig. 4a,b). This analysis confirmed that F. novicida reside
inside the macrophage and assemble T6SS sheaths.
Next, we imaged IglA-sfGFP and ClpB-mCherry2 dynamics
within F. novicida in live macrophages and observed that the
sheaths cycled through assembly, contraction and disassembly.
Importantly, ClpB-mCherry2 dynamically localized into spots
that colocalized with the contracted sheaths, suggesting that
ClpB is responsible for disassembly of the contracted sheaths
also within phagosomes of infected macrophages (Fig. 4c;
Supplementary Movie 6). In total, we analysed 30 sheath
assembly, contraction and disassembly events inside live macro-
phages and all of the assemblies originated from the cell pole
(Fig. 4c; Supplementary Movie 6). Together, these data suggest
that sheath dynamics and subcellular localization observed
during imaging of F. novicida on agarose pads is similar to that
of the sheath in the bacteria residing inside of live macrophages.
To determine the importance of ClpB for F. novicida pathogen-
esis, we infected BMDMs with F. novicida wild-type, DpdpB and
DclpB and determined the percentage of phagosomal and cytosolic
bacteria using a phagosome-protection assay based on selective
permeabilization of the plasma membrane with digitonin9.
F. novicida DclpB had a significant defect in phagosomal escape
at 4 h post infection, similarly to bacteria lacking the essential
structural component PdpB (Fig. 3d; Supplementary Fig. 3a).
Consistent with reduced cytosolic localization, we observed
significantly reduced levels of pyroptosis induction and cytokine
release in LPS-primed BMDMs infected for 10 h with F. novicida
DpdpB and DclpB, while the wild-type strain elicited strong
immune responses (Fig. 3e). Finally, we evaluated the role of ClpB
in vivo in a mouse model of tularaemia. We infected age- and sex-
matched wild-type C57BL/6 mice subcutaneously with 104 colony-
forming units (CFUs) of F. novicida wild-type, DpdpB and DclpB
and measured the bacterial burden at 2 days post infection. Mice
infected with F. novicida DclpB displayed significantly reduced
bacterial counts in the liver and spleen as compared to the mice
infected with F. novicida wild type, and in many cases no bacteria
could be recovered, similarly to what was observed with F. novicida
DpdpB (Supplementary Fig. 3b). Overall these results indicate that
ClpB acts as an unfoldase for the FPI-encoded T6SS sheath, and
that its activity is essential for T6SS dynamics and consequently
F. novicida virulence.
Differential requirement of FPI genes for sheath dynamics.
Almost all FPI genes were shown to be required for intracellular
replication probably due to a lack of phagosomal escape, however,
many genes of the FPI cluster have no known homologues or
were not characterized in detail14. Importantly, both structural
components of T6SS as well as putative effectors secreted by T6SS
are in principle essential for overall T6SS function, however,
effectors may be to a certain degree dispensable for T6SS
assembly. To provide an insight into which FPI genes are
required for assembly of T6SS and which may potentially encode
secreted effectors, we generated in-frame deletions of genes
for which we were unable to predict function based on homology
to known canonical T6SS components (Fig. 1). IglA-sfGFP
subcellular localization was then imaged in those strains under
the same conditions as used before for the parental strain.
In DiglF and DiglG strains, we detected on average 1 dynamic
sheath assembly per 400 and 500 cells, respectively, in 5min
(Supplementary Movie 2). This suggests that IglF and IglG may
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be required for efficient initiation of T6SS assembly. On the other
hand, iglI and iglJ are essential for sheath assembly as no sheath
assemblies were detected in more than 1,000 cells in 5min even
though IglA-sfGFP was expressed to the same level as in the
parental strain (Fig. 5a; Supplementary Movie 2). Consistent with
the defect in T6SS assembly, we found that DiglF, DiglG, DiglI and
DiglJ strains were unable to escape into the cytosol of the infected
macrophages, and consequently failed to activate cytosolic innate
immune signalling (Fig. 5b,c). We cannot completely rule out the
possibility that the observed phenotypes of mutants are due to
polar effects on expression of other T6SS genes. However, defect
in intracellular growth was previously successfully complemented
for iglF, iglG and iglI genes55.
Single deletion of pdpE, pdpC, pdpD and anmK or deletion of
both pdpD and anmK (DpdpD/anmK) or pdpC and pdpD (DpdpC/
pdpD) had no significant influence on sheath dynamics or
localization (Fig. 6a; Supplementary Movie 1). Only deletion of
all three genes pdpC, pdpD and anmK in the same strain decreased
frequency of sheath assembly by 30% from an average of one
structure per three cells to about one structure per five
cells (Supplementary Fig. 4a). Nevertheless, sheath assemblies in
DpdpC/pdpD/anmK still preferentially localized to the cell pole,
assembled with a similar speed and cycled through extension,
contraction and disassembly like in the parental strain
(Supplementary Fig. 4b,c; Supplementary Movie 1). Importantly,
DpdpE and DpdpC/pdpD/anmK assembled sheaths with dynamics
undistinguishable from the parental strain within infected macro-
phages (Supplementary Fig. 5e,f). In conclusion, our analysis
allowed us to identify FPI genes (iglF, iglG, iglI and iglJ) essential for
T6SS assembly and a distinct set of FPI genes (pdpE, pdpC, pdpD
and anmK) that are dispensable for T6SS assembly.
PdpC and PdpD are required for phagosomal escape. To test
whether pdpE, pdpC, pdpD and anmK genes are required for the
escape of F. novicida from phagosome, we infected BMDMs with
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Figure 3 | Phagosomal rupture and AIM2 inflammasome activation is dependent on disassembly of T6SS sheaths by ClpB. (a) T6SS dynamics in
F. novicida U112 iglA-sfGFP DclpB. Arrowheads indicate T6SS sheath assembly, contraction and location of sheath after contraction. Empty arrowheads
indicate non-dynamic IglA-sfGFP foci. First image is a merge of phase contrast and GFP channels, following images represent GFP channel only.
(b) Kymogram of F. novicida U112 iglA-sfGFP DclpB over 5min (3 s per pixel). First image is a merge of phase contrast and GFP channels, following images
represent GFP channel only. (c) Colocalization of ClpB-mCherry2 with IglA-sfGFP (arrows) in F. novicida U112 iglA-sfGFP clpB-mCherry2. First image is a
merge of phase contrast, GFP and mCherry channels, following images represent GFP channel (upper panel) and mCherry channel (lower panel).
(d) Quantification of cytosolic bacteria in unprimed wild-type BMDMs 4h after infection with F. novicida U112 iglA-sfGFP wild type, DpdpB or DclpB
(normalized to wild type). (e) Release of LDH and mature IL-1b from primed wild-type BMDMs 10 h after infection with F. novicida U112 iglA-sfGFP wild type,
DpdpB or DclpB (NI—noninfected control). (a–c) 3.3 3.3mm fields of view are shown. Scale bars, 1 mm. (d,e) Data are pooled from three independent
experiments (d) (mean and s.d. are shown) or representatives of three independent experiments (e) (mean and s.d. of triplicate wells are shown).
**Po0.01 and ****Po0.0001 (two-tailed unpaired t-test with Welch’s correction).
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F. novicida DpdpE, DanmK, DpdpC, DpdpD, DpdpD/anmK or
DpdpC/pdpD/anmK and determined the percentage of phagoso-
mal and cytosolic bacteria compared to wild-type and DpdpB
bacteria as outlined above (Supplementary Fig. 3a). Interestingly,
we found that deletion of pdpC resulted in a very strong defect in
phagosomal escape in comparison to wild-type bacteria, although
the reduction was smaller than with bacteria lacking the
structural component PdpB (Fig. 6b). F. novicida DpdpD and
DpdpD/anmK also showed a defect in phagosomal escape, which
was however less severe than the phenotype of a pdpC or pdpB
deletion. No significant difference in phagosomal escape was
observed between DpdpD and DpdpD/anmK strains, indicating
that AnmK plays no role in phagosomal escape, consistent
with the finding that phagosomal escape of the DanmK strain
was indistinguishable from the wild-type strain (Fig. 6b). To
determine whether the effect of a pdpC and pdpD deletion was
additive, we generated a strain lacking pdpC, pdpD and also
anmK. Interestingly, bacteria lacking pdpC/pdpD/anmK were
unable to escape from the phagosomal compartment similarly to
the DpdpB strain. In contrast, deletion of pdpE had no significant
effect on phagosomal escape (Fig. 6b).
Next, we tested the role of pdpE, pdpC, pdpD and anmK in
cytosolic innate immune detection of F. novicida. Consistent
with the reduced level of cytosolic localization, we found that
F. novicida DpdpC and DpdpC/pdpD/anmK induced significantly
lower levels of type I IFN production in unprimed BMDMs
infected for 10 h at an MOI of 100 (Supplementary Fig. 5c). The
triple mutant DpdpC/pdpD/anmK had the most severe phenotype
and only elicited IFN levels in the range of the DpdpB strain
(Supplementary Fig. 5c).
Since type I IFNs control the activation of the AIM2
inflammasome during F. novicida infection5, we examined the
level of inflammasome activation in LPS-primed infected
macrophages at different time points (Fig. 6c; Supplementary
Fig. 5a). While infection with F. novicida lacking pdpC or pdpD
resulted in significantly reduced levels of inflammasome activation,
only the deletion of both pdpC and pdpD completely abrogated cell
death induction and cytokine production in infected macrophages,
which was consistent with the reduced levels of cytosolic
localization and type I IFN induction in macrophages infected
with mutants lacking both proteins (Fig. 6b; Supplementary
Fig. 5c). Cell death induction and cytokine production in infected
macrophages was unchanged between cells infected with wild-type
and DanmK bacteria indicating that AnmK is not involved in
modulating inflammasome activation (Fig. 6c). Consistently, cell
death and cytokine production was comparable between cells
infected with F. novicida DpdpC/pdpD and DpdpC/pdpD/anmK or
F. novicida DpdpD and DpdpD/anmK. Importantly, the observed
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Figure 4 | T6SS dynamics in bone marrow-derived macrophages (BMDMs). (a) Merged wide field image and orthogonal view of BMDMs infected for
1 h with F. novicida U112 iglA-sfGFP clpB-mCherry2; in grey: actin staining, in magenta: LPS staining, in green: IglA-sfGFP. 4141mm field of view,
scale bar, 5 mm. (b) Close up and orthogonal SIM view of bacterium highlighted with arrowheads in a; magenta: LPS staining, green: IglA-sfGFP. 5.1 5.1mm
field of view, scale bar, 1mm. (c) Time-lapse images of unprimed wild-type BMDMs infected with F. novicida U112 iglA-sfGFP clpB-mCherry2 for 1 h. First
image consists of merged phase contrast, GFP and mCherry channels. 30 30mm field of view is shown. Scale bar, 5 mm. Close ups consist of GFP channel
(upper panel) and mCherry channel (lower panel). Close ups show 5 5 mm. Scale bar, 1mm. Arrowheads indicate T6SS sheath assembly, contraction and
location of sheath after contraction.
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changes in inflammasome activation were independent of
macrophage priming, since unprimed macrophages infected with
wild-type or mutant F. novicida responded similarly
(Supplementary Fig. 5b). Deletion of pdpE had no significant
effect on the level of type I IFN induction, pyroptosis and cytokine
release (Supplementary Fig. 5a–c).
Previous work has implicated the FPI in intracellular replication55,
therefore, we also examined intracellular replication of wild-type
or mutant F. novicida. We monitored growth over 24h of infection
in BMDMs lacking the inflammasome adaptor protein ASC as they
fail to trigger pyroptosis in response to bacterial infection8.
F. novicida wild-type and DpdpE replicated over the course of the
infection (Supplementary Fig. 5d), while bacteria that lacked
a dynamic T6SS (DpdpB or DclpB) or bacteria that had a dynamic
T6SS, but were deficient in phagosomal escape (DpdpC or
DpdpC/pdpD/anmK), were cleared over the course of the infection.
Consistent with reduced phagosomal escape, pdpD/anmK-deficient
bacteria also displayed a reduced rate of replication compared to
wild-type bacteria, however, the difference was not significant.
Finally, we examined the role of potential T6SS effectors
in vivo. Age- and sex-matched wild-type C57BL/6 mice were
infected subcutaneously with 104 CFUs of F. novicida wild-type
or strains deficient for the putative effectors, and the bacterial
burden in the liver and spleen as well as serum IL-18 levels were
assessed at 2 days post infection (Fig. 6d,e). The bacterial burden
closely correlated with phagosomal escape, in that a partial
reduction in virulence could be observed in DpdpC and
DpdpD/anmK-infected mice. Deletion of pdpC alone had a
stronger effect than deletion of pdpD/anmK although this
difference was only significant in the liver. Deleting all three
potential effectors, DpdpC/pdpD/anmK, rendered the bacteria
largely avirulent, similarly to the deletion of the T6SS structural
component pdpB. Consistent with the reduced levels of
inflammasome activation in vitro (Fig. 6c; Supplementary
Fig. 5a), we found that deletion of pdpB, pdpC, pdpD/anmK or
pdpC/pdpD/anmK resulted in significantly lower levels of serum
IL-18. A deficiency in pdpE appeared to have no effect on
virulence or host response, since infection with F. novicida DpdpE
resulted in bacterial burden and cytokine levels that were
comparable to infections with F. novicida wild type (Fig. 6d,e).
In summary, these results confirm previous studies indicating
that PdpC and PdpD are T6SS-secreted effectors. Moreover, we
show that PdpC and PdpD are dispensable for T6SS dynamics
and specifically facilitate the escape of F. novicida from the
phagosome into the host cell cytosol and therefore are essential
for Francisella virulence.
Discussion
We show here that Francisella T6SS sheath is under certain
conditions highly dynamic and ClpB is necessary for sheath
disassembly. Since ClpB-mCherry2 specifically colocalizes with
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Figure 5 | Identification of genes required for assembly and function of F. novicida T6SS. (a) IglA-sfGFP localization in F. novicida U112 iglA-sfGFP
wild type, DiglF, DiglG, DiglI and DiglJ. The GFP channel is shown. The numbers above the images represent the ratio of average GFP intensity of mutants
compared to the parental strain with s.d. The average GFP intensities were quantified in three independent experiments. Thirty bacteria were analysed per
experiment; 39 26 mm fields of view are shown. Scale bars, 5 mm. (b) Quantification of cytosolic bacteria in unprimed wild-type BMDMs 4h after
infection with F. novicida U112 iglA-sfGFP wild type, DpdpB, DiglF, DiglG, DiglI or DiglJ (normalized to wild type). (c) Release of LDH and IL-1b from primed
wild-type BMDMs 10 h after infection with F. novicida U112 iglA-sfGFP wild type, DpdpB, DiglF, DiglI or DiglJ (NI—noninfected control). (b,c) Data are pooled
from three independent experiments (b) (mean and s.d. are shown) or are representatives of three independent experiments (c) (mean and s.d. of triplicate
wells are shown).
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the contracted sheaths, our data suggest that ClpB is directly
involved in Francisella sheath disassembly similarly to ClpV in
canonical T6SS (refs 24,49,50,56,57). Interestingly, Francisella
ClpB was also shown to alter the immune response in vivo58 and
to be required for heat shock survival52. However, we show here
that T6SS activity is dispensable for heat shock survival
(Supplementary Fig. 2d). This suggests that, in contrast to
canonical T6SS where ClpV is apparently solely dedicated to
sheath disassembly, Francisella ClpB has a dual role. This raises
the question how ClpB recognizes different substrates and
whether a specific adaptor protein is required to recognize
contracted sheaths similarly to adaptor proteins that recognize
substrates for AAAþ -mediated unfolding59–62. We show that
ClpB is important for F. novicida virulence, which is consistent
with what was shown previously52–54,58. Since all virulence
related phenotypes of clpB-negative strain correlated with the
phenotypes of the other strains with impaired T6SS dynamics
(Fig. 3; Supplementary Figs 2 and 3), we propose that in vivo
ClpB is mainly important for T6SS sheath disassembly. However,
refolding of substrates unrelated to T6SS may be required to
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Figure 6 | Contribution of uncharacterized FPI genes to T6SS function. (a) T6SS sheath assembly (arrowheads) in F. novicida U112 iglA-sfGFP DpdpE,
DanmK, DpdpC, DpdpD, DpdpD/anmK, DpdpC/pdpD and DpdpC/pdpD/anmK. GFP channel and 3.3 3.3mm fields of view are shown. Scale bars, 1 mm.
(b) Quantification of cytosolic bacteria in unprimed wild-type BMDMs 4h after infection with F. novicida U112 iglA-sfGFP wild type, DpdpB, DpdpE, DanmK,
DpdpC, DpdpD, DpdpD/anmK or DpdpC/pdpD/anmK (normalized to wild type). (c) Release of LDH and IL-1b from primed wild-type BMDMs 10 h after
infection with F. novicida U112 iglA-sfGFP wild type, DpdpB, DanmK, DpdpC, DpdpD, DpdpD/anmK, DpdpC/pdpD or DpdpC/pdpD/anmK (NI—noninfected
control). (d,e) Bacterial burden (as colony-forming units (CFUs) per gram tissue) in the spleen and liver (d) and serum IL-18 levels (e) of wild-type
C57BL/6JRj mice infected subcutaneously for 2 days with 1 104 F. novicida U112 iglA-sfGFP wild type, DpdpB, DpdpE, DpdpC, DpdpD/anmK and
DpdpC/pdpD/anmK. Small horizontal lines indicate the mean. Each symbol represents an individual mouse (n¼ 5 per experiment). Graphs show pooled
data from two independent biological replicates with n¼ 5 per experiment (n¼ 10 total per group); small horizontal lines indicate the mean. (b–e) Data are
pooled from three independent experiments (b) (mean and s.d. are shown) or two independent experiments (d,e) or are representatives of three
independent experiments (c) (mean and s.d. of triplicate wells are shown). **Po0.01, ***Po0.001 and ****Po0.0001 (two-tailed unpaired t-test
with Welch’s correction (b,c) or Mann–Whitney test (d,e)).
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survive certain stresses, which Francisella encounter during
pathogenesis.
Detailed analysis of subcellular localization of dynamic T6SS
sheath shows that Francisella T6SS assembles on the bacterial cell
poles both in vitro as well as during infection of macrophages
(Figs 2e,f and 3c; Supplementary Fig. 5e,f). Interestingly, similarly
to what we show here for Francisella, ClpV-5 from T6SS-5 of
Burkholderia thailandensis was found to preferentially localize to
spots on bacterial poles63. Those spots were however less dynamic
than ClpB spots in Francisella and thus it remains to be directly
tested if assembly of T6SS-5 of B. thailandensis indeed initiates at
the poles. Interestingly, both T6SS-5 of B. thailandensis and
Francisella T6SS are required for manipulation of the eukaryotic
cells after bacterial internalization. However, unlike in Francisella,
T6SS-5 of B. thailandensis is only required for formation of
multinucleated giant cells after bacteria escape from endosomes
using T3SS63–67. Since T6SS sheaths almost always assemble as
long as the bacteria, one possible advantage of the polar
localization could be that the sheaths assembled from the pole
in rod shaped bacteria would be generally longer than the sheaths
assembled from the side of the cells. Given that the T6SS sheaths
only contract to about half of their extended size25, longer sheaths
may increase the distance to which T6SS can deliver effectors.
Interestingly, restricted subcellular localization was shown to
decrease T6SS efficiency in inter-bacterial competitions despite
increased overall activity51. However, since F. novicida is
completely surrounded by phagosome membrane, restricted
directionality of T6SS assembly should have no consequences
for delivery of effectors to the host cell. In addition, polar
localization of T6SS may increase chances of puncturing
phagosomal membranes, as those may be physically closer to
the bacterial poles when bacteria are in a tight membrane
compartment. As it was shown previously for inter-bacterial
interactions, proper aiming of the T6SS apparatus at the target
bacteria increases efficiency of substrate translocation37,51.
The primary function of the Francisella T6SS is to promote the
escape of Francisella from the phagosome. We show that
phagosome escape depends entirely on PdpC and PdpD, which
are dispensable for T6SS assembly and dynamics (Fig. 6a,b;
Supplementary Movie 1), suggesting that these proteins function
as effectors necessary for phagosomal escape. It is also possible
that PdpD and PdpC are required for activity or secretion
of yet uncharacterized T6SS effectors to promote phagosomal
escape, however previous work by Eshraghi et al.42 has shown
that F. novicida PdpC and PdpD are released by the T6SS in an
in vitro secretion assay, supporting the hypothesis that these
proteins function as secreted effectors in the target cell. Moreover,
F. tularensis and F. holarctica lacking pdpC are unable to escape
from the phagosome, induce cytotoxicity and replicate
intracellularly, and they are avirulent in a mouse model of
tularaemia43,44,46–48. These observations support our conclusions
that PdpC contribute to Francisella virulence, independent of the
Francisella tularensis subspecies. Whereas pdpC is conserved in all
subspecies of Francisella tularensis, pdpD is differentially
encoded45. Therefore, PdpD might have subspecies-specific
virulence related functions.
PdpC and PdpD share no homology with known effectors or
pore forming toxins, such as Listeriolysin O, type C phospho-
lipases or phenol-soluble modulins, that allow other cytosolic
bacteria (Listeria monocytogenes, Shigella flexneri, Burkholderia
thailandensis or Staphylococcus aureus) to escape from the
phagosome, and thus might represent a novel class of effectors
with membranolytic function68,69. The exact mechanism of how
these effectors destabilize the phagosomal membrane and if
this results in the recruitment of galectin-8, a marker of ruptured
vacuoles that recruits antimicrobial autophagy70, remains to be
analysed. The Francisella O-antigen allows the bacteria to avoid
ubiquitination and uptake into LC3-positive compartments71,
but whether Francisella can actively inhibit or escape autophagy
by injected effectors, as reported for Listeria and Shigella
is unknown72.
PdpE and AnmK, which are dispensable for T6SS assembly and
phagosomal escape (Fig. 6a,b), might be effectors whose function
is required once the bacteria enter the cytosol. However,
their contribution to overall bacterial replication and virulence
in vivo is minor (Fig. 6d,e; Supplementary Fig. 5d). In addition,
OpiA and OpiB, encoded outside of the FPI cluster, were recently
identified as T6SS secreted proteins, however, their contribution
to intracellular replication is also minimal in comparison to
the effects of a pdpC or pdpD deletion42. It is possible that
these effectors have tissue-specific functions, or that they are
required for Francisella replication in amoeba or within
arthropod hosts73,74.
Live-cell imaging of T6SS sheath dynamics suggests that IglF,
IglG, IglI and IglJ are putative structural components required for
T6SS assembly in Francisella (Fig. 5a; Supplementary Movie 2).
These proteins could be homologues of components of canonical
T6SS baseplate, which are difficult to identify using homology
modelling14,75 (Fig. 1). However, it is also conceivable that some
of these proteins may be secreted effectors or be required for
effector secretion, because deletion of certain effectors decreases
T6SS function in V. cholerae37,76. Nonetheless, our finding that
the dynamics of Francisella T6SS is possible to image in vitro will
help to dissect the assembly of this non-canonical T6SS and to
differentiate between structural components and translocated
substrates. Further analysis of the structural components will
reveal principles of T6SS evolution and defining the molecular
mechanisms by which Francisella effectors modulate host cell
signalling will significantly contribute to our understanding of
Francisella virulence.
Methods
Bacterial strains and growth conditions. Francisella tularensis subsp. novicida
strain U112 (hereafter F. novicida) and the derivative strains were grown at
37 C with aeration in brain heart infusion (BHI) medium supplemented with
0.2% L-cysteine (Sigma) and appropriate antibiotics. Antibiotic concentrations
used were 100 mgml 1 ampicillin (AppliChem) or 15 mgml 1 kanamycin
(AppliChem). A detailed strain list can be found in Supplementary Table 1. For
infection with F. novicida, BHI medium was inoculated with bacteria from BHI
agar plate (supplemented with 0.2% L-cysteine (Sigma) and appropriate antibiotics)
and were grown overnight at 37 C with aeration.
Bacterial mutagenesis. All in-frame deletions were generated by homologous
recombination using the suicide vector pDMK3 as previously described77. A list of
plasmids, primers as well as remaining peptides encoded by deleted genes can be
found in Supplementary Table 2. To obtain single colonies after recombination,
bacteria were grown overnight at 37 C on Mueller-Hinton agar (MHA)
supplemented with 0.1% D-glucose (Millipore), 0.1% FCS (BioConcept),
100 mgml 1 ampicillin (AppliChem) and 0.1% L-cysteine (Sigma) (hereafter MHA
plate). Cloning product sequences were verified and chromosomal mutations were
tested by PCR using primers located outside of the replaced region. Sites of
homologous recombination of the chromosomal mutations were verified by
sequencing.
Heat shock survival assay. Heat shock survival assay was adapted from ref. 52.
In brief, bacteria were grown overnight as described above, diluted 1:40 in BHI
medium and grown for 3 h at 37 C with aeration. Then bacteria were diluted
1:10 in 250ml BHI in a 1.5ml tube and incubated in a water bath at 50 C for
0, 15 or 30min. At each time point the bacteria were transferred on ice and serial
dilutions were plated on MHA plates. The next day, CFUs were counted and the
concentration of surviving bacteria was calculated.
Fluorescence microscopy. Procedures and settings to detect a fluorescence signal
in F. novicida were employed as previously described37,41. All imaging was carried
out at 37 C and humidity was regulated to 95% using a T-unit (Oko-lab). The
exposure time was set to 150ms for all channels. For bacterial imaging on agarose
pads, F. novicida strains from BHI plate were washed once with BHI, diluted
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1:40 in BHI medium and grown at 37 C with aeration for 3–4 h. Bacteria from
1ml culture were re-suspended in 50–100 ml phosphate-buffered saline (PBS),
spotted on a pad of 1% agarose in PBS, covered with a cover glass (Roth) and either
imaged directly or incubated at 37 C for 1 h before imaging. Images were collected
every 3 s for T6SS assembly speed quantification and every 30 s for assessment of
T6SS dynamics. For imaging of infected macrophages, BMDMs were seeded onto
cover glass (VWR) in 24-well plates at a density of 1.5 105 cells per well and
infected with F. novicida at a multiplicity of infection of 100 in 1ml OptiMEM
(Life Technologies) as described below. Thirty minutes post infection, the BMDMs
were washed three times with OptiMEM and the cover glass was mounted on a pad
of 1% agarose in PBS BMDMs facing down. Images were collected every 30 s for
assessment of T6SS dynamics.
Image analysis. Fiji78 was used for all image analysis and manipulations as
described previously37,51. The ‘Time Series Analyzer V3.0’ plugin was used for
quantification of GFP signal intensity. For comparison of GFP signal intensities of
mutants and wild type, only bacteria without assembled T6SS structures were
considered. For quantification of T6SS activity in different mutants from 5min
time-lapse movies the ‘temporal colour code’ function was used. For kymograms
and T6SS assembly speed quantification the ‘reslice’ function was used. For
determination of subcellular localization of T6SS assembly the surface area of
bacteria was divided into an equally sized polar and mid cell area. The surface area
was calculated based on the model of a capsule using the manually measured length
and width of the bacteria (see formulas below). T6SS assemblies initiating in one of
the two pole areas were considered as T6SS assemblies at pole.
hm ¼ Heightmeasured
lm ¼ Lengthmeasured
r ¼ hm
2
lCylinder ¼ lm  hm
Atotal ¼ ASphere þACylinder ¼ 4pr2 þ 2prlCylinder
A0:5 ¼ 0:5Atotal
For determination of subcellular localization of T6SS assembly, images of
V. cholerae 2740-80 were reanalysed from ref. 37. Contrast on compared sets of
images was adjusted equally. All imaging experiments were performed with at least
two biological replicates.
Structured illumination microscopy. BMDMs were seeded onto cover glass
(VWR) in 24-well plates at a density of 1.25 105 cells per well and infected with
F. novicida at a multiplicity of infection of 100 for 1 h as described below. BMDMs
were washed three times with PBS and fixed for 10min at 37 C with 4%
paraformaldehyde (Electron Microscopy Science). Cover glass was incubated with
chicken anti-F. novicida (1:2,000; a gift from D.M. Monack, Stanford University)
for 1 h at room temperature, then was washed three times with PBS, incubated with
goat anti-chicken coupled to Alexa 568 (1:500; Life Technologies) and
DY-647-Phalloidin (1:500; Dyomics) for another 45min at room temperature,
washed three times with PBS and was mounted on glass slides with Vectashield
(Vector labs). 3D-SM was performed on a microscope system DeltaVision
OMX-Blaze version 4 (Applied Precision, Issaquah, WA). Images were acquired
using a Plan Apo N 60 1.42 numerical aperture oil immersion objective lens
(Olympus) and four liquid-cooled sCMOS cameras (pco Edge, full frame
2,560 2,160; Photometrics). Optical z-sections were separated by 0.125 mm. The
laser lines 488 and 568 were used for 3D-SIM acquisition. Exposure times were
typically between 10 and 140ms, and the power of each laser was adjusted to
achieve optimal intensities of between 5,000 and 8,000 counts in a raw image of
15-bit dynamic range at the lowest laser power possible to minimize
photobleaching. Phalloidin Alexa-647 was acquired using the widefield mode
of the system. Raw 3D-SIM images were processed and reconstructed using the
DeltaVision OMX SoftWoRx software package (Applied Precision).
Cell culture and infection. Primary wild-type BMDMs from C57BL/6JRj mice
(Janvier) were differentiated in DMEM (Sigma) with 20% M-CSF (supernatants of
L929 mouse fibroblasts), 10% v/v FCS, 10mM HEPES, nonessential amino acids
and penicillin (100 IUml 1)/streptomycin (100 mgml 1) (all BioConcept). One
day before infection, BMDMs were seeded into 24- or 96-well plates (Eppendorf) at
a density of 1.5 105 or 5 104 cells per well in DMEM (Sigma) with 10% M-CSF
(supernatants of L929 mouse fibroblasts), 10% v/v FCS, 10mM HEPES and
nonessential amino acids (all BioConcept). Where required, BMDMs were
pre-stimulated overnight with LPS (from Escherichia coli strain O111:B4
(InvivoGen; tlr-3pelps)). F. novicida were grown overnight at 37 C with aeration
as described above. The bacteria were added to the BMDMs at a multiplicity of
infection of 100 or the indicated value. The plates were centrifuged for 5min at
500g to ensure similar adhesion of the bacteria to the cells and were incubated for
120min at 37 C. Next, the medium was replaced with fresh medium containing
10 mgml 1 gentamicin (BioConcept) to kill extracellular bacteria, then plates were
incubated at 37 C for the indicated length of time.
Cytokine and LDH release measurement. IL-1b and IL-18 were measured by
enzyme-linked immunosorbent assay (eBioscience). Lactate dehydrogenase (LDH)
was measured with an LDH Cytotoxicity Detection Kit (Takara). To correct for
spontaneous cell lysis and to normalize the values, the percentage of LDH release
was calculated as follows:
LDH valueinfected  LDH valueuninfected
LDH valuetotal lysis  LDH valueuninfected 100
Phagosome protection assay. The amount of cytoplasmic and vacuolar bacteria
was measured as previously described79. In brief, BMDMs were seeded into 24-well
plates at a density of 1.5 105 cells per well and F. novicida were grown for 4 h at
37 C with aeration as described above. BMDMs were infected with F. novicida at a
multiplicity of infection of 100 for 4 h as outlined above. BMDMs were washed
three times with KHM buffer (110mM potassium acetate, 20mM Hepes, 2mM
MgCl2) and incubated for 1min with 75 mgml 1 digitonin (Sigma) followed by
differential staining of cytoplasmic and total bacteria. Antibodies used for staining
were chicken anti-F. novicida (1:2,000; a gift from D.M. Monack, Stanford
University) and goat anti-chicken coupled to Alexa 647 (cytoplasmic bacteria) or
Alexa 488 (total bacteria) (1:500; both from Life Technologies). Stained bacteria
were analysed on a FACS-Canto-II. Percentage of cytosolic bacteria were
normalized to wild-type F. novicida as follows:
FACS value FACS valueDpdpB
FACS valuewt  FACS valueDpdpB 100
Intracellular bacterial growth assay. BMDMs were seeded into 24-well plates at
a density of 1.5 105 cells per well and infected with F. novicida at a multiplicity of
infection of 1 as described above. After 2 and 24 h of infection, the BMDMs were
washed three times with PBS and lysed with 0.1% Triton-X 100 (Promega) for
10min at 37 C. The bacteria were stained for 10min with chicken anti-F. novicida
(1:2,000; a gift from D.M. Monack, Stanford University), washed once with PBS
and stained for 10min with goat anti-chicken coupled to Alexa 647 and Alexa 488
(1:500 each; both from Life Technologies). A volume of 20 ml 123count eBeads
(eBioscience) was added to each sample. The samples were analysed on a
FACS-Canto-II by counting the number of bacteria per 5,000 beads. The CFU ratio
was calculated by dividing the number of bacteria at 24 h (output) with the number
of bacteria at 2 h (input).
Type I interferon measurement. One day before infection, ISRE-L929 reporter
cells (a gift from D.M. Monack, Stanford University) were seeded into black 96-well
plates with micro-clear bottom (Greiner) at a density of 1 105 cells per well in
DMEM (Sigma) with 10% v/v FCS and penicillin (100 IUml 1)/streptomycin
(100 mgml 1) (both BioConcept). BMDMs were seeded into 96-well plates at a
density of 5 104 cells per well and infected with F. novicida at a multiplicity of
infection of 100 as described above. After 10 h of infection, type I IFN production
was measured with the Bright-Glo Luciferase Assay System (Promega) as
previously described80.
Animal infection. All animal experiments were approved (licence 2535-26742,
Kantonales Veterina¨ramt Basel-Stadt) and were performed according to local
guidelines (Tierschutz-Verordnung, Basel-Stadt) and the Swiss animal protection
law (Tierschutz-Gesetz). Female 10 weeks old wt C57BL/6JRj mice (Janvier) were
infected subcutaneously with 104 CFUs of indicated stationary-phase F. novicida
strain in 50ml PBS. Mice were killed 48 h post infection. Bacterial load of spleen
and liver was analysed by plating the bacteria on MHA plates. The plates were
incubated for 24 h at 37 C. IL-18 levels in the blood were measured by
enzyme-linked immunosorbent assay (eBioscience). No randomization or
‘blinding’ of researchers to sample identity was used.
Statistical analysis. Statistical data analysis was done using Prism 6.0h
(GraphPad Software, Inc.). To evaluate the difference between two groups
(T6SS per cell, T6SS assembly speed, subcellular localization of T6SS, bacterial
survival, cell death, cytokine release, phagosomal escape, bacterial growth and
IFN production) the unpaired two-tailed t-test with Welch’s correction was used.
Animal experiments were evaluated with a two-tailed Mann–Whitney test. P values
are given in the figure legends.
Data availability. The authors declare that the data supporting the findings of this
study are available within the paper and its Supplementary Information files.
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Supplementary Figures: 
 
Supplementary Figure 1: Assembly speed varies between bacteria. (a) Kymograms of slow (~ 5 nm s-1) to 
fast (~ 14 nm s-1) T6SS assemblies (arrowheads) over 5 minutes (3 s per pixel) in F. novicida U112 iglA-
sfGFP. First image is a merge of phase contrast and GFP channel, following images represent GFP channel 
only. 3.3 x 3.3 μm fields of view are shown. Scale bars represent 1 μm. (b) GFP intensities were measured a 
frame before and a frame after a complete assembly-disassembly cycle in two independent experiments. 30 
bacteria were analyzed per experiment. GFP intensities measured in F. novicida U112 iglA-sfGFP wild-type 
and ΔpdpB were compared in four independent experiments. 30 bacteria were analyzed per experiment. 
Standard deviation was calculated. 
a
Assembly: 9.8 nm s-1 
Assembly: 14 nm s-1 
b
Assembly: 5.7 nm s-1 
0 s 126 s 300 s 
0 s 114 s 300 s 
0 s 114 s 300 s 
-130- III. Results
 Supplementary Figure 2: T6SS activity is required for ClpB spot localization but dispensable for ClpB-
dependent heat tolerance. (a) IglA-sfGFP localization and foci (empty arrowheads) in F. novicida U112 iglA-
sfGFP ΔclpB/pdpB. First image is a merge of phase contrast and GFP channels, following images represent 
GFP channel only. 3.3 x 3.3 μm fields of view are shown. Scale bars represent 1 μm. (b) IglA-sfGFP and ClpB-
mCherry2 localization in F. novicida U112 iglA-sfGFP clpB-mCherry2 ΔpdpB. First image is a merge of phase 
contrast, GFP and mCherry channels, following images represent GFP channel (upper panel) and mCherry 
channel (lower panel). (c) ClpB-mCherry2 localization dynamics in F. novicida U112 clpB-mCherry2. First 
image is a merge of phase contrast and mCherry channels, following images represent mCherry channel only. 
Arrowheads indicate ClpB recruitment. (d) Heat shock survival assay performed with F. novicida U112 iglA-
sfGFP wild-type, ΔpdpB, ΔiglF, ΔpdpD/anmK, ΔclpB and clpB-mCherry2 at 50 °C for 0, 15 and 30 min. Data 
are pooled from three independent experiments. *P < 0.05 (two-tailed unpaired t-test with Welch’s correction). 
(a-c) 3.3 x 3.3 μm fields of view are shown. Scale bar represents 1 μm.  
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 Supplementary Figure 3: F. novicida U112 iglA-sfGFP ΔclpB fails to escape into the cytosol and is 
avirulent in vivo. (a) Representative FACS blots from the quantification of cytosolic (white gates) and vacuolar 
bacteria (grey gates) by flow cytometry in unprimed wild-type BMDMs 4 h after infection with F. novicida U112 
iglA-sfGFP wild-type, ΔpdpB or ΔclpB. Numbers next to the gates indicate the percentage of cytosolic and 
vacuolar bacteria. (b) Bacterial burden (as colony-forming units (CFU) per gram tissue) in the spleen and liver 
of wild-type C57BL/6JRj mice infected subcutaneously for 2 days with 1 x 104 F. novicida U112 iglA-sfGFP 
wild-type, ΔpdpB or ΔclpB. Each symbol represents an individual mouse (n = 8 (wild-type), 10 (ΔpdpB), 15 
(ΔclpB) (spleen), or n = 13 (wild-type), 10 (ΔpdpB), 15 (ΔclpB) (liver)); small horizontal lines indicate the mean. 
Data are pooled from two independent experiments. ****P < 0.0001; NS - not significant (Mann-Whitney test).  
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-132- III. Results
 Supplementary Figure 4: pdpE, anmK, pdpC and pdpD and play no role in T6SS sheath localization and 
dynamics. (a) Quantification of number of T6SS sheath structures per bacterium within 5 min of imaging. (b) 
Quantification of T6SS sheath assembly at poles. (c) Quantification of T6SS assembly speed. Averages of 
three independent experiments. 30 bacteria per experiment were analyzed. Error bars represent standard 
deviation. No significant differences to wild-type (two-tailed unpaired t-test with Welch’s correction).  
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III. Results -133-
 Supplementary Figure S5: Putative effector mutants show distinct innate immune activation and 
survival within macrophages. Release of LDH and IL-1β from (a) LPS-primed wild-type BMDMs 10 h or (b) 
unprimed wild-type BMDMs 24 h after infection with F. novicida U112 iglA-sfGFP wild-type, ΔpdpB, ΔpdpE, 
ΔpdpC, ΔpdpD, ΔpdpD/anmK, ΔpdpC/pdpD/anmK or ΔclpB (NI - noninfected control). (c) Quantification of 
type-I-interferon release in the supernatant of unprimed wild-type BMDMs infected for 10 h with F. novicida 
U112 iglA-sfGFP wild-type, ΔpdpB, ΔpdpE, ΔpdpC, ΔpdpD, ΔpdpD/anmK, ΔpdpC/pdpD/anmK or ΔclpB. (d) 
Intracellular growth within Asc-/- BMDMs during the first 24 h of infection with F. novicida U112 iglA-sfGFP wild-
type, ΔpdpB, ΔpdpE, ΔpdpC, ΔpdpD/anmK, ΔpdpC/pdpD/anmK or ΔclpB. Growth was calculated as ratio of 
number of bacteria at 24 h (output) divided by the number of bacteria at 2 h (input). (f, e) Timelapse images 
from BMDMs infected for 1 h with F. novicida U112 iglA-sfGFP ΔpdpE (e) and ΔpdpC/pdpD/anmK (f). 30 x 30 
μm fields of view are shown. First image consists of merged phase contrast channel and GFP channel. Scale 
bar represents 5 μm. The close ups show 5 x 5 μm. Scale bar represents 1 μm. Close ups consist of GFP 
channel. (a-d) Data are representatives of three independent experiments (a-c) (mean and standard deviation 
of triplicate wells are shown) or pooled from three independent experiments (small horizontal lines indicate the 
mean) (d). *P < 0.05 and **P < 0.01; NS - not significant (two-tailed unpaired t-test with Welch’s correction). 
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2.1 Additional results related to research article II
Introduction
After macrophage phagocytosis, Francisella rapidly ruptures the phagosome to sur-
vive and replicate within the cytosol (chapter I, section 2.2). Although we showed
that Francisella uses the FPI-encoded T6SS to rupture the phagosome (chapter
III, section 2), it remains unclear what signal causes Francisella to activate the
T6SS and thus induce phagosomal rupture. Two independent research groups re-
ported that Francisella escape from the phagosome by sensing phagosomal acidifi-
cation [429,430]. However in 2009, another research group found that phagosomal
acidification has no impact on Francisella escape from the phagosome [431]. Given
the conflicting reports in current literature, it remains unclear whether or not
phagosomal acidification is the trigger to activate the T6SS, and therefore escape
from the phagosome. This work sought to address the role of phagosomal acidifi-
cation in the Francisella escape from the phagosome. Francisella escape from the
phagosome is the critical point for Francisella in establishing a successful bacterial
infection and therefore for its virulence. Furthermore, determining if phagosomal
acidification triggers T6SS activity is important, since understanding the mecha-
nism of T6SS activation could be a promising starting point for the development
of a successful antibacterial drug.
Material and Methods
Cell culture and infection. Primary murine bone marrow derived macrophages
(BMDMs) were seeded into 24- or 96-well plates at a density of 1.5 x 105 or 5
x 104 cells per well and infected with wild-type Francisella novicida U112 at a
multiplicity of infection of 100 as previously described (chapter III, section 2) or
transfected with 0.5 µg poly(dA:dT) (Invivogen) using our home-made PEI trans-
fection reagent. Unless otherwise indicated, BMDMs were pre-treated 30 min prior
to infection with 100 nM bafilomycin A1 (BafA1; Sigma). The concentration of
BafA1 was kept constant over the entire course of infection.
Cytokine and LDH release measurement. IL-1β was measured by enzyme-
linked immunosorbent assay (eBioscience). Lactate dehydrogenase (LDH) was mea-
sured with an LDH Cytotoxicity Detection Kit (Takara). To correct for spontaneous
cell lysis and to normalize the values, the percentage of LDH release was calculated
as follows:
(LDH infected - LDH uninfected) / (LDH total lysis - LDH uninfected) x 100.
Phagosome protection assay. BMDMs were seeded into 24-well plates at a
density of 1.5 x 105 cells per well and infected with wild-type Francisella novicida
U112 at a multiplicity of infection of 100, as previously described (chapter III,
section 2). BMDMs were pretreated for 30 min with 100 nM BafA1 (Sigma) and
-140- III. Results
the concentration was kept constant over the entire course of infection.
Poly(dA:dT) electroporation. BMDMs were prestimulated for 4 h with lipopolysac-
charide (from Escherichia coli strain O111:B4;InvivoGen) and 30 min with 100
nM BafA1. BMDMs were washed three times with warm 1x phosphate buffered
saline (PBS) and 0.25 x 106 cells per reaction were electroporated with 0.25 µg
poly(dA:dT) using the Neon transfection system (Invitrogen). 5 x 104 cells were
seeded per well of a 96-well plate and LDH as well as IL-1β release assessed 3 h
post electroporation as described above.
Results
To investigate the role of phagosomal acidification in Francisella escape from the
phagosome, we analyzed the amount of cytosolic wild-type Francisella novicida
U112 (hereafter F. novicida) in wild-type BMDMs left untreated or pretreated
with 100 nM Bafilomycin A1 (BafA1), a vacuolar specific potassium ATPase in-
hibitor. After 4 h of infection, on average 50 % of F. novicida escaped into the
cytosol (Figure III.1 a). Following Bafilomycin A1 treatment, a significant reduc-
tion in the number of cytosolic bacteria was observed, resulting in 30 % cytosolic
bacteria. These data suggest that phagosomal acidification is partially required for
Francisella to escape from the phagosome.
After escaping into the cytosol, Francisella activates two distinct innate im-
mune pathways by releasing bacterial DNA into the cytosol. Bacterial DNA can
be detected by cGAS leading to type-I-interferon production via STING-TBK1-
IRF3 [169, 170] or by AIM2 leading to the formation of the AIM2 inflamma-
some [162164]. AIM2 inflammasome activation is critical for the immune system
for Francisella clearance. In cell culture experiments, inflammasome activation is
analyzed by LDH and IL-1β release to the supernatant. When we assessed AIM2
inflammasome activation in BMDMs after F. novicida infection, BafA1 pretreat-
ment completely abolished LDH as well as IL-1β release up to 12 hours post-
infection; however, both measures increased over the course of infection in un-
treated BMDMs (Figure III.1 b). As we pretreated the BMDMs with BafA1 before
infection, we could not determine if phagosomal acidification is critical to escape
from the phagosome or to activate the AIM2 inflammasome. To analyze at which
level of the infection BafA1 is influencing AIM2 inflammasome activation, we ap-
plied BafA1 at different time points after Francisella infection and analyzed cell
death and IL-1β release at 10 hours post-infection. While applying BafA1 during
the first 2 hours of infection abolished AIM2 inflammasome activation, applying
BafA1 later than 2 hours post infection had no significant impact on AIM2 in-
flammasome activation (Figure III.1 c). We observed a similar phenomenon when
we transfected BMDMs with the DNA analog poly(dA:dT) (Figure III.1 d) sug-
gesting that BafA1 could directly impact AIM2 inflammasome activation or as-
sembly. On the other hand, BafA1 might interfere with the delivery of DNA into
III. Results -141-
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Figure III.1 BafA1 blocks AIM2 inflammasome activation in a type-I-interferon-
dependent manner. (a) Quantification of cytosolic bacteria in unprimed wild-type primary
murine bone marrow derived macrophages (BMDMs) 4 h after infection with wild-type F. novi-
cida U112. (b) Release of LDH and IL-1β from primed wild-type BMDMs at indicated time
points after wild-type F. novicida U112 infection pre-treated or not for 30 min with 100 nM
Bafilomycin A1 (BafA1) (c) Release of LDH and IL-1β from primed wild-type BMDMs 10 h
after infection with wild-type F. novicida U112 treated at indicated time points with 100 nM
BafA1. (d) Release of LDH and IL-1β from primed wild-type BMDMs 3 h after transfection of
0.5 µg poly(dA:dT) treated at indicated time points with 100 nM BafA1. (e) Release of LDH and
IL-1β from 30 min 100 nM BafA1 pre-treated, primed wild-type BMDMs 3 h after electropora-
tion of 0.25 µg poly(dA:dT). Data are pooled from two experiments (a) or are representatives of
two independent experiments (b-e) (mean and standard deviation of triplicate wells). *P < 0.05
and **P < 0.01; NS, not significant (two-tailed unpaired t-test with Welch's correction).
the cytosol, since the transfection reagents require endosomal acidification. We
thus electroporated poly(dA:dT) into BMDMs and thereby directly activated the
AIM2 inflammasome without need for transfection. Importantly, AIM2 activation
by electroporated poly(dA:dT) was unaffected by BafA1 pretreatment (Figure III.1
e). These data suggest that phagosomal acidification is specifically required during
Francisella infection and poly(dA:dT) transfection to activate the AIM2 inflam-
masome, but does not impact AIM2 inflammasome activation or assembly.
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Discussion
This work established that phagosomal acidification partially blocks Francisella
escape into the cytosol, but completely blocks F. novicida-dependent AIM2 in-
flammasome activation. The AIM2 inflammasome is only impaired if phagosomal
acidification is blocked during the first 2 hours of Francisella infection and BafA1
treatment does not impair directly AIM2 inflammasome activation or assembly.
Most likely, phagosomal acidification renders F. novicida competent to activate
the AIM2 inflammasome while the bacteria still reside in the phagosome. If this
relates however directly to AIM2 activation or rather is linked to the propensity
to activate type-I-interferon signaling, has not been assessed in this study.
A prerequisite for efficient AIM2 inflammasome activation is the induction of type
I interferon through cGAS/STING and the consequent expression of interferon reg-
ulated genes (IRGs) (chapter I, section 2.2). Among them are GBP2 and GBP5,
which lyse Francisella and expose thereby bacterial DNA to AIM2 [458, 463]. In-
terestingly, cGAS also recognizes bacterial DNA to trigger type-I-interferon induc-
tion [169,170]. One can speculate that phagosomal acidification specifically exposes
bacterial DNA only recognized by cGAS but not AIM2 to the cytosol. If this DNA
could also be detected by AIM2, inflammasome activation would start as soon as
DNA is exposed to the cytosol, as the essential inflammasome components AIM2,
ASC and caspase-1 are constitutively expressed in macrophages. However, this is
not what we observe in Francisella infection [249]. In line with the hypothesis of
acidification-dependent DNA exposure, Alnemri and colleagues observed no type-
I-interferon induction in macrophages pretreated with BafA1 [302], suggesting that
the initial exposure of Francisella to phagosomal acidification primes for cGAS-
dependent type-I-interferon induction.
What explicit impact phagosomal acidification has on Francisella requires further
investigation and could help to understand and discriminate the target specificity
of cGAS and AIM2, two important receptors to detect foreign DNA in the cytosol.
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Abstract 
Recognition of pathogens by the innate immune system relies on germline-
encoded pattern recognition receptors (PRRs) that recognize unique microbial 
molecules, so-called pathogen-associated molecular patterns (PAMPs). 
Nucleic acids and their derivatives are one of the most important groups of 
PAMPs, and are recognized by a number of surface-associated as well as 
cytosolic PRRs. Cyclic GMP-AMP synthase (cGAS) recognizes the presence 
of pathogen- or host-derived dsDNA in the cytosol and initiates type-I-IFN 
production. Here, we describe a methodology that allows for evaluating the 
association of cGAS with released bacterial dsDNA during Francisella 
novicida infection of macrophages, by fluorescence confocal microscopy. This 
method can be adapted to the study of cGAS-dependent responses elicited 
by other intracellular bacterial pathogens and in other cell types. 
 
 
Key words: cGAS; dsDNA; F. novicida; innate immunity; fluorescence 
confocal microscopy. 
 
1. Introduction 
Microbial pathogens, including viruses, parasites and bacteria, constantly 
challenge eukaryotic organisms, which have thus evolved mechanisms of 
defense, collectively called immunity. The first line of host defense against 
invading microbes is the innate immune system, which has diverse germline-
encoded pattern recognition receptors (PRRs) that detect conserved 
pathogen-associated molecular patterns (PAMPs), allowing microbe 
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phagocytosis and induction of inflammation (1). In the cell, PRRs can have 
different subcellular locations, thus allowing a more precise and regulated 
detection of PAMPs. For example, PRRs located on the plasma membrane or 
on endosomal membranes, such as Toll-like receptors (TLRs), typically 
recognize extracellular PAMPs. On the other hand, cytosolic PRRs, including 
NOD-like receptors (NLRs), RIG-I-like receptors and a group of diverse DNA 
sensors, allow the detection of intracellular PAMPs (1-3), thus triggering 
different antimicrobial responses such as autophagy (4), production of type-I 
interferons (IFNs) (5) or assembly of cytosolic multiprotein complexes called 
inflammasomes (6). 
Different host sensors can recognize DNA that is released by invading 
microbes into the host cytosol. This group of PRRs is crucial for mounting an 
innate immune response, but to date this response remains poorly 
characterized. Examples of cytosolic double stranded (ds) DNA sensors 
include IFNγ-inducible protein 16 (IFI16), absent in melanoma 2 (AIM2) and 
cyclic GMP-AMP synthase (cGAS) (7-9). Here, we focus on the mechanisms 
of cGAS detection of cytosolic dsDNA and the downstream events. cGAS is 
an enzyme that directly binds dsDNA and catalyzes the production of the 
second messenger cyclic GMP-AMP (cGAMP) from ATP and GTP (8, 10). 
cGAMP then binds to and activates the ER-resident adaptor protein STING, 
which in turn recruits and activates TBK1 and the transcription factor IRF3 by 
phosphorylation (8, 10, 11). IRF3 then dimerizes and translocates into the 
nucleus to induce the production of type-I IFNs, which signal in an autocrine 
and paracrine manner through the IFN-α/β receptor (IFNAR), inducing over 
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300 IFN-stimulated genes that are involved in modulating immune responses 
against microbial infections (12, 13). 
Francisella tularensis subspecies (subsp.) tularensis is an intracellular 
gram-negative bacterial pathogen that causes tularemia, a life-threatening 
zoonotic disease that can affect humans leading to severe morbidity and 
mortality (14). Interestingly, the closely related Francisella tularensis subsp. 
novicida (F. novicida) is an exciting model organism to study host cytosolic 
immune responses triggered by DNA. In the mammalian host, F. novicida’s 
main intracellular niche is the macrophage, which phagocytoses the bacteria 
into a phagosomal compartment, called the Francisella-containing 
phagosome (FCP). Rupture of the FCP membrane occurs rapidly, generally 
within 1-4 hours upon bacterial uptake, leading to bacterial escape into the 
host cytosol, where F. novicida undergoes extensive replication (15-18). The 
exact mechanism of FCP membrane rupture with consequent bacterial 
escape into the host cytosol is unknown, but it requires the expression of the 
Francisella pathogenicity island (FPI), a cluster of genes encoding a type VI 
secretion system (T6SS) (19, 20). Even though F. novicida escape from the 
FCP into the host cytosol is essential for bacterial pathogenesis, it also allows 
cytosolic innate immune recognition and initiation of host defense 
mechanisms. In parallel with FCP rupture, F. novicida lysis can occur, in a yet 
unknown mechanism, resulting in release of bacterial dsDNA into the 
macrophage cytosol, which functions as a danger signal that triggers innate 
immunity (21, 22). F. novicida dsDNA released into the host cytosol is 
recognized by cGAS, thus triggering STING-mediated production of type-I 
IFNs (22). Then, autocrine and paracrine type-I IFN signaling induce 
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production of AIM2, which contributes to the assembly and activation of the 
AIM2 inflammasome around released bacterial dsDNA (23) to activate 
caspase-1-mediated cell death and secretion of IL-1 family proinflammatory 
cytokines. 
The cGAS-STING-dependent pathway also plays an important role in 
immune responses elicited by other intracellular bacterial pathogens. Escape 
of Listeria monocytogenes from its endocytic vacuole to the host cytosol leads 
to the detection of bacterial dsDNA by cGAS, triggering type-I IFN production 
in myeloid cells (24), which is thought to promote bacteria dissemination and 
proliferation (12). Moreover, recent studies have shown that Mycobacterium 
tuberculosis releases its genomic DNA into the cytosol of macrophages, 
which associates with cGAS, thus eliciting anti-mycobacterial immunity (25-
27).  
Collectively, these studies highlight the importance of cytosolic dsDNA 
recognition during bacterial infection, which is most likely initiated in a cGAS-
dependent manner. Therefore, it is important to have methods to track when 
and where cGAS associates with bacterial dsDNA within the host cell, to 
better understand how this danger signal initiates an innate immune 
response. Here, we describe a methodology that allows evaluation of the 
association of cGAS with bacterial dsDNA released during F. novicida 
infection of macrophages, by fluorescence confocal microscopy. In addition, 
this method can be applied to the study of cGAS-dependent responses 
elicited by other intracellular bacterial pathogens and in other cell types.  
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2. Materials 
2.1 Generation of murine bone marrow-derived macrophages (BMDMs). 
1. Cell culture facility and equipment including water-jacketed CO2 
incubator and laminar flow hood. 
2. Mice. 
3. CO2 tank including flow regulation. 
4. Ice bucket. 
5. Ice. 
6. 70% ethanol. 
7. Flushing medium: Dulbecco's Modified Eagle Medium (DMEM) high 
glucose, unsupplemented. 
8. 20% Macrophage medium: DMEM high glucose with 20% 
Macrophage-Colony Stimulating Factor (M-CSF), 10% Fetal Calf 
Serum (FCS), 1x Non-Essential Amino Acids (NEAA), 1x Hepes and 
100 units/mL Pen/Strep. 
9. Sterile 50 mL tubes. 
10. Sterile 2, 5, 10 and 25 mL pipettes. 
11. 10 mL syringes. 
12. 26 G 3/8 inch needles. 
13. 1000 μL pipette. 
14. Autoclaved scissors and forceps. 
15. Paper towels. 
16. Centrifuge with a rotor fitting 50 mL tubes. 
17. Hemocytometer. 
18. Inverted light microscope. 
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19. Sterile, non-tissue culture treated 10 cm petri dishes. 
20. Ice-cold 1x phosphate-buffered saline (PBS), tissue culture grade. 
21. Cell scrapers. 
22. Ice-cold FCS. 
23. Dimethyl sulfoxide (DMSO), tissue culture grade. 
24. 2 mL cryotubes. 
25. Isopropanol freezing chamber. 
 
2.2 Thawing and propagation of murine bone marrow-derived 
macrophages (BMDMs). 
1. Cell culture facility and equipment including water-jacketed CO2 
incubator and laminar flow hood. 
2. Fridge. 
3. Cryotube containing 1x107 frozen murine BMDMs in 10 % DMSO / 
FCS. 
4. 37°C water bath. 
5. Sterile 50 mL tube. 
6. 1000 μL pipette. 
7. Sterile 2, 5, 10 and 25 mL pipettes. 
8. Centrifuge with a rotor fitting 50 mL tubes. 
9. Sterile, non-tissue culture treated 10 cm petri dishes.  
10. Inverted light microscope. 
11. Ice-cold 1x PBS, tissue culture grade. 
12. Flushing medium: DMEM high glucose, unsupplemented. 
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13. 20% macrophage medium: DMEM high glucose with 20% M-CSF, 10% 
FCS, 1x NEAA, 1x Hepes and 100 units/mL Pen/Strep. 
 
2.3 Harvesting and seeding BMDMs for F. novicida infection 
1. Cell culture facility and equipment including water-jacketed CO2 
incubator and laminar flow hood. 
2. Fridge. 
3. Ice bucket. 
4. Ice. 
5. Sterile 50 mL tube. 
6. Sterile 1.5 mL tubes. 
7. Sterile 2, 5, 10 and 25 mL pipettes. 
8. Centrifuge with a rotor fitting 50 mL tubes. 
9. Hemocytometer. 
10. Inverted light microscope. 
11. Sterile tissue culture treated 24-well plates. 
12. Sterile glass coverslips. 
13. Ice-cold 1x PBS, tissue culture grade. 
14. 10 % macrophage medium: DMEM high glucose with 10% M-CSF, 
10% FCS, 1x NEAA and 1x Hepes. 
15. Sterile, non-tissue culture treated 10 cm petri dishes. 
16. Brain Heart Infusion (BHI) broth. 
17. 10% L-cysteine stock solution in ddH2O. 
18. Ampicillin stock (100 mg/mL). 
19. F. novicida frozen glycerol stocks. 
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20. BHI agar plates supplemented with 0.2% L-cysteine and 100 μg/mL 
Ampicillin. 
21. Sterile bacterial culture tubes. 
22. Bacterial incubator with rotor. 
 
2.4 Infection of murine BMDMs with F. novicida 
1. Cell culture facility and equipment including water-jacketed CO2 
incubator and laminar flow hood. 
2. Spectrophotometer. 
3. Plastic cuvettes. 
4. 15 mL tubes. 
5. BHI broth. 
6. 10% macrophage medium: DMEM high glucose with 10% M-CSF, 10% 
FCS, 1x NEAA and 1x Hepes. 
7. Gentamicin liquid stock (5000 μg/mL). 
8. Centrifuge with swing-out buckets suitable for 24-well plates. 
 
2.5 Fixation and staining of F. novicida-infected murine BMDMs 
1. Cell culture facility and equipment including water-jacketed CO2 
incubator and laminar flow hood. 
2. 4% Paraformaldehyde (PFA) diluted in 1x PBS. 
3. 1x PBS, tissue culture grade. 
4. Immunofluorescence (IF) buffer: 3% BSA, 0.1% azide, 0.2% Saponin in 
1x PBS. 
5. Forceps. 
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6. Paper towels. 
7. Primary antibodies for cGAS [goat anti-cGAS (N-17), Santa Cruz sc-
245858], F. novicida [chicken anti-F. novicida, Denise M. Monack 
laboratory] 
8. Fluorophore-coupled secondary antibodies [donkey anti-goat Alexa-
Fluor 488, goat anti-chicken Alexa-Fluor 568 (Molecular Probes)]. 
9. Hoechst. 
10. Alexa-Fluor 647 Phalloidin (Molecular Probes). 
11. Humidified chamber: non-tissue culture treated 15 cm petri dish, 
parafilm, paper towel, aluminium foil.  
12. Mounting solution: Vecta Shield. 
13. Microscopy glass slide. 
14. 70% ethanol. 
15. Transparent nail polish. 
16. Confocal fluorescence microscope. 
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3. Methods 
3.1 Generation of BMDMs 
1. Fill one ice bucket with ice and place it next to the laminar flow hood.  
2. Fill two 50 mL tubes with 70% Ethanol ethanol and place them under 
the laminar flow hood.  
3. Put two forceps and one pair of scissors in each 50 mL tube and label 
one tube with “outer tools” and the other with “inner tools” (see Note 1). 
The separate use of exterior and interior surgical tools reduces 
potential contamination. 
4. Fill one 50 mL tube with 5 mL, one with 25 mL and one with 50 mL 
flushing medium. Put the three 50 mL tubes on ice.  
5. Place paper towel under the laminar flow hood to prepare the working 
space.  
6. Euthanize the mice with CO2 directly in their cage (see Note 2). 
Thereby minimizing stress applied to the mice as they stay in their 
known environment. Always observe the mice during euthanasia. Once 
the mice stop breathing, wait another 30 sec before you stop the CO2 
supply.  
7. Take the mice out of the cage, place them under the laminar flow hood 
and spray them with 70% ethanol. 
8. Make a small incision into the sternum above the pneumothorax. 
Thereby the pressure in the pneumothorax drops and the lungs 
collapse. This is one method to confirm euthanasia. 
9. Transfer one mouse onto a new paper towel under the laminar flow 
hood. 
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10. Start with the outer tools. Hold one hind leg with one forceps and 
make a small incision underneath the ankle. Make sure to only cut the 
skin but not the flesh.  
11. Starting form this incision, cut the skin from the ankle to the belly.  
12. Still holding the foot with the forceps, extend the small incision fully 
around the ankle. Now, pull the skin upward over the foot and 
downward over the leg until the whole leg and the lower part of the 
body is exposed.  
13. Spray the exposed leg with 70% ethanol to remove hair and disinfect 
the area.  
14. Using scissors cut the anterior and posterior thigh muscles diagonal to 
the femur to gain clear access to the hipbone. Next, cut the hipbone to 
separate the leg from the body.  Be careful not to cut the femur at this 
step. 
15. Remove the entire leg, cut off the foot below the ankle, place the leg in 
a 50 mL tube filled with 25 mL flushing medium and put it back on ice.  
16. Repeat the procedure for the other leg and if necessary for the other 
mice that are already euthanized.  
17. Take out one of the legs from the 50 mL tube. 
18. Switch to inner tools. Using scissors and forceps, remove the flesh 
around femur and tibia of each leg until the bones are exposed. 
19. Separate femur and tibia by over bending the knee, and store them in a 
non-tissue culture treated 10 cm dish. Add a few drops of flushing 
medium on the bones to prevent them from drying out. 
20. Repeat the procedure for the other legs. 
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21. To flush out the bone marrow, cut the femur/tibia on both ends. The 
bone marrow cavity with the bright red bone marrow should now be 
accessible.  
22. Fill the 10 mL syringe with flushing medium, add the 26 G 3/8 inch 
needle and carefully insert the needle into the bone marrow cavity. 
Flush out the bone marrow from both sides of the bone into the 50 mL 
tube containing 5 mL flushing medium. The bone should now be 
white/transparent and no bone marrow should be visible anymore (The 
likelihood of contamination can be reduced by flushing each individual 
bone into a separate 50 mL tube and process each tube individually). 
23. Repeat the procedure for the other bones. 
24. Centrifuge the bone marrow for 5 min at 180 x g at 4°C, remove the 
supernatant and resuspend the bone marrow in 1 mL 20% 
macrophage medium using a 1000 μL pipette.  
25. Add an additional 9 mL of 20% macrophage medium slowly and mix by 
swirling the tube (if only one mouse was processed, only add an 
additional 4 mL of 20% macrophage medium). 
26. Count the progenitor cells under the microscope using a 
hemocytometer and determine the total number of progenitor cells in 
the suspension.  
27. Plate 5 x 106 progenitor cells per non-treated 10 cm petri dish, add 10 
mL of 20% macrophage medium and move all plates into the incubator 
set to 37°C / 5% CO2. 
28. After 3 days, add an additional 4 mL pre-warmed 20% macrophage 
medium to each non-cell culture treated 10 cm petri dish and move 
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them back to the incubator for another 3 days. This step ensures that 
the cells have enough MCSF to fully differentiate (see Note 3). 
29. After 6 days, all progenitor cells should have been fully differentiated 
into BMDMs and are now adherent. Aspirate the medium from each 
petri dish before adding 5 mL of ice-cold 1x tissue-culture grade PBS to 
each dish and move the dishes into the fridge for 15 min.  
30. With a cell scraper, gently scrape off the BMDMs and transfer them 
into a 50 mL tube. Scrape up to 5 petri dishes and combine them into 
the same 50 mL tube.  
31. Centrifuge the cells for 5 min at 180 x g at 4°C, remove the supernatant 
and resuspend the cell pellet in 1 mL flushing medium using a 1000 μL 
pipette. Gently pipette up and down five times to disrupt cell clumps 
and obtain a single cell suspension.  
32. Add an additional 9 mL flushing medium while constantly swirling the 
tube, and count the cells again with a hemocytometer under the 
microscope. 
33. Centrifuge the cells for 5 min at 180 x g at 4°C, remove the supernatant 
and resuspend the cell pellet in 1 mL ice-cold FCS using a 1000 μL 
pipette. Prepare a 10% DMSO solution in ice-cold FCS to reach a final 
cell concentration of 107 cells/mL.  
34. Aliquot 1 mL of the final cell suspension into cryotubes and freeze the 
cells in a -80°C freezer using isopropanol freezing chambers.  
35. After 3-4 days, transfer the cryotubes to liquid nitrogen for long-term 
storage.  
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3.2 Thawing and propagation of murine BMDMs 
1. Obtain the required amount of tubes containing frozen BMDMs from 
liquid nitrogen storage. From one vial containing 1 x 107 BMDMs, it is 
possible to expand the cell number up to 3 x 107 BMDMs (the following 
protocol describes how to thaw one tube). 
2. Quickly place the cryotube in a 37°C water bath just until the frozen 
liquid is entirely thawed. Move the tube to the laminar flow hood.  
3. Transfer the BMDMs into a 50 mL tube using a 1 or 2 mL pipette. 
4. Slowly add 9 mL of cold flushing medium drop-wise while swirling. 
5. Centrifuge the BMDMs for 5 min at 180 x g at 4°C, remove the 
supernatant and resuspend the cell pellet in 1 mL cold 20% 
macrophage medium using a 1000 μL pipette. Gently pipette up and 
down five times to disrupt cell clumps and obtain a single cell 
suspension. 
6. Slowly add 9 mL of cold 20% macrophage medium drop-wise while 
swirling. 
7. Transfer the BMDMs to one non-tissue culture treated 10 cm petri dish 
and incubate them overnight in the incubator at 37°C / 5% CO2. 
8. Check the macrophages under the microscope. Most of the BMDMs 
should be adherent the next day. 
9. Remove the medium and add 5 mL cold tissue-culture grade PBS. 
Incubate the BMDMs at 4°C for 15 min in the fridge.  
10. Gently scrape off the BMDMs and transfer them to a 50 mL tube. Rinse 
the petri dish with an additional 5 mL of cold tissue-culture grade PBS 
and add it to the same 50 mL tube.  
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11. Repeat step 5 and 6 of section 3.2. 
12. Prepare five non-tissue culture treated 10 cm petri dishes with 8 mL of 
cold 20% macrophage medium in each. Add 2 mL of BMDM 
suspension per petri dish, distribute the BMDMs equally by rotating the 
petri dish and incubate them for 4 days in the incubator at 37°C / 5% 
CO2. The BMDMs are now ready to be seeded for an experiment as 
outlined in section 3.3.  
 
3.3 Harvesting and seeding BMDMs for an infection with F. novicida 
1. Transfer the all non-tissue culture treated 10 cm petri dishes containing 
BMDMs to the laminar flow hood.  
2. Remove the medium and add 5 mL cold tissue-culture grade PBS to 
each petri dish. Incubate the BMDMs at 4°C for 15 min.  
3. Gently scrape off the BMDMs and transfer them to a 50 mL tube. Rinse 
the petri dishes with an additional 5 mL cold tissue-culture grade PBS 
and add it to the same 50 mL tube.  
4. Centrifuge the BMDMs for 5 min at 180 x g at 4°C, remove the 
supernatant and resuspend the cell pellet in 1 mL cold 10% 
macrophage medium using a 1000 μL pipette. Gently pipette up and 
down five times to disrupt cell clumps and obtain a single cell 
suspension. 
5. Slowly add 9 mL cold 10% macrophage medium drop-wise while 
swirling. 
6. Count the BMDMs under the microscope using a hemocytometer and 
determine the concentration of BMDMs per mL in the suspension.  
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7. Add one sterile glass coverslip to each well of a sterile tissue culture 
treated 24-well plate.  
8. Seed 1.5 x 105 BMDMs per well in 1 mL 10% macrophage medium on 
top of each glass coverslip.  
9. Leave the seeded 24-well plate for 10 min in the laminar flow hood. 
This allows the BMDMs to adhere and distribute more equally 
throughout the well.  
10. Incubate the BMDMs overnight in the incubator at 37°C / 5% CO2. 
11. Start an overnight culture of F. novicida: Inoculate the bacteria from a 
BHI agar plate supplemented with 0.2% L-cysteine and 100 μg/mL 
Ampicillin into 2 mL BHI broth supplemented with 0.2% L-cysteine / 
100 μg/mL Ampicillin. (see Note 4).  
12. Incubate F. novicida containing culture overnight at 37°C with agitation. 
 
3.4 Infection of murine BMDMs with F. novicida 
1. Transfer the F. novicida overnight culture to the laminar flow hood.  
2. Measure the OD600 of the F. novicida overnight culture with a 
spectrophotometer. As an approximation, an OD600 of 1 converts to 10
9 
bacteria per mL.  
3. Prepare a F. novicida dilution in warm 10% macrophage medium to 
reach a multiplicity of infection (MOI) of 100 bacteria per cell (MOI 
100).  
4. Transfer the seeded 24-well plate to the laminar flow hood, remove the 
medium and seed 1 mL of F. novicida suspension at MOI 100 per well.  
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5. Centrifuge the 24-well plate for 5 min at 200 x g at 37°C to synchronize 
the infection.  
6. Incubate the 24-well plate at 37°C / 5% CO2 for 2 h.  
7. Transfer the 24-well plate to the laminar flow hood and remove the cell 
medium (which contains extracellular F. novicida), gently wash the 
cells once with 1 mL warm 10% macrophage medium and add 1 mL 
warm 10% macrophage medium containing 10 μg/mL gentamicin to kill 
extracellular bacteria.  
8. Transfer the 24-well plate back to the incubator at 37°C / 5% CO2 for 
another 2 h.  
 
3.5 Fixation and staining of F. novicida-infected murine BMDMs 
1. After a total of 4 h of F. novicida infection, move the 24-well plate to the 
laminar flow hood, wash the cells three times with 0.5 mL warm 1x 
PBS per well and add 0.3 mL warm 4% PFA per well (the PFA can be 
diluted in 1x PBS). 
2. Transfer the 24-well plate back to the incubator at 37°C / 5% CO2 for 
10 min to fix the BMDMs.  
3. Remove the PFA and wash the fixed BMDMs three times with 0.5 mL 
1x PBS per well.  
4. With the help of forceps and a needle, gently transfer the coverslip 
cells onto the parafilm of the humidified chamber. Immediately cover 
the glass coverslip with 100 μL 1x PBS so the BMDMs do not dry out 
(see Note 5). The next steps are carried out in the humidified chamber. 
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5. Replace the 1x PBS with 100 μL immunofluorescence (IF) buffer and 
incubate the glass coverslips for 30 min at room temperature to block 
non-specific antibody binding.  
6. Replace the IF buffer with 100 μL IF buffer containing 1:100 goat anti-
cGAS primary antibody per glass coverslip and incubate for 1 h at 
room temperature.  
7. Wash the glass coverslips three times with 1x PBS.  
8. Add 100 μL IF buffer containing 1:200 donkey anti-goat Alexa-Fluor 
488 secondary antibody and incubate for 45 min at room temperature. 
9. Wash the glass coverslips three times with 1x PBS.  
10. Add 100 μL IF buffer containing 1:4000 chicken anti-F. novicida 
primary antibody and incubate for 1 h at room temperature (see Note 
6). 
11. Wash the glass coverslips three times with 1x PBS.  
12. Add 100 μL IF buffer containing 1:500 goat anti-chicken Alexa-Fluor 
568 secondary antibody, 1:5000 Hoechst and 1:500 Alexa-Fluor 647 
Phalloidin (see Note 7); and incubate for 45 min at room temperature. 
13. Wash the glass coverslips three times with 1x PBS. 
14. Clean a microscopy glass slide with 70% ethanol and add 2 μL of 
Vecta Shield per glass coverslip. 
15. Using forceps, gently lift the glass coverslips and remove residual 1x 
PBS by blotting the edge and the side not containing the cells on paper 
towel. 
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16. Dip the glass coverslip 3-5 times into ddH2O to wash away any residual 
salt contaminations. This is important as salt crystals can negatively 
influence the subsequent imaging quality. 
17. Dry the coverslip again on paper towel by blotting the edge and the 
side not containing the cells on paper towel. 
18. Mount the glass coverslip with BMDMs facing down on the microscopy 
glass slide containing Vecta Shield.  
19. Seal the glass coverslip on the microscopy glass slide using 
transparent nail polish.  
20. Visualise the cells using a confocal fluorescence microscope (Figure 
1.). Fluorescence microscopy was performed in a PerkinElmer 
UltraView spinning disk confocal microscope, and Z-stacks of 200 nm 
step size were acquired using a 100 x/1.45 NA oil objective. The 
following excitation lasers were used: 405, 488, 561 and 640 nm. 
Fluorescence emission was detected with 445 (W60), 525 (W50), 615 
(W70) and 705 (W90) nm filters, respectively. Data were analyzed and 
processed using FiJi software and all derived images shown 
correspond to maximum 3D projections. 
21. The mounted glass coverslips can be stored at 4°C in the dark for later 
examination. 
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 Figure 1 – cGAS associates with wild-type F. novicida but not with F. 
novicida ∆FPI (see Note 8). BMDMs were infected with F. novicida U112 
(upper panel) or with the isogenic ∆FPI mutant (lower panel) for 4 hours, fixed 
and immunostained for cGAS and bacterial LPS. DNA was stained with 
Hoechst and F-actin with Phalloidin. Examples of cGAS-positive (arrow) or 
cGAS-negative bacteria (arrowhead) are depicted. Scale bar corresponds to 
10 µm. 
 
Notes 
1. The “outer tools” are used to manipulate the exterior of the mouse, 
whereas the “inner tools” are only used once the fur has been removed. 
The separate use of surgical tools reduces potential contamination. 
2. Euthanizing the mice directly in their cage minimizes stress applied to the 
animals, given that they are kept in their known environment. Always 
observe the mice during euthanasia and once the mice stop breathing, wait 
another 1 min before stopping the CO2 supply.  
3. Bone marrow progenitor cells can differentiate into various cell types 
depending on the differentiation conditions. The macrophage colony-
-164- III. Results
stimulating factor (M-CSF), also known as colony-stimulating factor-1 
(CSF-1) is a hematopoietic growth factor differentiating bone marrow 
progenitor cells into non-dividing mature macrophages, so called bone-
marrow derived macrophages (BMDMs) (28). M-CSF is produced in-house 
from 3T3 cells constitutively expressing M-CSF (3T3-MCSF). As M-CSF is 
secreted from these cells, the cell supernatant is collected into 50 mL 
aliquots and stored in an -80°C freezer. The M-CSF can be stored for 3-4 
months in an -80°C freezer.  
4. Infectivity of F. novicida depends a lot on the chosen growth condition and 
can drop dramatically when the growth conditions are not set up properly. 
For best growth, bacterial overnight cultures should be inoculated from 
plates instead of frozen stock. For this, F. novicida is streaked on a BHI 
plate supplemented with 0.2% L-cysteine and 100 μg/mL Ampicillin and 
incubated overnight in a 37°C bacterial incubator. Plates should not be kept 
longer than one week as this also negatively affects infectivity. 
5. As an alternative, the coverslips can each be placed “cells-side down” on a 
drop of antibody solution on some parafilm, within a humidified chamber. A 
humidified chamber can be prepared by placing wet paper towel in the 
bottom of a petri dish covered with aluminum foil, preventing drying of the 
preparation and allowing incubation in the dark, which is crucial when 
handling fluorophores and fluorescent proteins. It is essential that the 
coverslips do not dry out at any step during the procedure, thus the 
antibody solutions must cover the whole coverslip. 
6. In this protocol, both sets of primary and secondary antibodies are added 
sequentially (first primary followed by first fluorophore-conjugated 
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secondary antibody; followed by second primary followed by second 
fluorophore-conjugated secondary antibody). This is done because the 
donkey anti-goat secondary antibody used to stain cGAS would also 
recognize the goat anti-chicken secondary antibody used to stain the 
bacteria. By performing the staining sequentially, it is possible to avoid 
cross-reactivity between different antibodies, which is crucial in all 
immunofluorescence studies. 
7. Phalloidin is a toxin isolated from the deadly Amanita phalloides “death 
cap" mushroom. It selectively binds filamentous actin (F-actin) and is used 
to reveal the distribution of these filaments in eukaryotic cells. 
8. To activate a type-I IFN response, F. novicida needs to escape from the 
Francisella containing vacuole (FCP) into the cytosol. In the cytosol, cGAS 
is recruited to F. novicida and induces type-I IFNs via the 
STING/TBK1/IRF3 pathway (8). The Francisella pathogenicity island (FPI) 
is absolutely required for the escape into the cytosol (19). Therefore, a F. 
novicida mutant lacking the FPI (∆FPI) serves as an ideal negative control 
for unspecific co-localization of cGAS and F. novicida antibody.  
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4 The composition of the canonical inflammasome
complex.
4.1 Introduction
Canonical inflammasomes are cytosolic immune signaling complexes that are acti-
vated by various PAMPs and DAMPs (for more details see chapter I, section 1.4).
The canonical inflammasome complex consists minimally of three components: a
pattern recognition receptor (PRR), the adaptor molecule ASC and caspase-1.
After receptor activation by specific PAMPs and DAMPs, ASC molecules are re-
cruited to the receptor and oligomerize into a large structure called the ASC speck.
The ASC speck then recruits and activates caspase-1 leading to the induction of
cell death and the release of IL-1β. Our group has demonstrated that oligomeriza-
tion of ASC and thereby formation of the ASC speck is crucial for inflammasome
signaling and responsible for efficient caspase-1 cleavage and IL-1β release [277].
Over the years, much evidence has suggested that phosphorylation, ubiquitination,
and interaction with regulatory proteins can influence inflammasome activation and
ASC speck formation, and are thus critical for inflammasome function and regu-
lation [290, 292, 327, 328, 525, 526]. Tight regulation of inflammasome activation is
crucial, as misregulation of the inflammasome is frequently associated with severe
and persistent autoimmune and autoinflammatory diseases [527]. While several
posttranslational modifications were discovered over the last few years, the compo-
sition and stoichiometry of the inflammasome complex and its interaction partners
is poorly characterized.
Characterization of canonical inflammasome activation is important to better un-
derstand the function and mode of action of innate immunity, and could reveal
novel targets for the treatment of autoimmune and autoinflammatory diseases.
Much progress was achieved in the activation mechanisms of different inflamma-
somes and many inflammasome activation stimuli were identified. However, de-
tailed information about the canonical inflammasome complexes is missing. Thus,
we sought to characterize the composition of canonical inflammasome complexes
by identifying novel components of the ASC speck. Moreover, we characterized the
stoichiometry of the inflammasome components within ASC specks and determined
interaction partners of caspase-1.
-170- III. Results
4.2 Material and Methods
Cell culture and infection.
Immortalized primary murine bone marrow-derived macrophages (iMACs) were
grown in DMEM (Sigma) with 10 % M-CSF (supernatants of L929 mouse fibrob-
lasts), 10 % v/v FCS, 10 mM HEPES, and penicillin (100 IU/ml)/streptomycin
(100 µg/ml) (all BioConcept). 1 day before infection or treatment, iMACs were
seeded into 6- or 96-well plates (all Greiner) at a density of 1.5 x 106 or 4 x 104
cells per well or in 10 cm petri dishes (Falcon) at a density of 15 x 106 per petri
dish in DMEM with 10 % M-CSF, 10 % v/v FCS, 10 mM HEPES. iMACs were
pre-stimulated for 4 h with lipopolysaccharide (LPS) (from Escherichia coli strain
O111:B5 (InvivoGen)). To analyze NLRC4 activation, wild-type S. Typhimurium
strain SL1344 was grown overnight at 37 ◦C with aeration in LB containing 90
µg/ml streptomycin (Sigma). Salmonella were subcultured for 4 h and were added
to the iMACs at a multiplicity of infection of 20. The plates were centrifuged for 5
min at 500xg to ensure similar adhesion of the bacteria to the iMACs and were incu-
bated for 90 min at 37 ◦C. To analyze NLRP3 activation, iMACs were treated with
5 mM ATP (Merck) for 90 min at 37 ◦C. Where indicated, 25 nM pan-caspase-
inhibitor Z-Val-Ala-DL-Asp fluoromethylketone (zVAD) (Bachem) was added to
the iMACs together with the treatment/infection.
Retroviral transduction.
iMACs were obtained from wild-type or asc-deficient primary murine bone marrow-
derived macrophages (BMDMs) and complemented with the indicated GFP, ASC
or caspase-1 constructs as previously described [252]. Immortalized caspase-1/
caspase-11 -deficient BMDMs transiently expressing caspase-11 are used to com-
plement with the indicated caspase-1 constructs.
In brief, per transduced iMAC well, supernatant of 3 wells of a 6-well plate are
needed. In these 3 wells, GP2 cells were seeded at a density of 5 x 105 cells
per well in DMEM with 10 % v/v FCS, 10 mM HEPES, and penicillin (100
IU/ml)/streptomycin (100 µg/ml) at day 1. At day 2, 9 µg of construct of in-
terest was mixed with 6 µg VSVg construct and filled up to 0.75 ml with DMEM.
37.5 ul Lipofectamine 2000 (Invitrogen) was gently mixed with 0.75 ml DMEM
and incubated for 5 min at room temperature. After 5 min incubation, the Lipo-
fectamine 2000 was gently mixed with DNA and incubated for 20 min at room
temperature. Add 0.5 ml Lipofectamine 2000/DNA complex solution per GP2 well
drop-wise and incubate overnight at 37 ◦C. At day 3, the medium was removed
from the GP2 cells and replaced with warm DMEM with 10 % M-CSF, 10 % v/v
FCS, 10 mM HEPES, and penicillin (100 IU/ml)/streptomycin (100 ug/ml) and
the GP2 cells moved to 32 ◦C. Per construct, iMACs were seeded in 1 well of a 6-
well plate at density of 5 x 105 cells per well in DMEM with 10 % M-CSF, 10 % v/v
FCS, 10 mM HEPES, and penicillin (100 IU/ml)/streptomycin (100 µg/ml) and
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incubated at 37 ◦C. At day 4, the combined supernatant of the 3 transfected GP2
cell wells was filtered with a 0.45 µm filter (Sarstedt) and 12.5 µg/ml polybrene
(Millipore) was added to favor cellular virus attachment. Then 1 ml of iMACs su-
pernatant was removed, the GP2 supernatant was added drop-wise to the iMACs,
the iMACs centrifuged for 2 h at 2900 rpm and incubated overnight at 32 ◦C.
At day 5, the transduced iMACs were moved to 37 ◦C, expanded and sorted into
96-well plates using a FACSAria III (BD Biosciences).
Pull down protocol for mass spectrometry.
iMACs were seeded in 10 cm petri dishes and treated with 5 mM ATP or in-
fected with S. Typhimurium as described above. Where indicated, 25 nM zVAD
was added to the iMACs. After 90 min, the iMACs were collected into a 15 ml
tube and centrifuged at 4 ◦C, 88xg for 5 min. The cell pellets were resuspended in
1 ml lysis buffer (20 mM Hepes pH 7.4, 10 mM KCl, 1 mM EDTA, 0.1 mM phenyl-
methylsulfonyl fluoride, 1 mM Na3VO4, 5 mM NaF, 0.5 % NP-40 (all Sigma), 1x
protease inhibitor cocktail (Roche)), transferred into 2 ml Eppendorf tubes, vor-
texed for 10 s and lysed for 10 min on ice. The lysates were sonicated 5 times for
7 s (Hielscher) to break the ASC specks and centrifuged for 15 min at 10.000xg at
4 ◦C. 10 µl anti-HA magnetic beads (Thermo) were added to the supernatant and
incubated for 1 h at 4 ◦C on a rotor. The magnetic beads were washed four times
with 500 µl 0.1 M ammoniumbicarbonate (ABC) (Sigma) and the proteins were
eluted by on bead digest. For this, beads were incubated with buffer 1 (5 µg/ml
trypsine (Promega) in 1.6 M urea (AppliChem)/0.1 M ABC) for 30 min at 27 ◦C
800 rpm on Thermomixer (Eppendorf), the supernatant transferred to a new 1.5
ml Eppendorf tube, the beads washed two times with 40 µl buffer 2 (1 mM TCEP
(Sigma) in 1.6 M urea/0.1 M ABC) and the supernatants combined into the same
1.5 ml tube. Protein digest was continued overnight on the bench.
The samples were acidified with 5 % trifluoroacetic acid (TFA) (Thermo) to reach
a pH below 3. C18-columns (Harvard Apparatus) were conditioned twice with 150
ul acetonitrile (VWR) (1600 rpm, 30 s on table top centrifuge (Eppendorf)) and
equilibrated three times with 150 µl buffer A (0.1 % TFA) (2400 rpm, 30 s on table
top centrifuge). Samples were loaded on C18-columns and centrifuged into a new 2
ml Eppendorf tube (1800 rpm, 2 min on table top centrifuge). The flow through was
reloaded on the same C18-columns and centrifuged again into the same tubes. The
C18-columns were washed three times with 100 µl buffer C (5 % acetonitrile, 0.1 %
TFA, 95 % HPLC water (v/v) (Fisher)) (2400 rpm, 30 s on table top centrifuge),
the peptides eluted into new 2 ml Eppendorf tubes three times with 100 µl buffer B
(50 % acetonitrile, 0.1 % TFA, 50 % HPLC water (v/v)) (1600 rpm, 30 s on table
top centrifuge) and the peptides concentrated under vacuum to dryness. Peptides
were either stored at -80 ◦C or resolved in 50 µl buffer A by ultrasonication for
10 s and incubation for 5 min at room temperature on Thermomixer and applied
for mass spectrometry analysis. Mass spectrometry analysis and peptide analysis
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using label-free quantification was done as described in chapter III, section 1.
ASC speck purification.
iMACs were seeded in 10 cm petri dishes and treated with ATP or infected with
S. Typhimurium as described above. Sample preparation for mass spectrometry
analysis was done as described above.
For ASC speck purification, the cell lysates were centrifuged at 400xg for 10 min
at 4 ◦C and then the supernatants were centrifuged again at 2500xg at 4 ◦C for 30
min to spin down ASC specks before sonication. Then the pull down protocol was
followed as described above continuing with sonication.
Immunoblot analysis.
iMACs were seeded in 6-well plates and treated with 5 mM ATP or infected with
S. Typhimurium as described above. At different steps of the pull down proto-
col, protein samples were subjected to SDS-polyacrylamid gels and electroporated
onto PVDF membranes. Primary antibodies used were mouse anti-HA.11 (Enzo-
LifeScience; 1:1000), rat anti-Casp1p20 (Genentech; 1:1000) and rabbit anti-ASC
(AdipoGen; 1:1000) and the membranes incubated overnight at 4 ◦C with the
primary antibodies. Secondary antibodies used were anti-mouse HRP, anti-rabbit
HRP (both Southern Biotech; 1:3000) and anti-rat HRP (GE Healthcare; 1:3000),
the membranes incubated with the appropriate secondary antibody for 1 h at
room temperature and the membrane analyzed on an ImageQuant LAS 4000 (GE
Healthcare).
Cytokine and LDH release measurement.
IL-1β was measured by enzyme-linked immunosorbent assay (eBioscience). Lac-
tate dehydrogenase (LDH) was measured with an LDH Cytotoxicity Detection Kit
(Takara). To correct for spontaneous cell lysis and to normalize the obtained val-
ues, the percentage of LDH release was calculated as follows:
(LDH infected - LDH uninfected) / (LDH total lysis - LDH uninfected) x 100.
ASC speck quantification with immunofluorescence.
iMACs were seeded onto cover glass (VWR) in 24-well plates at a density of 1.25
x 105 cells per well and infected with 5 mM ATP as described below. iMACs were
washed three times with PBS and fixed for 10 min at 37 ◦C with 4 % Paraformalde-
hyde (Electron Microscopy Science). Cover glass was incubated with rabbit anti-
ASC (AdipoGen; 1:500; iWTGFPNter) or mouse anti-HA.11 (EnzoLifeScience; 1:500;
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iASCN/Cter) for 1 h at room temperature, then was washed three times with PBS,
was incubated with Hoechst (1:5000); and donkey anti-rabbit coupled to Alexa 568
(1:500) or goat anti-mouse coupled to Alexa 568 (1:500) (all Life technologies) for
another 45 min at room temperature, was washed three times with PBS and was
mounted on glass slides with Vectashield (Vector labs). Glass slides were analyzed
with a point scanning confocal microscope (Leica).
siRNA transfection.
Wild-type BMDMs were grown in DMEM with 20 % M-CSF, 10 % v/v FCS, 10
mM HEPES, and penicillin (100 IU/ml)/streptomycin (100 ug/ml) (BioConcept).
1 day before siRNA treatment, BMDMs were seeded into 96-well plates (Greiner)
at a density of 3 x 104 or cells per well in DMEM (Sigma) with 10 % M-CSF
(supernatants of L929 mouse fibroblasts), 10 % v/v FCS, 10 mM HEPES and
nonessential aminoacids (BioConcept). 100 µl 1x GenMute Buffer, 2.5 µl GenMute
reagent (SignaGen) and 2 µl 10 µM siRNA (Dharmacon; for details see chapter
V, section 3) were mixed and incubated for 10 min at room temperature. 1 ml
prewarmed 10 % macrophages medium was added, mixed, the supernatant from
the macrophages removed and 105 µl of the siRNA/GenMute complexes added per
well to be transfected. 48 h posttransfection, the BMDMs were prestimulated for
4 h with LPS (from Escherichia coli strain O111:B5) and treated with 5 mM ATP
or 20 µM nigericin (Adipogen) for 90 min at 37 ◦C.
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4.3 Results
The canonical inflammasome complex.
To study the composition of canonical inflammasome complexes, we first devel-
oped a mass spectrometry-based pull down approach. The approach was based
on the analyses of inflammasome activation in immortalized primary murine bone
marrow-derived macrophages (iMACs) complemented with HA-tagged versions of
inflammasome components. iMACs are the closest murine macrophage-like cell line
that are suitable for stable gene expression. In addition, iMACs deficient for inflam-
masomes components were readily available. Complementation of these deficient
iMACs with the HA-tagged gene of interest avoided competition between untagged
endogenous and tagged ectopically expressed protein.
First, we analyzed the composition of canonical inflammasomes. Canonical inflam-
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Figure III.2 Functional analyses of iASCNter and iASCCter. Monoclonal cell lines of
iWTGFPNter, iASCNter or iASCCter were treated with 5 mM ATP for 90 min.(a) LDH and IL-1β
release and (b) immunofluorescence pictures of ASC specks. Blue, nucleus; red, ASC. (c) ASC
speck quantification of (b). cl., clone; Nter, N-terminal HA tag; Cter, C-terminal HA tag. (a) Data
are representatives of two independent experiments (mean and standard deviation of triplicate
wells).
masomes form ASC specks, which are multiprotein complexes of about a micron
in diameter and mostly build of crosslinked ASC filaments [277]. To efficiently
pull down the inflammasome complex, we cloned the major canonical inflamma-
some component ASC to a HA-tag and expressed the constructs in Asc-deficient
iMACs. We tagged ASC at the N- or C-terminus (named iASCNter and iASCCter,
respectively). Wild-type iMACs expressing GFP-HA (iWTGFPNter) served as neg-
ative control for nonspecific binding in the pull down approach. After cloning all
constructs, we produced monoclonal cell lines of the ASC-HA and GFP-HA con-
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structs. Based on functional analyses, we selected clone C of iWTGFPNter, clone Z
of iASCNter and clone G of iASCCter for pull down experiments (Figure III.2).
The NLRP3 inflammasome is activated by over 30 different stimuli, among them
extracellular ATP [528]. To induce NLRP3 inflammasome activation, we treated
iWTGFPNter, iASCNter and iASCCter with 5 mM ATP for 90 min and performed
pull down experiments on cell lysate samples and identified the bound proteins by
mass spectrometry (Figure III.3).
We identified a total of 2773 proteins in NLRP3-activated cells with a false discov-
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Figure III.3 Pull down of iWTGFPNter, iASCNter and iASCCter. iWTGFPNter, iASCNter
and iASCCter were treated with 5 mM ATP for 90 min and samples from different steps of the pull
down protocol were analyzed with western blot. 1, input; 2, supernatant beads; 3, first wash, 4,
second wash; 5, fourth wash; 6, eluate; 7, beads only. Nter, N-terminal HA tag; Cter, C-terminal
HA tag.
ery rate of 1 % (data available upon request). We enriched ASC from iASCNter and
iASCCter but not iWTGFPNter samples, demonstrating specific ASC enrichment and
therefore validity of the pull down experiment (Table III.1). In addition to ASC,
we detected caspase-1 in the iASCNter and iASCCter but not iWTGFPNter samples,
with roughly 20 % of ASC molecules binding caspase-1 (Table III.1). Interest-
ingly, we only detected inflammasome-bound caspase-1 in iMACs treated with the
pan-caspase inhibitor zVAD (Table III.1). Since zVAD blocks autoprocessing and
autoactivation of pro-caspase-1, this finding indicates that active caspase-1 rapidly
dissociates from the ASC speck, and that blocking activation prevents this dis-
sociation, effectively trapping pro-caspase-1 within the structure, as suggested by
Broz and colleagues [252]. Moreover, we detected a specific enrichment of NLRP3
in iASCNter and iASCCter samples (Table III.1), showing roughly 10 % of ASC
molecules binding NLRP3. Interestingly, the inflammasome receptors AIM2 and
NLRC4 were detected in iASCNter and iASCCter, but not iWTGFPNter samples.
As ATP specifically activates the NLRP3 inflammasome [528], it is possible that
NLRC4 and AIM2 bound to ASC after the ASC specks have been formed, most
likely during the prolonged incubation of the lysates with anti-HA beads. How-
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Table III.1 Selected proteins identified in pull downs of NLRP3-activated cells.
iWTGFPNter, iASCNter and iASCCter were treated with 5 mM ATP for 90 min and HA beads-
enriched samples were analyzed with mass spectrometry. Numbers represent the quantitative
total spectra identified with mass spectrometry from total cell lysates, purified inflammasome
samples (*) or total cell lysates without zVAD treatment (#). Nter, N-terminal HA tag; Cter,
C-terminal HA tag.
Protein iWTGFPNter iASCNter iASCCter
GFP 21.5 0 0
GFP* 50.1 0 0
GFP# 21.5 0 0
ASC 0 71.1 46.5
ASC* 0 89.5 56.5
ASC# 1.3 82.3 32.7
Caspase-1 0 13.8 19.5
Caspase-1* 0 2.4 5.6
Caspase-1# 0 0 0
NLRP3 1.7 6.4 7.4
NLRP3* 0 7.3 0
NLRP3# 0 0 0
NLRC4 0 1.1 2.8
NLRC4* 0 0 0
NLRC4# 0 0 0
AIM2 0 4.2 0
AIM2* 0 0 0
AIM2# 0 0 0
CASP8 0 5.3 0
CASP8* 0 0 0
CASP8# 0 0 0
NEK7 0 0 0
NEK7* 0 0 0
NEK7# 0 0 0
ever, if inflammasome receptors bind to ASC specks after ASC oligomerization is
currently unknown, as it is thought that the HIN200 and LRR domains of AIM2
and NLRC4, respectively, keep the PYD and CARD domain of the receptors in an
inactive state before ligand recognition [249].
To test the possibility whether inflammasome receptors associate unspecifically
with the ASC speck during beads incubation, we activated NLRP3 with 5 mM
ATP and isolated the inflammasome complex from cell lysates by centrifugation
before subjecting them to anti-HA beads. Mass spectrometry analyses of isolated
inflammasome complexes showed NLRP3 but not AIM2 or NLRC4 binding to ASC
(Table III.1), indicating that indeed NLRC4 and AIM2 are recruited to ASC specks
after inflammasome activation (Table III.1). However, how AIM2 and NLRC4 are
activated upon specific NLRP3 activation and their biological relevance in this ex-
perimental setting is currently unknown.
In 2014, Martin and colleagues showed interaction of ASC with IKKα and IKKα-
dependent phosphorylation of ASC [328]. Moreover, three independent groups
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demonstrated additional critical ASC phosphorylation events for ASC speck for-
mation [326,327,529]. However, we neither detected an interaction between IKKα
and ASC nor ASC phosphorylation in our experimental setting (data available
upon request).
After analyzing the NLRP3 inflammasome complex, we investigated the NLRC4
Table III.2 Selected proteins identified in pull downs of NLRC4-activated cells. Se-
lected proteins from NLRC4 (STm) or NLRP3 (ATP)-activated iMACs. Numbers represent
the quantitative total spectra identified with mass spectrometry from total cell lysates or pu-
rified inflammasome samples (*). The purified inflammasome samples originate only from S.
Typhimurium-infected cells. STm, S. Typhimurium; Nter, N-terminal HA tag; Cter, C-terminal
HA tag.
Protein iWTGFPNter iASCNter iASCCter
ATP STm ATP Stm ATP STm
GFP 14.8 21.1 0 0 0 0
GFP* - 12.8 - 0 - 0
ASC 0 0 48.6 52.1 32.2 24.2
ASC* - 0 - 5.3 - 25.0
Caspase-1 0 0 6.6 4.8 20.5 9.7
Caspase-1* - 0 - 1.5 - 8.9
NLRP3 1.5 2.1 4.2 6.4 4.2 6.4
NLRP3* - 2.6 - 3.8 - 14.3
NLRC4 0 0 0 0 2.2 0
NLRC4* - 0 - 0 - 0.9
AIM2 0 0 2.4 4.3 0 0
AIM2* - 0 - 0 - 3.6
Casp8 0 0 1.8 3.2 0.7 0
Casp8* 0 0 0.9
NEK7 0 0 0.6 0.5 0 1.2
NEK7* 0 0 0
inflammasome complex. NLRC4 is activated by bacterial ligands such as flag-
ellin or components of type 3 secretion systems. To activate NLRC4, we infected
iWTGFPNter, iASCNter and iASCCter with exponentially growing S. Typhimurium,
pulled down the NLRC4 inflammasome complexes and analyzed them by mass
spectrometry. We identified a total of 3304 proteins in NLRC4-activated cells with
a false discovery rate of 1 % (data available upon request). Compared to NLRP3-
activated samples (Table III.1 and Table III.2), we detected comparable amounts
of ASC and caspase-1 in lysate samples of iASCNter and iASCCter (Table III.2).
Interestingly, we were unable to detect NLRC4 bound to ASC in NLRC4-activated
cells (Table III.2). In contrast, we detected AIM2 and NLRP3 in lysate samples of
iASCNter and iASCCter (Table III.2). These observations suggest that unspecific in-
flammasome receptor binding is true for the NLRC4 inflammasome as well. To test
this hypothesis, we performed pulldown experiments on purified inflammasome
samples to examine receptor binding after ASC speck formation. In purified in-
flammasome samples, we detected NLRC4 in NLRC4-activated cells (Table III.2).
Moreover, the amount of detected AIM2 decreased in purified inflammasome sam-
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ples indicating that AIM2 bound to ASC after inflammasome activation (Table
III.2). In contrast, the amount of NLRP3 between cell lysate and purified inflam-
masome samples was unchanged indicating that NLRP3 is recruited to the ASC
speck in NLRC4-activated cells (Table III.2). Our observations are consistent with
a publication by Qu and colleagues where they showed NLRC4-dependent NLRP3
recruitment into the NLRC4 inflammasome complex after S. Typhimurium infec-
tion [530].
In 2013, Man and colleagues reported apoptotic caspase-8 recruitment to and
caspase-8 activation at canonical inflammasome complexes [531]. In line with these
observations, we identified ASC-bound caspase-8 in NLRP3- and NLRC4-activated
samples (Table III.1 and III.2).
Taken together, iASCNter and iASCCter pull down experiments successfully enriched
the NLRP3 and NLRC4 inflammasome complex and confirmed ASC as the major
component of the canonical inflammasome complex. Irrespective of the activated
inflammasome receptor, around 20 % of ASC bind caspase-1 in the canonical in-
flammasome complex. Pull down experiments comparing zVAD-treated and un-
treated cells showed that ASC interacts only with inactive caspase-1 and that the
interaction with active, processed caspase-1 is transient, most likely since processed
caspase-1 dissociates from the inflammasome complex after activation. Our analy-
ses showed that ASC and caspase-1 are the major components of the inflammasome
complex. Besides ASC and caspase-1, we observed the recruitment of multiple in-
flammasome receptors in NLRC4- and NLRP3-activated iMACs. Whereas a recent
paper could explain NLRP3 recruitment to the NLRC4 inflammasome [530], the
biological function of NLRC4 and AIM2 recruitment by the NLRP3 inflammasome
remains elusive and requires further examination.
Caspase-1 interaction partners.
Caspase-1 is recruited to and proteolytically activated at the canonical inflam-
masome complex and is the common executioner of all known canonical inflam-
masomes. Active caspase-1 cleaves intracellular substrates to induce pyroptosis,
a lytic, pro-inflammatory form of cell death associated with cytokine production.
Caspase-1 function and therefore induction of cell death and cytokine release fully
depends on its catalytic activity and ability to be cleaved in the ASC speck [252].
Nevertheless, the recruitment to the ASC speck does not require catalytic activity
and thus happens before caspase-1 cleavage.
The three best studied cleavage substrates of caspase-1 are Gasdermin-D and the
two cytokines IL-1beta and IL-18 [249]. Gasdermin-D forms holes in the plasma
membrane resulting in cell lysis, whereas IL-1β and IL-18 attract immune cells
and induce inflammation in the surrounding tissue [249,261264]. However, Agard
and colleagues reported more potential caspase-1 cleavage substrates, though their
function in pyroptosis is not well understood [532]. To address this, we used our
pull down approach to identify caspase-1 interaction partners and assessed their
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contribution to the phenotype of pyroptosis.
We tagged caspase-1 at the N- or C-terminus with a HA-tag and expressed the
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Figure III.4 Functional analyses of monoclonal iWTGFP, iCasp1wtNter and
iCasp1wtCter. (a) Cell death and IL-1β release of monoclonal iWTGFPNter and iWTGFPCter in-
fected with S. Typhimurium for 90 min. (b) LDH and IL-1β release of monoclonal iWTGFPNter,
iCasp1wtNter and iCasp1wtNter 90 min after 5 mM ATP treatment or S. Typhimurium infection.
cl., clone; wt, wild-type; Casp1, Caspase-1; Nter, N-terminal HA tag; Cter, C-terminal HA tag.
(a,b) Data are representatives of two independent experiments (mean and standard deviation of
triplicate wells).
constructs in caspase-1 -deficient iMACs (named iCasp1wtNter and iCasp1wtCter, re-
spectively). The previously constructed iWTGFPNter served as negative control for
unspecific binding in the pull down approach. After stable construct expression,
we produced monoclonal cell lines of the caspase-1-HA constructs. Based on func-
tional analyses, we selected clone C of iCasp1wtNter and clone A of iCasp1wtCter for
pull down experiments (Figure III.4).
To specifically identify caspase-1 interaction partners before and after inflamma-
some recruitment, we slightly adapted the pull down protocol and skipped the
sonication step. Without sonication, the inflammasome complex is not efficiently
pulled down, whereas caspase-1 and GFP are efficiently recovered after beads elu-
tion (Figure III.5).
Using mass spectrometry, we identified a total of 1239 proteins in the iWTGFPNter
and iCasp1wtNter samples with a false discovery rate of 1 % in NLRP3-activated
cells (data available upon request). Out of these 1239 proteins, 273 proteins were
exclusively found and 122 proteins enriched in the iCasp1wtNter samples compared
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Figure III.5 iCasp1wtNter pull down. (a) iWTGFPNter, iASCNter and iASCCter were treated
with 5 mM ATP for 90 min and samples from different steps of the pull down protocol without
sonication were analyzed with western blot. 1, nuclear pellet; 2, input; 3, supernatant beads;
4, first wash; 5, fourth wash; 6, eluate; 7, cooked beads. (b) iWTGFPNter and iCasp1Nter were
treated with 5 mM ATP for 90 min and samples from different steps of the pull down protocol
without sonication were analyzed with western blot. 1, nuclear pellet; 2, input; 3, supernatant
beads; 4, first wash; 5, eluate; 6, cooked beads. Where indicated, cells were treated with 25 nM
zVAD. Casp1, Caspase-1; Nter, N-terminal HA tag; Cter, C-terminal HA tag.
to iWTGFPNter samples (data available upon request). Among the proteins exclu-
sively found in iCasp1wtNter samples were IL-1β, Gasdermin-D, Zyxin, MCM4 and
Wdr1 (Table III.3), which based on previous publications are directly cleaved by
caspase-1 or secreted in a caspase-1-dependent manner [532, 533]. These results
demonstrated the validity of our pull down approach and its ability to detect
caspase-1 interaction partners and cleavage substrates.
We validated 20 potential caspase-1 interaction partners for their impact on cell
death and IL-1β release by siRNA knock down experiments in primary murine bone
marrow-derived macrophages (BMDMs) (Table III.3) . We transfected BMDMs
with a pooled siRNA library and treated them with the pore-forming bacterial
toxin nigericin to induce NLRP3 inflammasome activation. We used nigericin in-
stead of ATP as we observed IL-1β but not cell death in ATP-treated BMDMs in
this experimental setup (Figure III.6 a). Knock down of the positive control NLRP3
reproducibly reduced cell death and IL-1β release by 50 %, whereas none of the 20
potential caspase-1 interaction partners showed an impairment in cell death and
IL-1β release (Figure III.6 b). Thus we could not observe an involvement of the 20
proteins in NLRP3-dependent cell death and IL-1β release. However, we cannot
exclude that they account for other phenotypic characteristics of pyroptosis.
Another interesting protein found in our pull down experiment was Zyxin. Zyxin
has a reported dual function in apoptosis, another form of programmed cell death
[534, 535]. Zyxin promotes apoptosis through CARP-1 binding [534], but can also
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Table III.3 Selected proteins identified in the caspase-1 pull down. Selected proteins
from NLRP3-activated iMACs treated with (*) or without the pan-caspase inhibitor zVAD. Num-
bers indicate the total spectrum counts identified with mass spectrometry in total lysates. #,
validated proteins with siRNA. Casp1, Caspase-1; Nter, N-terminal HA tag; Cter, C-terminal
HA tag.
Protein iWTGFPNter iWTGFPNter(*) iCasp1wtNter iCasp1wtNter(*)
GFP 96 89 3 1
Caspase-1 0 0 41 43
IL-1β 0 0 2 2
Gasdermin-D 0 0 3 2
Zyxin 0 0 0 2
MCM4 0 0 9 12
Tgm2# 0 0 21 19
Gart# 0 0 20 12
Wdr1# 0 0 14 18
Samhd1# 0 0 13 13
Cmpk2# 0 0 11 11
Drg2# 0 0 10 10
Hspa14# 0 0 10 6
Rnf213# 0 0 3 14
Lrrfip1# 1 0 15 28
Hcls1# 5 3 25 27
Snx5# 8 3 17 20
Ptpn6# 3 3 21 19
Coro1c# 1 0 17 19
Ifit3# 2 2 13 17
Arpc1b# 4 1 17 16
Swap70# 1 0 8 15
Sec23b# 1 1 15 13
Rnh1# 1 0 11 12
Adsl# 2 0 11 12
Fyb# 1 0 7 12
block chromatin condensation, a hallmark of apoptosis [535]. To block chromatin
condensation, Zyxin binds Acinus in the nucleus and thereby prevents Acinus from
apoptotic caspase-dependent cleavage. Intriguingly, nuclear condensation is also
observed in caspase-1-dependent cell death [249]. Moreover, Zyxin was validated
as caspase-1 cleavage substrate by Agard and colleagues [532]. Thus we wondered
what impact Zyxin had on canonical inflammasome activation. We tested zyxin-
deficient BMDMs for their ability to induce various canonical inflammasomes, but
could not observe a reduction of cell death and IL-1β release in zyxin-deficient
compared to wild-type BMDMs (Figure III.7). Nevertheless, the effect of Zyxin on
caspase-1-induced nuclear condensation remains unclear and further investigations
could uncover the role of Zyxin cleavage in caspase-1-induced nuclear condensation.
Taken together, caspase-1 pull down experiments identified known and potential
caspase-1 interaction partners. However, the validation of 20 potential interac-
tion partners did not show a defect in cell death and IL-1β release. Moreover,
we confirmed that Zyxin directly interacts with caspase-1. However, Zyxin had
-182- III. Results
0
20
40
60
80
C
el
l d
ea
th
 
(%
 L
D
H
 re
le
as
e)
Plate 1
nlr
p3
 si
RN
A
NT
 si
RN
A
tgm
2 s
iR
NA
lrr
fip
1 s
iR
NA
hc
ls1
 si
RN
A
sn
x5
 si
RN
A
0
200
400
600
800
1000
IL
-1
 re
le
as
e 
(p
g/
m
l)
0
20
40
60
80
C
el
l d
ea
th
 
(%
 L
D
H
 re
le
as
e)
Plate 2
0
20
40
60
80
C
el
l d
ea
th
 
(%
 L
D
H
 re
le
as
e)
Plate 3
0
20
40
60
80
C
el
l d
ea
th
 
(%
 L
D
H
 re
le
as
e)
Plate 4
nlr
p3
 si
RN
A
NT
 si
RN
A
fyb
 si
RN
A
ga
rt 
siR
NA
wd
r1 
siR
NA
sa
mh
d1
 si
RN
A
0
200
400
600
800
1000
1000
2000
IL
-1
 re
le
as
e 
(p
g/
m
l)
0
20
40
60
80
C
el
l d
ea
th
 
(%
 L
D
H
 re
le
as
e)
Plate 5
0
20
40
60
80
C
el
l d
ea
th
 
(%
 L
D
H
 re
le
as
e)
Plate 6
nlr
p3
 si
RN
A
NT
 si
RN
A
ptp
n6
 si
RN
A
co
ro
1c
 si
RN
A
ifit
3 s
iR
NA
arp
c1
b s
iR
NA
0
200
400
600
800
1000
IL
-1
 re
le
as
e 
(p
g/
m
l)
nlr
p3
 si
RN
A
NT
 si
RN
A
sw
ap
70
  s
iR
NA
se
c2
3b
 si
RN
A
rn
h1
 si
RN
A
ad
sl 
siR
NA
0
200
400
600
800
1000
IL
-1
 re
le
as
e 
(p
g/
m
l)
nlr
p3
 si
RN
A
NT
 si
RN
A
cm
pk
2 s
iR
NA
dr
g2
 si
RN
A
hs
pa
14
 si
RN
A
un
tre
ate
d
0
200
400
600
800
1000
1000
1500
IL
-1
 re
le
as
e 
(p
g/
m
l)
nlr
p3
 si
RN
A
NT
 si
RN
A
py
ca
rd
 si
RN
A
ca
sp
1 s
iR
NA
rn
f21
3 s
iR
NA
un
tre
ate
d
0
200
400
600
800
1000
1000
1100
IL
-1
 re
le
as
e 
(p
g/
m
l)
untreated
20 µM nigericin
NT
 si
RN
A
nlr
p3
 si
RN
A
ca
sp
1 s
iR
NA
0
20
40
60
C
el
l d
ea
th
 
(%
 L
D
H
 re
le
as
e)
NT
 si
RN
A
nlr
p3
 si
RN
A
ca
sp
1 s
iR
NA
0
500
1000
1500
IL
-1
 re
le
as
e 
(p
g/
m
l)
5 mM ATP
20 µM nigericin
a
b
Figure III.6 Impact of potential caspase-1 interaction partners on cell death and
IL-1β release. (a) LDH and IL-1β release from indicated siRNA-treated, 5mM ATP or 20 µM
stimulated primary murine bone marrow derived macrophages (BMDMs). (b) LDH and IL-1β
release from indicated siRNA-treated and 20 µM nigericin-stimulated wild-type BMDMs for 90
min. nlrp3 siRNA was used as positive control. NT, nontargeting. Data are representatives of
two independent experiments (mean and standard deviation of triplicate wells).
no impact on cell death and Il-1β release. Nevertheless, we cannot exclude that
the 20 validated proteins and zyxin play a role in other characteristics of pyrop-
tosis, such as chromosome condensation. Identifying proteins contributing to the
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Figure III.7 Canonical inflammasome activation in zyxinKO. LDH and IL-1β release in
wild-type (wt), zyxinKO or caspase-1/caspase-11 dKO (C1C11dKO) primary murine bone marrow
derived macrophages 90 min after treatment with 5 mM ATP or 20 µM nigericin to induce
NLRP3, transfection of poly(dA:dT) to induce AIM2 or infection with S. Typhimurium to induce
NLRC4 activation. Data are representatives of two independent experiments (mean and standard
deviation of triplicate wells).
pyroptotic phenotype would greatly enhance our understanding about caspase-1
cleavage substrates and their function in inflammasome-induced inflammation. As
the contribution to inflammation of other pyroptotic phenotypes besides cell death
and cytokine release is unclear, identifying the responsible proteins would help to
understand their contribution to inflammation.
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4.4 Discussion and Outlook
The canonical inflammasome complex is an important mediator of inflammation
and its misregulation is associated with autoinflammatory and autoimmune dis-
eases [249,536]. Whereas many activation signals of canonical inflammasomes were
described so far, the composition and stoichiometry of canonical inflammasomes
is not well understood. Canonical inflammasomes activate caspase-1, which then
executes cell death and cytokine release to induce inflammation by cleaving cellular
substrates. However, only a few cleavage substrates of caspase-1 are described so
far. In the work presented here, we established a pull down protocol to identify
the composition and stoichiometry of canonical inflammasome complexes and to
identify interaction partners of caspase-1.
The analyses of the NLRP3 and NLRC4 inflammasome complex confirmed ASC
as the major component of the inflammasome complex irrespective of the type of
canonical inflammasome. We discovered that 20 % of ASC molecules bind caspase-
1 indicating that caspase-1 is the second most abundant protein in the canonical
inflammasome complex. It is important to mention that we only detected ASC-
caspase-1 interaction when we used zVAD to block caspase-1 activation. These
observations suggest that the interaction between caspase-1 and the inflamma-
some is transient, where inactive caspase-1 is recruited and active caspase-1 im-
mediately dissociates from the complex again. Moreover, we identified multiple
inflammasome receptors associated to the inflammasome complex upon NLRP3-
and NLRC4-specific stimuli. However, it is unclear if the recruitment of multiple
inflammasome receptors to the same inflammasome complex is of biological rele-
vance.
The analyses of caspase-1 pull downs identified known and unknown caspase-1
interaction partners. Interestingly, the number of interactions between caspase-1
and known cleavage substrates was low, indicating that the substrates only bind
caspase-1 at the moment of cleavage. The validation of identified unknown caspase-
1 interaction partners could not reveal an important role for these proteins in
inflammasome-dependent cell death and IL-1β release. However, we cannot ex-
clude that these proteins result in different phenotypic characteristics of pyroptosis,
besides membrane permeabilization and cytokine release, such as nuclear conden-
sation.
Taken together, we demonstrated for the first time an in depth analysis of the com-
position and stoichiometry of the canonical inflammasome complex. Besides ASC
and caspase-1, we could not identify any other highly abundant protein, indica-
tion that ASC specks are composed only of ASC and caspase-1. Moreover, several
interesting questions and potential follow up projects arose from these analyses.
Some of these questions and potential projects are discussed in the next paragraphs.
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Why are multiple receptors recruited to the canonical inflammasome?
We identified multiple inflammasome receptors bound to one canonical inflamma-
some complex. AIM2 and NLRC4 were detected in NLRP3-activated samples and
AIM2 and NLRP3 in NLRC4-activated samples, therefore the specificity of recep-
tor binding in respect to the applied stimuli was not given.
An explanation for stimuli-independent receptor binding could be of technical rea-
sons during sample preparation. The pull down protocol included a sonication step
to break up the large ASC speck. This sonication step was absolutely required
for efficient inflammasome complex pull down. Sonication could create blunted
ASC filament ends, which serve as new interaction and recruitment sites for in-
flammasome receptors. During beads incubation with cell lysates after sonication,
receptors would bind to these free ASC oligomers and are thereby detected in
our analyses. Therefore, separating the cytosolic content from inflammasome com-
plexes would reduce this phenomenon. Indeed, when we purified the inflammasome
complex before sonication and beads incubation, we detected no AIM2 and NLRC4
in NLRP3-activated samples, indicating that free ASC binding sites might be oc-
cupied by inflammasome receptors. However, we still detected NLRP3 in NLRC4-
activated samples. Moreover, it is unclear how multiple inflammasome receptors
get activated upon receptor-specific stimuli.
Inflammasome receptors only bind ASC upon global conformational changes in-
duced by direct or indirect ligand recognition. In the case of NLRC4, receptor
activation is initiated through NAIP proteins that recognize the different bacterial
ligands. The activated NAIPs then serve as initiators of NLRC4 oligomerization in
a domino-like reaction associated with global structural domain rearrangements in
NLRC4 [276]. These rearrangements make NLRC4 competent for ASC recruitment.
As we detected NLRC4 in NLRP3-activated cells, it is possible that bacterial con-
taminants introduced during sample preparation activated NLRC4. However, there
is also the possibility that ASC oligomers can induce NLRC4 activation. Therefore,
the activation of NLRC4 in NLRP3-activated cells requires further investigation.
In contrast to NLRC4, AIM2 is activated by double stranded DNA (dsDNA) in
the cytosol; forming a similar ASC recruitment platform as seen for NLRC4 [304].
As nuclear dsDNA is present in cell lysates, AIM2 could be activated during beads
incubation after cell lysis and thereby detected in our pull down analyses.
In contrast, the activation mechanism and oligomerization of NLRP3 is not under-
stood. NLRP3 is activated in the cytosol by over 30 different stimuli, which are all
indicators of cellular metabolic issues [249]. As the pull down approach included
cell lysis, the loss of cell integrity could have been the trigger of NLRP3 activation
and binding to ASC in NLRC4-activated cells.
Therefore, we could hypothesize that caspase-1-dependent Gasdermin-D pore for-
mation in NLRC4-activated cells results in potassium eux and therefore NLRP3
activation. Indeed, our analyses of caspase-11-dependent NLRP3 activation has
shown that caspase-11, Gasdermin-D-dependent cell lysis activates NLRP3 and
consequently the release of mature IL-1β [263,348]. Moreover, it has been reported
that the induction of another form of lytic cell death called necroptosis, which is
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mediated by MLKL pore formation in the plasma membrane, triggers NLRP3 ac-
tivation [537, 538]. Therefore, it might be that NLRP3 activation occurs in every
form of lytic cell death and thus every activated ASC speck recruits NLRP3.
Alternatively, Qu and colleagues postulated that NLRC4 recruits NLRP3 to the in-
flammasome complex upon Salmonella infection [530]. However, we did not detect
any ASC-bound NLRC4 in the same samples. In general, we detected less NLRC4
than NLRP3 associated with ASC. Thus, it is possible that NLRC4 initially bound
to ASC and recruited NLRP3, but the NLRC4-ASC interaction was lost during
sample preparation due to differential receptor binding affinities to ASC. It might
be that the ASC-NLRC4 binding over CARD domains is not as stable as ASC-
NLRP3 binding over PYD domains. Measuring the binding affinity of purified,
activated inflammasome receptors to oligomerized ASC could clarify the possibil-
ity of differential receptor ASC binding affinities.
In 2016, Shi and colleagues discovered NEK7 as an important protein for NLRP3
inflammasome activation and ASC speck formation [539]. Intriguingly, we detected
NEK7 bound to ASC in some conditions in our pull down experiments. The exact
function of NEK7 is unknown, but it could be speculated that NEK7 serves as sen-
sor protein for NLRP3 as NAIPs do for NLRC4. With our established pull down
protocol on hand, we could identify NLRP3 interaction partners and potentially
the activator of NLRP3, be it a sensor protein as in the case of NLRC4 or a ligand
molecule like dsDNA as seen for AIM2. To perform the pull down experiment, I
would express HA-tagged NLRP3 in Asc-deficient cells because of three reasons.
First, NLRP3 can be activated in Asc-deficient cells and oligomerizes without ASC
recruitment, leading to a small receptor complex instead of the large ASC speck.
This could lead to better NLRP3 enrichment. Second, Asc-deficient cells do not
induce NLRP3-dependent cell death and therefore cellular content is not lost in
the supernatant during NLRP3 activation. Third, ASC speck formation and sub-
sequent caspase-1 activation could induce negative feedback loops that block addi-
tional NLRP3 activation. As Asc-deficient cells do not induce NLRP3-dependent
caspase-1 activation, cells could activate more NLRP3 oligomers and consequently
accumulate potential NLRP3 interaction partners. This is of special importance
as mass spectrometry analyses detect only highly abundant proteins in complex
samples. As NLRC4 oligomers only contain one initiating NAIP protein and this
activation mechanism could hold true for NLRP3 oligomers as well, the NLRP3
initiator would be above the detection threshold of mass spectrometry.
In addition to the identification of NLRP3 interaction partners and the poten-
tial NLRP3 initiator, electron microscopy studies of the activated, purified NLRP3
oligomer could solve its three dimensional architecture and give insights into NLRP3
oligomerization.
Taken together, understanding the activation mechanism of NLRP3 is of huge
interest as misregulated NLRP3 is associated with autoimmune and autoinflam-
matory diseases in humans [527]. Studying the activation mechanism of NLRP3
could reveal new potential interventions to block or interfere NLRP3 activation and
therefore mitigate NLRP3-associated autoinflammatory and autoimmune diseases.
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Can we distinguish Caspase-1 interaction partners responsible for cell
death and IL-1β release?
To detect caspase-1 in the canonical inflammasome complex we added the pan-
caspase inhibitor zVAD, because wild-type caspase-1 dissociates from the inflam-
masome complex after activation. Full caspase-1 activation depends on its catalytic
activity and ability to be cleaved in the ASC speck [252]. Nevertheless, the recruit-
ment of caspase-1 to the ASC speck does not require catalytic activity or caspase-1
cleavage. Therefore, uncleavable and catalytic dead caspase-1 mutants could accu-
mulate in the inflammasome complex and there trap caspase-1 interaction partners.
By performing pull down experiments with caspase-1 mutants, we could analyze
the composition of the inflammasome complex and caspase-1 interaction partners
in the same experiment.
We already expressed HA-tagged catalytic dead and uncleavable caspase-1 mu-
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Figure III.8 Protein expression of monoclonal iWTGFPNter, iCasp1cd and iCasp1uncl.
Westernblot analysis of Caspase-1 in various untreated monoclonal cell lines. Actin served as
loading control. cl., clone; cd, catalytic dead; uncl., uncleavable; Casp1, Caspase-1; Nter, N-
terminal HA tag; Cter, C-terminal HA tag.
tants in caspase-1 -deficient iMACs and produced monoclonal cell lines (Figure
III.8). Moreover, we obtained promising data from a first pull down experiment
comparing wild-type and uncleavable caspase-1 constructs, where we detected sim-
ilar levels of caspase-1 and ASC (Table III.4). Moreover, we could reduce unspecific
binding of inflammasome receptors to ASC and detected higher levels of specific
NLRP3 and NLRC4 binding with the uncleavable caspase-1 construct. Therefore,
we might obtain even better results using uncleavable or catalytic dead caspase-1
instead of ASC constructs to analyze the composition of canonical inflammasome
complexes.
Besides potential improvements in the analyses of the inflammasome complex, the
usage of caspase-1 mutant constructs could differentiate caspase-1 interaction part-
ners depending on its activation state. Wild-type caspase-1 is fully active and in-
duces cell death and IL-1β release, whereas uncleavable caspase-1 only induces cell
death but not IL-1β release and catalytic dead caspase-1 is deficient for both [252].
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Table III.4 Caspase-1 pull down of NLRC4- and NLRP3-activated cells. Selected pro-
teins from NLRC4 (STm) and NLRP3 (ATP) activated iMACs. Numbers indicate the total
spectrum counts identified with mass spectrometry from purified inflammasome samples. STm,
S. Typhimurium; Casp1, Caspase-1; Nter, N-terminal HA tag; Cter, C-terminal HA tag.
Protein iWTGFPNter iCasp1wtNter iCasp1unclNter
ATP STm ATP Stm ATP STm
GFP 2 6 0 0 0 0
Caspase-1 1 1 15 17 11 31
ASC 0 0 4 11 1 14
NLRP3 0 5 0 1 3 6
NLRC4 0 0 0 1 0 4
AIM2 0 0 5 6 0 1
Therefore, comparing pull down experiments from the three different caspase-1
constructs could determine proteins responsible for cell death, IL-1β release or
both. Proteins interacting with all three caspase-1 constructs are components of
the canonical inflammasome as they are all recruited by the inflammasome complex.
In addition, proteins interacting with all three caspase-1 constructs could be inter-
action partners of inactive caspase-1 in the cytosol. Cytosolic and inflammasome
complex interaction partners of caspase-1 could be discriminated by comparing
pull downs of cell lysates with inflammasome-purified samples. Proteins associated
with caspase-1 in the inflammasome complex would be enriched in the purified in-
flammasome samples, whereas cytosolic caspase-1 interaction partners are absent
or reduced in these samples compared to cell lysate samples.
The comparison of wild-type and uncleavable caspase-1 could discriminate between
caspase-1 interaction partners critical for cell death and IL-1β release. Proteins only
interacting with wild-type and uncleavable caspase-1 are involved in cell death,
whereas proteins only interacting with wild-type caspase-1 but not uncleavable
caspase-1 are involved in IL-1β release. In addition, these proteins should not in-
teract with the catalytic dead caspase-1, as this construct does not induce cell
death and IL-1β release.
Taken together, the analyses of uncleavable and catalytic dead caspase-1 constructs
could improve the analyses of canonical inflammasome components and their stoi-
chiometry, as these caspase-1 mutants are recruited to the inflammasome complex
but are not released anymore. Moreover, comparing pull down results of wild-type,
uncleavable and catalytic dead caspase-1 constructs could discriminate caspase-1
interaction partners responsible for cell death from those responsible for IL-1β re-
lease. This could discover the cellular mechanism that releases IL-1β independent
of cell death. Indeed, under certain conditions and stimuli, innate immune cells like
monocytes, neutrophils or dendritic cells only release IL-1β without the induction
of cell death [540542]. Only releasing IL-1β but not the entire cellular content
could be an important immune regulatory step of the organism to activate the
immune system but at the same time reducing inflammation and thereby tissue
damage.
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Does Caspase-8 induce inflammasome-dependent, Gasdermin-D-
independent cell death?
Recently, three individual groups identified Gasdermin-D as the most important
downstream target of caspase-1 to induce pyroptosis [258260]. Nevertheless, canon-
ical inflammasome activation induces at late time points lytic cell death and
IL-1β release in GsdmD-deficient macrophages. Under these conditions, He and
colleagues detected caspase-3 cleavage; indicating caspase-8 activation [260]. Our
results support these observations as we found caspase-8 being recruited by the
NLRP3 and NLRC4 inflammasome. While caspase-8 has already been shown to
cleave IL-1β [531], it should not induce a lytic form of cell death, but apoptosis, a
immunologically silent form of death.
However a recent report by Rogers and colleagues has shown that lytic cell death
can occur after stimulation of cells with apoptotic triggers, and that this in-
volves caspase-3-dependent cleavage of a protein called DFNA5 [543]. Intriguingly,
DFNA5 and Gasdermin-D both belong to the gasdermin protein family, and both
share the ability to form membrane pores. Furthermore, caspase-3 is a cleavage
substrate of caspase-8, thus potentially directing caspase-8 activation to lytic cell
death. Therefore, I speculate that the inflammasome has a dual mode to induce
cell death: If Gasdermin-D is present, caspase-1 induces rapid cell death and IL-1β
release through Gasdermin-D cleavage. If Gasdermin-D is not present, the inflam-
masome induces at late time points a lytic form of cell death through caspase-8- and
caspase-3-dependent DFNA5 cleavage and thereby IL-1β release. It needs to be in-
vestigated how similar Gasdermin-D-dependent pyroptosis and DFNA5-dependent
lytic cell death is, but data published by Feng Shao's group indicate that they in-
duce a similar type of lytic cell death [258]. Given that caspase-1 is still activated
in GsdmD-deficient macrophages, all cleavage substrates except Gasdermin-D are
present and thus it is likely that the other characteristics of pyroptosis are present as
well. However, if inflammasomes induce cell death in a Gasdermin-D-independent,
but DFNA5-dependent manner requires the generation of Gsdmd/DFNA5 double
knockout mice. The characterization of inflammasome-dependent, Gasdermin-D-
independent cell death would describe an alternative inflammasome-dependent cell
death mechanism if caspase-1 fails to induce cell death and IL-1β release. This
would inform our understanding how the immune response is transferred from a
cellular immune reaction induced by inflammasomes into a multifunctional and
global immune response.

Chapter IV
Discussion and Outlook
During my PhD, I investigated innate immune cell activation upon Salmonella and
Francisella infections. The activation of innate immune cells is particularly impor-
tant, because it determines how efficient an infection is cleared. During my PhD,
I contributed to five different publications, which are listed in chapter III, section
1, 2 and 3; and chapter V, section 1 and 2.
In the following sections, I discuss the findings of research article I (chapter III,
section 1) and research article II (chapter III, section 2). Moreover, working with
Francisella directed my attention to the recognition of cytosolic double stranded
DNA by AIM2, and consequently the activation of the AIM2 inflammasome. There-
fore, one important aspect of cytosolic AIM2 inflammasome activation is discussed
in the last section of this chapter.
1 How can we improve the new phosphoproteomics
approach?
Phosphorylation is one of the most frequent post-translational modifications to
regulate intracellular signaling pathways. Upon pathogen infections, immune sig-
naling pathways are activated, which involve phosphorylation cascades and result
in a change of the cellular gene expression pattern [109, 180]. In the context of
Salmonella infections, host immune signaling pathways, such as TLR4 signaling,
activate pro-inflammatory genes and type-I-interferon production, which coopera-
tively fight the bacterial infection [544].
Presently, mass spectrometry is the method of choice to analyze phosphorylation
changes in signaling pathways. However, we noticed that despite the recent techni-
cal improvements in mass spectrometry, the number of detected phosphopeptides
was significantly lower than the expected number of cellular phosphopeptides (see
research article I in chapter III, section 1). Moreover, phosphorylation changes in
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immune signaling pathways were underrepresented in a mass spectrometric analysis
of phospho-enriched samples from Salmonella-infected primary murine bone mar-
row derived macrophages (BMDMs). For example, TRIF signaling which causes
type-I-interferon production, was not detected in phospho-enriched samples, al-
though it is a signature response of cells to Salmonella infection [350,351].
It is currently under debate why fewer phosphopeptides are detected. In research
article I in chapter III, section 1, we addressed the issue of low phosphopeptide
detection in mass spectrometry. We demonstrated that the presence of negatively
charged phosphate groups globally suppressed peptide signal intensities in MS1
spectra and therefore decreased the number of detected phosphopeptides. In mass
spectrometry, the formation of positively charged peptide ions is required for pep-
tide identification. Given that the phosphate group added a negative charge of 2
to phosphorylated peptides, the compensation of the additional negative charge of
the phosphate group during peptide ionization was more difficult. Consequently,
enzymatic removal of the phosphate group by phosphatases increased the signal
intensities. Therefore, we detected three-times more peptides after phosphatase
treatment in Salmonella-infected BMDMs, compared to phospho-enriched sam-
ples.
Even though phosphatase treatment increased the number of detected peptides, it
had the disadvantage that the localization information of phosphate groups was
lost during the process. Therefore, we validated the newly identified peptides with
western blot, bioinformatical methodologies and targeted mass spectrometry. These
analyses revealed that the newly identified peptides after phosphatase treatment
enlarged the picture of activated immune signaling pathways upon Salmonella in-
fection and revealed the important TRIF signaling pathway.
Even though phosphatase treatment is an excellent method to increase the number
of detected phosphopeptides, a method that eliminates phosphate group-dependent
peptide ionization suppression while preserving its localization would advance our
method. Here, two different concepts are described which could lead to an improve-
ment of the method.
The first concept removes the phosphate group from the phosphopeptides without
losing the phosphosite information. This can be achieved by chemical β-elimination
where the chemical removal of the phosphate group leaves a double bond scar
[545,546]. We tested this approach to validate our phosphatase approach, but were
unable to detect the same amount of peptides as detected in phosphatase-treated
samples. A possible explanation for this is that a large amount of newly detected
peptides after phosphatase treatment were not initially phosphorylated and we
detected a lot of false positives in our analyses. However this explanation seems
unlikely because different validation experiments showed that most of the newly
detected peptides are initially phosphorylated. Therefore, the low detection rate of
phosphopeptides after β-elimination must have been caused by something else.
Chemical beta-elimination only removes phosphate groups from serine and threo-
nine, but not tyrosine residues [547]. Even though serine and threonine make up
about 98 % of all phosphorylation events, the residual phosphate groups on tyrosine
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residues cannot be removed by chemical β-elimination and might therefore account
for efficient ionization suppression in β-eliminated samples [548]. Additionally, we
showed that β-elimination only removes 80 % of all phosphate groups, compared to
over 99 % in phosphatase-treated samples. Therefore, inefficient phosphate group
removal in β-eliminated samples was most likely responsible for ionization suppres-
sion.
Besides chemical β-elimination, enzymatic β-elimination exists in nature, partic-
ularly in bacteria. The Shigella protein OspF and Salmonella protein SpvC are
phosphothreonine lyases, which specifically dephosphorylate threonine residues by
β-elimination [383, 549551]. Given that OspF and SpvC are very target specific,
it is unclear if they can be engineered to dephosphorylate serine, threonine and
tyrosine residues irrespective of the peptide sequence.
In contrast to phosphate group removal, the second concept is based on the modi-
fication of phosphate groups to compensate for their negative charge.
In a chemical reaction, the two critical oxygen atoms of the phosphate group can
be esterified. This chemical reaction requires an ester donor, such as methanol and
the resulting product is called dimethylphosphate [552]. However, such chemical
reactions are normally performed under harsh conditions and the impact of such re-
actions on the global peptide behavior in mass spectrometry analysis is not known.
Instead of a chemical reaction, phosphate groups can be enzymatically modified.
Francisella expresses multiple enzymes, which facilitate the addition of galac-
tosamine to the phosphate group of LipidA, thereby reducing its negative charge
[553, 554]. Moreover, enzymes of Neisseria and Acenitobacter modify phosphate
groups of LipidA with ethanolamine, thereby compensating for its negative charge
[555, 556]. However, the chemical environment of the phosphate group of LipidA
is very different from the one of phosphopeptides. Therefore it remains unclear
whether or not enzymes can be engineered that compensate the negative charge of
phosphate groups on phosphopeptides.
In summary, we discovered that the negative charged phosphate group adversely
influences the detection of phosphorylated peptides with mass spectrometry by
global suppression of peptide ionization efficacy. Therefore, this negative charge
needs to be removed or compensated before mass spectrometry analyses. We pro-
pose the removal of phosphate groups by phosphatases, because it is a very effective
and timesaving method. Using this method, we increased the number of detected
peptides threefold compared to phospho-enriched samples, but lost the localization
of the phosphate group. Thus, our method improved the identification and under-
standing of cellular signaling pathways, but requires careful validation to elucidate
if and where a peptide was initially phosphorylated.
To preserve the phosphorylation site information, two concepts are plausible. The
first approach removes the phosphate groups while leaving a scar to mark the initial
phosphorylation site. The second approach compensates for the negative charge by
adding residues to the problematic oxygen atoms of the phosphate group. Irre-
spective of the approach, it is important that the phosphate manipulation is very
efficient as residual or unmodified phosphate groups suppress ionization efficiency.
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2 The Francisella pathogenicity island encodes a
functional T6SS
Almost ten years ago the Francisella pathogenicity island (FPI) was discovered as
key factor for Francisella tularensis virulence in vitro and in vivo [557]. Since then,
it has been speculated that the FPI encodes a type 6 secretion system (T6SS) due
to homology analyses with known T6SS-encoding bacteria [477]. However, only a
limited number of FPI genes show homology with known T6SSs, which makes it
difficult to verify if the FPI encodes a functional T6SS. In 2015, Clemens and col-
leagues demonstrated that the FPI-encoded proteins IglA and IglB of F. novicida
form filaments that display structural characteristics of T6SS sheaths [523, 558].
Even though the formation of IglA/IglB sheaths has been shown by Clemens
and colleagues [523], it remains unclear whether or not the Francisella T6SS is
functional and dynamic. Therefore, we asked if the FPI of F. novicida encodes a
dynamic and functional T6SS and assigned functions as effectors or parts of the
machinery to individual FPI genes (research article II in chapter III, section 2).
We showed for the first time that F. novicida assembles a dynamic and functional
T6SS. Moreover, we demonstrated that a dynamic T6SS is required for F. novicida
escape from the phagosome to the cytosol. In addition, we identified the unfoldase
ClpB, which disassembles the contracted T6SS sheath and subsequently enables
the bacteria for another round of T6SS assembly.
Moreover, we identified the FPI-encoded genes iglG, iglF, iglI and iglJ as struc-
tural components of the Francisella T6SS, whereas pdpE, pdpD, pdpC and anmK
were not involved in T6SS assembly and therefore encode potential T6SS effector
proteins. Indeed, PdpC and PdpD showed reduced virulence in vitro and in vivo.
Thus, our analyses identified PdpC and PdpD as potential T6SS effector proteins,
which orchestrate directly or indirectly Francisella escape from the phagosome.
We based our studies on F. novicida, which is the common lab strain to analyze
Francisella tularensis. However, F. tularensis is the major cause of tularemia, a
fatal disease in humans. Even though the infection process of F. novicida and F.
tularensis is similar and phagosomal escape is the essential virulence step in F.
tularensis as well, it would be important to confirm our results in F. tularensis.
Moreover, Francisella tularensis does not only infect humans, but also infects in-
sects and amoebae. As described in chapter I, section 2.2, the expression of FPI-
encoded genes results in a different life style in various hosts. Therefore, it would
be important to verify whether effector proteins with no impact in mice, such as
PdpE or AnmK, are important for virulence in other hosts.
Besides our observations, a recent publication by Eshraghi and colleagues propose
PdpC and PdpD as potential T6SS effector proteins [559]. However, it remains
unclear how PdpC and PdpC induce phagosomal rupture. Therefore, the next two
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paragraphs discuss similarities and differences between our findings and observa-
tions by Eshraghi and colleagues, as well as potential mechanisms of PdpC and
PdpD-induced phagosomal rupture.
Are PdpC and PdpD the only T6SS effector proteins responsible for
phagosomal escape?
We demonstrated that PdpC and PdpD are not involved in T6SS dynamics but
are the two Francisella T6SS effectors necessary for phagosomal escape. Our ob-
servations were partially confirmed by a recent publication of Eshraghi and col-
leagues [559], in which they identified that VgrG, IglC, OpiA, OpiB-1, OpiB-3,
PdpD and PdpC are secreted to the bacterial supernatant in a T6SS-dependent
manner, using a mass spectrometry-based approach.
VgrG has been identified as the main component of the T6SS tip complex in Vibrio
and IglC shows homology to the T6SS inner tube protein Hcp [482,494]. Given that
Eshraghi and colleagues identified the tip complex protein VgrG and the inner tube
protein IglC in the Francisella supernatant, as seen for functional T6SSs of Vibrio
and Pseudomonas [482], their detection in the Francisella supernatant confirms
our observations of a dynamic Francisella T6SS.
In contrast to the other secreted proteins, opiA, opiB-1 and opiB-3 are not encoded
on the FPI. However, their expression is regulated by the transcription factor MglA,
which also induces the expression of FPI genes [413, 559]. OpiB-1 and opiB-3 are
encoded on one operon consisting of opiB-1, opiB-2 and opiB-3 in F. novicida and
therefore most likely originate from gene duplication. In line with this assumption,
F. tularensis and F. holarctica only harbor one opiB gene. Importantly, Eshraghi
and colleagues generated a triple knockout of opiB-1, opiB-2 and opiB-3 (named
opiB mutant) and used this mutant for all functional experiments.
First they assessed phagosomal escape of F. novicida. They showed that the pdpC/
pdpD/opiA/opiB quadruple knockout is unable to escape to the cytosol anymore.
However, they showed no data on phagosomal escape of single mutants. In con-
trast, we analyzed phagosomal escape of pdpC and pdpD single mutants and the
pdpC/pdpD double mutant. Our results showed that both the pdpC and pdpD sin-
gle mutant is impaired in phagosomal escape, with a stronger reduction in cytosolic
bacteria observed for the pdpC mutant. Moreover, we showed that the number of
cytosolic pdpC/pdpD double mutants is comparable to FPI mutants. Thus, their
results of the pdpC/pdpD/opiA/opiB quadruple mutant phenocopied our results
of the pdpC/pdpD double mutant, suggesting that opiA and opiB have a minor
impact on phagosomal escape. However, based on our analyses we cannot exclude
that PdpC and PdpD facilitate the delivery of OpiA and OpiB or a yet to be iden-
tified T6SS effector protein that is responsible for phagosomal rupture.
Besides phagosomal escape, Eshraghi and colleagues analyzed intracellular growth
of different bacterial mutants. They showed a significant reduction in intracellular
growth of the pdpC single mutant and the pdpD/opiA/opiB triple mutant, how-
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ever the pdpD, opiA and opiB single mutants grew like wild-type bacteria in the
human macrophage-like cell line THP-1. Additional knockout of pdpC in the triple
mutant background or the pdpC/pdpD double mutant showed intracellular growth
rates comparable to FPI-mutants. Interestingly, intracellular growth was minimally
restored in a quadruple knockout complemented with opiA.
Alternatively, we analyzed the number of intracellular bacteria of pdpC and pdpD
single and pdpD/pdpC double mutants 24 hours post-infection in BMDMs. We ob-
served a significant reduction in intracellular pdpC - and pdpC/pdpD-deficient F.
novicida, whereas pdpD-deficient F. novicida showed a reduced but not significant
drop in intracellular bacteria compared to wild-type F. novicida. Thus, the obser-
vations in intracellular bacterial growth are similar between the two studies with
respect to pdpD and pdpC single mutants and pdpD/pdpC double mutant.
However, in contrast to Eshraghi and colleagues, we also analyzed the different
bacterial mutants with respect to AIM2 inflammasome activation and virulence
in a mouse infection model. PdpC -, pdpD- and pdpC/pdpD-deficient F. novicida
showed significantly reduced AIM2 inflammasome activation. In line with these
observations, mice infected with pdpC -, pdpD- or pdpC/pdpD-deficient F. novi-
cida showed significantly reduced bacterial burden in the spleen and liver two days
post-infections compared to wild-type F. novicida-infected mice. Importantly the
bacterial burden of pdpC/pdpD-deficient F. novicida in the spleen and liver was
comparable to an FPI mutant.
Based on our profound analyses including phagosomal escape, AIM2 inflammasome
activation, intracellular growth and virulence in vivo, we propose a different con-
clusion than Eshraghi and colleagues. They concluded that PdpC, PdpD, OpiA
and OpiB are cooperatively required for phagosomal escape and therefore viru-
lence, whereas our data suggests that only PdpC and PdpD are required to escape
from the phagosome. However, we cannot exclude that opiA and opiB contribute
to phagosomal escape in a different experimental setting or in a specific cell type,
or that opiA and opiB facilitate intracellular growth but not phagosomal escape.
Thus, further analyses of these newly identified T6SS effectors are required. Ad-
ditionally, given that pdpD is not conserved in Francisella tularensis strains, it is
important to determine the function of PdpD in the highly virulent F. tularensis
and F. holarctica strains.
Based on our analyses, we cannot exclude that effector proteins have different func-
tions in specific cell types. Supporting this possibility, Long and colleagues infected
mice intranasal with wild-type and pdpC -deficient F. tularensis [522]. In mice,
wild-type F. tularensis disseminated from the lung to the spleen and liver, thereby
establishing a detrimental infection. In contrast, all mice survived the infection of
pdpC -deficient F. tularensis. However, pdpC -deficient F. tularensis disseminated
from the lung to the spleen but not the liver during the early phase of infection.
In line with their observations, we recovered more pdpC -deficient F. novicida from
the spleen than the liver, suggesting that PdpC is more important in the infection
of the liver than the spleen. These results suggest that Francisella effectors have
tissue- and cell type-specific functions, at least to some degree. Thus, the involve-
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ment of PdpC in liver and spleen infections and the characterization of the infected
cell types in these two organs require further investigation.
In addition to the publication of Eshraghi and colleagues; T6SS analyses in Vibrio
and Pseudomonas showed that the tip complex of T6SSs contains a limited num-
ber of effector proteins. As a consequence, only a small amount of effector proteins
are delivered per T6SS contraction [482]. Therefore, we propose that F. novicida
utilizes its T6SS several times to deliver a critical amount of PdpC and PdpD into
host cells to escape from the phagosome. In agreement with our assumption, we
observed that clpB -deficient F. novicida could not escape into the cytosol anymore.
Interestingly, clpB -deficient F. novicida assembled and contracted one T6SS per
bacteria, but could not disassemble the contracted T6SS sheath and was therefore
unable to assemble another T6SS (see research article II in chapter III, section 2).
Thus, it is important to determine the critical number of T6SS assemblies that
allow Francisella to escape to the cytosol.
How do the Francisella effectors PdpC and PdpD induce phagosomal
escape?
We demonstrated that PdpC and PdpD mediate bacterial escape from the phago-
some to the cytosol, thereby preventing phagosomal killing. However, it is unclear
how PdpC and PdpD induce phagosomal rupture to enable F. novicida escape into
the cytosol.
First, it is possible that PdpC and PdpD facilitate the secretion of a yet unknown
effector protein that induces phagosomal rupture directly or indirectly. However,
no other secreted protein was detected by Eshraghi and colleague, suggesting that
PdpC and PdpC facilitate phagosomal rupture [559].
Second, it is unknown whether the Francisella T6SS delivers PdpC and PdpD to
the phagosome or to the host cytosol. If PdpC and PdpD are delivered to the
phagosome, they induce phagosomal rupture from the inside, whereas PdpC and
PdpD delivered to the cytosol induce phagosomal rupture from the outside. As
T6SSs are shown to deliver effector proteins into eukaryotic target cells, it is tech-
nically feasible that the Francisella T6SS delivers PdpC and PdpD into the host
cytosol [482]. However, whether PdpC and PdpD are delivered to the phagosome
or to the cytosol remains to be elucidated.
Cellular localization of PdpC and PdpD can be analyzed with PdpC and PdpD
overexpression experiments in eukaryotic cells, which have been used in the func-
tional analyses of T3SS effector proteins [560]. In a preliminary experiment, we
transiently expressed Hek293 cells with HA-tagged versions of PdpC and PdpD
under a doxycycline-inducible promoter. Even though up to 80 % of Hek293 cells
were successfully transfected with the expression vector, we were unable to detect
PdpC and PdpD after doxycycline induction by western blot (data not shown).
This observation suggests that PdpC and PdpD cannot be expressed in eukaryotic
cells. However, the used nucleotide sequences of pdpC and pdpD were not codon
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optimized for eukaryotic expression systems and therefore could pose a problem
for PdpC and PdpD expression in eukaryotic cells.
Another method for analyzing PdpC and PdpD localization is to follow the se-
cretion of endogenous bacterial PdpC and PdpD into host cells. Upon PdpC and
PdpD delivery into the host cell, intracellular localization of PdpC and PdpD can
be visualized by immunofluorescence. An advantage of this method is the usage
of endogenous PdpC and PdpD, which removes any overexpression artifacts. How-
ever, due to the unavailability of antibodies for PdpC and PdpD, we endogenously
attached a HA-tag to PdpC and PdpD. Even though we detected HA-tagged PdpC
in the bacterial supernatant after T6SS induction using western blot, we were un-
able to detect HA-tagged PdpC in infected primary murine bone marrow derived
macrophages (BMDMs) using immunofluorescence confocal microscopy, suggesting
that there is not enough delivered PdpC-HA for a robust signal in confocal mi-
croscopy. Given that there is only a small amount of delivered PdpC-HA, one could
try to analyze PdpC-HA localization by super resolution or structured illumination
microscopy as these techniques are more sensitive and can increase the signal to
noise ratio.
As an alternative to the HA-tag, PdpC and PdpD localization might be examined
with the split GFP system. The split GFP system was described by Cabantous and
colleagues [561]. The principle of the split GFP system is the differential expression
of two non-fluorescent GFP fragments. One GFP fragment only represents GFP
β-strand 11 (GFP11), whereas the second fragment composes of GFP β-strands
1-10 (GFP1-10). Given that GFP11 is around 10 amino acids long and therefore in
the size range of the HA tag, PdpC and PdpD can be tagged with GFP11 possibly
without disturbing its T6SS-dependent delivery. In contrast to the GFP11-tagged
bacterial effectors, GFP1-10 is expressed in the host cytosol. Upon T6SS-dependent
effector secretion, GFP11-PdpC interacts with GFP1-10 at the site of PdpC local-
ization and induces a GFP signal.
Third, it is unclear how PdpC and PdpD mechanistically induce phagosomal rup-
ture. Structural prediction analyses of PdpC and PdpD did not revealed any do-
mains that facilitate PdpC and PdpD insertion into membranes. Thus, PdpC and
PdpD probably represent a new group of membrane destabilizing/rupturing pro-
teins or recruit and activate host proteins, which then rupture the phagosome.
Artificial liposomes could reveal mechanistic insights into PpdC- and PdpD- de-
pendent phagosomal rupture. The principle of liposomal leakage assays is to mix
liposomes with purified proteins, in our case PdpC and/or PdpD [263]. Liposomes
are generated from purified lipids, which allows for customization of their lipid
composition. In a first step, purified PdpC and PdpD recruitment by liposomes
can be assessed by western blot or analytical ultracentrifugation, therefore deter-
mining the required lipid composition for their recruitment. This information can
then be used for liposomal leakage assays [263], in which liposomes are preloaded
with a fluorescent dye. Given that the dye is auto-quenched within liposomes, light
emission is only detectable if PdpC and/or PdpD are able to rupture liposomes. If
purified PdpC and/or PdpD alone cannot bind to and rupture liposomes, I would
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add cell lysates to the reaction mixture and repeat the experiment.
Given that PdpC and PdpD were cloned with a HIS-tag for protein purification,
PdpC and PdpD pull down experiments could identify their interaction partners
in the host cell by mass spectrometry. Additionally, mass spectrometry analysis of
purified liposomes might determine the interaction complex of PdpC and/or PdpD
at the liposomes.
As a first step to perform liposomal leakage assays, we cloned PdpC and PdpD
into a bacterial expression vector already containing in frame a 6x His tag for pro-
tein purification. Even though we could express smaller proteins, such as IglC with
this method, we were unable to express PdpC and PdpD. Very long Francisella
genes are probably not suitable for expression in a common E. coli expression
strain. E. coli codon optimization or purification of 6x His-PdpC/-PdpD from F.
novicida could perhaps solve this issue. However, it could be possible that PdpC
and/or PdpD lyse E. coli and therefore cannot be expressed in bacteria. Indeed,
it has been shown that other T6SS-positive bacteria express immunity proteins to
neutralize the toxic effect of their T6SS effectors. However, we mutated all genes
encoded on the FPI and did not observed the presence of immunity proteins on
the FPI. Nevertheless, it is possible that Francisella expresses immunity proteins
outside the FPI. Thus, in the case of effector-induced bacterial toxicity, an insect-
based expression system might be suitable.
Taken together, we showed that F. novicida expresses a functional T6SS and ClpB
disassembles the contracted sheath again. PdpC and PdpD are the two T6SS effec-
tors that mediate bacterial escape from the phagosome to the cytosol. Escaping the
phagosome is the essential virulence step in Francisella infections as Francisella
lacking a functional T6SS is completely avirulent in vitro and in vivo. Thus, our
findings contribute greatly to the understanding of the Francisella T6SS and Fran-
cisella virulence.
3 Why is the AIM2 inflammasome not activated
during mitosis?
AIM2 is a cytosolic DNA sensor that recognizes foreign double stranded DNA
(dsDNA) originating from bacteria or viruses, and mislocalized self-dsDNA. Upon
dsDNA recognition, AIM2 oligomerizes and forms a canonical inflammasome to
activate caspase-1. Active caspase-1 induces a pro-inflammatory, lytic form of cell
death called pyroptosis. A hallmark of pyroptosis is caspase-1-dependent cleavage
and therefore activation of IL-1β and IL-18, two important pro-inflammatory cy-
tokines [249]. Beside its importance in pathogenic infections, prostate and colorec-
tal cancer cells reduce cellular AIM2 levels. Thereby, the cancer cells avoid AIM2
activation, mostly likely because nuclear DNA is accessible for AIM2 due to a dis-
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continued nuclear envelope in these cells [305308]. In line with this assumption,
it has been demonstrated that pharmacological disruption of the nuclear envelope
leads to the exposure of nuclear DNA to the cytosol, resulting in AIM2 inflamma-
some activation [312]. In contrast, an increase in AIM2 inflammasome activation is
linked to psoriasis, abdominal aortic aneurysm and systemic lupus erythematosus,
three severe autoimmune diseases [309311].
Cell division is not only a essential step in the development of an organism, but
is also important for the homeostasis of tissue integrity and the replenishment
of circulating immune cells. During the prometaphase of mitosis, the nuclear en-
velope breaks down and the duplicated chromosomes segregate equally into the
daughter cells [562]. However, when the nuclear envelope is broken down, the DNA
is theoretically accessible for AIM2 recognition. Yet no AIM2 inflammasome ac-
tivation is observed during mitosis, raising the question how mitotic cells avoid
AIM2-inflammasome-dependent cell death. Several possible mechanisms could en-
able mitosis without the induction of AIM2 inflammasome-dependent cell death.
One possibility is the transcriptional downregulation of important inflammasome
components during cell division. The expression of AIM2 inflammasome compo-
nents might oscillate in parallel with the cell cycle. Before nuclear envelope break
down, the expression of AIM2 inflammasome components is temporarily downreg-
ulated and the DNA is not recognized by AIM2. Instead of transcriptional down-
regulation of AIM2 inflammasome components, an AIM2 inflammasome inhibitor
could be specifically expressed during mitosis.
Alternatively, the expression of AIM2 inflammasome components is absent in pro-
liferative cells and only expressed in fully differentiated cells, as these cells do not
divide anymore. However, this is less likely, given that primary murine bone mar-
row derived macrophages (BMDMs) undergo a few cell divisions in cell culture
without activating an AIM2 inflammasome. Nevertheless, we cannot ensure that
cell culture observations fully resemble the in vivo conditions.
Transcriptional regulation of AIM2 inflammasome activation can be analyzed by
first arresting cells at a specific point in their cell cycle. Afterwards the synchronized
cells are released from cell cycle arrest and the cellular transcript and protein abun-
dances are analyzed at different time points after release [563]. With this method,
transcriptional and translational regulation of known AIM2 inflammasome com-
ponents can be followed during cell cycle. However, it is difficult to identify new
AIM2 inflammasome regulators during mitosis, as transcript and protein abun-
dances globally change over the cellular life cycle. Consequently, hundreds of po-
tential AIM2 inflammasome regulators are detected in these analyses and therefore
the discrimination between true- and false positives is difficult.
Therefore, the experimental set up to identify new regulators of AIM2 activation
during mitosis is a bit more complicated. I would perform a CRISPR screen in
Aim2 -deficient cells, which express AIM2 under an inducible promoter, but ex-
press ASC-mCherry constitutively. Aim2 -deficiency during the production of the
CRISPR knockout cells ensures that cells do not die during this process as cells
are dividing and the screen is looking for inhibitors of AIM2-dependent cell death
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during mitosis. Following the generation of the CRISPR knock out cells, they are
synchronized in respect to their cell cycle and AIM2 expression is induced before
cells are released from cell cycle arrest. During mitosis, cells with a mutation in an
AIM2 regulatory gene activate AIM2 and form an ASC speck. As we express ASC-
mCherry in all cells, the appearance of a red ASC speck is used as a readout. The
ASC-positive cells are sorted by FACS and their genome is sequenced to identify
the gene that inhibits AIM2 activation during mitosis.
Another possibility for AIM2 inhibition during mitosis might originate from the
nuclear DNA itself. AIM2 recognizes 4 base pairs in the big DNA groove [165]. It is
known that the DNA bases cytosine and adenine are methylated in eukaryotes and
prokaryotes [564]. During DNA replication, the newly synthesized DNA strand is
not methylated and the DNA is present in a hemimethylated state. Therefore, the
time window between DNA replication and DNA methylation could serve as lim-
iting step for AIM2 activation. However, several research groups have shown that
DNA replication and methylation are not temporally distinguishable [565, 566].
Thus, it could be more likely that DNA condensation during mitosis switches
DNA into a conformation that cannot be recognized by AIM2. Indeed it was shown
that the condensation state of DNA negatively correlates with transcription effi-
ciency [567].
To test the hypothesis of DNA modification, one could use surface plasmon res-
onance (SPR) [568], which measures binding capacities of a surface-immobilized
protein to a soluble interaction partner. To measure AIM2-DNA binding, I would
immobilize the HIN200 domain of AIM2 on the surface of the SPR and analyze
DNA from different time points during cell cycle for their AIM2 binding ability.
With SPR, not only the interaction but also the strength of the interaction between
AIM2 and DNA is measured. The comparison of binding-competent and binding
in-competent DNA should determine the specific DNA modifications or conforma-
tions that enable or inhibit AIM2 binding.
A third possibility for AIM2 inhibition during mitosis could be the segregation or
compartmentalization of important AIM2 inflammasome components. Three re-
cent publications have shown that NEK7 is essential for NLRP3 oligomerization
and thereby NLRP3 inflammasome activation [289, 290, 539]. In addition, NEK7
is involved in mitotic spindle formation [569]. Moreover, NLRP3 is activated by
perturbations of cell integrity, thus NLRP3 can be activated during mitosis. Given
that NEK7 is involved in mitosis, the authors propose that NEK7 is not available
for NLRP3-dependent inflammasome activation during mitosis. A similar mecha-
nism could hold true in AIM2-dependent inflammasome activation where a protein,
that is normally required for AIM2 inflammasome activation, has a specific mitotic
function and is therefore not able to assist AIM2 inflammasome activation.
Taken together, AIM2 is activated by cytosol-accessible dsDNA. During mitosis,
the nuclear envelope breaks down and nuclear DNA has access to the cytosol,
where AIM2 recognizes the DNA and induces AIM2 inflammasome-dependent cell
death. To prevent this, dividing cells have mechanisms to inhibit AIM2 activation,
however these mechanisms are completely unknown. In this paragraph, three dif-
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ferent mechanisms to prevent AIM2 activation during mitosis have been described.
However, these are not exclusive and many more mechanisms could result in AIM2
inflammasome inhibition during mitosis.
Moreover, AIM2 belongs to the family of PYHIN proteins, which all possess a PYD
and one or several HIN200 domains. Some of them are localized to the nucleus (such
as IFI16) and reported to bind dsDNA [570]. However, a recent publication shows
that only the HIN200 domain of AIM2 and IFI16 binds to dsDNA [168]. There-
fore it would be important to determine under which circumstances the AIM2 and
IFI16 HIN200 domain binds dsDNA and why the HIN200 domains of other PYHIN
proteins do not bind dsDNA.
Moreover, as described in chapter I, section 1.2, there are other cytosolic DNA
sensors which result in the induction of pro-inflammatory genes. In principle, these
DNA sensors need to be silenced during mitosis, otherwise the organism induces an
inflammatory response with every cell division. Constant inflammation is definitely
not in favor of an organism and thus tight regulation of nuclear DNA recognition
in the cytosol during mitosis is a very important but poorly understood mechanism.
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Caspase-11 activation requires lysis of
pathogen-containingvacuolesbyIFN-inducedGTPases
Etienne Meunier1, Mathias S. Dick1*, Roland F. Dreier1*, Nura Schu¨rmann1, Daniela Kenzelmann Broz2, Søren Warming3,
Merone Roose-Girma3, Dirk Bumann1, Nobuhiko Kayagaki3, Kiyoshi Takeda4, Masahiro Yamamoto4 & Petr Broz1
Lipopolysaccharide fromGram-negative bacteria is sensed in thehost
cell cytoplasmby a non-canonical inflammasome pathway that ulti-
mately results in caspase-11 activation and cell death1–3. In mouse
macrophages, activation of this pathway requires the production of
type-I interferons4,5, indicating that interferon-induced genes have
a critical role in initiating this pathway.Herewe report that a cluster
of small interferon-inducibleGTPases, the so-calledguanylate-binding
proteins, is required for the full activityof thenon-canonical caspase-11
inflammasome during infections with vacuolar Gram-negative bac-
teria.Weshowthatguanylate-bindingproteinsare recruited to intra-
cellular bacterial pathogens and are necessary to induce the lysis of
the pathogen-containing vacuole. Lysis of the vacuole releases bac-
teria into the cytosol, thus allowing the detection of their lipopo-
lysaccharide bya yet unknown lipopolysaccharide sensor.Moreover,
recognition of the lysed vacuole by the danger sensor galectin-8 ini-
tiates the uptake of bacteria into autophagosomes, which results in
a reduction of caspase-11 activation. These results indicate that host-
mediated lysis of pathogen-containing vacuoles is an essential immune
function and is necessary for efficient recognition of pathogens by
inflammasome complexes in the cytosol.
Previous studies have reported that induction of caspase-11-dependent
cell death by Gram-negative bacteria requires Trif-dependent production
of type-I interferons (type-I-IFNs)4,5 (Extended Data Fig. 1a). Type-I-
IFN production is however not required for pro-caspase-11 induction4,6,7
and is dispensable for caspase-11 activation by transfected lipopolysac-
charide (LPS; Extended Data Fig. 1b)2. This indicates that interferon-
stimulated genes (ISGs) play a major role in activating caspase-11 in
response to intracellular bacteria. To investigatewhich ISGswere involved
in activating caspase-11,weusedproteomics-based expression analysis
to identify proteins that were highly induced following Salmonella infec-
tion. Among the most strongly upregulated proteins were interferon-
inducedGTPases, suchas the large 65–67kDaguanylate-bindingproteins
(GBPs) and small 47 kDa immunity-related GTPases (IRGs) (data not
shown). These proteins function in cell-autonomous immunity, that is,
mechanismsthatallowhostcells tokillpathogensorrestrict their replication,
and have even been associatedwith the activation of inflammasomes8–10.
Mice have 11 GBPs, which are highly homologous and are clustered
in two genomic loci on chromosomes 3 and 5, respectively8,11. Recently,
GBPs on chromosome 3 have been shown to restrict the replication of
Toxoplasma gondii inperitonealmacrophages andmice11.We therefore
infected bone-marrow-derived macrophages (BMDMs) from Gbpchr3
KOmice,which lackGBP1, 2, 3, 5 and 7 (ExtendedData Fig. 2a–e), and
wild-type littermateswithanumberofGram-negativevacuolarpathogens
that trigger caspase-11 activation (data not shown)1,4,5 and determined
the activity of the non-canonical inflammasome pathway at 16 h post-
infection (Fig. 1a, b).Macrophages fromGbpchr3KOmice showed a sig-
nificant reduction of cell death (as measured by lactate dehydrogenase
(LDH) release) and IL-1b secretion when infected with wild-type Sal-
monella typhimurium, a type three secretion system (T3SS)-deficient
mutant of S. typhimurium (DSPI-2), Vibrio cholerae, Enterobacter clo-
acae or Citrobacter koseri (Fig. 1a), and this was independent of LPS
or polyinosinic:polycytidylic acid (poly(I:C)) priming (Extended Data
Fig. 2f, g).Gbpchr3-deficiency also reduced secretion of caspase-1 p20 sub-
unit, caspase-11andmature IL-1b, IL-18andIL-1a (Fig. 1b).Because inter-
ferons induceGBP expression (ExtendedData Fig. 2b, c)8, we investigated
whether IFN-c treatment would accelerate LDH release in response to
Salmonella infection. IFN-c-treated wild-type BMDMs released LDH
as soonas4hafter infection,whereasGbpchr3KOBMDMsfailed to release
LDHat early time points even after IFN-c priming (Fig. 1c), indicating
thatGBP inductionwas required for activityof thenon-canonical inflam-
masome pathway.
Wenext exploredwhetherGBPsplay a role in theactivationof canon-
ical inflammasomes. LPS-primed wild-type and Gbpchr3-deficient mac-
rophages released comparable levels of LDH and mature IL-1b when
infectedwith logarithmic phase S. typhimurium, which exclusively engage
theNLRC4inflammasomevia theSPI-1T3SS(Fig.1d)12. Similarly,Gbpchr3-
deficiency did not affect AIM2 inflammasome activation upon poly
(deoxyadenylic-deoxythymidylic) acid (poly(dA:dT)) transfection (Fig. 1d).
Although GBP5 had been previously linked to NLRP3 activation9, we
did not observe a defect in NLRP3 activation inGbpchr3KOs (Fig. 1d),
possibly owing to differentmodes of pre-stimulation. These data indi-
cate that GBPs are dispensable for canonical inflammasome activity,
but are required for the activation of the non-canonical inflammasome
pathway.
To investigate whether GBPs directlymediated the detection of intra-
cellular LPS, we engaged the non-canonical inflammasome by trans-
fecting macrophages with different types of ultra-pure LPS (Fig. 1e).
Cytoplasmic LPS triggered LDH release and IL-1b secretion to a sim-
ilar extent in both wild-type andGbpchr3-deficient BMDMs, indicating
that GBPswere required upstreamof LPS sensing and only during bac-
terial infection.Wenext investigated ifGBPswere required for immune
detection of vacuolar or cytosolic bacteria by infecting BMDMs with
DsifA S. typhimurium and Burkholderia thailandensis, which rapidly
enter the cytosol and activate caspase-11 (ref. 13). UnprimedGbpchr3KO
andwild-typeBMDMsrespondedcomparably to thesebacteria (Extended
Data Fig. 3a–c). Because GBPs might affect this response when pre-
induced, we also infected IFN-c-primed BMDMs with DsifA S. typhi-
murium (Extended Data Fig. 3d). IFN-c-priming indeed resulted in a
small difference betweenwild-type andGbpchr3KOBMDMsafter infec-
tion with DsifA Salmonella, yet not to the extent seen with wild-type
Salmonella (Fig. 1c), indicating that GBPs mainly participate in the
activation of the non-canonical inflammasome by vacuolar bacteria.
Finally, to investigate which GBP controls caspase-11 activation, all
11 murine Gbps were individually knocked down in BMDMs and the
cells were infected with flagellin-deficient Salmonella, which activate the
non-canonical inflammasome but not NLRC4 (Extended Data Fig. 4a
and Supplementary Information)4. Only knockdown of Gbp2 resulted
in reduced LDHrelease and IL-1b secretion (ExtendedData Fig. 4b–d).
*These authors contributed equally to this work.
1Focal Area Infection Biology, Biozentrum, University of Basel, CH-4056 Basel, Switzerland. 2Department Biomedicine, University of Basel, CH-4056 Basel, Switzerland. 3Genentech Inc., South San
Francisco, California 94080, USA. 4Department of Microbiology and Immunology, Osaka University, Yamadaoka, Suita, Osaka 565-0871, Japan.
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To validate these data we obtained BMDMs from Gbp22/2 mice and
wild-type littermates14 and infected themwith vacuolarGram-negative
bacteria. As expected, we observed reduced levels of cell death, cytokine
secretion and caspase release in Gbp22/2 BMDMs, indicating attenu-
ated activationof thenon-canonical inflammasome (Fig. 1f andExtended
Data Fig. 4e), whereas direct LPS sensing or the activation of canonical
inflammasomeswasnot affected (ExtendedData Fig. 4f, g). In contrast,
Gbp5-deficiency did not have any effect on canonical andnon-canonical
inflammasome activation (Extended Data Fig. 5). Nevertheless,Gbp2-
deficiencydidnot reduce caspase-11 activation asmarkedly asGbpchr3-
deficiency, indicating that whereas caspase-11 activationmainly requires
GBP2, other GBPs might also be partially involved.
Reducednumbers of intracellular bacteria could account for low levels
of caspase-11 activation in Gbpchr3- and Gbp2-deficient macrophages.
However, a comparison of wild-type andGbpchr3KOBMDMs showed
thatGbpchr3-deficiency resulted in significantly highernumbers of total
and live Salmonellaper cell (Fig. 2a), consistentwithhigher colony form-
ing units numbers in Gbpchr3 KO BMDMs (Extended Data Fig. 6). In
addition, fluorescence-activated cell sorting (FACS)-based analysis of
dead (mCherry-negative, FITC1) and live (mCherry-positive, FITC1)
Salmonella at 16 h post-infection found significantly fewer dead bac-
teria (,20%) inGBPchr3KOandGbp22/2BMDMswhen compared to
wild-type BMDMs (.30%) (Fig. 2b). Importantly, bacterial killing in
Casp112/2 BMDMswas comparable to wild-type BMDMs, indicating
that the control of bacterial replicationwas directly linked toGBP func-
tion and not to the activation of the non-canonical inflammasome
(Fig. 2b). In conclusion, we show that GBPs control bacterial replica-
tion on a cell-autonomous level,which is consistentwith a previous report
that GBP1 partially restrictsMycobacterium bovis and Listeria mono-
cytogenes replication10.
Restrictingbacterial replicationhas beenproposed to require the asso-
ciation ofGBPs with pathogen-containing vacuoles and the recruitment
of antimicrobial factors8.We therefore investigatedwhetherGBPs targeted
intracellular Gram-negative bacteria. Indeed, GBP2 could be detected
on intracellular bacteria within hours after infection (Fig. 2c). Very little
GBP-positive bacteriaweredetected in Stat12/2BMDMs,whichdonot
respond to type-I- and type-II-IFNs and largely failed to induce GBP
expression (data not shown). Remarkably, GBP-positive Salmonella
seemed to have lost mCherry expression (Fig. 2c), indicating that these
bacteria were dead. To determine whether GBPs are recruited to dead
bacteria we infected BMDMs with Salmonella killed by heat, parafor-
maldehydeor 70%ethanol treatment, yet only live Salmonella acquired
GBP staining andactivated the inflammasome(Fig. 2d). To examine this
mechanism in vivo, we immunostained spleen tissue sections of mice
infected with Salmonella for GBPs. Indeed, GBPs could also be found
associated with approximately 20% of bacteria in vivo, and a signifi-
cantly higher proportion of these bacteria were dead, based on the loss
of mCherry expression (Fig. 2e–g). Furthermore, treatment with IFN-
c-neutralizing antibodies reduced the percentage of GBP-positive bac-
teria (Fig. 2f), consistent with reports that IFN-c controls Salmonella
replication in vivo15,16. Taken together, these results indicated thatGBPs
either kill bacteria directly or control an antimicrobial effector pathway,
and raised the interesting possibility that GBP-mediated killing of bac-
teria might result in the release of LPS and caspase-11 activation2,3.
To identify the antimicrobial effector pathway that is controlled by
GBPs we first examined the role of free radicals8. Although GBP7 was
reported to be required for reactive oxygen species (ROS) production
and to interact with the phagosome oxidase complex10, we did not find
any role for ROS orNOproduction in caspase-11 activation (Extended
Data Fig. 7). Furthermore, GBPs were also proposed to recruit com-
ponents of the autophagymachinery to pathogen-containing vacuoles
(PCVs), possibly resulting in bacterial killingwithinautophagosomes8,10.
Indeed, many GBP-positive S. typhimurium, E. cloacae and C. koseri
co-stained for the commonly used autophagymarker LC3 (Fig. 3a and
ExtendedData Fig. 8a). Recruitment of LC3 to intracellular Salmonella
waspartiallyGBP-dependent, becausewe found significantly lowernum-
bers of LC3-positive Salmonella inGbpchr3KO compared to wild-type
macrophages (Fig. 3b, c). Therefore, we speculated that autophagy-
mediated killing might result in the release of LPS from bacteria and
caspase-11 activation. Unexpectedly, however, pharmacological inhi-
bition of autophagy with 3-methyladenine (3-MA) resulted in signifi-
cantly higher levels of LDH release, IL-1b secretion and caspase-1/
caspase-11 activation in macrophages infected with S. typhimurium,
E. cloacae orC. koseri (Fig. 3d, e), indicating increased activation of the
non-canonical inflammasome. Consistently, cell death was still caspase-
11-dependent because Casp112/2 BMDMs did not release LDHwhen
treated with 3-MA and infected with Gram-negative bacteria (Fig. 3f).
Direct activation of caspase-11 by LPS transfectionwas independent of
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Figure 1 | Caspase-11 activation by intracellular bacterial pathogens
requires GBPs. a, b, LDH release, IL-1b secretion (a) and immunoblots for
caspase-1, caspase-11, IL-1b, IL-18 and IL-1a (b) from unprimed BMDMs
infected for 16 h with the indicated bacteria (grown to stationary phase).
c, Time course measuring LDH release from unprimed or IFN-c-primed
BMDMs infected with S. typhimurium. d, e, LDH release and IL-1b secretion
from primed BMDMs infected with SPI-1-expressing logarithmic phase
S. typhimurium, treated with monosodium urate, alum and nigericin or
transfectedwith poly(dA:dT) and LPS. f, LDH release and IL-1b secretion from
unprimed wild-type andGbp22/2 BMDMs infected for 16 h with the indicated
bacteria (grown to stationary phase). Graphs show mean and s.d. of
quadruplicate wells and data are representative of two (b) and three
(a, c–f) independent experiments. *Crossreactive band; **P, 0.01; NS, not
significant (two-tailed t-test).
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autophagy (Fig. 3g), indicating that autophagy only counteracts non-
canonical inflammasome activation during bacterial infections. To fur-
ther confirmourdata,we infectedAtg52/2BMDMswithS. typhimurium
andwe also observed significantly higher levels of non-canonical inflam-
masome activation compared to wild-type BMDMs (Fig. 3h, i). Taken
together, these results indicated that, although GBPs promoted the
uptake of bacteria into autophagosomes, autophagy actually counter-
acted caspase-11 activation. Thus,GBP-dependent LPSdetection occurs
before bacteria are targeted to autophagosomes.
A possible explanation could be that autophagy sequesters bacteria
that had escaped from the vacuole, and thus prevents further LPS release
into the cytosol. Recently, the cytosolic danger receptor galectin-8 was
reported to function as a marker for lysed vacuoles. Galectin-8 binds
b-galactosides, which are normally found on the inner leaflet of the vac-
uolar membrane and get exposed to the cytosol upon vacuolar lysis17.
Indeed, quantification of galectin-8-positive Salmonella showed that
significantly fewer bacteria were targeted by galectin-8 in Gbpchr3 KO
BMDMs than in wild-type macrophages (Fig. 4a). Because galectin-8
colocalizedwithGBP- andLC3-positive Salmonella (Fig. 4b, c), we spec-
ulated that GBPs promote LC3 recruitment through galectin-8. Con-
sistently, we found lower levels of galectin-8-positive Salmonella among
LC3-positive Salmonella inGbpchr3KO compared to wild-type BMDMs
(Fig. 4d).Galectin-8 interactswith the autophagy adaptor proteinNDP52,
which in humans contains binding sites for galectin-8, ubiquitin and
LC318. In line with a role for NDP52 in linking galectin-8 to LC3, murine
NDP52 colocalizedwith galectin-8 on intracellular Salmonella (Extended
Data Fig. 8b). Targeting of Salmonella to autophagosomes might also
involve other autophagy cargo adaptors, because p62was associatedwith
themajority of LC3-positive bacteria, yet thiswas independent ofGBPs
(ExtendedData Fig. 8c, d).Altogether, these results suggested thatGBPs
might promote the lysis of vacuoles or help to recruit galectin-8 to lysed
vacuoles.
To confirm a direct role of GBPs in vacuolar lysis, we adapted a pha-
gosome integrity assay based on differential permeabilizationwith dig-
itonin (Extended Data Fig. 9). Comparing wild-type and GBPchr3 KO
BMDMs, we found significantly lower numbers of cytosolic (FITC1)
S. typhimurium inGbpchr3-deficient cells (Fig. 4e, f). Similarly,Gbp22/2
BMDMs also harboured fewer cytosolic S. typhimurium compared to
BMDMs from wild-type littermates (Fig. 4g). In contrast, we did not
find a defect in cytosolic localizationbetweenwild-type andGbpchr3KO
BMDMs infected with the specialized cytosolic pathogen Shigella flex-
neri, which uses its T3SS to destabilize the phagosome and escape into
the cytoplasm (Fig. 4h)19. Althoughwe cannot exclude thatGBPsmight
also be involved in the recruitment or assembly of the non-canonical
inflammasome, these results indicate that GBPs, in particular GBP2,
directly promote the destruction of vacuoles.
In conclusion, our data demonstrate that host-induced destruction
of PCVs or phagosomes is an essential immune function and assures
recognition of vacuolar bacteria by cytosolic innate immune sensors
(Extended Data Fig. 10). Additional studies are required to determine
howGBPsdistinguish ‘self’ and ‘non-self’membranes andbywhichmech-
anism phagosomes are lysed. In mice, this might involve the IRGM
proteins that can act as GDI (guanine nucleotide dissociation inhib-
itor) and inhibit IRG and GBP activity. Absence of IRGMs results in
mislocalization of both IRGs andGBPs and even in degradation of lipid
droplets20–22, supporting a model in which IRGM proteins would pro-
tect ‘self’-vacuoles frombeing targeted by host IRGs andGBPs23. Because
both commensals and pathogens activate caspase-11 (ref. 1), it can be
assumed thatGBPs are not specific towards pathogens but are a general
innate immune response against bacteria trapped in thephagosomes of
macrophages. Finally, given the important roleofLPS-induced caspase-11
activation in septic shock1–3, pharmaceutical targeting of the above-
described pathways might be used to modulate inflammation during
bacterial sepsis.
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Figure 2 | GBPs control bacterial replication. a, b, Quantification of live
(mCherry-positive) and dead (mCherry-negative) S. typhimurium per cell by
immunofluorescence (a) or as percent of total by flow-cytometry (b) in
unprimed BMDMs at 16 h post-infection. c, Immunostaining for GBP2 and
quantification of live and dead Salmonella at 4 h post-infection. Arrowheads,
bacteria shown in insets. d, Quantification of GBP-positive bacteria, LDH
release and IL-1b secretion at indicated time points fromBMDMs infectedwith
Salmonella, live or killed by different means. e, Immunohistochemistry for
GBP2 and Salmonella on spleen tissue from Salmonella (mCherry-positive)-
infected mice (representative of n5 3 per group). S. tm., S. typhimurium.
f, g, Quantification ofGBP-positive Salmonella in anti-IFN-c-treated or control
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Figure 3 | Autophagy reduces caspase-11
activation. a, b, Unprimed BMDMs infected with
S. typhimurium for 4 h and immunostained for
LC3 and GBP2. Arrowheads, bacteria shown in
insets. Scale bars, 10mm. c, Quantification of results
from b. d–g, LDH release and immunoblots for
caspase-1 and caspase-11 from BMDMs infected
for 16 h or transfected with LPS in presence or
absence of 3-methyladenine (3-MA). h, i, LDH
release and IL-1b secretion from BMDMs infected
for 16 h or transfected with LPS. Graphs show
mean and s.d. of quadruplicate wells and data
are representative of two (e, i) and three
(a–d, f–h) independent experiments.
*P, 0.05, **P, 0.01; NS, not significant
(two-tailed t-test).
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Figure 4 | GBP-mediated lysis of the PCV
releases Salmonella into the cytosol.
a, Quantification of galectin-8-positive Salmonella
in unprimed BMDMs at 4 h post-infection.
b, c, Unprimed BMDMs infected with
S. typhimurium for 4 h and immunostained for
galectin-8, GBP2 and LC3. Arrowheads,
bacteria shown in insets. Scale bars, 10mm.
d, Quantification of galectin-8/LC3-double-
positive Salmonella at indicated time points
post-infection. e–h, Quantification of cytosolic and
vacuolar bacteria by flow cytometry in BMDMs
infected with mCherry-positive S. typhimurium
(e–g) or S. flexneri (h, wild-type or DT3SS) for 4 h.
Graphs show mean and s.d. or 5–95 percentile
(Box plots) of technical triplicates. Data are
representative of 2 (g, h), 3 (a–d) and 4
(e, f) independent experiments. *P, 0.05,
**P, 0.01 (two-tailed t-test).
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METHODS SUMMARY
BMDMswere cultured and seeded for infections as described previously4. Priming
wasdoneovernightwithPAM3CSK4(1mgml21), LPSO111:B4 (0.1mgml21),murine
IFN-b or murine IFN-c (1 unit per ml). S. typhimurium, S. flexneri, V. cholerae,
E. cloacae,C.koseriandB. thailandensisweregrownovernight inLBorTSBmediumat
37 uC with aeration. Bacteria were diluted in fresh pre-warmed macrophage medium
and added to the macrophages at a multiplicity of infection (m.o.i.) of 100:1 for
measurements of caspase-11 and caspase-1 activity or 10:1 for all other assays. For
assaying NLRC4 activation, Salmonella were subcultured for 4 h to induce SPI-1
T3SS expression before infection (m.o.i. 20:1). S. flexneriwere subcultured for 3 h
to induceT3SS expression before infection (m.o.i. 30:1).When required, apocynin,
L-NG-nitroarginine methyl ester (L-NAME), 3-methyladenine or vehicle controls
were added 30min before infection. Plates were centrifuged for 15min at 500g to
synchronize the infectionandplaced at 37 uCfor 1 h.Next, 100mgml21 gentamycin
was added to kill extracellular bacteria. After 1 h incubation, the cells were washed
once with DMEM and given fresh macrophage medium containing 10mgml21
gentamicin for the remainder of the infection. Transfection with poly(dA:dT) or
MSU, alum or nigericin treatment was done as described previously2 or as indi-
cated.All animal experimentswere approved and performed according to local guide-
lines. Female BALB/c mice (10–14weeks old) were infected intravenously with
Salmonella (1,000 c.f.u.) and euthanized 4–5 days later. For antibody injections,
mice received on day 3 two intraperitoneal injections of 200ml PBS containing
0.2mg anti-IFN-c monoclonal or 0.2mg rat IgG1, k isotype control antibody.
Online Content Any additional Methods, ExtendedData display items and Source
Data are available in the online version of the paper; references unique to these
sections appear only in the online paper.
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METHODS
Bacterial strains and plasmids. Salmonella enterica serovar Typhimurium
(S. typhimurium) SL1344 and congenic mutants were published before12. Other
bacterial strains used were Shigella flexneri, Vibrio cholerae, Enterobacter cloacae,
Citrobacter koseri and Burkholderia thailandensis ATCC700388.
Mice. Gbpchr3 KO, Gbp22/2, Atg5fl/fl-Lyz-Cre, Cybb2/2 (gp91phox), Casp12/2/
Casp112/2 (a.k.a caspase-1 knockout), Casp112/2 and Casp12/2 (Casp12/2/Casp11tg)
mice have been previously described1,11,14,24,25. Mice were bred in the animal facil-
itiesof theUniversityofBasel,Genentech Inc.,Heinrich-Heine-UniversityDuesseldorf
or theUniversity of Osaka. Generation ofmice withGbp5KOalleles by zinc finger
nuclease (ZFN) technology: A ZFN pair was obtained from Sigma-Aldrich (SAGE
Labs). The ZFN pair recognizes a sequence in mouse Gbp5 exon 2 (cut site is
underlined): 59-TGCCATCACACAGCCAGTGGTGGTGGTAGCCATTGTGG
GT-39. ZFN mRNA and a donor plasmid harbouring a 10-bp deletion in Gbp5
exon 2was co-microinjected intoC57BL/6N zygotes using established procedures.
One male founder carrying the 10-bp deletion was obtained by homologous
recombination (10-bp deletion is underlined): 59-TGCCATCACACAGCCAGTG
GTGGTGGTAGCCATTGTGGGT-3.This founderwasbredwithC57BL/6Nfemales
togenerateheterozygousprogeny for subsequent intercrossing.Two founders (amale
and a female) carrying identical 1-bp deletionswere obtained bynon-homologous
end-joining (deleted bp is underlined): 59-TGCCATCACACAGCCAGTGGTGG
TGGTAGCCATTGTGGGT-3. These two founders were intercrossed to directly
generate homozygous progeny. Both the 10-bp (designated KO line 1) and 1 bp
(designated KO line 2) deletions lead to frameshifts and premature stop codons in
Gbp5 exon 2.
Animal infection.All animal experimentswere approved (license 2239,Kantonales
Veterina¨ramt Basel-Stadt) and performed according to local guidelines (Tierschutz-
Verordnung, Basel-Stadt) and the Swiss animal protection law (Tierschutz-Gesetz).
Female BALB/cmice (10–14weeks old) were infected intravenously withmCherry-
positive Salmonella (1,000 c.f.u.) and euthanized 4–5 days later. For antibody injec-
tions, mice (n5 3 per group) received on day 3 two intraperitoneal injections of
200ml PBS containing 0.2mg anti-IFN-c monoclonal antibody (Clone XMG1.2,
BioLegend) or 0.2mg rat IgG1, k isotype control antibody (clone RTK2071, Bio-
Legend). No randomization or blinding was performed.
Cell culture and infections. BMDMs were differentiated in DMEM (Invitrogen)
with 10% v/v FCS (Thermo Fisher Scientific), 10%MCSF (L929 cell supernatant),
10mMHEPES (Invitrogen), and nonessential amino acids (Invitrogen). 1 day before
infection, macrophages were seeded into 6-, 24-, or 96-well plates at a density
of 1.253 106, 2.53 105, or 53 104 per well. If required macrophages were pre-
stimulated with PAM3CSK4, LPS O111:B4 (InvivoGen), mIFN-b or mIFN-c
(eBioscience). For infectionswith S. typhimurium,V. cholerae,E. cloacae,C. koseri
and B. thailandensis, bacteria were grown overnight in LB or TSB at 37 uC with
aeration. The bacteria were diluted in fresh pre-warmedmacrophagemediumand
added to themacrophages at anmultiplicity of infection (m.o.i.) of 100:1 formea-
surements of caspase-11 and caspase-1 activity or 10:1 for all other assays. For
assaying Salmonella-induced NLRC4 activation, Salmonellawere subcultured for
4 h before infection to induce SPI-1 T3SS and flagellin expression. S. flexneriwere
cultured overnight in TSB medium and subcultured for 3 h before infection to
induceT3SS expression. IFN-c-primedBMDMs (to induceGBP expression)were
infectedwithm.o.i. of 30:1 with S. flexneri for FACS analysis.When required, che-
mical reagents, Apocynin (Sigma Aldrich, 100mM), L-NG-nitroarginine methyl
ester (L-NAME; Sigma Aldrich, 100mM) and 3-methyladenine (Sigma Aldrich,
5mM)were added 30minbefore infection. Theplateswere centrifuged for 15min
at 500 g to ensure comparable adhesion of the bacteria to the cells and placed at
37 uC for 60min. Next, 100mgml21 gentamycin (Invitrogen) was added to kill
extracellular bacteria. After a 60-min incubation, the cells were washed once with
DMEM and given fresh macrophage medium containing 10mgml21 gentamicin
for the remainder of the infection. For infections with killed bacteria, Salmonella
were grown as above. Shortly before the infection, bacteria were left untreated or
incubated for 30min at 95 uC, in 4% paraformaldehyde or in 70% ethanol. Fol-
lowing the treatment, bacteria were washed with PBS and prepared for infections
as outlined above. The effectiveness of the killing procedures was verified by plat-
ing serial dilutions. Transfection with poly(dA:dT) or treatment with MSU, alum
or nigericin was done as described previously2 or as indicated.
siRNA knockdown.Gene knockdown was done using GenMute (SignaGen) and
siRNApools (siGenome,Dharmacon). Briefly, wild-type BMDMswere seeded into
24-, or 96-well plates at a density of 1.53 105 or 33 104 per well. siRNA complexes
were prepared at 25nM siRNA in 13 GenMute Buffer according to the manufac-
turer’s instructions for forward knockdowns. siRNA complexes were mixed with
BMDM medium and added onto the cells. BMDMs were infected with S. typhi-
murium at an m.o.i. of 100:1 after 56 h of knockdown and analysed for inflamma-
some activation as outlined below. siRNA pools included: Casp11 (that is, Casp4)
(M-042432-01),Gbp1 (M-040198-01),Gbp2 (M-040199-00),Gbp3 (M-063076-01),
Gbp4 (M-047506-01), Gbp5 (M-054703-01), Gbp6 (M-041286-01), Gbp7 (M-
061204-01), Gbp8 (M-059726-01), Gbp9 (M-052281-01), Gbp10 (M-073912-00),
Gbp11 (M-079932-00) andNT(non-targeting)pool2 (D-001206-14). SeeSupplemen-
tary information for sequences.
LPS transfection.Macrophages were seeded as described above. Cells were pre-
stimulated with 10 ugml21 of PAM3CSK4 for 4 h in Opti-MEM and transfected
for 16 h with ultrapure LPS E. coliO111:B4, ultrapure LPS E. coli K12 or ultrapure
LPS Salmonellaminnesota (InvivoGen) in complexwith FuGeneHD (Promega) as
described previously2.
CytokineandLDHreleasemeasurement. IL-1band tumournecrosis factor (TNF)-a
was measured by ELISA (eBioscience). LDH was measured using LDH Cytotox-
icity Detection Kit (Clontech). To normalize for spontaneous lysis, the percentage
of LDH release was calculated as follows: (LDH infected2LDHuninfected)/(LDH
total lysis2LDH uninfected)*100.
Western blotting.Western blottingwas done as described before4. Antibodies used
were rat anti-mouse caspase-1 antibody (1:1,000; 4B4;Genentech), rat anti-mouse
caspase-11 (1:500; 17D9; Sigma), rabbit anti-IL-1a (1:1,000; ab109555; Abcam),
rabbit anti-IL-18 (1:500; 5180R; Biovision), goat anti-mouse IL-1b antibody (1:500;
AF-401-NA; R&D Systems) and rabbit anti-GBP2 and rabbit anti-GBP5 (1:1,000;
11854-1-AP/13220-1-AP; Proteintech). Cell lysates were probed with anti-b-actin
antibody (Sigma) at 1:2,000.
Statistical analysis. Statistical data analysis was done using Prism 5.0a (GraphPad
Software, Inc.). To evaluate the differences between two groups (cell death, cyto-
kine release, FACS, CFU and immunofluorescence-based counts) the two-tailed
t-test was used. In figures NS indicates ‘not significant’, P values are given in figure
legends.
Immunofluorescence.Macrophages were seeded on glass coverslips and infected
as described above. At the desired time points cells were washed 33with PBS and
fixed with 4% paraformaldehyde for 15min at 37 uC. Following fixation coverslips
were washed and the fixative was quenched with 0.1M glycine for 10min at room
temperature.Coverslipswere stainedwithprimaryantibodies at 4 uCfor16h,washed
43 with PBS, incubated for 1 h with appropriate secondary antibodies at room
temperature (1:500, AlexaFluor, Invitrogen), washed 43 with PBS and mounted
on glass slides with Vectashield containing 49,6-diamidino-2-phenylindole (DAPI)
(Vector Labs). Antibodies usedwere rabbit anti-LC3 (1:1,000; NB600-1384, Novus),
mouse anti-LC3 (1:100, 2G6, NanoTools), guinea-pig anti-p62 (1:100, GP62-C,
Progen), goat anti-Salmonella (1:500, CSA-1 andCSA-1-FITC,KPL),mouse anti-
galectin-8 (1:1,000, G5671, Sigma), goat anti-galectin-8 (1:100, AF1305, R&D),
rabbit anti-Optineurin (1:100, ab23666, Abcam), rabbit anti-NDP52 (1:100, D01,
Abnova), anti-PDI (1:100, ADI-SPA-890, Enzo Lifesciences), anti-Calnexin (1:100,
ADI-SPA-860-D, Enzo Lifesciences), goat anti-GBP1-5 (1:100, sc-166960, Santa
Cruz Biotech), rabbit anti-GBP2 and rabbit anti-GBP5 (1:100; 11854-1-AP/13220-
1-AP; Proteintech). Coverslipswere imaged on aZeiss LSM700 or a Leica SP8 at363
magnification.Colocalization studieswere performedas blinded experiments,with in
general a minimum count of 100 bacteria per coverslip and performed in triplicate.
Immunofluorescencebased counts of live (mCherry1/FITC1) anddead (mCherry2/
FITC1) bacteria were done as blinded experiment on z stacks taken from 15 ran-
dom fields in three biological replicates, with a total of approximately 10,000 bac-
teria counted.
Immunohistochemistry. Cryosections were blocked in 1% blocking reagent (Invi-
trogen) and2%mouse serum(Invitrogen) inTBST(0.05%Tween in13TBSpH7.4),
and stained with primary and secondary antibodies (goat anti-CSA1; 1:500; 01-
91-99-MG; KPL and anti-GBP2; 1:100; 11854-1-AP; Proteintech). Secondary
antibodies included Santa Cruz Biotech sc-362245 and Molecular Probes A21206,
A21445 and A21469.
ROS assay.Measurement of oxygen-dependent respiratory burst of BMDMs was
performed by chemiluminescence in the presence of 5-amino-2,3-dihydro-1,4-
phtalazinedione (luminol, Sigma Aldrich, 66mM) using a thermostatically (37 uC)
controlled luminometer. Both oxygen and nitrogen species were detected (O2
N2,
ONOO2, OHN). Chemiluminescence generation was monitored every minute for
1 h after IFN-c (100Uml21) and/or Salmonella challenge and expressed as counts
per minute.
NO assay. Nitrite production was measured by the Griess assay as previously
described26. Briefly, in 96-well plates, BMDMs were infected as described above
in presence or absence of IFN-cor IL-1b for 16h. Supernatantsweremixed1:1with
2.5% phosphoric acid solution containing 1% sulfanilamide and 0.1% naphthyle-
nediamine. After 30min incubation at room temperature, the nitrite concentration
was determined by measuring absorbance at 550nm. Sodium nitrite (Sigma) was
used as a standard to determine nitrite concentrations in the cell-free medium.
Digitonin assay. For flow-cytometry-based quantification of cytoplasmic and
vacuolar bacteria, macrophages were infected with mCherry1 S. typhimurium or
mCherry1 S. flexneri as described above.At the desired timepoint, cellswerewashed
33 with KHM buffer (110mM potassium acetate, 20mM HEPES, 2mMMgCl2,
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pH7.3) and incubated for 1min inKHMbufferwith150mgml21 digitonin (Sigma).
Cells were immediately washed 23with KHM buffer and then stained for 12min
with anti-Salmonella-FITC (1:500, CSA-1, KPL) or anti-Shigella (1:100, BP1064,
Acris) inKHMbufferwith 2%BSA. Secondary antibodies used for S. flexneri stain-
ing were: anti-Rabbit-488 (1:500, Invitrogen). Cells were washed 33with PBS and
lysed in PBS with 0.1% Triton-X (Sigma) and analysed on a FACS-Canto-II. Con-
trols were included in every assay and are described in (Extended Data Fig. 9).
Live/dead analysis by FACS. Infection of macrophages was performed using
mCherry1 bacteria as described above. At 16 h post-infection cells were washed
and lysedwithPBSsolution containing0.1%TritonX-100 (SigmaAldrich) to release
intracellular bacteria. Salmonellawere counterstained using an anti-Salmonella anti-
body (CSA-1, KPL) and analysed using a FACSCanto-II for fluorescence intensities
in FL-1 and FL-2 channels. Data were analysed with FlowJo 10.0.6 software. The
gate was set for the bacterial population based on the FSC/SSC and the anti-
Salmonella staining (CSA-1-FITC,KPL). Controls included livemCherry-expressing
andmCherry-negative Salmonella stainedwith anti-Salmonella antibodies (CSA-1,
KPL).
24. Mariathasan, S. et al. Differential activation of the inflammasome by caspase-1
adaptors ASC and Ipaf. Nature 430, 213–218 (2004).
25. Zhao, Z. et al.Autophagosome-independent essential function for the autophagy
protein Atg5 in cellular immunity to intracellular pathogens. Cell Host Microbe 4,
458–469 (2008).
26. Lima-Junior, D. S. et al. Inflammasome-derived IL-1b production induces nitric
oxide-mediated resistance to Leishmania. Nature Med. 19, 909–915 (2013).
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Extended Data Figure 1 | Type-I-interferon signalling is required to induce
caspase-11-dependent cell death in response to bacterial infection, but
not in response to LPS transfection. a, LDH release from unprimed
BMDMs infected for 16 h with wild-type (WT) S. typhimurium or DSPI-2
S. typhimurium grown to stationary phase. b, LDH release from primed
BMDMs transfected with LPS O111:B4. Graphs show the mean and s.d. of
quadruplicate wells and are representative of three independent experiments.
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Extended Data Figure 2 | BMDMs from Gbpchr3 KO mice have normal
responses to priming stimuli, but fail to activate the non-canonical
inflammasome during bacterial infections. a, Schematic representation of
the GBP locus on murine chromosome 3. The extent of the deletion in Gbpchr3
KO mice is indicated. b–d, Induction of pro-caspase-11, GBP2 and GBP5
expression in lysates of wild-type and Gbpchr3 KO BMDMs stimulated for 16 h
with the indicated amounts of murine IFN-b, murine IFN-c or LPS O111:B4.
e, TNF-a release fromBMDMs stimulated for 16 hwithLPSO111:B4. f, g, LDH
release and IL-1b secretion from wild-type and Gbpchr3 KO BMDMs infected
for 16 h with wild-type (WT) S. typhimurium, DSPI-2 S. typhimurium,
V. cholerae, E. cloacae orC. koseri grown to stationary phase. Cells were primed
overnight with LPS (f) or poly(I:C) (g). *Indicates background band. Graphs
show the mean and s.d. of quadruplicate wells and data are representative of
two independent experiments. **P, 0.01, NS, not significant (two-tailed
t-test).
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Extended Data Figure 3 | GBPs assist the detection of bacteria that escape
into the cytosol only in primed macrophages. a–c, LDH release, IL-1b
secretion and immunoblots for processed caspase-1 and caspase-11 released
from unprimed BMDMs infected for 8–16 h with DsifA S. typhimurium or
B. thailandensis grown to stationary phase. d, LDH release and IL-1b secretion
from unprimed or IFN-c-primed BMDMs infected for 16 h with DsifA
S. typhimurium grown to stationary phase. Ext, extract; SN, supernatant.
Graphs show the mean and s.d. of quadruplicate wells and data are
representative of two independent experiments. *P, 0.05; **P, 0.01; NS, not
significant (two-tailed t-test).
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Extended Data Figure 4 | Murine GBP2 controls non-canonical
inflammasome activation during Salmonella infection, but is dispensable
for direct LPS sensing and canonical inflammasomes. a, Schematic drawing
of the inflammasome pathways activated by flagellin-deficient Salmonella.
b–d, LDH release, IL-1b secretion and immunoblots for processed caspase-1
and processed IL-1b released from unprimed BMDMs infected for 17 h with
Dflag S. typhimurium grown to stationary phase. BMDMswere treated with the
indicated siRNA for 56 h before infection. e, Immunoblots for processed
caspase-1, IL-18 and caspase-11 released from unprimed BMDMs infected for
16 h with DSPI-2 S. typhimurium, E. cloacae or C. koseri grown to stationary
phase. f, g, LDH release and IL-1b secretion from primed wild-type and
Gbp22/2 BMDMs transfected with the indicated types of LPS for 16 h, treated
with nigericin for 1 h, infected with SPI-1 T3SS expressing logarithmic phase
wild-type S. typhimurium for 1 h, or transfected with poly(dA:dT) for 6 h.
Cell were primed with PAM3CSK4 in f or LPS g. Graphs show the mean and
s.d. of quadruplicate wells and data are representative of two (e) and three
(b–d, f, g) independent experiments. NT, non-targeting siRNA; GM,GenMute
transfection reagent; NS, not significant (two-tailed t-test).
RESEARCH LETTER
Macmillan Publishers Limited. All rights reserved©2014
V. Appendix -249-
Extended Data Figure 5 | Normal activation of non-canonical and
canonical inflammasomes in Gbp52/2 BMDMs. a, Expression of GBP5
in wild-type and two lines of Gbp52/2 BMDMs (1 and 2). *Indicates a
cross-reactive band. b–e, LDH release and IL-1b secretion from BMDMs
infected for 16 h with wild-type (WT) S. typhimurium,DSPI-2 S. typhimurium,
V. cholerae, E. cloacae or C. koseri grown to stationary phase (b), transfected
with the indicated LPS for 16 h (c) infected for 1 h with SPI-1 T3SS expressing
logarithmic phase wild-type S. typhimurium (d), or treated with 5mMATP or
20mM nigericin for 4 h (e). Cells were left unprimed (b) or primed with
PAM3CSK4 in (c) or LPS (d, e). Graphs show the mean and s.d. of triplicate or
quadruplicate wells and data are representative of three independent
experiments.
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Extended Data Figure 6 | GBPs control bacterial replication. c.f.u.s at 16 h
post-infection inwild-type andGbpchr3KOBMDMs infectedwith the indicated
bacterial strains. Experiments are representative of two independent
experiments.
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Extended Data Figure 7 | Inhibition of ROS and NO production does not
affect non-canonical inflammasome activation. a, b, ROS levels, LDH release
and IL-1b secretion in unprimed BMDMs left uninfected or infected for 16 h
with wild-type S. typhimurium grown to stationary phase. c–e, LDH release,
IL-1b secretion, ROS levels and immunoblots for processed caspase-1 and
caspase-11 released from unprimed BMDMs infected for 16 h with wild-type
(WT) S. typhimurium or E. cloacae grown to stationary phase in the presence of
the ROS inhibitor (apocynin) or a vehicle control (DMSO). f, g, LDH
release, IL-1b secretion and immunoblots for processed caspase-1 and
caspase-11 released from unprimed BMDMs infected for 16 h with wild-type
S. typhimurium or E. cloacae grown to stationary phase in the presence of the
iNOS inhibitor (L-NAME) or a vehicle control (DMSO). h, NO release from
unprimed or IFN-c-primed BMDMs infected for 16 h with S. typhimurium in
presence of the iNOS inhibitor (L-NAME) or a vehicle control (DMSO). Ext,
extract; SN, supernatant. Graphs show themean and s.d. of quadruplicate wells
and data are representative of two (a–c, e–g) and three (d, h) independent
experiments. NS, not significant (two-tailed t-test).
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Extended Data Figure 8 | Colocalization of GBPs and autophagy proteins
on intracellular bacteria. a, Colocalization of LC3 with GBPs in unprimed
wild-type BMDMs infected with E. cloacae or C. koseri for 4 h and stained
for LC3, GBP2 and DNA. b, Colocalization of galectin-8 and NDP52 in
unprimed wild-type BMDMs infected with wild-type S. typhimurium for 4 h
and stained for galectin-8, NDP52 and DNA. c, Colocalization of p62 and LC3
in unprimed wild-type BMDMs infected with wild-type S. typhimurium for
4 h and stained for LC3, p62 and DNA. d, Quantification of p62 and LC3
co-staining in wild-type and Gbpchr3 KO BMDMs at 4 h post-infection with
Salmonella. Arrowheads indicate region shown in insets. Scale bars, 1mm (a)
and 10mm(b, c). Graph shows themean and s.d. of triplicate counts and images
and graph are representative of at least two independent experiments. NS, not
significant (two-tailed t-test).
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Extended Data Figure 9 | Digitonin-based quantification of cytoplasmic
bacteria. a, Immunostaining for calnexin and PDI (protein disulphide
isomerase) in wild-type BMDMs left untreated or permeabilized with digitonin
or saponin. b, Differentially permeabilized macrophages stained for cytosolic
and vacuolar Salmonella at 4 h post-infection. c, Schematic representation of
FACS-based analysis of cytosolic and vacuolar bacterial populations of
Salmonella. Scale bars, 10mm.
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Extended Data Figure 10 | Model for the role of GBPs and autophagy in
caspase-11 activation. The pathogen-containing vacuole of vacuolar bacterial
pathogens is recognized by interferon-induced GBPs in an unknown manner.
GBPs promote the lysis of the PCV either directly or indirectly, resulting in
the release of the bacteria into the cytosol and activation of caspase-11 by
bacterial LPS. b-galactosides of the lysed vacuole serve as danger signals upon
exposure to the cytosol and are recognized by galectin-8 leading to the
recruitment of the autophagy machinery. p62 participates in this process by
recognizing ubiquitin-chains on the vacuole or the bacterium. Uptake of the
bacterium and the lysed vacuole into autophagosomes reduces caspase-11
activation by removing the source of LPS from the cytosol.
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Dharmacon Dharmacon 
Pool Catalog 
Number 
Duplex Catalog 
Number 
Gene Symbol Gene Accession GINumber Sequence 
M-042432-01 D-042432-01 Casp4 NM_007609 157951737 GUGCAACAAUCAUUUGAAA
M-042432-01 D-042432-02 Casp4 NM_007609 157951737 GCUAAUGUCUCAUGGCACA 
M-042432-01 D-042432-03 Casp4 NM_007609 157951737 GAUGUGCUACAGUAUGAUA 
M-042432-01 D-042432-04 Casp4 NM_007609 157951737 CGAAAGGCUCUUAUCAUAU 
M-040198-01 D-040198-01 GBP1 NM_010259 134031981 GCAACUACGUCAAGAGAUA 
M-040198-01 D-040198-02 GBP1 NM_010259 134031981 GGAAAGACUUCUCAAGCAA 
M-040198-01 D-040198-03 GBP1 NM_010259 134031981 GAUCAUGCACCAUACUUUA 
M-040198-01 D-040198-04 GBP1 NM_010259 134031981 CAACUCAGCUAACUUUGUG 
M-040199-00 D-040199-01 GBP2 NM_010260 6753949 UGAAGAAGCUGACUGAGAA 
M-040199-00 D-040199-02 GBP2 NM_010260 6753949 GAAGUGCACUAUACUCUGA 
M-040199-00 D-040199-03 GBP2 NM_010260 6753949 GGAGCUGUGUGGUGAAUUU 
M-040199-00 D-040199-04 GBP2 NM_010260 6753949 GGAGCUAACUGAUCUUAUC 
M-063076-01 D-063076-01 Gbp3 NM_018734 134053870 GAACGAAGCAGCAUCUAUU
M-063076-01 D-063076-02 Gbp3 NM_018734 134053870 GGACUUUGGUGCAGACCUA 
M-063076-01 D-063076-03 Gbp3 NM_018734 134053870 GGCCAUUGUUGGUUUAUAU 
M-063076-01 D-063076-04 Gbp3 NM_018734 134053870 CACAAGCGACAAACGUUUA 
M-047506-01 D-047506-01 Gbp4 NM_008620 126157520 GGACAUAACAUCAAGGAAA 
M-047506-01 D-047506-02 Gbp4 NM_008620 126157520 CCAAUUGGAUCCUACGUUU 
M-047506-01 D-047506-03 Gbp4 NM_008620 126157520 GAUAUAAGACACAAGCUGA 
M-047506-01 D-047506-04 Gbp4 NM_008620 126157520 GGAAUUGCGUCGAGAGAUC 
M-054703-01 D-054703-01 GBP5 NM_153564 91064875 CGCAGGAGUUCUAUCAUAA 
M-054703-01 D-054703-02 GBP5 NM_153564 91064875 UGACUGUGUUAUAAGCUAA 
M-054703-01 D-054703-03 GBP5 NM_153564 91064875 ACUCAGAUCUUUGCACUAG 
M-054703-01 D-054703-04 GBP5 NM_153564 91064875 GCGAGAGGCCAUAGAAAUC 
M-041286-01 D-041286-02 Mpa2l NM_194336 170650636 AAGAAACACUGAUCGAAUU
M-041286-01 D-041286-04 Mpa2l NM_194336 170650636 GGGACAGAAUCACGGCUUU 
M-041286-01 D-041286-05 Mpa2l NM_194336 170650636 GGAAUUAAUAGGAGAGAAC 
M-041286-01 D-041286-06 Mpa2l NM_194336 170650636 GCACAAUCAAGUCAGGUUA 
M-061204-01 D-061204-01 Gbp6 NM_001083312 134032013 AAGAAUAGCUCAUUGGGUG 
M-061204-01 D-061204-02 Gbp6 NM_001083312 134032013 CGACCUACGUGGAUGCUAU 
M-061204-01 D-061204-03 Gbp6 NM_001083312 134032013 GGACUAUACCGUACGGGAA 
M-061204-01 D-061204-04 Gbp6 NM_001083312 134032013 GACGUGCCGUGUUUAGAGA 
M-059726-01 D-059726-01 5830443L24RIK NM_029509 115292436 CACCAAAUCCUGAUGGAAU 
M-059726-01 D-059726-03 5830443L24RIK NM_029509 115292436 GUGACAACCUAUGUAGAUG 
M-059726-01 D-059726-17 5830443L24RIK NM_029509 115292436 AUUAAUAGGUGAGGCGAAA 
M-059726-01 D-059726-18 5830443L24RIK NM_029509 115292436 ACGGAGAGAUACAGCAACU 
M-052281-01 D-052281-01 BC057170 NM_172777 118129953 UAGAGAGACUGGAACAUAA
M-052281-01 D-052281-02 BC057170 NM_172777 118129953 GAGGAAGGAUUUACGAACA 
M-052281-01 D-052281-03 BC057170 NM_172777 118129953 GAUCUUCGCCCUAAGUGUG 
M-052281-01 D-052281-04 BC057170 NM_172777 118129953 AAACAUUGGUCCCAUUCUG 
M-073912-00 D-073912-09 Gbp10 NM_001039646 116812913 CCAUAUGAGUAAAGACACA 
M-073912-00 D-073912-10 Gbp10 NM_001039646 116812913 GGAAUUAAUAGGAGAGAAC 
M-073912-00 D-073912-11 Gbp10 NM_001039646 116812913 GCUGAUCCCAGGUGACAAA 
M-073912-00 D-073912-12 Gbp10 NM_001039646 116812913 AGAAACACUGAUCGAAUUA 
M-079932-00 D-079932-13 EG634650 NM_001039647 88900482 UGUAAGAGACCUUGCUUUA 
M-079932-00 D-079932-14 EG634650 NM_001039647 88900482 GGAAUUAAUAAGUGAGAAG 
M-079932-00 D-079932-15 EG634650 NM_001039647 88900482 GAAGAGAGAUCUAUCGACU 
M-079932-00 D-079932-16 EG634650 NM_001039647 88900482 GCUAUAAGAAGAAAGCUGA 
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The innate immune system detects invading pathogens through 
membrane-bound and cytosolic pattern-recognition receptors, 
which recognize microbe- and damage-associated molecular pat-
terns and induce conserved signaling pathways. Nucleic acids and 
their derivatives are detected by RIG-I-like receptors, cGAS, DAI and 
RNA polymerases, which results in the induction of type I interferons 
via the signaling molecule STING and the kinase TBK1 (refs. 1–3). 
Cytosolic microbial and host DNA also induces inflammasome forma-
tion through AIM2, a member of the PYHIN family of receptors4–7. 
AIM2 binds double-stranded DNA through its HIN-200 domain8 
and recruits the inflammasome adaptor ASC. ASC rapidly oligomer-
izes to form a macromolecular inflammasome complex known as an 
‘ASC speck’, which activates caspase-1. Active caspase-1 promotes 
the maturation and release of the pro-inflammatory cytokines 
interleukin 1B (IL-1B) and IL-18. In addition, it induces pyroptosis, 
a lytic form of cell death that restricts pathogen replication. The 
AIM2 inflammasome mediates the recognition of DNA viruses as 
well as that of various Gram-negative and Gram-positive cytosolic 
bacteria, such as Listeria monocytogenes, Legionella pneumophila, 
Mycobacterium species and Francisella tularensis subspecies novicida 
(F. novicida)8–14. Notably, several studies have shown that activation 
of AIM2 by these bacteria requires bacteriolysis and the subse-
quent release of bacterial chromosomal DNA into the cytosol10,12,15. 
However, whether the bacteriolysis is accidental or is an active, 
host-directed mechanism has remained unclear.
The activation of AIM2 via the transfection of synthetic DNA 
or during infection with a DNA virus is independent of signaling 
via Toll-like receptors or interferons9,13,16. In contrast, the 
activation of AIM2 during infection with F. novicida requires the 
production of type I interferons, which are induced as a result 
of the recognition of an as-yet-undefined F. novicida–derived 
nucleic acid ligand in the cytosol9,10,17–20. Consistent with that, 
the activation of AIM2 inflammasomes in F. novicida–infected 
cells requires signaling through STING and the transcription 
factor IRF3 (refs. 9,10,17). It has been speculated that interferon 
signaling is necessary to increase cellular AIM2 for the detection 
of F. novicida DNA9, yet interferon-mediated induction of AIM2 is 
contested, and even small amounts of transfected DNA efficiently 
trigger activation of AIM2 in an interferon-independent manner9. 
Therefore, it is likely that one or several interferon-inducible 
factor(s) is (are) required for efficient activation of AIM2 during 
bacterial infection.
Type I and type II interferons are potent cytokines that exert 
anti-microbial effects through the induction of a broad transcrip-
tional program involving ~2,000 genes, the so-called ‘interferon-
stimulated genes’ (ISGs), many of which remain uncharacterized. 
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Guanylate-binding proteins promote activation 
of the AIM2 inflammasome during infection with 
Francisella novicida
Etienne Meunier1,6, Pierre Wallet2,6, Roland F Dreier1, Stéphanie Costanzo2, Leonie Anton1, Sebastian Rühl1, 
Sébastien Dussurgey3, Mathias S Dick1, Anne Kistner1, Mélanie Rigard2, Daniel Degrandi4, Klaus Pfeffer4, 
Masahiro Yamamoto5, Thomas Henry2 & Petr Broz1
The AIM2 inflammasome detects double-stranded DNA in the cytosol and induces caspase-1-dependent pyroptosis as well as 
release of the inflammatory cytokines interleukin 1b (IL-1b) and IL-18. AIM2 is critical for host defense against DNA viruses  
and bacteria that replicate in the cytosol, such as Francisella tularensis subspecies novicida (F. novicida). The activation of 
AIM2 by F. novicida requires bacteriolysis, yet whether this process is accidental or is a host-driven immunological mechanism 
has remained unclear. By screening nearly 500 interferon-stimulated genes (ISGs) through the use of small interfering RNA 
(siRNA), we identified guanylate-binding proteins GBP2 and GBP5 as key activators of AIM2 during infection with F. novicida. 
We confirmed their prominent role in vitro and in a mouse model of tularemia. Mechanistically, these two GBPs targeted cytosolic 
F. novicida and promoted bacteriolysis. Thus, in addition to their role in host defense against vacuolar pathogens, GBPs also 
facilitate the presentation of ligands by directly attacking cytosolic bacteria.
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Prominent among the products of these ISGs are several families of 
interferon-inducible GTPases, such as the 47-kilodalton immunity- 
related GTPases and the 65- to 73-kilodalton guanylate-binding 
proteins (GBPs)21,22. GBPs are conserved among vertebrates, with 
11 GBPs in mice and 7 in humans, and exert anti-microbial effects 
on intracellular bacteria and protozoa23. GBP1 and GBP7 restrict 
Mycobacterium bovis bacillus Calmette-Guérin and L. monocytogenes 
by recruiting anti-microbial effectors to the pathogen-containing vac-
uole (PCV)24. Several GBPs are recruited onto the Toxoplasma para-
sitophorous vacuole25, and most are also required for restricting the 
replication of Toxoplasma gondii23,26–28. In addition, GBPs encoded 
by genes on mouse chromosome 3 promote recognition of the vacu-
olar, Gram-negative bacterium Salmonella typhimurium by the innate 
immune system by destabilizing its PCV, which leads to egress of the 
bacteria into the cytosol and subsequent detection of its lipopolysac-
charide (LPS) by the caspase-11 inflammasome29. In this study we 
found that GBPs encoded by genes on mouse chromosome 3 were a 
key factor for the activation of AIM2 during infection with F. novic-
ida. In particular, GBP2 and GBP5 controlled the activation of AIM2 
by targeting cytosolic F. novicida and inducing lysis of these bacte-
ria by an as-yet-uncharacterized mechanism. We demonstrated that 
GBP-deficient mice were unable to control infection with F. novicida 
in vivo. Together our data reveal a function for GBPs during micro-
bial infection, in that GBPs promoted bacteriolysis in the cytosol 
and the exposure of bacterial DNA to cytosolic sensors of the innate 
immune system.
RESULTS
AIM2 activation during F. novicida infection requires interferons
F. novicida is a facultative intracellular Gram-negative bacterium that 
avoids phagosomal degradation in phagocytes by escaping into the 
cytosol, a process that requires the Francisella pathogenicity island 
(FPI). After escaping from the phagosome, F. novicida replicates in 
the cytosol but also triggers AIM2-dependent activation of caspase-1 
(refs. 10,13). Infection of mouse bone marrow–derived macrophages 
(BMDMs) with wild-type F. novicida resulted in cell death (pyrop-
tosis; measured by the release of lactate dehydrogenase (LDH)) and 
the release of IL-1B dependent on AIM2, ASC and caspase-1, while 
a mutant lacking the FPI ($FPI) did not activate the inflammasome 
(Fig. 1a). STING is linked to the activation of AIM2 during infec-
tion with F. novicida10,12. Macrophages deficient in STING (via the 
‘goldenticket’ (Gt) N-ethyl-N-nitrosourea–induced nonfunctional 
mutation of alleles encoding Tmem173 (called ‘StingGt/Gt’ here)) had 
considerable attenuation of their ability to induce expression of type I 
interferons and activation of the AIM2 inflammasome upon infection 
with F. novicida5 (Fig. 1b and Supplementary Fig. 1a). Consistent 
with a role for type I interferons in activation of the AIM2 inflamma-
some17,19, macrophages from mice deficient in Ifnar1, which encodes 
the receptor for interferon-A (IFN-A) and IFN-B (IFNAR1), or Stat1, 
which encodes the transcription factor STAT1, displayed significantly 
less pyroptosis and release of IL-1B when infected with F. novicida 
than did their wild-type counterparts (Fig. 1c). To further confirm 
that activation of AIM2 during infection with F. novicida depended 
on signaling via type I interferons, we assessed whether exogenous 
interferons were able to restore inflammasome activation in STING-
deficient BMDMs. As expected, IFN-B restored cell death and the 
release of cytokines in StingGt/Gt BMDMs (Fig. 1d). The addition of 
IFN-G restored cell death and the release of cytokines in both StingGt/Gt 
BMDMs and Ifnar1−/− BMDMs (Fig. 1d), which indicated a require-
ment for a general interferon signature.
The induction of Aim2 mRNA could explain the considerable 
dependence on type I interferons and signaling via STAT1 during 
infection with F. novicida10. However, activation of the AIM2 inflam-
masome by transfection of DNA or infection with DNA viruses is 
independent of interferon signaling9,13,16. In accordance with those 
reports, induction of cell death by transfection of the synthetic 
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Figure 1 Products of ISGs are required for AIM2 activation during infection with F. novicida.  
(a–c) Release of LDH (assessing cell death) and IL-1B from unprimed wild-type (WT),  
Casp1−/−Casp11−/−, Asc−/− and Aim2−/− BMDMs (a), wild-type and StingGt/Gt BMDMs (b),  
or wild-type, Ifnar1−/− and Stat1−/− BMDMs (c) 8 h after infection with wild-type F. novicida  
strain U112 (FN WT) (a–c) or the $FPI F. novicida mutant (FN $FPI) (a). ND, not detectable.  
(d) Release of LDH and IL-1B from untreated (UT) or IFN-B- or IFN-G-primed wild-type, StingGt/Gt  
and Ifnar1−/− BMDMs 8 h after infection with wild-type F. novicida U112. (e) Release of LDH from  
wild-type, StingGt/Gt, Stat1−/− and Aim2−/− BMDMs transfected with increasing concentrations of poly(dA:dT) (horizontal axis). (f) Incorporation of 
propidium iodide (PI) (assessing cell death) and release of IL-1B by wild-type BMDMs primed with Pam3CSK4 and then transfected with increasing 
concentrations (wedges) of purified F. novicida (FN) genomic DNA or poly(dA:dT) (0, 20, 100, 250, 500 and 1000 ng/ml), assessed 1 h after 
transfection. *P < 0.01 and **P < 0.001 (two-tailed unpaired t-test). Data are representative of three (a,c,e) or two (b,d,f) independent experiments 
(mean and s.d. of quadruplicate wells).
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B-form double-stranded DNA poly(dA:dT) at a concentration of 
1 Mg/ml required AIM2 but was completely independent of STING 
and STAT1 (Fig. 1e). The transfection of large amounts of DNA 
might overload the system and render it independent of interferon 
signaling. To rule out this possibility, we ‘titrated down’ the amount 
of transfected DNA. The activation of AIM2 remained interferon 
independent even upon the transfection of small quantities of DNA 
(Fig. 1e). These results indicated that basal AIM2 was sufficient 
to initiate inflammasome activation9,13. Indeed, we observed only 
weak induction of Aim2 mRNA following infection with F. novicida 
(Supplementary Fig. 1b).
Finally, we confirmed that F. novicida genomic DNA was as stimu-
latory as synthetic DNA by transfecting increasing amounts of each 
into macrophages that had been primed with the synthetic lipopeptide 
Pam3CSK4 to induce expression of pro-IL-1B. Both types of DNA 
triggered similar cell death and release of IL-1B (Fig. 1f), which excluded 
the possibility that F. novicida DNA had properties that allowed it to 
evade recognition by AIM2. Together these results indicated that one 
(or several) IFN-B- or IFN-G-inducible gene(s) was (were) needed 
to activate AIM2 specifically during bacterial infection.
Identification of the GBP family by genetic screening
To identify ISGs encoding products involved in F. novicida–mediated 
activation of the AIM2 inflammasome, we screened BMDMs by 
RNA-mediated interference with small interfering RNA (siRNA). 
We selected 443 genes with at least twofold higher expression in 
F. novicida–infected wild-type macrophages than in F. novicida– 
infected Ifnar1−/− macrophages17 and selected 40 additional genes 
on the basis of published reports9,10,17,18 (data not shown and 
Supplementary Table 1). At 48 h after transfection of siRNA specific 
for those genes, we infected macrophages with F. novicida and moni-
tored inflammasome activation by measuring the release of IL-1B 
and incorporation of propidium iodide (as a measure of cell death). 
Knockdown of most of the 483 genes did not substantially affect the 
release of IL-1B or cell death (Fig. 2a). In contrast, knockdown of Gbp2 
or Gbp5 resulted in much less F. novicida–mediated release of IL-1B 
and macrophage death than that of cells treated with nontargeting 
siRNA, while knockdown of other GBP-encoding genes showed no 
comparable effect (Fig. 2a). Gbp2 and Gbp5 had the highest expres-
sion among the GBP-encoding genes in macrophages and were sub-
stantially and specifically induced upon infection with wild-type 
F. novicida in a STING- and IFNAR-dependent manner but independ-
ently of Toll-like receptor 2 and MyD88 (Fig. 2b and Supplementary 
Fig. 1c–e). We confirmed by RT-PCR the efficiency of siRNA- 
mediated knockdown of GBP-encoding genes expressed during 
infection with F. novicida (Supplementary Fig. 2a). We next 
confirmed the screening results by knocking down all 11 mouse 
GBP-encoding genes individually and measuring cell death and IL-1B 
release (Fig. 2c). Knockdown of Gbp2 and Gbp5 specifically decreased 
the F. novicida–mediated release of IL-1B and cell death, as assessed 
by two different techniques (Fig. 2c and Supplementary Fig. 2b). 
In conclusion, our screening approach identified GBP2 and GBP5 
as two possible ISG products that controlled the activation of AIM2 
during infection with F. novicida.
AIM2 activation requires GBP-encoding genes on chromosome 3
To confirm our screening data, we obtained macrophages from 
wild-type mice, mice deficient in both caspase-1 and caspase-11 
(Casp1−/−Casp4−/−; called ‘Casp1−/−Casp11−/−’ here) or mice that lack 
the locus on chromosome 3 encoding GBP1, GBP2, GBP3, GBP5 
and GBP7 (called ‘Gbpchr3’ here)23 and infected naive or primed 
macrophages with F. novicida. Consistent with defective activation 
of the AIM2 inflammasome, Gbpchr3-deficient BMDMs displayed a 
significant reduction in cell death and cytokine release and had a 
diminished abundance of processed caspase-1 p20 compared with 
that of their wild-type counterparts, even though their expression of 
pro-caspase-1, ASC and AIM2 protein was similar to that of wild-type 
cells (Fig. 3a,b and Supplementary Fig. 3a). Measuring the incorpo-
ration of propidium iodide in real time following infection showed 
that Gbpchr3-deficient BMDMs died with delayed kinetics compared 
with that of wild-type cells and similar to that of Ifnar1−/− BMDMs 
(Supplementary Fig. 3b). To determine if GBPs encoded by genes on 
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Figure 2 Screening by RNA-mediated interference identifies members of the GBP family as activators of AIM2. (a) Screening results for wild-type 
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chromosome 3 were directly involved in the activation of AIM2, we 
engaged AIM2 by transfecting synthetic DNA into unprimed wild-
type and Gbpchr3-deficient macrophages. Cytosolic DNA triggered 
LDH release to a similar extent in both groups of cells, even when 
the amount of transfected DNA was ‘titrated down’ (Fig. 3c). Wild-
type, Gbpchr3-deficient and Ifnar1−/− cells also responded similarly 
to the transfection of purified F. novicida genomic DNA (Fig. 3d). 
Thus, GBPs were not required in the context of DNA transfection, 
which suggested that they functioned upstream of AIM2-mediated 
DNA detection.
GBP2 and GBP5 direct parallel pathways of AIM2 activation
Since our screening data suggested that mainly GBP2 and GBP5 were 
required for the activation of AIM2 (Fig. 2a), we infected BMDMs 
from wild-type, Casp1−/−Casp11−/−, Gbpchr3-deficient, Gbp2−/− or 
Gbp5−/− mice with F. novicida and measured activation of the AIM2 
inflammasome. Gbp2−/− BMDMs displayed less death and cytokine 
release than did wild-type BMDMs (Fig. 4a,b). Similarly, Gbp5−/− 
BMDMs also displayed attenuated inflammasome activation when 
infected with F. novicida relative to that of their wild-type counterparts 
(Fig. 4a,b). Deficiency in Gbp2 or Gbp5 did not affect cell death in 
response to DNA transfection, even when we used very small amounts 
of DNA (Fig. 4c). To determine if expression of GBP2 or GBP5 could 
restore activation of the AIM2 inflammasome in Ifnar1−/− cells, we 
retrovirally transduced macrophages with constructs expressing GBP2 
or GBP5 or with an empty vector (control) and infected them with 
F. novicida. Such ectopic expression was not able to complement the 
deficiency in inflammasome activation (Supplementary Fig. 4a–c), 
which suggested that other products of ISGs might be required for 
the function of GBP2 and GBP5, in line with data showing that 
GBPs are active and correctly targeted only in the context of the 
interferon response25.
Single deficiency in Gbp2 or Gbp5 did not reduce the activation of 
AIM2 during infection with F. novicida as much as Gbpchr3 deficiency 
did (Fig. 4a,b), which suggested that GBP2 and GBP5 promoted acti-
vation of AIM2 through independent pathways. To investigate whether 
GBP2 and GBP5 acted sequentially or in parallel, we knocked down 
Gbp2 expression in wild-type, Gbp2−/− and Gbp5−/− BMDMs (control 
Figure 3 Macrophages from Gbpchr3-deficient 
mice have deficient activation of AIM2 in 
response to F. novicida. (a) Release of LDH and 
IL-1B from naive or IFN-G-primed wild-type,  
Gbpchr3-deficient (Gbpchr3-KO) and  
Casp1−/−Casp11−/− BMDMs 8 h after infection 
with wild-type F. novicida strain U112.  
(b) Immunoblot analysis of cleaved caspase-1  
(p20) and IL-18 (p19) in culture supernatants  
(Sup), and of GBP2, GBP5, pro-caspase-1  
(Pro-Casp1), pro-IL-18, pro-IL-1B, ASC and  
B-actin (loading control) in extracts (Extract),  
of wild-type and Gbpchr3-deficient BMDMs  
primed with LPS, IFN-B or IFN-G (below blots)  
and then infected with wild-type F. novicida  
strain U112, assessed 8 h after infection.  
(c) Release of LDH from wild-type and Gbpchr3-
deficient BMDMs 8 h after transfection of 
increasing concentrations (wedges) of poly(dA:dT) or poly(dG:dC) (0.25, 0.5 or 1 Mg/ml). (d) Release of LDH from wild-type, Gbpchr3-KO and Ifnar1−/− 
BMDMs 8 h after transfection of increasing concentrations (wedges) of F. novicida genomic DNA (0.1, 0.25, 0.5 or 1 Mg/ml). *P < 0.001 (two-tailed 
unpaired t-test). Data are representative of six (a) three (b,c) or two (d) independent experiments (mean and s.d. of quadruplicate wells in a,c,d).
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Figure 4 GBP2 and GBP5 independently control activation of AIM2  
during infection with F. novicida. (a,b) Release of LDH (a) and  
IL-1B (b) from naive or IFN-G-primed wild-type, Casp1−/−Casp11−/−,  
Gbp2−/−, Gbp5−/− and Gbpchr3-deficient BMDMs 6 h after infection  
with wild-type F. novicida strain U112. (c) Release of LDH from  
naive wild-type, Gbpchr3-deficient, Gbp2−/− and Gbp5−/− BMDMs  
transfected with increasing concentrations (wedges) of poly(dA:dT)  
(0.1, 0.25, 0.5 or 1 Mg/ml). (d) Release of LDH and IL-1B from  
naive wild-type, Gbp2−/− and Gbp5−/− BMDMs treated with  
nontargeting control siRNA or siRNA specific for the gene encoding GBP2 or GBP5 (horizontal axis), then, 22 h later, infected with wild-type F. novicida 
U112, assessed 8 h after infection. *P < 0.05, **P < 0.01 and ***P < 0.001 (two-tailed unpaired t-test). Data are representative of four (a,b), three (c) 
or two (d) independent experiments (mean and s.d. of quadruplicate wells).
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of siRNA knockdown efficacy, Supplementary Fig. 4d) and measured 
inflammasome activation after infection with F. novicida. Knockdown 
of Gbp2 reduced cell death and release of IL-1B in wild-type 
BMDMs but not in Gbp2-deficient BMDMs (Fig. 4d). Treatment 
with Gbp2-specific siRNA also significantly reduced inflammasome 
activation in Gbp5−/− BMDMs (Fig. 4d), which demonstrated that 
in Gbp5-deficient cells, GBP2 was still active and was able to pro-
mote activation of AIM2. Consistent with that, knockdown of Gbp5 
reduced activation of the inflammasome in both wild-type BMDMs 
and Gbp2−/− BMDMs (Fig. 4d). In conclusion, our data suggested 
that the interferon-inducible GTPases GBP2 and GBP5 controlled 
non-redundant, parallel pathways that promoted activation of AIM2 
during infection with F. novicida.
Escape of F. novicida from phagosomes is GBP independent
Since cytosolic localization of F. novicida is required for the activa-
tion of AIM2 and since GBPs promote the destabilization of phago-
somes and/or pathogen-containing vacuoles of protozoan parasites or 
bacteria23,27,29, we speculated that GBPs might facilitate the escape of 
F. novicida from phagosomes. We used a phagosome-protection 
assay29,30 based on selective permeabilization of the plasma membrane 
with digitonin to assay the escape of F. novicida from phagosomes. As 
reported before30, we observed that 90–95% of wild-type F. novicida  
escaped from phagosomes within a few hours of infection, but this 
frequency was similar for wild-type BMDMs and Gbpchr3-deficient 
BMDMs at various time points after infection (Fig. 5a). In contrast, 
$FPI F. novicida remained in the phagosome (data not shown).
F. novicida is naturally resistant to B-lactam antibiotics and secrete 
the B-lactamase FTN_1072. Taking advantage of this, we developed 
an alternative assay to detect cytosolic bacteria based on cleavage of 
the FRET (Förster resonance energy transfer) reporter probe CCF4 by 
FTN_1072, which leads to a loss of FRET activity31,32 (Supplementary 
Fig. 5). We preloaded wild-type, Gbp2−/− and Gbpchr3-deficient 
BMDMs with CCF4-AM, the membrane-permeable form of the 
reporter, and subsequently infected the cells with wild-type F. novicida, 
an FTN_1072-deficient strain (the B-lactamase mutant $bla) or the 
$FPI mutant. We observed no difference among wild-type, Gbp2−/− or 
Gbpchr3-deficient BMDMs in terms of FRET activity after infection with 
wild-type F. novicida (Fig. 5b and Supplementary Fig. 5). The $FPI 
and $bla mutant strains did not produce any significant FRET signals, 
similar to the signaling of uninfected macrophages (Supplementary 
Fig. 5). Thus, we concluded that GBPs did not control the activation of 
AIM2 by promoting the escape of F. novicida from phagosomes but that 
they were active after F. novicida reached the cytosol. This was consist-
ent with our data showing that in unprimed cells, F. novicida–induced 
expression of GBP-encoding mRNA was dependent on the FPI and on 
the escape from phagosomes (Fig. 2b) and that cytosolic recognition 
was required for interferon induction (Supplementary Fig. 1a).
GBPs promote cytosolic lysis of F. novicida
To identify the mechanism by which GBPs controlled the activation of 
AIM2 during infection with F. novicida, we investigated the subcellular 
localization of GBPs in infected cells. GBPs are known to co-localize 
with vacuolar pathogens such as S. typhimurium, M. bovis bacillus 
Calmette-Guérin and T. gondii, consistent with the ability of GBPs 
to recruit anti-microbial effector mechanisms to the pathogen and 
to destabilize PCVs24,27,29. We observed that both GBP2 and GBP5 
were targeted to intracellular F. novicida (Fig. 6a). Closer examination 
of GBP-positive F. novicida revealed that GBPs localized to different 
spots close to or onto the surface of the bacterium (data not shown). 
However, it was unclear if GBPs targeted the bacterium directly or 
targeted remnants of the host membrane (i.e., lysed phagosomes) or 
another closely associated membrane compartment.
Since the irregular shape of GBP-positive bacteria suggested 
that they were lysed, we next determined if wild-type and Gbpchr3-
deficient cells differed in the abundance of lysed intracellular 
F. novicida. Viable and lysed intracellular bacteria can be quantified 
on the basis of propidium iodide staining, since intact bacteria remain 
protected from the influx of propidium iodide33 (Fig. 6b). We tested 
the assay by quantifying lysed bacteria in wild-type BMDMs infected 
with wild-type F. novicida or an F. novicida mutant in which the 
gene encoding the outer membrane protein FopA is deleted ($fopA) 
and thus it has lower membrane stability that results in increased 
intracellular lysis and hyperactivation of the AIM2 inflammasome15. 
We detected significantly larger amounts of propidium iodide– 
positive $fopA F. novicida than wild-type F. novicida (Fig. 6c), which 
confirmed the validity of our assay. We next compared the frequency 
of lysed bacteria in wild-type and Gbpchr3-deficient macrophages. 
The Gbpchr3-deficient BMDMs had a significantly lower frequency 
of lysed bacteria (positive for staining with antibodies to F. novicida 
and propidium iodide) (23% on average) than the wild-type BMDMs 
had (40% on average) (Fig. 6c).
The macromolecular inflammasome complex known as the ‘ASC 
speck’ assembles on genomic DNA released from lysed cytosolic 
F. novicida10. Immunofluorescence analysis revealed mostly irreg-
ularly shaped F. novicida in the vicinity of ASC specks (Fig. 6d). 
These bacteria released DNA and were often also positive for GBP 
staining (Fig. 6d and Supplementary Fig. 6). Consistent with that, 
the number of ASC speck-containing cells was significantly lower 
in GBP-deficient (Gbp2−/−, Gbp5−/− or Gbpchr3-deficient) BMDMs 
than in wild-type BMDMs (Fig. 6e). In conclusion, these findings 
indicated that GBPs associated with cytosolic F. novicida and, by an 
as-yet-undefined mechanism, induced lysis of the bacterium, which 
resulted in DNA release and detection by the cytosolic DNA sensor 
AIM2, followed by oligomerization of ASC.
GBPs control F. novicida replication
Inflammasome-induced cell death (pyroptosis) restricts intra-
cellular bacteria by removing their replicative niche and reexposing 
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them to extracellular immunological mechanisms34. Cell-autonomous 
immunity, on the other hand, relies on cell-intrinsic mechanisms 
to restrict bacterial growth without the need for killing the host 
cell21. To determine whether GBPs restricted F. novicida growth 
through cell-autonomous mechanisms or inflammasome-dependent 
mechanisms, we infected wild-type, Aim2−/−, Gbpchr3-deficient 
and Ifnar1−/− BMDMs with wild-type F. novicida expressing green 
fluorescent protein (GFP) and used flow cytometry to quantify 
infected cells (more than two bacteria per cell, our specific 
fluorescence-detection threshold) among the live cell population. We 
observed a significantly higher percentage of live infected Aim2−/−, 
Gbpchr3-deficient and Ifnar1−/− BMDMs than live infected wild-
type BMDMs (Fig. 7a). This suggested that deficiency in Ifnar1 or 
Gbpchr3, similar to deficiency in Aim2, resulted in a reduction in 
inflammasome-mediated killing of host cells upon infection.
Cell-autonomous growth restriction is an interferon-induced 
mechanism that is at least partially independent of inflammasome-
mediated cell death35,36. Therefore, we next determined if Gbpchr3-
deficient BMDMs and Ifnar1-deficient BMDMs also had a defect 
in restricting intracellular bacterial replication. We infected mac-
rophages with GFP+ F. novicida and quantified bacteria (per cell) 
by both automated microscopy in flow and microscopy at various 
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Figure 7 GBPs restrict the intracellular replication 
of F. novicida. (a) Flow cytometry–based 
quantification of infected (GFP+) cells among 
live wild-type, Aim2−/−, Gbpchr3-deficient and 
Ifnar1−/− BMDMs 12 h after infection with GFP-
expressing wild-type F. novicida at a multiplicity  
of infection (MOI) of 1 (top) or 10 (bottom).  
*P < 0.001 (two-tailed unpaired t-test).  
(b) Quantification of bacterial loads in single cells 
among wild-type, Aim2−/−, Gbpchr3-deficient and 
Ifnar1−/− BMDMs 12 h after infection with GFP-
expressing wild-type F. novicida at a multiplicity 
of infection of 10, assessed by high-resolution 
microscopy in flow and presented as a comparison 
of all four genotypes (top left) or a comparison 
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representative of three independent experiments 
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time points after infection. Wild-type macrophages efficiently 
controlled intracellular replication, but Aim2−/− BMDMs contained 
large numbers of intracellular F. novicida (30 or more per cell) 
(Fig. 7b and Supplementary Fig. 7a,b), consistent with a loss of 
inflammasome-mediated killing of host cells. Bacterial loads were even 
higher in Gbpchr3-deficient or Ifnar1-deficient BMDMs, with many cells 
containing up to 100 bacteria (Fig. 7b and Supplementary Fig. 7a,b). 
The production of reactive oxygen species and nitric oxide is a potent 
cell-intrinsic anti-microbial mechanism that can also be activated in 
an interferon-dependent manner. GBP7 has been shown to recruit 
subunits of the NADPH oxidase to intracellular L. monocytogenes  
and M. bovis bacillus Calmette-Guérin24, and inducible nitric oxide 
synthase can restrict bacterial growth in a cell-intrinsic manner21. 
However, deficiency in these mechanisms achieved through the use 
of BMDMs deficient in both inducible nitric oxide synthase and 
Nox2 did not significantly alter bacteriolysis and inflammasome 
activation after infection with F. novicida (P = 0.3081, P = 0.2786 and 
P = 0.0529; Supplementary Fig. 8a,b). Overall, these data indicated 
that GBPs encoded by the locus on chromosome 3 participated in 
growth restriction in two ways: directly, by promoting the lysis of 
intracellular bacteria by an as-yet-unknown mechanism; and indi-
rectly, by promoting the inflammasome-mediated killing of host cells, 
thereby removing the intracellular replicative niche of F. novicida.
GBPs control F. novicida replication in vivo
AIM2, ASC and caspase-1 control the replication of F. novicida in vivo 
in mice9,10,37. Since GBPs are required for inflammasome activation 
in vitro, we investigated whether these proteins also have a physiologi-
cal role in host defense. We infected age- and sex-matched wild-type, 
Casp1−/−Casp11−/−, Gbp2−/− and Gbpchr3-deficient mice subcutane-
ously with 5 × 103 colony-forming units of wild-type F. novicida strain 
U112 and measured the bacterial burden in the liver and spleen at 
2 d after infection. As published before37, Casp1−/−Casp11−/− mice 
displayed a significantly higher bacterial burden in the liver and 
spleen than that of wild-type mice (Fig. 8a). Similarly, Gbp2−/− and 
Gbpchr3-deficient mice showed higher bacterial counts than wild-
type mice, similar to or even higher than those of Casp1−/−Casp11−/− 
mice (Fig. 8a). Consistent with diminished inflammasome activa-
tion in vivo, we detected a significantly lower serum concentration 
of IL-18 in Casp1−/−Casp11−/−, Gbp2−/− and Gbpchr3-deficient mice 
than in wild-type mice (Fig. 8b). To further assess the effects of GBP 
deficiency in vivo, we analyzed survival. Within 4 d of infection, all 
Casp1−/−Casp11−/−, Gbp2−/− and Gbpchr3-deficient mice died, while 
most wild-type mice survived until the end of the experiment (day 10) 
(Fig. 8c). These results confirmed the relevance of our in vitro data 
and demonstrated that GBPs encoded by the locus on chromosome 3 
were important for inflammasome activation and host defense against 
F. novicida in vivo.
DISCUSSION
Since the activation of AIM2 during infection with the cytosolic path-
ogen F. novicida required interferon signaling, we investigated the role 
of the products of ISGs in this process. Our results showed that the 
interferon-inducible GTPases GBP2 and GBP5 promoted F. novicida– 
mediated activation of the AIM2 inflammasome but were dispensa-
ble for the activation of AIM2 upon transfection of DNA. Members 
of the GBP family take part in interferon-induced cell-autonomous 
immunity and are known to induce disruption of the PCVs of vacuolar 
bacteria and parasites23,27,29. However, the cytosolic localization of 
F. novicida was similar in wild-type and Gbpchr3-deficient cells, which 
indicated that GBPs must have been involved later during infection, 
after the bacteria had entered the cytosol. This was consistent with 
results showing that the escape from phagosomes is an interferon-
independent process36 and that cytosolic localization of F. novicida 
is a prerequisite for interferon induction17. Since the activation of 
AIM2 during infection with F. novicida or L. monocytogenes is known 
to require cytosolic bacteriolysis12,15, we investigated whether GBPs 
controlled the bacteriolysis and replication of F. novicida in the cytosol. 
Significantly fewer lysed and more overall F. novicida were present in 
cells deficient in GBP-encoding genes or Ifnar1 than in wild-type cells, 
which indicated that GBPs were required for interferon-mediated cell-
autonomous immunity to the pathogen. Furthermore, our results 
demonstrated that in addition to their known function in destabilizing 
PCVs, GBPs can also promote the lysis of cytosolic bacteria.
GBPs are also critical for the cytosolic recognition of LPS and for 
activation of the caspase-11 inflammasome pathway. In this context, 
they act by promoting the release of vacuolar S. typhimurium into the 
cytosol or by promoting activation of caspase-11 during infection with 
L. pneumophila29,38. At present, no model fully explains how GBPs 
restrict pathogen growth during infection with microbes or protozoa 
Figure 8 GBPs control host defense against  
F. novicida in vivo. (a) Bacterial burden  
(as colony-forming units (CFU) of F. novicida 
(FN) per gram tissue) in the liver and spleen  
at day 2 after subcutaneous infection of  
wild-type, Casp1−/−Casp11−/−, Gbp2−/− and 
Gbpchr3-deficient mice with 5 × 103 wild-type  
F. novicida. Each symbol represents an 
individual mouse (n = 8 (wild-type),  
10 (Casp1−/−Casp11−/−), 7 (Gbp2−/−) and  
10 (Gbpchr3-deficient) (spleen), or n = 8  
(wild-type), 13 (Casp1−/−Casp11−/−),  
8 (Gbp2−/−) and 9 (Gbpchr3-deficient) (liver)); 
small horizontal lines indicate the mean.  
*P < 0.05, **P < 0.01 and ***P < 0.001 
(Mann-Whitney test). (b) IL-18 in serum 
obtained from wild-type mice (n = 12),  
Casp1−/−Casp11−/− mice (n = 11), Gbp2−/− mice 
(n = 12) and Gbpchr3-deficient mice (n = 14)  
16 h after subcutaneous infection with 1.5 × 105 wild-type F. novicida. *P < 0.01 and **P < 0.001 (Mann-Whitney test). (c) Survival of wild-type, 
Casp1−/−Casp11−/−, Gbp2−/− and Gbpchr3-deficient mice (n = 10 per genotype) after subcutaneous infection with 5 × 103 wild-type F. novicida.  
P < 0.0001, wild-type versus Casp1−/−Casp11−/− or wild-type versus Gbpchr3-deficient, and P = 0.0005, wild-type versus Gbp2−/− (log-rank (Mantel-Cox)  
test). Data are representative of two independent experiments (a,c) or are pooled from two individual experiments (b; with 10th–90th percentiles).
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and at the same time control inflammasome signaling. It is, however, 
conceivable that the membrane-destabilizing activity of GBPs in com-
bination with their bacteriolytic activity could not only result in the 
entry of bacteria into the cytosol but also release microbe-associated 
molecular patterns (for example, LPS and DNA) directly. Such a model 
might explain their effect on both the caspase-11 pathway38 and the 
AIM2 pathway in response to cytosolic bacteria. Thus, bacteriolysis 
would also release F. novicida LPS into the cytosol. However, since 
F. novicida LPS is tetra-acylated, it does not trigger caspase-11 
activation39. Conversely, we would expect GBPs to lyse cytosolic 
Salmonella or Legionella, which would result in activation of AIM2. 
But in this case, activation of AIM2 is most probably masked by a high 
degree of caspase-11-dependent cell death and cytokine release.
GBP-mediated bacteriolysis might also be expected to release 
DNA and amplify the production of type I interferons via STING. 
Notably, what triggers initial STING signaling and the induction of 
GBP-encoding genes during infection with F. novicida is still unde-
fined, but two possibilities exist. One is the direct activation of STING 
via a secreted bacterial cyclic nucleotide, analogous to infection with 
L. monocytogenes40, and another is activation of the DNA sensor 
cGAS by F. novicida DNA and subsequent production of the cyclic 
dinucleotide cGAMP41,42. Lysis of F. novicida within the phagosome 
followed by translocation of its DNA into the cytosol could trigger 
interferon production9. Alternatively, low levels of F. novicida extra-
cellular DNA could reach the cytosol by sticking to the surface of the 
infecting bacteria, as suggested for infection with M. tuberculosis43. 
Finally, small amounts of spontaneous bacteriolysis might occur in 
the host-cell cytosol. If DNA indeed triggers initial STING-mediated 
production of interferons, it remains to be shown why it is insufficient 
to trigger activation of AIM2. Additional experiments are needed to 
determine the relative DNA-binding affinities of cGAS and AIM2 and 
how their signaling hierarchy is controlled.
Our results have revealed an underappreciated, close connection 
between cell-autonomous immunity and recognition by the innate 
immune system. The attack of GBPs on PCVs or pathogens liberates 
microbe-associated molecular patterns and thus ensures subsequent 
immunological recognition of the pathogen, which explains the role 
of interferon signaling in the detection of bacterial DNA by AIM2 
or LPS from vacuolar bacteria by the caspase-11 pathway9,10,13,44,45. 
Additional questions remain, such as how GBP targeting is regulated 
and how GBPs act mechanistically. Ectopic expression of GBP2 or 
GBP5 did not ‘rescue’ the inflammasome deficiency of Ifnar1−/− cells, 
which suggests that other products of ISGs are necessary for proper 
targeting and activity of GBPs24,25. Indeed, members of the IRGM 
family, a subclass of the immunity-related GTPases, can act as guanine-
 dissociation inhibitors and control the targeting of both immunity-
related GTPases and GBPs to pathogen-containing vacuoles, yet the 
molecular mechanism of this is still unclear46–49. Additional biochemi-
cal studies are needed to define the mechanism of GBP targeting and 
action during bacterial infection and how this promotes the exposure 
of bacterial ligands to cytosolic recognition pathways.
METHODS
Methods and any associated references are available in the online 
version of the paper.
Note: Any Supplementary Information and Source Data files are available in the 
online version of the paper.
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ONLINE METHODS
Bacterial strains and plasmids. F. novicida strain U112 and isogenic $FPI 
mutants have been published10. Where applicable, strains were transformed 
with the plasmid pKK219-GFP (Supplementary Table 2). The B-lactamase 
mutant $bla was generated by PCR-mediated homologous recombination 
with a kanamycin selection cassette through use of the following primers 
(upper case indicates F. novicida sequence; lower case indicates the 
 kanamycin-resistance casette sequence): ForUpstream, GTCGAGTACGCT
AATATAAAAATTCTAAAAA; RevUpstream, gcttatcgataccgtcgacctcGGGA 
TTAATGATAAAGTTGTAACTAATATACGC; ForDownstream, gatatcgat 
cctgcagctatgcCACTTATAAATAAGCGGTACGCCAC; and RevDownstream, 
AAGACGGTGATGTACCATTTGTCTATAG. The kanamycin-resistance 
casette was removed by transformation of the mutant obtained with the ther-
mosensitive plasmid pFFlp (provided by L. Gallagher and C. Manoil) encod-
ing the recombinase Flp. Following loss of the plasmid, genomic deletion was 
verified by sequencing.
Mice. Gbpchr3-deficient, Gbp2−/−, Gbp5−/−, Nos2−/−Cybb−/−, Casp1−/−Casp11−/− 
(‘caspase-1-knockout’), Asc−/−, Aim2−/−, Stat1−/−, Ifnar1−/−, StingGt/Gt, Tlr2−/− 
and Myd88−/− mice have been described3,10,23,27,29,44. Mice were bred in 
the animal facilities of the University of Basel or at the Plateau De Biologie 
Expérimentale De La Souris.
Animal infection. All animal experiments were approved (license 2535, 
Kantonales Veterinäramt Basel-Stadt and ENS_2012_061) and were per-
formed according to local guidelines (Tierschutz-Verordnung, Basel-Stadt and 
CECCAPP, Lyon) and the Swiss animal protection law (Tierschutz-Gesetz). 
Age- and sex-matched mice (8–10 weeks of age) were infected subcutaneously 
with 5 × 103 or 1.5 × 105 colony-forming units of stationary-phase wild-type 
F. novicida strain U112 in 50 Ml PBS. Mice were killed at the appropriate time 
point after infection. No randomization or ‘blinding’ of researchers to sample 
identity was used.
Cell culture and infection. BMDMs were differentiated in DMEM (Invitrogen) 
with 10% vol/vol FCS (Thermo Fisher Scientific), 10% MCSF (supernatants 
of L929 mouse fibroblasts), 10 mM HEPES (Invitrogen) and nonessential 
amino acids (Invitrogen). 1 d before infection, macrophages were seeded into 
6-, 24- or 96-well plates at a density of 1.25 × 106, 2.5 × 105 or 5 × 104 cells 
per well. Where required, macrophages were pre-stimulated with Pam3CSK4 
(tripalmitoyl cysteinyl seryl tetralysine), LPS (from Escherichia coli strain 
O111:B4 (InvivoGen)), mouse IFN-B or mouse IFN-G  (eBioscience). For infec-
tion with F. novicida, bacteria were grown overnight at 37 °C with aeration in 
brain-heart–infusion medium or tryptic soy broth. The bacteria were added to 
the macrophages at a multiplicity of infection of 100 or the appropriate value. 
The plates were centrifuged for 15 min at 500g to ensure similar adhesion of 
the bacteria to the cells and were incubated for 120 min at 37 °C. Next, cells 
were washed and fresh medium with 10 Mg/ml gentamycin (Invitrogen) was 
added to kill extracellular bacteria, then plates were incubated for the desired 
length of time. Transfection with poly(dA:dT) or poly(dG:dC) was done as 
described29 or as indicated in the figures and legends (Figs. 1 and 3).
siRNA-mediated knockdown. Genes were knocked down with GenMute 
(SignaGen Laboratories) and siRNA pools (siGenome; Dharmacon). Wild-
type BMDMs were seeded into 24- or 96-well plates at a density of 1.5 × 105 
or 3 × 104 cells per well. siRNA complexes were prepared at a concentration 
of 25 nM siRNA in GenMute Buffer according to the manufacturer’s instruc-
tions for forward knockdown (SignaGen laboratories). siRNA complexes were 
mixed with BMDM medium (described above) and were added onto the cells. 
After 22–48 h of gene knockdown, BMDMs were infected with F. novicida at a 
multiplicity of infection of 100:1 and were analyzed for inflammasome activa-
tion as outlined below. siRNA pools targeted the following genes (numbers 
in parentheses indicate Dharmacon reference): Aim2 (M-044968-01), Casp11 
(that is, Casp4) (M-042432-01), Gbp1 (M-040198-01), Gbp2 (M-040199-00), 
Gbp3 (M-063076-01), Gbp4 (M-047506-01), Gbp5 (M-054703-01), Gbp6 
(M-041286-01), Gbp7 (M- 061204-01), Gbp8 (M-059726-01), Gbp9 
(M-052281-01), Gbp10 (M-073912-00), Gbp11 (M-079932-00) and NT (non-
targeting) pool 2 (D-001206-14).
siRNA screening. Knockdown of the 483 selected genes was performed as 
described above in the 36 central wells of 96-well plates; this included the 
nontargeting control siRNA and siRNA specific for Asc and Aim2 on each 
plate. Macrophages were infected with F. novicida at a multiplicity of infection 
of 100:1 and, following a wash at 1 h after infection, cells were incubated with 
medium supplemented with propidium iodide at 5 Mg/ml. At 6 h after infec-
tion, the fluorescence of propidium iodide was determined on a plate reader 
(Tecan) and supernatants were collected for analysis of the release of IL-1B 
by enzyme-linked immunosorbent assay (DuoSet; R&D Systems). The fluo-
rescence of propidium iodide and concentration of IL-1B in cells transfected 
with each siRNA were normalized to the average value of the full plate set, set 
as 100, and to the value obtained with Aim2-specific siRNA, set as 0, with the 
following calculation (for gene ‘X’): normalized value obtained with X-specific 
siRNA = (value obtained with X-specific siRNAx − value obtained with 
Aim2-specific siRNA) / (average value obtained with siRNA − value obtained 
with Aim2-specific siRNA). All the siRNA presenting variation of more 
than 50% in either one of the two parameters have been retested two or three 
times. Average normalized values are presented in the display items.
Ectopic expression of GBP2 and GBP5. Mouse Gbp2 and Gbp5 were cloned 
into the lentiviral plasmid TRIP iziE-SSFV-GFP with the following prim-
ers and restriction enzymes (upper case indicates gene sequence; lower case 
indicates restriction site (underlined) and four bases flanking in the 5` direc-
tion): For_mGBP2_AvrII, attacctaggGACATGGCCTCAGAGATCCACATG; 
Rev_mGBP2_EcoRV, aatagataTCAGAGTATAGTGCACTTCCCAGACG; 
For_mGBP5_AvrII, aaatcctagGACATGGCCCCAGAGATTCACATG; and 
Rev_mGBP5_HpaI, atttgttaacTTAGCTTATAACACAGTCATGATGATGT 
CTAC. The production of lentiviruses in 293T human embryonic kidney cells 
and the transduction of primary BMDMs were performed by standard meth-
ods. IFNAR1-deficient macrophages were transduced after 8 d of differentia-
tion by spin-inoculation (1,500g for 2 h at room temperature). Transduced 
macrophages were infected 48 h later. Transduction frequency was determined 
by flow cytometry based on GFP expression. Specific ectopic expression was 
checked by quantitative RT-PCR.
Cytokine and LDH release measurement. IL-1B, IL-18 and tumor-necrosis 
factor were measured by enzyme-linked immunosorbent assay (eBioscience). 
LDH was measured with an LDH Cytotoxicity Detection Kit (Clontech). To 
normalize for spontaneous lysis, the percentage of LDH release was calcu-
lated as follows: (LDH infected − LDH uninfected) / (LDH total lysis − LDH 
uninfected) × 100.
Immunoblot analysis. Immunoblot analysis was done as described29. 
Antibodies used were rat anti–mouse caspase-1 (1:1,000 dilution; 4B4; 
Genentech), rabbit anti-IL-1A (1:1,000 dilution; ab109555; Abcam), rabbit 
anti-IL-18 (1:500 dilution; 5180R; Biovision), goat anti–mouse IL-1B (1:500 
dilution; AF-401-NA; R&D Systems), rabbit anti-GBP2 (1:1,000 dilution; 
11854-1-AP; Proteintech) and rabbit anti-GBP5 (1:1,000 dilution; 13220-1-AP; 
Proteintech). Cell lysates were probed with monoclonal anti-B-actin (1:2,000 
dilution; AC-15; A1978; Sigma). Secondary antibodies were as follows (all 
conjugated to horseradish peroxidase and all at a dilution of 1:3,000): goat anti-
rat (NA935V; GE Healthcare), goat anti-rabbit (G21234; Invitrogen), rabbit 
anti-goat (811620; Invitrogen) and rabbit anti-mouse (816720; Invitrogen).
Real-time PCR. Primers used for mRNA quantification are in Supplementary 
Table 3. Experiments were performed with an iCycler (Bio-Rad) and SYBR 
green (Applied Biosystems) with standard protocols.
Statistical analysis. Prism 5.0a software (GraphPad Software) was used for 
statistical analysis of data. For evaluation of the differences between two 
groups (cell death, cytokine release, flow cytometry, colony-forming units 
and immunofluorescence-based counts), a two-tailed t-test was used. The 
Kolmogorov-Smirnov test was used for comparison of the cell distribu-
tion as determined by ImageStream microscopy in flow. P values were 
adjusted for multiple comparisons with the Bonferroni correction approach. 
Animal experiments were evaluated with the Mann-Whitney or log-rank 
Cox-Mantel test.
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Immunofluorescence. Macrophages were seeded on glass coverslips and were 
infected as described above. At the desired time points, cells were washed 
three times with PBS and were fixed for 15 min at 37 °C with 4% parafor-
maldehyde. Following fixation, coverslips were washed, and the fixative was 
quenched for 10 min at room temperature with 0.1 M glycine. Coverslips were 
stained for 16 h at 4 °C with primary antibodies (identified below), then were 
washed with PBS and then incubated for 1 h at room temperature with the 
appropriate Alexa Fluor–conjugated secondary antibodies (identified below) 
(1:500 dilution; Invitrogen), then were washed with PBS and mounted on 
glass slides with Vectashield containing DAPI (6-diamidino-2-phenylindole; 
Vector Labs). Antibodies used were chicken anti–F. novicida (1:1,000 dilution; 
a gift from D. Monack), rat anti-ASC (1:1,000 dilution; Genentech), rabbit 
anti-GBP2 (1:100 dilution; 11854-1-AP; Proteintech) and rabbit anti-GBP5 
(1:100 dilution; 13220-1-AP; Proteintech). Secondary antibodies used were 
as folllows (all at a dilution of 1:500 and all from Life Technologies): goat anti-
rat coupled to Alexa Fluor 488 (A11006), Alexa Fluor 568 (A11077) or Alexa 
Fluor 633 (A21094); goat anti-rabbit coupled to Alexa Fluor 488 (A11008) or 
Alexa Fluor 568 (A10042); and goat anti-chicken coupled to Alexa Fluor 488 
(A11032), Alexa Fluor 568 (A11047) or Alexa Fluor 633 (A21103). Coverslips 
were imaged on a Zeiss LSM700 or a Leica SP8 at a magnification of ×63 and 
vacuolar versus cytosolic bacteria, total intracellular bacteria or ASC specks 
were quantified as described in the figure legends.
Phagosome protection assay. For quantification of cytoplasmic and vacuolar 
bacteria, macrophages were infected with GFP+ F. novicida as described 
above. At the desired time point, cells were washed with KHM buffer (110 mM 
potassium acetate, 20 mM HEPES and 2 mM MgCl2, pH 7.3), followed 
by incubation for 1 min in KHM buffer with 50 Mg/ml digitonin (Sigma). 
Cells were immediately washed three times with KHM buffer and then were 
stained for 12 min with Texas Red–coupled chicken antibody to F. novicida 
(identified above) in KHM buffer with 2% BSA. Cells were washed with PBS, 
then were fixed and analyzed by microscopy. Controls were included in every 
assay as described29.
Intracellular viability measurement. For measurement of the intracellu-
lar lysis of F. novicida, we adapted a published propidium iodide–staining 
method33. Infected BMDMs were incubated for 12 min at 37 °C with Alexa 
Fluor 488–conjugated mouse antibody to F. novicida (identified above) and 
2.6 MM propidium iodide (Sigma) in KHM buffer (described above) for label-
ing of accessible cytosolic bacteria and compromised bacteria, respectively, 
in permeabilized cells. Cells were fixed and imaged as described above.
CCF4 measurements. Quantification of escape from vacuoles with the 
B-lactamase–CCF4 assay was performed following manufacturer’s instructions 
(Life Technologies). Macrophages seeded onto non-treated plates were 
infected for 1 h as described above, washed and then incubated for 1 h at 
room temperature in CCF4 in the presence of 2.5 mM probenicid (Sigma). 
Live (propidium iodide–negative) cells were used for quantification of cells 
containing cytosolic F. novicida, with excitation at 405 nm and detection at 
450 nm (cleaved CCF4) or 510 nm (intact CCF4).
Flow cytometry. For assessment of bacterial replication by flow cytometry, 
macrophages seeded onto untreated plates were infected as described above 
with GFP-expressing F. novicida strains. At 8 h after infection, cells were 
lifted with trypsin and were immediately analyzed by flow cytometry on a 
FACSCanto II cytometer (BD Biosciences). Dead cells were excluded on the 
basis of staining with propidium iodide.
ImageStream flow cytometry. Macrophages infected with GFP-expressing 
bacteria were fixed in 4% PFA and were analyzed on an ImageStream X Mark II 
(Amnis; EMD-Millipore) with Inspire software, with the extended depth- 
of-field function activated to increase the accuracy of spot counts. Images of 
single cells were analyzed with Ideas software (Amnis; EMD-Millipore) with 
the following steps (each step being confirmed by visualization of at least 20 
single cells). Doublets and debris were excluded by morphological param-
eters (aspect ratio and area in the brightfield channel). Defocused images 
were eliminated by the Gradient RMS function of the brightfield function. 
For spot counts and definition of the mean fluorescence of single bacterium, 
the specific GFP fluorescence signal was defined by application of a mask 
combining an intensity threshold and a spot to cell background ratio (peak) 
function. Automatic spot counts were performed with the mask described 
above. Cells containing a single spot (either a single bacterium or a tight cluster 
of several bacteria) were gated. The area of the specific signal was analyzed in 
single cells on the gated population. For the exclusion of bacterial clusters and 
quantification of the fluorescence of single bacterium, the mean fluorescence 
intensity was calculated on the GFP+ signal covering an area of 1 o 0.5 Mm2 
in 1,599 cells.
Bacteria in single cells were quantified by the automatic spot count 
function or their numbers were calculated based on the fluorescence of single 
bacterium. The quantification was identical for cells containing fewer than 
seven bacteria (R2 > 0.99). For higher intracellular burden, the spot-count 
function largely underestimated the number of bacteria per cell due to 
the difficulty to discriminate bacterial cluster. We thus relied on the specific 
fluorescence of the bacteria within the cells as defined by the mask described 
above and the calculated fluorescence value of single intracellular bacterium 
to quantify bacteria per cell. The mask was applied to at least 10,000 images of 
single cells per sample to extract the specific fluorescence of the intracellular 
bacteria in single cells.np
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Supplementary Figure 1 
Induction of Ifnb, Aim2 or Gbp mRNA in dependence of STING and IFNAR signaling. 
(a) Induction of Ifnb expression from unprimed wild-type (WT), Tlr2–/–, Myd88–/–, Trif–/– and Stinggt/gt bone-marrow derived macrophages 
(BMDMs) following infection with wild-type F. novicida U112 for 6 h. (b–e) Induction of Gbp2, Gbp3, Gbp5 or Aim2 expression from 
unprimed wild-type, Tlr2–/–, Myd88–/–, Ifnar1–/– and Stinggt/gt BMDMs following infection with wild-type F. novicida U112 for 6 h. Graphs 
show mean and s.d. of quadruplicate assays and data are representative of two (b-d) or three (a) independent experiments. 
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Supplementary Figure 2 
Gbp knockdown efficiency and real-time cell death after knock-down of Gbps. 
(a) Induction of the expression of individual Gbps from LPS/IFN-primed wild-type BMDMs treated with Non-Targeting (NT) or the 
indicated gene-specific siRNA for 22 h. Graph shows mean and s.d. of quadruplicate wells. Gbp1, 4, 6/10, 11 were not tested due to 
their low expression (see Fig. 2b). (b) Cell death as measured by propidium iodide (PI) influx in real-time in unprimed wild-type BMDMs 
infected with wild-type F. novicida U112. BMDMs were treated with Non-Targeting (NT) or indicated gene-specific siRNA for 48 h 
before infection. Graphs show mean and s.d. of triplicate assays and data are representative of three• independent experiments. *, 
p<0.05; **, p<0.01; NS, not significant (two-tailed unpaired t-test). 
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Supplementary Figure 3 
Aim2 induction and real-time cell death assay in Gbp-deficient and Ifnar1-deficient cells. 
(a) Induction of Aim2 expression from unprimed wild-type, Gbpchr3-deleted and Ifnar1–/– BMDMs infected with wild-type F. novicida U112 
for 6 h. *, p<0.01; NS, not significant (two-tailed unpaired t-test). (b) Cell death as measured by propidium iodide influx in real-time in 
unprimed wild-type, Gbpchr3-deleted and Ifnar1–/– BMDMs left uninfected (UI) or infected with wild-type F. novicida U112. Graphs show 
mean and s.d. of triplicate assays and data are representative of two (a) and three (b) independent experiments. 
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Supplementary Figure 4 
Ectopic expression of GBPs in Ifnar1–/– cells and efficiency of Gbp2 and Gbp5 knockdown. 
(a–c) Ectopic expression of GBP2 or GBP5 do not complement type-I-IFN receptor deficiency. Ifnar1–/– macrophages were transduced
with lentivirus encoding either GFP only (EV = empty vector) and GFP-GBP2 and GFP-GBP5. 48 h post transduction, macrophages 
were infected with F. novicida at the indicated MOI. IL-1 concentration in the supernatant was determined at 7 h and 10.5 h post
infection (a). Specific ectopic expression was verified by quantifying the Gbp3 (control), Gbp2 and Gbp5 transcript levels. Results are 
expressed as fold induction relative to the transcript level in Ifnar1–/– macrophages transduced with empty vector control (b). Graphs 
show mean and s.d. of triplicate assays. The percentage of transduced cells was determined by flow cytometry based on GFP
expression (c). (d) RT-PCR for Gbp2 and Gbp5 expression from unprimed wild-type, Gbp2–/– and Gbp5–/– BMDMs treated with Non-
Targeting or the indicated gene-specific siRNA for 22 h and infected for 8 h with wild-type F. novicida U112. Graphs show mean and 
s.d. of quadruplicate assays and data are representative of independent two experiments. *, p<0.05; **, p<0.01; NS, not significant
(two-tailed unpaired t-test). ND, not detected. 
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Supplementary Figure 5 
Phagosomal rupture assay using the CCF4/-lactamase system. 
Wild-type, Ifnar1–/– and Gbpchr3-deleted BMDMs were primed for 16 h with IFN- (500 units/ml), infected for 1 h with wild-type F. novicida
(FN) U112, a -lactamase-deficient mutant (bla) or a FPI mutant and loaded with CCF4-AM for 1 h before analysis by flow cytometry. 
Phagosomal rupture is associated with -lactamase (encoded by FTN_1072) release into the cytosol and cleavage of the CCF4
substrate (maximum emission at 520 nm) into a product which emits with a maximum of fluorescence at 447 nm. FACS plots show
pooled data from three independent samples and representative of three independent experiments. Live cells (propidium iodide
negative) are shown. 
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Supplementary Figure 6 
GBPs co-localize with irregularly shaped bacteria next to ASC specks. 
Wild-type BMDMs infected with wild-type F. novicida for 8 h, stained for DNA (DAPI), GBP2, F. novicida and ASC. Scale bars: 10 m. 
Data are representative of three• independent experiments. 
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Supplementary Figure 7 
Analysis of bacterial replication in infected macrophages. 
(a) Quantification of bacterial loads in single cells by high-resolution microscopy in flow over time. Wild-type BMDMs were left 
uninfected or infected with GFP+-wild-type F. novicida or a FPI mutant at an MOI of 10 for 0-12 h, fixed and analyzed by 
ImageStreamTM microscopy in flow. Each bar corresponds to the number of cells with the indicated numbers of bacteria per cell grouped 
by increments of 5... Wild-type UI vs. wild-type MOI 10 3h p>0.9999, wild-type UI vs. wild-type MOI 10 6h p>0.9999, wild-type UI vs. 
wild-type MOI 10 9h p<0.0001, wild-type UI vs. wild-type MOI 10 12h p<0.0001, wild-type MOI 10 12h vs. FPI MOI 10 12h p<0.0001 
Kolmogorov-Smirnov test with Bonferroni correction). (b) Quantification of bacterial loads as determined by microscopy. Wild-type, 
Aim2–/–, Gbpchr3-deleted and Ifnar1–/– BMDMs were infected with GFP+-wild-type F. novicida at an MOI of 10 for 16 h, fixed and analyzed 
by confocal microscopy. Graph show pooled data from 2 independent experiments (n>1000 bacteria counted). *, p<0.05; **, p<0.01;
***, p<0.001 (two-tailed unpaired t-test). 
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Supplementary Figure 8 
Bacteriolysis and cell death during F. novicida infection are independent of ROS or NO production. 
(a) Quantification of lysed (propidium iodide+ F. novicida) in IFN--primed wild-type and Nos2–/–/Cybb–/–BMDMs infected for 8 h with wild-
type F. novicida. Imaging of lysed (propidium iodide+) F. novicida in IFN--primed wild-type and Nos2–/–/Cybb–/–BMDMs infected for 8 h 
with wild-type F. novicida. Arrowheads indicate region in insets. Scale bars 10 m. (b) LDH release from naïve or IFN--primed wild-
type and Nos2–/–/Cybb–/– BMDMs infected for 8 h with wild-type F. novicida U112. Graphs show mean and s.d. of quadruplicate wells 
and data are representative of three• independent experiments. NS, not significant (two-tailed unpaired t-test). 
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Supplementary Table 2 Bacterial strains and plasmid used in this study. 
   Name Parental strain Characteristic 
wild-type  
F. novicida U112 _ _ 
∆FPI 
wild-type  
F. novicida U112 ∆FTN_1309-1325::Kan 
∆bla 
wild-type  
F. novicida U112 ∆FTN_1072 
∆fopA 
wild-type  
F. novicida U112 fopA::T20 
pKK219-GFP  _ 
GFP expressing 
plasmid 
 
Supplementary Table 3 | Primers used for qRT-PCR. Target gene, sequence and 
size of amplicon are indicated. 
Target 
gene Forward primer Reverse primer 
Amplicon 
(bp) 
mGBP1 aataagctggctggaaagca tgtgtgagactgcacagtgg 60 
mGBP2 accagctgcactatgtgacg tcagaagtgacgggttttcc 172 
mGBP3 gtctggagaacgcagtgaca gtgctccatgaagacagcaa 182 
mGBP4 gagcagctcatcaaagacca ttcctcacggaaagtcttttg 72 
mGBP5 ccagagtaaagcggaacaag gtgcaactcttgccttctcc 158 
mGBP6/10 tggagcagctgcattatgtc gcattctgggtttgtcacct 228 
mGBP7 aacagcatgagcaccatcaa gaagtggactttgccctgat 89 
mGBP8 tgctatgacccaaccacaaa ccttggtctgagactgcaca 227 
mGBP9 tgtgcagtctcagaccaagg aagcacacttagggcgaaga 154 
mGBP11 agcaactgagaaggaagctga caaggagagccttttgttcct 99 
mβ-actin gtggatcagcaagcaggagt agggtgtaaaacgcagctca 96 
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3 Dharmacon siRNA library
Pool Catalog Number GENE ID Gene Accession GI Number Sequence
L-058899-00 21817 NM_009373 31543859 GCAACGACUUCGACGUGUU
L-058899-00 21817 NM_009373 31543859 CCGAUGAUGUGUACCUAGA
L-058899-00 21817 NM_009373 31543859 GAACAGCAUCCCACUUCGA
L-058899-00 21817 NM_009373 31543859 CGACGGGAAUAUGUCCUUA
L-047145-01 16978 NM_008515 6678721 CCAUAAGGAGCGAACGAGA
L-047145-01 16978 NM_008515 6678721 CUGACGAAGACGAGCGCUU
L-047145-01 16978 NM_008515 6678721 GCGAUGGUCUAGACGUAAA
L-047145-01 16978 NM_008515 6678721 CGGAGAAACACGUCGGCUU
L-046134-01 15163 NM_008225 6680186 GGGCAUGAUGUAUCGGUUU
L-046134-01 15163 NM_008225 6680186 CCAAGGAGAGGGAAGCGAU
L-046134-01 15163 NM_008225 6680186 UGGAAGAGCCAGUGUACGA
L-046134-01 15163 NM_008225 6680186 GUAAAGAUGAGCCGAGAAG
L-060939-01 69178 NM_024225 31560123 CUUACUGAAACAACGGAUU
L-060939-01 69178 NM_024225 31560123 AGUGUUAGACGGAAGAAUA
L-060939-01 69178 NM_024225 31560123 AUUUCAGAGCCCAGAGUUU
L-060939-01 69178 NM_024225 31560123 CGAGAGAAGAUGCAGAAAC
L-041172-00 15170 NM_013545 7305132 GGUAAAGAAUCUACACCAA
L-041172-00 15170 NM_013545 7305132 AUACAAACUGCGAACAUUA
L-041172-00 15170 NM_013545 7305132 AUAUCAAGGUUAUGUGUGA
L-041172-00 15170 NM_013545 7305132 AGAUAUGGCACUACCAGUA
L-040984-01 23790 NM_011779 31542412 CGAACUAGCUCGCGUUUCU
L-040984-01 23790 NM_011779 31542412 CCGUUGAAUUAAUUACGUA
L-040984-01 23790 NM_011779 31542412 GUAUAAACACUCACGAGAA
L-040984-01 23790 NM_011779 31542412 GGUUGAGAGAGGCGGGAGU
L-040963-01 15959 NM_010501 6754287 GAACUGAGACGAUUAACGA
L-040963-01 15959 NM_010501 6754287 GGAAGAAAUGAACGAGCAA
L-040963-01 15959 NM_010501 6754287 ACUCAGAUCUCAUCGAUUU
L-040963-01 15959 NM_010501 6754287 GGAAGGAUGGACACGCCUA
L-047321-01 11867 NM_023142 12963526 GCACGGACCGCAAUGCCUA
L-047321-01 11867 NM_023142 12963526 GCACUGUAUGCCUGGUAGA
L-047321-01 11867 NM_023142 12963526 GCUUCAAAAUGUGGGCUAA
L-047321-01 11867 NM_023142 12963526 GGGAACUGCCUAUUUAACA
L-050915-01 20947 NM_009302 40789274 AGUUGGAGUUGGAGCGGAA
L-050915-01 20947 NM_009302 40789274 AGACAACAGAGGCGGAGAA
L-050915-01 20947 NM_009302 40789274 GAAAGGUCACAAACGGAAA
L-050915-01 20947 NM_009302 40789274 GCAGUAUGAGGGAGUUAAA
L-063252-02 27054 NM_001252545 357527457 UGUAAAGACCUCUCGGGAA
L-063252-02 27054 NM_001252545 357527457 GUGAAAGGGCCAUGCGUGU
L-063252-02 27054 NM_001252545 357527457 CGUUGUUGAUAGCGUCCUA
L-063252-02 27054 NM_001252545 357527457 AGAAAGAUAACGCACGAUU
L-064059-01 107702 NM_145135 31981747 CCUCCAAAGCUUCGCUACA
L-064059-01 107702 NM_145135 31981747 CCAUGAACCUGGUGUCCGU
L-064059-01 107702 NM_145135 31981747 GAGCUUUGGUUGGGAGACU
L-064059-01 107702 NM_145135 31981747 CAAUAAGCACUGUGGUCUU
L-064380-01 11564 NM_009634 31982252 GUCCGAAAGCUGCGGGCAU
L-064380-01 11564 NM_009634 31982252 CAGAUUGGCUCCAGUGCGA
L-064380-01 11564 NM_009634 31982252 GGACAGACGUACACACGGA
L-064380-01 11564 NM_009634 31982252 GGUACAAGUUCCAGACGUG
L-043701-00 23880 NM_011815 33469118 CGAGAUCUAUGACGGAAUA
L-043701-00 23880 NM_011815 33469118 GUACGACGGUGAAAUUCGA
L-043701-00 23880 NM_011815 33469118 GGAGGGAGCCCAAGAUUUG
L-043701-00 23880 NM_011815 33469118 GGGCAAAUAUGGUUAUGUC
L-054838-01 14450 NM_010256 93102414 GCACAAGACCAUAAGCGAU
J-058899-06
J-058899-07
J-058899-08
Duplex Catalog Number Gene Symbol
J-058899-05 Tgm2
Tgm2
J-047145-12
J-046134-09
J-046134-10
J-047145-09
J-047145-10
J-047145-11
J-060939-10
J-060939-11
J-060939-12
J-046134-11
J-046134-12
J-060939-09
J-041172-08
J-040984-09
J-040984-10
J-041172-05
J-041172-06
J-041172-07
J-040963-10
J-040963-11
J-040963-12
J-040984-11
J-040984-12
J-040963-09
J-047321-12
J-050915-09
J-050915-10
J-047321-09
J-047321-10
J-047321-11
J-063252-10
J-063252-12
J-063252-19
J-050915-11
J-050915-12
J-063252-09
J-064059-12
J-064380-09
J-064380-10
J-064059-09
J-064059-10
J-064059-11
J-043701-06
J-043701-07
J-043701-08
J-064380-11
J-064380-12
J-043701-05
J-054838-09 Gart
Fyb
Fyb
Fyb
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Adsl
Adsl
Adsl
Rnh1
Rnh1
Rnh1
Rnh1
Sec23b
Sec23b
Sec23b
Sec23b
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Swap70
Swap70
Swap70
Arpc1b
Arpc1b
Arpc1b
Arpc1b
Ifit3
Ifit3
Ifit3
Ifit3
Coro1c
Coro1c
Coro1c
Coro1c
Ptpn6
Ptpn6
Ptpn6
Ptpn6
Snx5
Snx5
Snx5
Snx5
Hcls1
Hcls1
Hcls1
Hcls1
Lrrfip1
Lrrfip1
Lrrfip1
Lrrfip1
Tgm2
Tgm2
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Pool Catalog Number GENE ID Gene Accession GI Number Sequence
L-054838-01 14450 NM_010256 93102414 AGAUGUAGAUGCCGGACAA
L-054838-01 14450 NM_010256 93102414 CCGCUUUGGUGAUCCGGAA
L-054838-01 14450 NM_010256 93102414 ACUCGUAGUUGUCGGACCA
L-047667-01 22388 NM_011715 6755994 UGGAUGACACAGUGCGGUA
L-047667-01 22388 NM_011715 6755994 CUACAGUGGACAAGGCGUU
L-047667-01 22388 NM_011715 6755994 CAACAGGGAGUGAUGAUAA
L-047667-01 22388 NM_011715 6755994 GGAGCAUCUUCUAAAGUAU
L-065589-01 56045 NM_018851 46909601 UCACUAAGUUGACGGAUAA
L-065589-01 56045 NM_018851 46909601 CAGAUCAGUGAGCGAGAUA
L-065589-01 56045 NM_018851 46909601 GGAAUGGCAUCGACGUAGA
L-065589-01 56045 NM_018851 46909601 GAUUACAAGGAUCGAGACA
L-048239-01 22169 NM_020557 31340573 GAAAUGACGUACCAGCGUA
L-048239-01 22169 NM_020557 31340573 CCAAUAAUGUGUUUCGUCA
L-048239-01 22169 NM_020557 31340573 CUGAAUAGGAAGUCGUAGU
L-048239-01 22169 NM_020557 31340573 CGUGGAUUCUGGAACGAGA
L-047866-01 13495 NM_021354 10946677 GGAGAUCGCUCGAACGCAG
L-047866-01 13495 NM_021354 10946677 CGAGGUACUCUUCCGAGAA
L-047866-01 13495 NM_021354 10946677 UGGAACACACAAACGGGAA
L-047866-01 13495 NM_021354 10946677 CUAUGGAGCAUGAGGACGU
L-048873-01 50497 NM_015765 82880661 GGGCCGAUGUGGUUGCAAA
L-048873-01 50497 NM_015765 82880661 GUGAACAGGUGGUUGGACU
L-048873-01 50497 NM_015765 82880661 GCACAGUAGUGAAAGUGAA
L-048873-01 50497 NM_015765 82880661 CAAAGUAGAAUAAGACAUG
L-167568-00 672511 XM_001477846 407263730 CGGAGGAGCUGUACCGAAA
L-167568-00 672511 XM_001477846 407263730 CAAGAUCGCUAGUGGAUAA
L-167568-00 672511 XM_001477846 407263730 GCGUUUAACCCACGGGAUA
L-167568-00 672511 XM_001477846 407263730 UCACAAAACUGUCGAGAAU
L-051439-01 66824 NM_023258 31581581 CGAGAAGGCUAUGGGCGCA
L-051439-01 66824 NM_023258 31581581 GAAACAAACCAGUCCGUAG
L-051439-01 66824 NM_023258 31581581 GCUACUAUCUGGAGUCGUA
L-051439-01 66824 NM_023258 31581581 GAGCAGAGCUGAGGUAUCU
L-053455-00 216799 NM_145827 48675839 GGUGAAAUGUACUUAAAUC
L-053455-00 216799 NM_145827 48675839 GGAUGGGUUUGCUGGGAUA
L-053455-00 216799 NM_145827 48675839 ACACACCUCUAUCUACGAA
L-053455-00 216799 NM_145827 48675839 GAAGUGGACUGCGAGAGAU
J-054838-12
J-047667-09
J-047667-10
J-054838-10
J-054838-11
J-065589-10
J-065589-11
J-065589-12
J-047667-11
J-047667-12
J-065589-09
J-048239-12
J-047866-09
J-047866-10
J-048239-09
J-048239-10
J-048239-11
J-048873-10
J-048873-11
J-048873-12
J-047866-11
J-047866-12
J-048873-09
J-053455-05
J-167568-08
J-051439-09
J-051439-10
J-167568-05
J-167568-06
J-167568-07
Nlrp3
Nlrp3
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J-051439-12
Nlrp3
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Rnf213
Rnf213
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Hspa14
Hspa14
Hspa14
Drg2
Drg2
Drg2
Drg2
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Cmpk2
Cmpk2
Cmpk2
Samhd1
Samhd1
Samhd1
Samhd1
Wdr1
Wdr1
Wdr1
Wdr1
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Gart
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